miRNA-corp.d0.s0	Identification of blood microRNAs associated to Parkinsońs disease.   	miRNA-corp.d0.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d0.s0	Identification of blood microRNAs associated to Parkinsońs disease.   	miRNA-corp.d0.s0.e1	Diseases	Parkinsońs disease 	2
miRNA-corp.d0.s0	Identification of blood microRNAs associated to Parkinsońs disease.   	miRNA-corp.d0.s0.e2	Relation_Trigger	associated 	3
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e0	Diseases	PD 	1
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e1	Specific_miRNAs	miR-1 	2
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e2	Specific_miRNAs	miR-22 	3
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e3	Specific_miRNAs	miR-29 	4
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e4	Specific_miRNAs	miR-16-2 	5
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e5	Specific_miRNAs	miR-26a2 	6
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e6	Specific_miRNAs	miR30a 	7
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e7	Relation_Trigger	expression levels allowed to distinguish 	8
miRNA-corp.d0.s1	While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.  	miRNA-corp.d0.s1.e8	Species	patients 	9
miRNA-corp.d0.s2	They form two groups according to their expression profile in control, non-treated, early-onset and treated Parkinson's disease subjects.  	miRNA-corp.d0.s2.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d0.s3	A set of six differentially expressed microRNAs were identified.  	miRNA-corp.d0.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d0.s3	A set of six differentially expressed microRNAs were identified.  	miRNA-corp.d0.s3.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d0.s4	The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD).  	miRNA-corp.d0.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d0.s4	The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD).  	miRNA-corp.d0.s4.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d0.s4	The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD).  	miRNA-corp.d0.s4.e2	Diseases	PD 	3
miRNA-corp.d0.s4	The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD).  	miRNA-corp.d0.s4.e3	Relation_Trigger	associated 	4
miRNA-corp.d0.s5	This study is innovative in contributing to the development of effective PD biomarkers.    	miRNA-corp.d0.s5.e0	Diseases	PD 	1
miRNA-corp.d1.s0	This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.    	miRNA-corp.d1.s0.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s0	This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.    	miRNA-corp.d1.s0.e1	Diseases	meningioma tumor 	2
miRNA-corp.d1.s0	This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.    	miRNA-corp.d1.s0.e2	Diseases	meningiomas 	3
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e1	Diseases	meningioma 	2
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e2	Genes/Proteins	beta-catenin 	3
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e3	Relation_Trigger	downregulation 	4
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e4	Relation_Trigger	upregulation 	5
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e5	Relation_Trigger	correlation 	6
miRNA-corp.d1.s1	A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.  	miRNA-corp.d1.s1.e6	Species	human 	7
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e1	Genes/Proteins	E-cadherin 	2
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e3	Diseases	meningiomas 	4
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e4	Relation_Trigger	tumor suppressor 	5
miRNA-corp.d1.s2	Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.  	miRNA-corp.d1.s2.e5	Genes/Proteins	beta-catenin 	6
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e1	Genes/Proteins	beta-catenin 	2
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e2	Relation_Trigger	inhibiting its translation 	3
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e3	Relation_Trigger	blocking 	4
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e4	Relation_Trigger	directly target 	5
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e5	Genes/Proteins	beta-catenin 	6
miRNA-corp.d1.s3	miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.  	miRNA-corp.d1.s3.e6	Diseases	cancer 	7
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e1	Genes/Proteins	cyclin D1 	2
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e2	Genes/Proteins	beta-catenin 	3
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e3	Diseases	meningiomas 	4
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e4	Relation_Trigger	Downregulation 	5
miRNA-corp.d1.s4	Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation.  	miRNA-corp.d1.s4.e5	Relation_Trigger	increased expression 	6
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e1	Genes/Proteins	ZEB1 	2
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e2	Genes/Proteins	E-cadherin 	3
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e3	Relation_Trigger	Upregulation 	4
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e4	Relation_Trigger	decreased the expression 	5
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e5	Relation_Trigger	increased expression 	6
miRNA-corp.d1.s5	Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation.  	miRNA-corp.d1.s5.e6	Relation_Trigger	associated 	7
miRNA-corp.d1.s6	Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.  	miRNA-corp.d1.s6.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s6	Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.  	miRNA-corp.d1.s6.e1	Diseases	meningioma 	2
miRNA-corp.d1.s6	Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.  	miRNA-corp.d1.s6.e2	Relation_Trigger	Elevated levels 	3
miRNA-corp.d1.s6	Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.  	miRNA-corp.d1.s6.e3	Relation_Trigger	inhibited 	4
miRNA-corp.d1.s6	Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.  	miRNA-corp.d1.s6.e4	Diseases	tumor 	5
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e0	Specific_miRNAs	miR-200a 	1
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e4	Diseases	Meningiomas 	5
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e5	Diseases	neurofibromatosis type 2 	6
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e6	Relation_Trigger	downregulated 	7
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e7	Relation_Trigger	associated 	8
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e8	Relation_Trigger	associated 	9
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e9	Diseases	brain tumors 	10
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e10	Diseases	meningioma 	11
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e11	Relation_Trigger	associated 	12
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e12	Species	human 	13
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e13	Species	human 	14
miRNA-corp.d1.s7	Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.  	miRNA-corp.d1.s7.e14	Diseases	tumor 	15
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e0	Specific_miRNAs	microRNA-200a 	1
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e1	Genes/Proteins	E-cadherin 	2
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e2	Diseases	meningiomas 	3
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e3	Relation_Trigger	Downregulated 	4
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e4	Genes/Proteins	beta-catenin 	5
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e5	Relation_Trigger	activating 	6
miRNA-corp.d1.s8	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.   	miRNA-corp.d1.s8.e6	Diseases	tumor 	7
miRNA-corp.d2.s0	These data support the hypothesis that patterns of miRNA expression in cortical GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression observed early in the disease would be predicted to cause profound changes in gene expression.    	miRNA-corp.d2.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d2.s0	These data support the hypothesis that patterns of miRNA expression in cortical GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression observed early in the disease would be predicted to cause profound changes in gene expression.    	miRNA-corp.d2.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d2.s0	These data support the hypothesis that patterns of miRNA expression in cortical GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression observed early in the disease would be predicted to cause profound changes in gene expression.    	miRNA-corp.d2.s0.e2	Diseases	AD 	3
miRNA-corp.d2.s0	These data support the hypothesis that patterns of miRNA expression in cortical GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression observed early in the disease would be predicted to cause profound changes in gene expression.    	miRNA-corp.d2.s0.e3	Relation_Trigger	changes in gene expression 	4
miRNA-corp.d2.s1	Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter.   	miRNA-corp.d2.s1.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d2.s1	Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter.   	miRNA-corp.d2.s1.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d2.s1	Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter.   	miRNA-corp.d2.s1.e2	Species	human 	3
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e3	Diseases	Alzheimer's disease 	4
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e4	Diseases	AD 	5
miRNA-corp.d2.s2	MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology.  	miRNA-corp.d2.s2.e5	Species	human 	6
miRNA-corp.d2.s4	miRNA profiling experiments were performed using state-of-the-art Exiqon(©) LNA-microarrays.  	miRNA-corp.d2.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d2.s5	A subset of miRNAs that appeared to be strongly expressed according to the microarrays did not appear to be conventional miRNAs according to Northern blot analyses.  	miRNA-corp.d2.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d2.s5	A subset of miRNAs that appeared to be strongly expressed according to the microarrays did not appear to be conventional miRNAs according to Northern blot analyses.  	miRNA-corp.d2.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d2.s6	Some well-characterized miRNAs were substantially enriched in WM as expected.  	miRNA-corp.d2.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d2.s7	However, most of the miRNA expression variability that correlated with the presence of early AD-related pathology was seen in GM.  	miRNA-corp.d2.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d2.s7	However, most of the miRNA expression variability that correlated with the presence of early AD-related pathology was seen in GM.  	miRNA-corp.d2.s7.e1	Diseases	AD 	2
miRNA-corp.d2.s7	However, most of the miRNA expression variability that correlated with the presence of early AD-related pathology was seen in GM.  	miRNA-corp.d2.s7.e2	Relation_Trigger	expression variability that correlated 	3
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e1	Relation_Trigger	downregulation 	2
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e2	Specific_miRNAs	miR-29 	3
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e3	Relation_Trigger	correlated 	4
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e4	Diseases	amyloid plaques 	5
miRNA-corp.d2.s8	We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue.  	miRNA-corp.d2.s8.e5	Specific_miRNAs	miR-15/107 	6
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e4	Diseases	AD 	5
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e5	Diseases	AD 	6
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e6	Specific_miRNAs	miR-424 	7
miRNA-corp.d2.s9	A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD.  	miRNA-corp.d2.s9.e7	Specific_miRNAs	miR-212 	8
miRNA-corp.d2.s10	The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology.  	miRNA-corp.d2.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d2.s10	The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology.  	miRNA-corp.d2.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d2.s10	The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology.  	miRNA-corp.d2.s10.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d2.s10	The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology.  	miRNA-corp.d2.s10.e3	Relation_Trigger	expression of certain miRNAs correlates 	4
miRNA-corp.d2.s10	The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology.  	miRNA-corp.d2.s10.e4	Diseases	AD 	5
miRNA-corp.d3.s1	Speculations on the development of miRNAs as potential therapeutic targets are also presented.  	miRNA-corp.d3.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d3.s1	Speculations on the development of miRNAs as potential therapeutic targets are also presented.  	miRNA-corp.d3.s1.e1	Relation_Trigger	potential therapeutic targets 	2
miRNA-corp.d3.s3	Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases.  	miRNA-corp.d3.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d3.s3	Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases.  	miRNA-corp.d3.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d3.s3	Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases.  	miRNA-corp.d3.s3.e2	Relation_Trigger	therapeutic targets 	3
miRNA-corp.d3.s3	Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases.  	miRNA-corp.d3.s3.e3	Relation_Trigger	associated 	4
miRNA-corp.d3.s3	Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases.  	miRNA-corp.d3.s3.e4	Species	human 	5
miRNA-corp.d3.s4	The importance of miRNAs has steadily gained appreciation and miRNA biology has exploded into a massive swell of interest with enormous range and potential in almost every biological discipline because of their widespread expression and diverse functions in both animals and humans.  	miRNA-corp.d3.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d3.s4	The importance of miRNAs has steadily gained appreciation and miRNA biology has exploded into a massive swell of interest with enormous range and potential in almost every biological discipline because of their widespread expression and diverse functions in both animals and humans.  	miRNA-corp.d3.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d3.s4	The importance of miRNAs has steadily gained appreciation and miRNA biology has exploded into a massive swell of interest with enormous range and potential in almost every biological discipline because of their widespread expression and diverse functions in both animals and humans.  	miRNA-corp.d3.s4.e2	Species	humans 	3
miRNA-corp.d3.s5	It has been established that miRNAs are critical regulators of apoptosis of various cell types.  	miRNA-corp.d3.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d3.s5	It has been established that miRNAs are critical regulators of apoptosis of various cell types.  	miRNA-corp.d3.s5.e1	Relation_Trigger	regulators 	2
miRNA-corp.d3.s7	Once ignored completely or overlooked as cellular detritus, microRNAs (miRNAs) that were discovered only a decade ago, have recently taken many by surprise.  	miRNA-corp.d3.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d3.s7	Once ignored completely or overlooked as cellular detritus, microRNAs (miRNAs) that were discovered only a decade ago, have recently taken many by surprise.  	miRNA-corp.d3.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d3.s8	MicroRNA: A matter of life or death.   	miRNA-corp.d3.s8.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d3.s9	Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders.  	miRNA-corp.d3.s9.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d3.s9	Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders.  	miRNA-corp.d3.s9.e1	Diseases	hypertensive 	2
miRNA-corp.d3.s9	Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders.  	miRNA-corp.d3.s9.e2	Diseases	heart disease 	3
miRNA-corp.d3.s9	Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders.  	miRNA-corp.d3.s9.e3	Diseases	neurodegenerative disorders 	4
miRNA-corp.d3.s10	This editorial aims to convey this message and to boost up the research interest by providing a timely, comprehensive overview on regulation of apoptosis by miRNAs and a synopsis on the pathophysiologic implications of this novel regulatory network based on the currently available data in the literature.  	miRNA-corp.d3.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d3.s10	This editorial aims to convey this message and to boost up the research interest by providing a timely, comprehensive overview on regulation of apoptosis by miRNAs and a synopsis on the pathophysiologic implications of this novel regulatory network based on the currently available data in the literature.  	miRNA-corp.d3.s10.e1	Relation_Trigger	regulation 	2
miRNA-corp.d3.s10	This editorial aims to convey this message and to boost up the research interest by providing a timely, comprehensive overview on regulation of apoptosis by miRNAs and a synopsis on the pathophysiologic implications of this novel regulatory network based on the currently available data in the literature.  	miRNA-corp.d3.s10.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d3.s11	It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells.  	miRNA-corp.d3.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d3.s11	It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells.  	miRNA-corp.d3.s11.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d3.s11	It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells.  	miRNA-corp.d3.s11.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d3.s11	It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells.  	miRNA-corp.d3.s11.e3	Relation_Trigger	regulating 	4
miRNA-corp.d3.s11	It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells.  	miRNA-corp.d3.s11.e4	Diseases	cancer 	5
miRNA-corp.d4.s0	METHODS: We prospectively collected surgical outcome data for 2 to 11 years for 134 consecutive patients who specifically had MTLE and unilateral HS, according to magnetic resonance imaging (MRI) and confirmed by histopathology.  	miRNA-corp.d4.s0.e0	Diseases	MTLE 	1
miRNA-corp.d4.s0	METHODS: We prospectively collected surgical outcome data for 2 to 11 years for 134 consecutive patients who specifically had MTLE and unilateral HS, according to magnetic resonance imaging (MRI) and confirmed by histopathology.  	miRNA-corp.d4.s0.e1	Diseases	HS 	2
miRNA-corp.d4.s0	METHODS: We prospectively collected surgical outcome data for 2 to 11 years for 134 consecutive patients who specifically had MTLE and unilateral HS, according to magnetic resonance imaging (MRI) and confirmed by histopathology.  	miRNA-corp.d4.s0.e2	Species	patients 	3
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e0	Diseases	mesial temporal lobe epilepsy 	1
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e1	Diseases	MTLE 	2
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e2	Diseases	hippocampal sclerosis 	3
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e3	Diseases	HS 	4
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e4	Diseases	TLE 	5
miRNA-corp.d4.s1	PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.  	miRNA-corp.d4.s1.e5	Species	patients 	6
miRNA-corp.d4.s2	Survival analysis of the surgical outcome of temporal lobe epilepsy due to hippocampal sclerosis.   	miRNA-corp.d4.s2.e0	Diseases	temporal lobe epilepsy 	1
miRNA-corp.d4.s2	Survival analysis of the surgical outcome of temporal lobe epilepsy due to hippocampal sclerosis.   	miRNA-corp.d4.s2.e1	Diseases	hippocampal sclerosis 	2
miRNA-corp.d4.s3	Of the patients tested, 26% of those operated on the left side and 22% of those operated on the right had postoperative decline of >1 SD in verbal or visual memory, respectively.  	miRNA-corp.d4.s3.e0	Species	patients 	1
miRNA-corp.d4.s4	CONCLUSIONS: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.    	miRNA-corp.d4.s4.e0	Species	patients 	1
miRNA-corp.d4.s4	CONCLUSIONS: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.    	miRNA-corp.d4.s4.e1	Diseases	MTLE 	2
miRNA-corp.d4.s4	CONCLUSIONS: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.    	miRNA-corp.d4.s4.e2	Diseases	HS 	3
miRNA-corp.d4.s4	CONCLUSIONS: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.    	miRNA-corp.d4.s4.e3	Diseases	seizure 	4
miRNA-corp.d4.s5	RESULTS: Kaplan-Meier estimates of complete seizure freedom (Engel's class IA) for years 1, 2, 5, and 10 were 85%, 77%, 74%, and 66%, and of Engel's class I were 89%, 86%, 83%, and 81%.  	miRNA-corp.d4.s5.e0	Diseases	seizure 	1
miRNA-corp.d4.s6	Only nine (6.7%) patients had outcome classes III or IV at any point during follow-up.  	miRNA-corp.d4.s6.e0	Species	patients 	1
miRNA-corp.d4.s8	Outcome was analyzed by using Engel's classification (a) through Kaplan-Meier estimated survival curves (as a function of the time to seizure recurrence), (b) as percentage of patients in each outcome class on a yearly basis, and (c) at the last updated follow-up.  	miRNA-corp.d4.s8.e0	Diseases	seizure 	1
miRNA-corp.d4.s8	Outcome was analyzed by using Engel's classification (a) through Kaplan-Meier estimated survival curves (as a function of the time to seizure recurrence), (b) as percentage of patients in each outcome class on a yearly basis, and (c) at the last updated follow-up.  	miRNA-corp.d4.s8.e1	Species	patients 	2
miRNA-corp.d5.s0	Western blot analysis of human glioblastoma specimens showed high levels of PKM2 protein, but none was observed in normal brain samples.  	miRNA-corp.d5.s0.e0	Genes/Proteins	PKM2 	1
miRNA-corp.d5.s0	Western blot analysis of human glioblastoma specimens showed high levels of PKM2 protein, but none was observed in normal brain samples.  	miRNA-corp.d5.s0.e1	Diseases	glioblastoma 	2
miRNA-corp.d5.s0	Western blot analysis of human glioblastoma specimens showed high levels of PKM2 protein, but none was observed in normal brain samples.  	miRNA-corp.d5.s0.e2	Relation_Trigger	high levels of PKM2 protein 	3
miRNA-corp.d5.s0	Western blot analysis of human glioblastoma specimens showed high levels of PKM2 protein, but none was observed in normal brain samples.  	miRNA-corp.d5.s0.e3	Species	human 	4
miRNA-corp.d5.s1	Our data suggest PKM2 inhibition as a therapy for glioblastoma, with the potential for minimal toxicity to the brain.    	miRNA-corp.d5.s1.e0	Genes/Proteins	PKM2 	1
miRNA-corp.d5.s1	Our data suggest PKM2 inhibition as a therapy for glioblastoma, with the potential for minimal toxicity to the brain.    	miRNA-corp.d5.s1.e1	Diseases	glioblastoma 	2
miRNA-corp.d5.s1	Our data suggest PKM2 inhibition as a therapy for glioblastoma, with the potential for minimal toxicity to the brain.    	miRNA-corp.d5.s1.e2	Relation_Trigger	inhibition 	3
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e0	Specific_miRNAs	miR-326 	1
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e1	Specific_miRNAs	miR-326 	2
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e2	Genes/Proteins	PKM2 	3
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e3	Genes/Proteins	PKM2 	4
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e4	Relation_Trigger	high levels 	5
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e5	Relation_Trigger	expressed lower levels 	6
miRNA-corp.d5.s2	Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326.  	miRNA-corp.d5.s2.e6	Relation_Trigger	regulation 	7
miRNA-corp.d5.s3	Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor.  	miRNA-corp.d5.s3.e0	Diseases	glioma 	1
miRNA-corp.d5.s3	Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor.  	miRNA-corp.d5.s3.e1	Diseases	brain tumor 	2
miRNA-corp.d5.s3	Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor.  	miRNA-corp.d5.s3.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d5.s3	Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor.  	miRNA-corp.d5.s3.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d5.s3	Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor.  	miRNA-corp.d5.s3.e4	Diseases	tumor 	5
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e0	Genes/Proteins	Pyruvate kinase M2 	1
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e1	Specific_miRNAs	microRNA-326 	2
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e2	Diseases	glioma 	3
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e4	Relation_Trigger	tumor-suppressive 	5
miRNA-corp.d5.s4	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.   	miRNA-corp.d5.s4.e5	Relation_Trigger	regulates 	6
miRNA-corp.d5.s5	Their important targets in this tumor are not well understood.  	miRNA-corp.d5.s5.e0	Relation_Trigger	targets 	1
miRNA-corp.d5.s5	Their important targets in this tumor are not well understood.  	miRNA-corp.d5.s5.e1	Diseases	tumor 	2
miRNA-corp.d5.s6	We recently found that the Notch pathway is a target of miRNA-326.  	miRNA-corp.d5.s6.e0	Specific_miRNAs	miRNA-326 	1
miRNA-corp.d5.s6	We recently found that the Notch pathway is a target of miRNA-326.  	miRNA-corp.d5.s6.e1	Relation_Trigger	target 	2
miRNA-corp.d5.s7	Ectopic expression of miRNA-326 in glioma and glioma stem cells induced their apoptosis and reduced their metabolic activity.  	miRNA-corp.d5.s7.e0	Specific_miRNAs	miRNA-326 	1
miRNA-corp.d5.s7	Ectopic expression of miRNA-326 in glioma and glioma stem cells induced their apoptosis and reduced their metabolic activity.  	miRNA-corp.d5.s7.e1	Diseases	glioma 	2
miRNA-corp.d5.s7	Ectopic expression of miRNA-326 in glioma and glioma stem cells induced their apoptosis and reduced their metabolic activity.  	miRNA-corp.d5.s7.e2	Relation_Trigger	Ectopic expression 	3
miRNA-corp.d5.s7	Ectopic expression of miRNA-326 in glioma and glioma stem cells induced their apoptosis and reduced their metabolic activity.  	miRNA-corp.d5.s7.e3	Diseases	glioma 	4
miRNA-corp.d5.s8	Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326.  	miRNA-corp.d5.s8.e0	Specific_miRNAs	miRNA-326 	1
miRNA-corp.d5.s8	Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326.  	miRNA-corp.d5.s8.e1	Genes/Proteins	pyruvate kinase type M2 	2
miRNA-corp.d5.s8	Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326.  	miRNA-corp.d5.s8.e2	Genes/Proteins	PKM2 	3
miRNA-corp.d5.s8	Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326.  	miRNA-corp.d5.s8.e3	Relation_Trigger	target 	4
miRNA-corp.d5.s8	Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326.  	miRNA-corp.d5.s8.e4	Relation_Trigger	target 	5
miRNA-corp.d5.s9	PKM2 has recently been shown to play a key role in cancer cell metabolism.  	miRNA-corp.d5.s9.e0	Genes/Proteins	PKM2 	1
miRNA-corp.d5.s9	PKM2 has recently been shown to play a key role in cancer cell metabolism.  	miRNA-corp.d5.s9.e1	Diseases	cancer 	2
miRNA-corp.d5.s10	To investigate whether it might be a functionally important target of miR-326, we used RNA interference to knockdown PKM2 expression in glioma cells.  	miRNA-corp.d5.s10.e0	Specific_miRNAs	miR-326 	1
miRNA-corp.d5.s10	To investigate whether it might be a functionally important target of miR-326, we used RNA interference to knockdown PKM2 expression in glioma cells.  	miRNA-corp.d5.s10.e1	Genes/Proteins	PKM2 	2
miRNA-corp.d5.s10	To investigate whether it might be a functionally important target of miR-326, we used RNA interference to knockdown PKM2 expression in glioma cells.  	miRNA-corp.d5.s10.e2	Diseases	glioma 	3
miRNA-corp.d5.s10	To investigate whether it might be a functionally important target of miR-326, we used RNA interference to knockdown PKM2 expression in glioma cells.  	miRNA-corp.d5.s10.e3	Relation_Trigger	target 	4
miRNA-corp.d5.s11	Transfection of the established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels, and activated AMP-activated protein kinase.  	miRNA-corp.d5.s11.e0	Genes/Proteins	PKM2 	1
miRNA-corp.d5.s11	Transfection of the established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels, and activated AMP-activated protein kinase.  	miRNA-corp.d5.s11.e1	Diseases	glioma 	2
miRNA-corp.d5.s11	Transfection of the established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels, and activated AMP-activated protein kinase.  	miRNA-corp.d5.s11.e2	Diseases	glioma 	3
miRNA-corp.d5.s11	Transfection of the established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels, and activated AMP-activated protein kinase.  	miRNA-corp.d5.s11.e3	Relation_Trigger	activated 	4
miRNA-corp.d5.s12	The cytotoxic effects exhibited by PKM2 knockdown in glioma and glioma stem cells were not observed in transformed human astrocytes.  	miRNA-corp.d5.s12.e0	Genes/Proteins	PKM2 	1
miRNA-corp.d5.s12	The cytotoxic effects exhibited by PKM2 knockdown in glioma and glioma stem cells were not observed in transformed human astrocytes.  	miRNA-corp.d5.s12.e1	Diseases	glioma 	2
miRNA-corp.d5.s12	The cytotoxic effects exhibited by PKM2 knockdown in glioma and glioma stem cells were not observed in transformed human astrocytes.  	miRNA-corp.d5.s12.e2	Diseases	glioma 	3
miRNA-corp.d5.s12	The cytotoxic effects exhibited by PKM2 knockdown in glioma and glioma stem cells were not observed in transformed human astrocytes.  	miRNA-corp.d5.s12.e3	Species	human 	4
miRNA-corp.d6.s0	Membership in this group is defined based on sequence similarity near the mature miRNAs' 5' end: all include the sequence AGCAGC.  	miRNA-corp.d6.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e1	Specific_miRNAs	miR-15/107 	2
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e5	Non-Specific_miRNAs	miRNAs 	6
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e6	Relation_Trigger	regulated 	7
miRNA-corp.d6.s1	Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases.  	miRNA-corp.d6.s1.e7	Species	human 	8
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e0	Specific_miRNAs	miR-15a 	1
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e1	Specific_miRNAs	miR-15b 	2
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e2	Specific_miRNAs	miR-16 	3
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e3	Specific_miRNAs	miR-103 	4
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e4	Specific_miRNAs	miR-107 	5
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e5	Specific_miRNAs	miR-195 	6
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e6	Specific_miRNAs	miR-424 	7
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e7	Specific_miRNAs	miR-497 	8
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e8	Specific_miRNAs	miR-503 	9
miRNA-corp.d6.s2	While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646.  	miRNA-corp.d6.s2.e9	Specific_miRNAs	miR-646 	10
miRNA-corp.d6.s3	Phylogeny of this group of miRNAs is incomplete; thus, a definitive taxonomic classification (e.g., designation as a "superfamily") is currently not possible.  	miRNA-corp.d6.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d6.s4	We present data on the expression of all known miR-15/107 group members in human cerebral cortical gray matter and white matter using new miRNA profiling microarrays.  	miRNA-corp.d6.s4.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s4	We present data on the expression of all known miR-15/107 group members in human cerebral cortical gray matter and white matter using new miRNA profiling microarrays.  	miRNA-corp.d6.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d6.s4	We present data on the expression of all known miR-15/107 group members in human cerebral cortical gray matter and white matter using new miRNA profiling microarrays.  	miRNA-corp.d6.s4.e2	Species	human 	3
miRNA-corp.d6.s5	Multiple different miRNAs in the miR-15/107 group are expressed at moderate to high levels in human tissues.  	miRNA-corp.d6.s5.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s5	Multiple different miRNAs in the miR-15/107 group are expressed at moderate to high levels in human tissues.  	miRNA-corp.d6.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d6.s5	Multiple different miRNAs in the miR-15/107 group are expressed at moderate to high levels in human tissues.  	miRNA-corp.d6.s5.e2	Relation_Trigger	high levels 	3
miRNA-corp.d6.s5	Multiple different miRNAs in the miR-15/107 group are expressed at moderate to high levels in human tissues.  	miRNA-corp.d6.s5.e3	Species	human 	4
miRNA-corp.d6.s6	The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.   	miRNA-corp.d6.s6.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s6	The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.   	miRNA-corp.d6.s6.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d6.s6	The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.   	miRNA-corp.d6.s6.e2	Species	human 	3
miRNA-corp.d6.s7	The miR-15/107 group of microRNA (miRNA) gene is increasingly appreciated to serve key functions in humans.  	miRNA-corp.d6.s7.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s7	The miR-15/107 group of microRNA (miRNA) gene is increasingly appreciated to serve key functions in humans.  	miRNA-corp.d6.s7.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d6.s7	The miR-15/107 group of microRNA (miRNA) gene is increasingly appreciated to serve key functions in humans.  	miRNA-corp.d6.s7.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d6.s7	The miR-15/107 group of microRNA (miRNA) gene is increasingly appreciated to serve key functions in humans.  	miRNA-corp.d6.s7.e3	Species	humans 	4
miRNA-corp.d6.s8	These miRNAs regulate gene expression involved in cell division, metabolism, stress response, and angiogenesis in vertebrate species.  	miRNA-corp.d6.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d6.s8	These miRNAs regulate gene expression involved in cell division, metabolism, stress response, and angiogenesis in vertebrate species.  	miRNA-corp.d6.s8.e1	Relation_Trigger	regulate gene expression 	2
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e2	Diseases	cardiovascular disease 	3
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e3	Diseases	cancers 	4
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e4	Diseases	neurodegenerative disease 	5
miRNA-corp.d6.s9	The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease.  	miRNA-corp.d6.s9.e5	Species	human 	6
miRNA-corp.d6.s10	In conclusion, the miR-15/107 group of miRNA genes is a fascinating topic of study for evolutionary biologists, miRNA biochemists, and clinically oriented translational researchers alike.    	miRNA-corp.d6.s10.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s10	In conclusion, the miR-15/107 group of miRNA genes is a fascinating topic of study for evolutionary biologists, miRNA biochemists, and clinically oriented translational researchers alike.    	miRNA-corp.d6.s10.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d6.s10	In conclusion, the miR-15/107 group of miRNA genes is a fascinating topic of study for evolutionary biologists, miRNA biochemists, and clinically oriented translational researchers alike.    	miRNA-corp.d6.s10.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e0	Specific_miRNAs	miR-16 	1
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e1	Specific_miRNAs	miR-103 	2
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e3	Relation_Trigger	targeted 	4
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e4	Relation_Trigger	target 	5
miRNA-corp.d6.s11	We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition.  	miRNA-corp.d6.s11.e5	Diseases	cancer 	6
miRNA-corp.d6.s12	There is extensive overlap in the mRNAs targeted by miR-15/107 group members.  	miRNA-corp.d6.s12.e0	Specific_miRNAs	miR-15/107 	1
miRNA-corp.d6.s12	There is extensive overlap in the mRNAs targeted by miR-15/107 group members.  	miRNA-corp.d6.s12.e1	Relation_Trigger	targeted 	2
miRNA-corp.d7.s0	Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease.   	miRNA-corp.d7.s0.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d7.s0	Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease.   	miRNA-corp.d7.s0.e1	Genes/Proteins	GAD67 	2
miRNA-corp.d7.s0	Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease.   	miRNA-corp.d7.s0.e2	Species	rat 	3
miRNA-corp.d7.s1	METHODS: To normalize the GAD67 expression in the striatum after dopamine depletion, we developed several lentiviral vectors that express RNA interference (RNAi) directed against GAD67 mitochondrial RNA.  	miRNA-corp.d7.s1.e0	Genes/Proteins	GAD67 	1
miRNA-corp.d7.s1	METHODS: To normalize the GAD67 expression in the striatum after dopamine depletion, we developed several lentiviral vectors that express RNA interference (RNAi) directed against GAD67 mitochondrial RNA.  	miRNA-corp.d7.s1.e1	Genes/Proteins	GAD67 	2
miRNA-corp.d7.s2	The vectors were injected into the striatum of hemiparkinsonian rats and the level of GAD67 protein as well as a marker of neuronal activity, mtCO1, was analyzed using western blots.  	miRNA-corp.d7.s2.e0	Genes/Proteins	GAD67 	1
miRNA-corp.d7.s2	The vectors were injected into the striatum of hemiparkinsonian rats and the level of GAD67 protein as well as a marker of neuronal activity, mtCO1, was analyzed using western blots.  	miRNA-corp.d7.s2.e1	Genes/Proteins	mtCO1 	2
miRNA-corp.d7.s2	The vectors were injected into the striatum of hemiparkinsonian rats and the level of GAD67 protein as well as a marker of neuronal activity, mtCO1, was analyzed using western blots.  	miRNA-corp.d7.s2.e2	Species	rats 	3
miRNA-corp.d7.s3	BACKGROUND: Dopamine depletion of the striatum is one of the hallmarks of Parkinson's disease.  	miRNA-corp.d7.s3.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d7.s4	The loss of dopamine upregulates GAD67 expression in the striatal projection neurons and causes other changes in the activity of the basal ganglia circuit.  	miRNA-corp.d7.s4.e0	Genes/Proteins	GAD67 	1
miRNA-corp.d7.s4	The loss of dopamine upregulates GAD67 expression in the striatal projection neurons and causes other changes in the activity of the basal ganglia circuit.  	miRNA-corp.d7.s4.e1	Relation_Trigger	upregulates GAD67 expression 	2
miRNA-corp.d7.s5	Using a lentiviral vectors with a synthetic miRNA scaffold to deliver RNAi, we were able to normalize the GAD67 protein levels in the parkinsonian rat striatum.  	miRNA-corp.d7.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d7.s5	Using a lentiviral vectors with a synthetic miRNA scaffold to deliver RNAi, we were able to normalize the GAD67 protein levels in the parkinsonian rat striatum.  	miRNA-corp.d7.s5.e1	Genes/Proteins	GAD67 	2
miRNA-corp.d7.s5	Using a lentiviral vectors with a synthetic miRNA scaffold to deliver RNAi, we were able to normalize the GAD67 protein levels in the parkinsonian rat striatum.  	miRNA-corp.d7.s5.e2	Species	rat 	3
miRNA-corp.d7.s6	In addition, we were able to normalize the increased neural activity, which resulted from the loss of dopamine as measured by the marker mtCO1.  	miRNA-corp.d7.s6.e0	Genes/Proteins	mtCO1 	1
miRNA-corp.d7.s7	RESULTS: Unilateral lesions of the dopamine neurons in substantia nigra resulted in an increased level of GAD67 protein in the ipsilateral striatum.  	miRNA-corp.d7.s7.e0	Genes/Proteins	GAD67 	1
miRNA-corp.d7.s7	RESULTS: Unilateral lesions of the dopamine neurons in substantia nigra resulted in an increased level of GAD67 protein in the ipsilateral striatum.  	miRNA-corp.d7.s7.e1	Relation_Trigger	increased level of GAD67 protein 	2
miRNA-corp.d7.s8	Furthermore, we detected significantly higher levels of mtCO1, after dopamine depletion in the striatum.  	miRNA-corp.d7.s8.e0	Genes/Proteins	mtCO1 	1
miRNA-corp.d7.s8	Furthermore, we detected significantly higher levels of mtCO1, after dopamine depletion in the striatum.  	miRNA-corp.d7.s8.e1	Relation_Trigger	higher levels 	2
miRNA-corp.d7.s9	CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease.  	miRNA-corp.d7.s9.e0	Genes/Proteins	GAD67 	1
miRNA-corp.d7.s9	CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease.  	miRNA-corp.d7.s9.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d7.s9	CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease.  	miRNA-corp.d7.s9.e2	Relation_Trigger	dysregulation 	3
miRNA-corp.d7.s9	CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease.  	miRNA-corp.d7.s9.e3	Species	rat 	4
miRNA-corp.d8.s5	They are transmitted through sex contact, parenterally and from mother to child.  	miRNA-corp.d8.s5.e0	Species	child 	1
miRNA-corp.d8.s8	It is endemic worldwide, including the North of Argentina where both associated diseases have also been detected.  	miRNA-corp.d8.s8.e0	Relation_Trigger	associated 	1
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e0	Species	Human 	1
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e1	Diseases	Adult T-cell Leukemia 	2
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e2	Diseases	ATL 	3
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e3	Diseases	HTLV-1 Associated Mielopathy 	4
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e4	Diseases	Tropical Spastic Paraparesis 	5
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e5	Diseases	HAM 	6
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e6	Diseases	TSP 	7
miRNA-corp.d8.s9	Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).  	miRNA-corp.d8.s9.e7	Species	human 	8
miRNA-corp.d8.s11	No etiologic role has been described for HTLV-2, although it has been associated with HAM/TSP-like neurologic syndromes.  	miRNA-corp.d8.s11.e0	Relation_Trigger	associated 	1
miRNA-corp.d8.s11	No etiologic role has been described for HTLV-2, although it has been associated with HAM/TSP-like neurologic syndromes.  	miRNA-corp.d8.s11.e1	Diseases	HAM 	2
miRNA-corp.d8.s11	No etiologic role has been described for HTLV-2, although it has been associated with HAM/TSP-like neurologic syndromes.  	miRNA-corp.d8.s11.e2	Diseases	TSP 	3
miRNA-corp.d8.s11	No etiologic role has been described for HTLV-2, although it has been associated with HAM/TSP-like neurologic syndromes.  	miRNA-corp.d8.s11.e3	Diseases	neurologic syndromes 	4
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e0	Diseases	AD 	1
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e3	Relation_Trigger	up-regulated 	4
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e4	Relation_Trigger	correlate 	5
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e5	Relation_Trigger	highly transient effectors of CNS gene expression 	6
miRNA-corp.d9.s0	The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.    	miRNA-corp.d9.s0.e6	Diseases	AD 	7
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e1	Specific_miRNAs	miRNA-9 	2
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e2	Specific_miRNAs	miRNA-125b 	3
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e3	Specific_miRNAs	miRNA-146a 	4
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e4	Diseases	AD 	5
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e5	Relation_Trigger	up-regulated 	6
miRNA-corp.d9.s1	In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders.  	miRNA-corp.d9.s1.e6	Diseases	neurological disorders 	7
miRNA-corp.d9.s2	In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs.  	miRNA-corp.d9.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d9.s2	In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs.  	miRNA-corp.d9.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d9.s2	In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs.  	miRNA-corp.d9.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d9.s2	In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs.  	miRNA-corp.d9.s2.e3	Species	human 	4
miRNA-corp.d9.s2	In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs.  	miRNA-corp.d9.s2.e4	Species	human 	5
miRNA-corp.d9.s3	Micro-RNA (miRNA) mediated regulation of messenger RNA (mRNA) complexity in the central nervous system (CNS) is emerging as a critical factor in the control of CNS-specific gene expression during development, plasticity, aging and disease.  	miRNA-corp.d9.s3.e0	Non-Specific_miRNAs	Micro-RNA 	1
miRNA-corp.d9.s3	Micro-RNA (miRNA) mediated regulation of messenger RNA (mRNA) complexity in the central nervous system (CNS) is emerging as a critical factor in the control of CNS-specific gene expression during development, plasticity, aging and disease.  	miRNA-corp.d9.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d9.s3	Micro-RNA (miRNA) mediated regulation of messenger RNA (mRNA) complexity in the central nervous system (CNS) is emerging as a critical factor in the control of CNS-specific gene expression during development, plasticity, aging and disease.  	miRNA-corp.d9.s3.e2	Relation_Trigger	regulation 	3
miRNA-corp.d9.s4	Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex.   	miRNA-corp.d9.s4.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d9.s4	Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex.   	miRNA-corp.d9.s4.e1	Non-Specific_miRNAs	Micro-RNA 	2
miRNA-corp.d9.s4	Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex.   	miRNA-corp.d9.s4.e2	Species	human 	3
miRNA-corp.d10.s0	While confirmation is required, this study suggests that microRNA mutations can contribute to schizophrenia.    	miRNA-corp.d10.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d10.s0	While confirmation is required, this study suggests that microRNA mutations can contribute to schizophrenia.    	miRNA-corp.d10.s0.e1	Diseases	schizophrenia 	2
miRNA-corp.d10.s1	One ultra-rare variant was identified in a control sample (with a history of depression) (8/193 versus 1/191, p = 0.02 by one-sided Fisher's exact test, odds ratio = 8.2).  	miRNA-corp.d10.s1.e0	Diseases	depression 	1
miRNA-corp.d10.s3	CONCLUSIONS: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression levels.  	miRNA-corp.d10.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d10.s3	CONCLUSIONS: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression levels.  	miRNA-corp.d10.s3.e1	Relation_Trigger	miRNA precursors demonstrate loss 	2
miRNA-corp.d10.s3	CONCLUSIONS: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression levels.  	miRNA-corp.d10.s3.e2	Relation_Trigger	ectopically expressed 	3
miRNA-corp.d10.s3	CONCLUSIONS: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression levels.  	miRNA-corp.d10.s3.e3	Relation_Trigger	altered expression levels 	4
miRNA-corp.d10.s4	In addition, components required for miRNA processing and/or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the wide ranging involvement of miRNAs in disease.  	miRNA-corp.d10.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d10.s4	In addition, components required for miRNA processing and/or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the wide ranging involvement of miRNAs in disease.  	miRNA-corp.d10.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d10.s4	In addition, components required for miRNA processing and/or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the wide ranging involvement of miRNAs in disease.  	miRNA-corp.d10.s4.e2	Diseases	X-linked mental retardation 	3
miRNA-corp.d10.s4	In addition, components required for miRNA processing and/or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the wide ranging involvement of miRNAs in disease.  	miRNA-corp.d10.s4.e3	Diseases	neoplastic diseases 	4
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e3	Diseases	schizophrenia 	4
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e4	Diseases	schizophrenia 	5
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e5	Diseases	schizophrenia 	6
miRNA-corp.d10.s5	METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia.  	miRNA-corp.d10.s5.e6	Relation_Trigger	amplified 	7
miRNA-corp.d10.s6	Here we provide the first association of microRNA gene dysfunction with schizophrenia.  	miRNA-corp.d10.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d10.s6	Here we provide the first association of microRNA gene dysfunction with schizophrenia.  	miRNA-corp.d10.s6.e1	Diseases	schizophrenia 	2
miRNA-corp.d10.s6	Here we provide the first association of microRNA gene dysfunction with schizophrenia.  	miRNA-corp.d10.s6.e2	Relation_Trigger	association 	3
miRNA-corp.d10.s6	Here we provide the first association of microRNA gene dysfunction with schizophrenia.  	miRNA-corp.d10.s6.e3	Relation_Trigger	dysfunction 	4
miRNA-corp.d10.s7	Eight ultra-rare variants in the precursor or mature miRNA were identified in eight distinct miRNA genes in 4% of analyzed males with schizophrenia.  	miRNA-corp.d10.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d10.s7	Eight ultra-rare variants in the precursor or mature miRNA were identified in eight distinct miRNA genes in 4% of analyzed males with schizophrenia.  	miRNA-corp.d10.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d10.s7	Eight ultra-rare variants in the precursor or mature miRNA were identified in eight distinct miRNA genes in 4% of analyzed males with schizophrenia.  	miRNA-corp.d10.s7.e2	Diseases	schizophrenia 	3
miRNA-corp.d10.s8	Evidence for X-chromosomal schizophrenia associated with microRNA alterations.   	miRNA-corp.d10.s8.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d10.s8	Evidence for X-chromosomal schizophrenia associated with microRNA alterations.   	miRNA-corp.d10.s8.e1	Relation_Trigger	associated 	2
miRNA-corp.d10.s8	Evidence for X-chromosomal schizophrenia associated with microRNA alterations.   	miRNA-corp.d10.s8.e2	Diseases	X-chromosomal schizophrenia 	3
miRNA-corp.d10.s9	BACKGROUND: Schizophrenia is a severe disabling brain disease affecting about 1% of the population.  	miRNA-corp.d10.s9.e0	Diseases	Schizophrenia 	1
miRNA-corp.d10.s9	BACKGROUND: Schizophrenia is a severe disabling brain disease affecting about 1% of the population.  	miRNA-corp.d10.s9.e1	Diseases	brain disease 	2
miRNA-corp.d10.s9	BACKGROUND: Schizophrenia is a severe disabling brain disease affecting about 1% of the population.  	miRNA-corp.d10.s9.e2	Diseases	Schizophrenia 	3
miRNA-corp.d10.s10	Individual microRNAs (miRNAs) affect moderate downregulation of gene expression.  	miRNA-corp.d10.s10.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d10.s10	Individual microRNAs (miRNAs) affect moderate downregulation of gene expression.  	miRNA-corp.d10.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d10.s10	Individual microRNAs (miRNAs) affect moderate downregulation of gene expression.  	miRNA-corp.d10.s10.e2	Relation_Trigger	downregulation of gene expression 	3
miRNA-corp.d11.s0	We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.    	miRNA-corp.d11.s0.e0	Diseases	HD 	1
miRNA-corp.d11.s0	We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.    	miRNA-corp.d11.s0.e1	Genes/Proteins	REST 	2
miRNA-corp.d11.s0	We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.    	miRNA-corp.d11.s0.e2	Genes/Proteins	REST 	3
miRNA-corp.d11.s0	We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.    	miRNA-corp.d11.s0.e3	Relation_Trigger	dysregulation of gene expression 	4
miRNA-corp.d11.s1	Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.   	miRNA-corp.d11.s1.e0	Diseases	Huntington's disease 	1
miRNA-corp.d11.s1	Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.   	miRNA-corp.d11.s1.e1	Relation_Trigger	Transcriptional dysregulation 	2
miRNA-corp.d11.s2	HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum.  	miRNA-corp.d11.s2.e0	Diseases	HD 	1
miRNA-corp.d11.s2	HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum.  	miRNA-corp.d11.s2.e1	Diseases	Huntington's disease 	2
miRNA-corp.d11.s2	HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum.  	miRNA-corp.d11.s2.e2	Diseases	neurodegenerative disorder 	3
miRNA-corp.d11.s2	HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum.  	miRNA-corp.d11.s2.e3	Diseases	neuronal dysfunction 	4
miRNA-corp.d11.s3	This is followed by progressive chorea, dementia and emotional dysfunction, eventually resulting in death.  	miRNA-corp.d11.s3.e0	Diseases	chorea 	1
miRNA-corp.d11.s3	This is followed by progressive chorea, dementia and emotional dysfunction, eventually resulting in death.  	miRNA-corp.d11.s3.e1	Diseases	dementia 	2
miRNA-corp.d11.s3	This is followed by progressive chorea, dementia and emotional dysfunction, eventually resulting in death.  	miRNA-corp.d11.s3.e2	Diseases	emotional dysfunction 	3
miRNA-corp.d11.s4	HD is caused by an expanded CAG repeat in the first exon of the HD gene that results in an abnormally elongated polyQ (polyglutamine) tract in its protein product, Htt (Huntingtin).  	miRNA-corp.d11.s4.e0	Diseases	HD 	1
miRNA-corp.d11.s4	HD is caused by an expanded CAG repeat in the first exon of the HD gene that results in an abnormally elongated polyQ (polyglutamine) tract in its protein product, Htt (Huntingtin).  	miRNA-corp.d11.s4.e1	Genes/Proteins	Htt 	2
miRNA-corp.d11.s4	HD is caused by an expanded CAG repeat in the first exon of the HD gene that results in an abnormally elongated polyQ (polyglutamine) tract in its protein product, Htt (Huntingtin).  	miRNA-corp.d11.s4.e2	Genes/Proteins	Huntingtin 	3
miRNA-corp.d11.s5	Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction.  	miRNA-corp.d11.s5.e0	Diseases	HD 	1
miRNA-corp.d11.s5	Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction.  	miRNA-corp.d11.s5.e1	Genes/Proteins	Htt 	2
miRNA-corp.d11.s5	Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction.  	miRNA-corp.d11.s5.e2	Genes/Proteins	Htt 	3
miRNA-corp.d11.s5	Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction.  	miRNA-corp.d11.s5.e3	Genes/Proteins	Htt 	4
miRNA-corp.d11.s5	Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction.  	miRNA-corp.d11.s5.e4	Relation_Trigger	dysfunction 	5
miRNA-corp.d11.s6	While a number of specific transcription factors and co-factors have been proposed as mediators of mutHtt toxicity, the causal relationship between these Htt/transcription factor interactions and HD pathology remains unknown.  	miRNA-corp.d11.s6.e0	Diseases	HD 	1
miRNA-corp.d11.s6	While a number of specific transcription factors and co-factors have been proposed as mediators of mutHtt toxicity, the causal relationship between these Htt/transcription factor interactions and HD pathology remains unknown.  	miRNA-corp.d11.s6.e1	Genes/Proteins	Htt 	2
miRNA-corp.d11.s7	Previous work has highlighted REST [RE1 (repressor element 1)-silencing transcription factor] as one such transcription factor.  	miRNA-corp.d11.s7.e0	Genes/Proteins	REST 	1
miRNA-corp.d11.s7	Previous work has highlighted REST [RE1 (repressor element 1)-silencing transcription factor] as one such transcription factor.  	miRNA-corp.d11.s7.e1	Genes/Proteins	RE1 (repressor element 1)-silencing transcription factor 	2
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e3	Diseases	HD 	4
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e4	Diseases	HD 	5
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e5	Genes/Proteins	REST 	6
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e6	Genes/Proteins	REST 	7
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e7	Relation_Trigger	regulates 	8
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e8	Relation_Trigger	dysregulated 	9
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e9	Relation_Trigger	regulatory 	10
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e10	Relation_Trigger	regulate neuronal gene expression 	11
miRNA-corp.d11.s8	Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD.  	miRNA-corp.d11.s8.e11	Relation_Trigger	repression 	12
miRNA-corp.d11.s9	Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor).  	miRNA-corp.d11.s9.e0	Diseases	HD 	1
miRNA-corp.d11.s9	Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor).  	miRNA-corp.d11.s9.e1	Genes/Proteins	BDNF 	2
miRNA-corp.d11.s9	Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor).  	miRNA-corp.d11.s9.e2	Genes/Proteins	brain-derived neurotrophic factor 	3
miRNA-corp.d11.s9	Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor).  	miRNA-corp.d11.s9.e3	Relation_Trigger	target 	4
miRNA-corp.d11.s10	REST is a master regulator of neuronal genes, repressing their expression.  	miRNA-corp.d11.s10.e0	Genes/Proteins	REST 	1
miRNA-corp.d11.s10	REST is a master regulator of neuronal genes, repressing their expression.  	miRNA-corp.d11.s10.e1	Relation_Trigger	regulator 	2
miRNA-corp.d11.s10	REST is a master regulator of neuronal genes, repressing their expression.  	miRNA-corp.d11.s10.e2	Relation_Trigger	repressing their expression 	3
miRNA-corp.d12.s0	BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.  	miRNA-corp.d12.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d12.s0	BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.  	miRNA-corp.d12.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d12.s0	BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.  	miRNA-corp.d12.s0.e2	Relation_Trigger	aberrant expression 	3
miRNA-corp.d12.s0	BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.  	miRNA-corp.d12.s0.e3	Relation_Trigger	associated 	4
miRNA-corp.d12.s0	BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers.  	miRNA-corp.d12.s0.e4	Diseases	cancers 	5
miRNA-corp.d12.s1	In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.  	miRNA-corp.d12.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d12.s1	In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.  	miRNA-corp.d12.s1.e1	Diseases	astrocytoma 	2
miRNA-corp.d12.s1	In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.  	miRNA-corp.d12.s1.e2	Diseases	intracranial tumour 	3
miRNA-corp.d12.s2	METHODS: We screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR.  	miRNA-corp.d12.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d12.s2	METHODS: We screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR.  	miRNA-corp.d12.s2.e1	Diseases	astrocytoma 	2
miRNA-corp.d12.s3	The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples.  	miRNA-corp.d12.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d12.s3	The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples.  	miRNA-corp.d12.s3.e1	Diseases	astrocytoma 	2
miRNA-corp.d12.s4	The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.  	miRNA-corp.d12.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d12.s4	The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.  	miRNA-corp.d12.s4.e1	Relation_Trigger	correlation 	2
miRNA-corp.d12.s4	The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.  	miRNA-corp.d12.s4.e2	Diseases	astrocytoma 	3
miRNA-corp.d12.s5	RESULTS: After a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples.  	miRNA-corp.d12.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d12.s5	RESULTS: After a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples.  	miRNA-corp.d12.s5.e1	Diseases	astrocytoma 	2
miRNA-corp.d12.s6	Unsupervised clustering analysis further revealed the great potential of the 7-miRNA profile to differentiate between tumours and normal brain tissues.  	miRNA-corp.d12.s6.e0	Diseases	tumours 	1
miRNA-corp.d12.s6	Unsupervised clustering analysis further revealed the great potential of the 7-miRNA profile to differentiate between tumours and normal brain tissues.  	miRNA-corp.d12.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d12.s7	The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease.  	miRNA-corp.d12.s7.e0	Diseases	astrocytomas 	1
miRNA-corp.d12.s7	The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease.  	miRNA-corp.d12.s7.e1	Relation_Trigger	down-regulation 	2
miRNA-corp.d12.s7	The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease.  	miRNA-corp.d12.s7.e2	Relation_Trigger	associated 	3
miRNA-corp.d12.s7	The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease.  	miRNA-corp.d12.s7.e3	Specific_miRNAs	hsa-miR-137 	4
miRNA-corp.d12.s8	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.   	miRNA-corp.d12.s8.e0	Diseases	astrocytoma 	1
miRNA-corp.d12.s8	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.   	miRNA-corp.d12.s8.e1	Specific_miRNAs	hsa-miR-21 	2
miRNA-corp.d12.s8	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.   	miRNA-corp.d12.s8.e2	Specific_miRNAs	hsa-miR-181b 	3
miRNA-corp.d12.s8	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.   	miRNA-corp.d12.s8.e3	Specific_miRNAs	hsa-miR-106a 	4
miRNA-corp.d12.s8	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.   	miRNA-corp.d12.s8.e4	Relation_Trigger	prognostic indicators 	5
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e0	Specific_miRNAs	hsa-miR-181b 	1
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e1	Relation_Trigger	low expression 	2
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e2	Relation_Trigger	high expression 	3
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e3	Relation_Trigger	associated 	4
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e4	Specific_miRNAs	hsa-miR-21 	5
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e5	Specific_miRNAs	hsa-miR-106a 	6
miRNA-corp.d12.s9	Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival.  	miRNA-corp.d12.s9.e6	Species	patient 	7
miRNA-corp.d12.s10	CONCLUSIONS: Our results suggest a great potential for the use of miRNA profiling as a powerful diagnostic and prognostic marker in defining the signature of astrocytomas and in predicting the post-surgical outcome.    	miRNA-corp.d12.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d12.s10	CONCLUSIONS: Our results suggest a great potential for the use of miRNA profiling as a powerful diagnostic and prognostic marker in defining the signature of astrocytomas and in predicting the post-surgical outcome.    	miRNA-corp.d12.s10.e1	Diseases	astrocytomas 	2
miRNA-corp.d13.s0	Expression profiling showed strong miRNA and isomiR expression deregulation in HD, most being common to both FC and ST.  	miRNA-corp.d13.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d13.s0	Expression profiling showed strong miRNA and isomiR expression deregulation in HD, most being common to both FC and ST.  	miRNA-corp.d13.s0.e1	Diseases	HD 	2
miRNA-corp.d13.s0	Expression profiling showed strong miRNA and isomiR expression deregulation in HD, most being common to both FC and ST.  	miRNA-corp.d13.s0.e2	Relation_Trigger	expression deregulation 	3
miRNA-corp.d13.s1	Around 80-90% of the miRNAs presented modifications in the 3'-terminus mainly in the form of trimming and/or as nucleotide addition variants, while the 5'-terminus of the miRNAs was specially protected from changes.  	miRNA-corp.d13.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d13.s1	Around 80-90% of the miRNAs presented modifications in the 3'-terminus mainly in the form of trimming and/or as nucleotide addition variants, while the 5'-terminus of the miRNAs was specially protected from changes.  	miRNA-corp.d13.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d13.s2	Deep sequencing revealed length and sequence heterogeneity (IsomiRs) for the vast majority of miRNAs.  	miRNA-corp.d13.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d13.s3	More than 80% of the small-RNAs were annotated as microRNAs (miRNAs) in all samples.  	miRNA-corp.d13.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d13.s3	More than 80% of the small-RNAs were annotated as microRNAs (miRNAs) in all samples.  	miRNA-corp.d13.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d13.s4	We have applied the Illumina massively parallel sequencing to deeply analyze the small RNA populations of two different forebrain areas, the frontal cortex (FC) and the striatum (ST) of healthy individuals and individuals with HD.  	miRNA-corp.d13.s4.e0	Diseases	HD 	1
miRNA-corp.d13.s5	Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain.  	miRNA-corp.d13.s5.e0	Diseases	Huntington disease 	1
miRNA-corp.d13.s5	Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain.  	miRNA-corp.d13.s5.e1	Diseases	HD 	2
miRNA-corp.d13.s5	Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain.  	miRNA-corp.d13.s5.e2	Diseases	neurodegenerative disorder 	3
miRNA-corp.d13.s6	A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing.   	miRNA-corp.d13.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d13.s6	A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing.   	miRNA-corp.d13.s6.e1	Diseases	Huntington's disease 	2
miRNA-corp.d13.s7	Our results show that miRNA variability is a ubiquitous phenomenon in the adult human brain, which may influence gene expression in physiological and pathological conditions.    	miRNA-corp.d13.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d13.s7	Our results show that miRNA variability is a ubiquitous phenomenon in the adult human brain, which may influence gene expression in physiological and pathological conditions.    	miRNA-corp.d13.s7.e1	Species	human 	2
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e1	Diseases	HD 	2
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e2	Relation_Trigger	deregulated 	3
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e3	Relation_Trigger	altered expression 	4
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e4	Relation_Trigger	targets 	5
miRNA-corp.d13.s8	The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD.  	miRNA-corp.d13.s8.e5	Relation_Trigger	aberrant gene expression 	6
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e2	Genes/Proteins	RE1-Silencing Transcription Factor 	3
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e3	Genes/Proteins	REST 	4
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e4	Genes/Proteins	P53 	5
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e5	Diseases	HD 	6
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e6	Relation_Trigger	downregulation 	7
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e7	Relation_Trigger	regulatory 	8
miRNA-corp.d13.s9	The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD.  	miRNA-corp.d13.s9.e8	Relation_Trigger	co-regulated 	9
miRNA-corp.d14.s0	To determine the role of possible pathogenic cofactors such as geographic, ethnic, genetic, and cultural features, further pertinent surveys are required in subtropical northwestern Argentina.    	miRNA-corp.d14.s0.e0	Species	ethnic 	1
miRNA-corp.d14.s1	Considering the HAM/TSP cluster described here plus previously reported isolated cases in neighboring Salta Province, we speculate that the Puna Jujeña region and regions in that vicinity would be a microepidemic focus of disease.  	miRNA-corp.d14.s1.e0	Diseases	HAM 	1
miRNA-corp.d14.s1	Considering the HAM/TSP cluster described here plus previously reported isolated cases in neighboring Salta Province, we speculate that the Puna Jujeña region and regions in that vicinity would be a microepidemic focus of disease.  	miRNA-corp.d14.s1.e1	Diseases	TSP 	2
miRNA-corp.d14.s4	No history of risk factors was disclosed, except for a single transfusion in 1 patient.  	miRNA-corp.d14.s4.e0	Species	patient 	1
miRNA-corp.d14.s5	Most patients (9/11) were born in Cochinoca Department, located in an Andes highland area called Puna Jujeña, situated at more that 3400 m above sea level.  	miRNA-corp.d14.s5.e0	Species	patients 	1
miRNA-corp.d14.s6	Accordingly, a clinically diagnosed and serologically confirmed cluster of cases in 1 man and 10 women, including 2 sisters, is described here.  	miRNA-corp.d14.s6.e0	Species	man 	1
miRNA-corp.d14.s6	Accordingly, a clinically diagnosed and serologically confirmed cluster of cases in 1 man and 10 women, including 2 sisters, is described here.  	miRNA-corp.d14.s6.e1	Species	women 	2
miRNA-corp.d14.s7	Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out.  	miRNA-corp.d14.s7.e0	Species	human 	1
miRNA-corp.d14.s7	Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out.  	miRNA-corp.d14.s7.e1	Diseases	HTLV-I-associated myelopathy 	2
miRNA-corp.d14.s7	Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out.  	miRNA-corp.d14.s7.e2	Diseases	tropical spastic paraparesis 	3
miRNA-corp.d14.s7	Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out.  	miRNA-corp.d14.s7.e3	Diseases	HAM 	4
miRNA-corp.d14.s7	Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out.  	miRNA-corp.d14.s7.e4	Diseases	TSP 	5
miRNA-corp.d14.s8	A cluster of human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Jujuy, Argentina.   	miRNA-corp.d14.s8.e0	Diseases	human T-cell lymphotropic virus type I-associated myelopathy 	1
miRNA-corp.d14.s8	A cluster of human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Jujuy, Argentina.   	miRNA-corp.d14.s8.e1	Diseases	tropical spastic paraparesis 	2
miRNA-corp.d14.s8	A cluster of human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Jujuy, Argentina.   	miRNA-corp.d14.s8.e2	Species	human 	3
miRNA-corp.d15.s1	OBJECTIVE: : To compare presentation of Alzheimer disease (AD) at the time of initial evaluation at a university specialty clinic across three ethnoracial groups in order to understand similarities and differences in the demographic, clinical, cognitive, psychiatric, and biologic features.  	miRNA-corp.d15.s1.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d15.s1	OBJECTIVE: : To compare presentation of Alzheimer disease (AD) at the time of initial evaluation at a university specialty clinic across three ethnoracial groups in order to understand similarities and differences in the demographic, clinical, cognitive, psychiatric, and biologic features.  	miRNA-corp.d15.s1.e1	Diseases	AD 	2
miRNA-corp.d15.s2	Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center.   	miRNA-corp.d15.s2.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d15.s3	The apolipoprotein E-4 genotype was not associated with AD in the Latino cohort.  	miRNA-corp.d15.s3.e0	Diseases	AD 	1
miRNA-corp.d15.s3	The apolipoprotein E-4 genotype was not associated with AD in the Latino cohort.  	miRNA-corp.d15.s3.e1	Genes/Proteins	apolipoprotein E 	2
miRNA-corp.d15.s5	There was more depression in the Latinos compared with African Americans and WNHs.  	miRNA-corp.d15.s5.e0	Diseases	depression 	1
miRNA-corp.d15.s6	In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status.  	miRNA-corp.d15.s6.e0	Diseases	cognitive impairment 	1
miRNA-corp.d15.s6	In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status.  	miRNA-corp.d15.s6.e1	Diseases	cognitive impairment 	2
miRNA-corp.d15.s6	In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status.  	miRNA-corp.d15.s6.e2	Diseases	AD 	3
miRNA-corp.d15.s8	MEASUREMENTS: : Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups.  	miRNA-corp.d15.s8.e0	Relation_Trigger	impairments 	1
miRNA-corp.d15.s8	MEASUREMENTS: : Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups.  	miRNA-corp.d15.s8.e1	Diseases	AD 	2
miRNA-corp.d15.s8	MEASUREMENTS: : Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups.  	miRNA-corp.d15.s8.e2	Genes/Proteins	apolipoprotein E 	3
miRNA-corp.d15.s11	CONCLUSIONS: : Minority groups in Philadelphia, especially Latinos, exhibit a more severe profile of AD at the time of presentation than WNHs.  	miRNA-corp.d15.s11.e0	Diseases	AD 	1
miRNA-corp.d16.s0	Furthermore, methods to profile miRNAs from formalin-fixed, paraffin-embedded (FFPE) archival tissues or to study their cellular and subcellular localization in FFPE tissues have been lacking.  	miRNA-corp.d16.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d16.s1	Here we report the coordinated miRNA expression analysis from the tissue level to the subcellular level, using the RAKE (RNA-primed, array-based, Klenow Enzyme) miRNA microarray platform in conjunction with Locked Nucleic Acid (LNA)-based in situ hybridization (LNA-ISH) on archival FFPE human brains and oligodendroglial tumors.  	miRNA-corp.d16.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d16.s1	Here we report the coordinated miRNA expression analysis from the tissue level to the subcellular level, using the RAKE (RNA-primed, array-based, Klenow Enzyme) miRNA microarray platform in conjunction with Locked Nucleic Acid (LNA)-based in situ hybridization (LNA-ISH) on archival FFPE human brains and oligodendroglial tumors.  	miRNA-corp.d16.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d16.s1	Here we report the coordinated miRNA expression analysis from the tissue level to the subcellular level, using the RAKE (RNA-primed, array-based, Klenow Enzyme) miRNA microarray platform in conjunction with Locked Nucleic Acid (LNA)-based in situ hybridization (LNA-ISH) on archival FFPE human brains and oligodendroglial tumors.  	miRNA-corp.d16.s1.e2	Diseases	oligodendroglial tumors 	3
miRNA-corp.d16.s1	Here we report the coordinated miRNA expression analysis from the tissue level to the subcellular level, using the RAKE (RNA-primed, array-based, Klenow Enzyme) miRNA microarray platform in conjunction with Locked Nucleic Acid (LNA)-based in situ hybridization (LNA-ISH) on archival FFPE human brains and oligodendroglial tumors.  	miRNA-corp.d16.s1.e3	Species	human 	4
miRNA-corp.d16.s2	The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAs in human diseases.    	miRNA-corp.d16.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d16.s2	The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAs in human diseases.    	miRNA-corp.d16.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d16.s2	The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAs in human diseases.    	miRNA-corp.d16.s2.e2	Species	human 	3
miRNA-corp.d16.s2	The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAs in human diseases.    	miRNA-corp.d16.s2.e3	Relation_Trigger	accelerate 	4
miRNA-corp.d16.s3	RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.   	miRNA-corp.d16.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d16.s3	RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.   	miRNA-corp.d16.s3.e1	Species	human 	2
miRNA-corp.d16.s4	microRNAs (miRNAs) are small (approximately 22 nucleotide) regulatory RNAs which play fundamental roles in many biological processes.  	miRNA-corp.d16.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d16.s4	microRNAs (miRNAs) are small (approximately 22 nucleotide) regulatory RNAs which play fundamental roles in many biological processes.  	miRNA-corp.d16.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d16.s4	microRNAs (miRNAs) are small (approximately 22 nucleotide) regulatory RNAs which play fundamental roles in many biological processes.  	miRNA-corp.d16.s4.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e2	Relation_Trigger	expression of many miRNAs is altered 	3
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e3	Diseases	tumors 	4
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e4	Relation_Trigger	tumor suppressor 	5
miRNA-corp.d16.s5	Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes.  	miRNA-corp.d16.s5.e5	Species	human 	6
miRNA-corp.d16.s6	However, with the exception of glioblastoma multiforme, the expression of miRNAs in brain tumors is unknown.  	miRNA-corp.d16.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d16.s6	However, with the exception of glioblastoma multiforme, the expression of miRNAs in brain tumors is unknown.  	miRNA-corp.d16.s6.e1	Diseases	glioblastoma multiforme 	2
miRNA-corp.d16.s6	However, with the exception of glioblastoma multiforme, the expression of miRNAs in brain tumors is unknown.  	miRNA-corp.d16.s6.e2	Diseases	brain tumors 	3
miRNA-corp.d17.s0	Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction.  	miRNA-corp.d17.s0.e0	Specific_miRNAs	miR-124 	1
miRNA-corp.d17.s0	Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction.  	miRNA-corp.d17.s0.e1	Diseases	MCAO 	2
miRNA-corp.d17.s0	Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction.  	miRNA-corp.d17.s0.e2	Relation_Trigger	concentrations of miR-124 were significantly elevated 	3
miRNA-corp.d17.s1	Thus, plasma concentration of miR-124 provides a promising candidate biomarker for early detection of cerebral infarction.    	miRNA-corp.d17.s1.e0	Diseases	cerebral infarction 	1
miRNA-corp.d17.s1	Thus, plasma concentration of miR-124 provides a promising candidate biomarker for early detection of cerebral infarction.    	miRNA-corp.d17.s1.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d17.s2	In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases.  	miRNA-corp.d17.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d17.s2	In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases.  	miRNA-corp.d17.s2.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d17.s2	In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases.  	miRNA-corp.d17.s2.e2	Diseases	neurological diseases 	3
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e0	Diseases	cerebral infarction 	1
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e1	Diseases	cerebral infarction 	2
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e3	Diseases	middle cerebral artery occlusion 	4
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e4	Diseases	MCAO 	5
miRNA-corp.d17.s3	We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat.  	miRNA-corp.d17.s3.e5	Species	rat 	6
miRNA-corp.d17.s4	MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes.  	miRNA-corp.d17.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d17.s4	MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes.  	miRNA-corp.d17.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d17.s4	MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes.  	miRNA-corp.d17.s4.e2	Relation_Trigger	downregulating 	3
miRNA-corp.d17.s4	MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes.  	miRNA-corp.d17.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d17.s5	Recently, plasma miRNAs have been investigated as biomarkers for various diseases.  	miRNA-corp.d17.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d17.s6	Plasma miR-124 as a biomarker for cerebral infarction.   	miRNA-corp.d17.s6.e0	Diseases	cerebral infarction 	1
miRNA-corp.d17.s6	Plasma miR-124 as a biomarker for cerebral infarction.   	miRNA-corp.d17.s6.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d18.s1	CONCLUSIONS: An earlier age at symptom onset suggests that US mainland Latino individuals may experience an increased burden of AD compared with Anglo individuals.  	miRNA-corp.d18.s1.e0	Diseases	AD 	1
miRNA-corp.d18.s2	OBJECTIVE: To compare the age at AD symptom onset in Latino and Anglo individuals.  	miRNA-corp.d18.s2.e0	Diseases	AD 	1
miRNA-corp.d18.s3	BACKGROUND: Latino individuals are the largest minority group and the fastest growing population group in the United States, yet there are few studies comparing the clinical features of Alzheimer disease (AD) in this population with those found in Anglo (white non-Latino) patients.  	miRNA-corp.d18.s3.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d18.s3	BACKGROUND: Latino individuals are the largest minority group and the fastest growing population group in the United States, yet there are few studies comparing the clinical features of Alzheimer disease (AD) in this population with those found in Anglo (white non-Latino) patients.  	miRNA-corp.d18.s3.e1	Diseases	AD 	2
miRNA-corp.d18.s3	BACKGROUND: Latino individuals are the largest minority group and the fastest growing population group in the United States, yet there are few studies comparing the clinical features of Alzheimer disease (AD) in this population with those found in Anglo (white non-Latino) patients.  	miRNA-corp.d18.s3.e2	Species	patients 	3
miRNA-corp.d18.s4	Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals.   	miRNA-corp.d18.s4.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d18.s5	RESULTS: After adjusting for center, sex, and years of education, Latino patients had a mean age at symptom onset 6.8 years earlier (95% confidence interval, 3.5-10.3 years earlier) than Anglo patients.  	miRNA-corp.d18.s5.e0	Species	patients 	1
miRNA-corp.d18.s5	RESULTS: After adjusting for center, sex, and years of education, Latino patients had a mean age at symptom onset 6.8 years earlier (95% confidence interval, 3.5-10.3 years earlier) than Anglo patients.  	miRNA-corp.d18.s5.e0	Species	patients 	2
miRNA-corp.d18.s6	PATIENTS: We evaluated 119 Latino and 55 Anglo patients who had a diagnosis of AD. MAIN OUTCOME MEASURE: Age at symptom onset.  	miRNA-corp.d18.s6.e0	Diseases	AD 	1
miRNA-corp.d18.s6	PATIENTS: We evaluated 119 Latino and 55 Anglo patients who had a diagnosis of AD. MAIN OUTCOME MEASURE: Age at symptom onset.  	miRNA-corp.d18.s6.e1	Species	PATIENTS 	2
miRNA-corp.d18.s6	PATIENTS: We evaluated 119 Latino and 55 Anglo patients who had a diagnosis of AD. MAIN OUTCOME MEASURE: Age at symptom onset.  	miRNA-corp.d18.s6.e2	Species	patients 	3
miRNA-corp.d18.s8	DESIGN: Cross-sectional assessment using standardized methods to collect and compare age at AD symptom onset, demographic variables, and medical variables.  	miRNA-corp.d18.s8.e0	Diseases	AD 	1
miRNA-corp.d19.s0	We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.    	miRNA-corp.d19.s0.e0	Specific_miRNAs	miR-17/92 	1
miRNA-corp.d19.s0	We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.    	miRNA-corp.d19.s0.e1	Diseases	medulloblastomas 	2
miRNA-corp.d19.s0	We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.    	miRNA-corp.d19.s0.e2	Non-Specific_miRNAs	miR 	3
miRNA-corp.d19.s0	We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.    	miRNA-corp.d19.s0.e3	Relation_Trigger	aberrant expression 	4
miRNA-corp.d19.s0	We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.    	miRNA-corp.d19.s0.e4	Relation_Trigger	amplification 	5
miRNA-corp.d19.s1	Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh.  	miRNA-corp.d19.s1.e0	Genes/Proteins	Shh 	1
miRNA-corp.d19.s1	Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh.  	miRNA-corp.d19.s1.e1	Genes/Proteins	Shh 	2
miRNA-corp.d19.s1	Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh.  	miRNA-corp.d19.s1.e2	Specific_miRNAs	miR-17/92 	3
miRNA-corp.d19.s1	Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh.  	miRNA-corp.d19.s1.e3	Relation_Trigger	Ectopic miR-17/92 expression 	4
miRNA-corp.d19.s2	In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression.  	miRNA-corp.d19.s2.e0	Genes/Proteins	Gli1 	1
miRNA-corp.d19.s2	In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression.  	miRNA-corp.d19.s2.e1	Genes/Proteins	Shh 	2
miRNA-corp.d19.s2	In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression.  	miRNA-corp.d19.s2.e2	Specific_miRNAs	miR-17/92 	3
miRNA-corp.d19.s2	In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression.  	miRNA-corp.d19.s2.e3	Genes/Proteins	N-myc 	4
miRNA-corp.d19.s2	In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression.  	miRNA-corp.d19.s2.e4	Relation_Trigger	induced miR-17/92 expression 	5
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e0	Genes/Proteins	Shh 	1
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e1	Genes/Proteins	Shh 	2
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e2	Specific_miRNAs	miR-17/92 	3
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e3	Diseases	medulloblastomas 	4
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e4	Relation_Trigger	increased miR-17/92 expression 	5
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e5	Genes/Proteins	Shh 	6
miRNA-corp.d19.s3	Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.  	miRNA-corp.d19.s3.e6	Relation_Trigger	regulation 	7
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e0	Genes/Proteins	MYC 	1
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e1	Genes/Proteins	MYCN 	2
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e2	Specific_miRNAs	miR-17/92 	3
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e3	Diseases	Medulloblastomas 	4
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e4	Relation_Trigger	up-regulated 	5
miRNA-corp.d19.s4	Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.  	miRNA-corp.d19.s4.e5	Relation_Trigger	elevated levels of MYC/MYCN expression 	6
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e0	Specific_miRNAs	miR-17/92 	1
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e1	Diseases	medulloblastomas 	2
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e2	Diseases	medulloblastoma 	3
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e3	Relation_Trigger	Expression of miR-17/92 was highest 	4
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e4	Relation_Trigger	associated 	5
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e5	Relation_Trigger	activation 	6
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e6	Genes/Proteins	sonic hedgehog 	7
miRNA-corp.d19.s5	Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.  	miRNA-corp.d19.s5.e7	Genes/Proteins	Shh 	8
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e0	Specific_miRNAs	miR-17/92 	1
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e1	Diseases	medulloblastoma 	2
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e5	Diseases	medulloblastomas 	6
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e6	Relation_Trigger	highly up-regulated 	7
miRNA-corp.d19.s6	Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.  	miRNA-corp.d19.s6.e7	Species	human 	8
miRNA-corp.d19.s7	We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.  	miRNA-corp.d19.s7.e0	Specific_miRNAs	miR-17/92 	1
miRNA-corp.d19.s7	We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.  	miRNA-corp.d19.s7.e1	Relation_Trigger	amplification 	2
miRNA-corp.d19.s7	We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.  	miRNA-corp.d19.s7.e2	Diseases	pediatric medulloblastomas 	3
miRNA-corp.d19.s7	We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.  	miRNA-corp.d19.s7.e3	Diseases	medulloblastoma 	4
miRNA-corp.d19.s7	We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.  	miRNA-corp.d19.s7.e4	Species	human 	5
miRNA-corp.d19.s8	Medulloblastoma is the most common malignant pediatric brain tumor, and mechanisms underlying its development are poorly understood.  	miRNA-corp.d19.s8.e0	Diseases	Medulloblastoma 	1
miRNA-corp.d19.s8	Medulloblastoma is the most common malignant pediatric brain tumor, and mechanisms underlying its development are poorly understood.  	miRNA-corp.d19.s8.e1	Diseases	brain tumor 	2
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e0	Specific_miRNAs	miR-17/92 	1
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e1	Genes/Proteins	sonic hedgehog 	2
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e2	Diseases	medulloblastomas 	3
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e3	Genes/Proteins	N-myc 	4
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e4	Relation_Trigger	up-regulated 	5
miRNA-corp.d19.s9	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.   	miRNA-corp.d19.s9.e5	Genes/Proteins	sonic hedgehog 	6
miRNA-corp.d20.s0	MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.   	miRNA-corp.d20.s0.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d20.s0	MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.   	miRNA-corp.d20.s0.e1	Non-Specific_miRNAs	MicroRNA 	2
miRNA-corp.d20.s0	MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.   	miRNA-corp.d20.s0.e2	Relation_Trigger	modulation 	3
miRNA-corp.d20.s0	MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.   	miRNA-corp.d20.s0.e3	Relation_Trigger	regulation of IFN-beta protein expression 	4
miRNA-corp.d20.s1	In primary primate macrophages, the main cell type implicated in HIV and SIV infection in the CNS, specific miRNAs reduce, whereas miRNA inhibitors enhance, IFN-beta protein production.  	miRNA-corp.d20.s1.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d20.s1	In primary primate macrophages, the main cell type implicated in HIV and SIV infection in the CNS, specific miRNAs reduce, whereas miRNA inhibitors enhance, IFN-beta protein production.  	miRNA-corp.d20.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d20.s1	In primary primate macrophages, the main cell type implicated in HIV and SIV infection in the CNS, specific miRNAs reduce, whereas miRNA inhibitors enhance, IFN-beta protein production.  	miRNA-corp.d20.s1.e2	Relation_Trigger	inhibitors 	3
miRNA-corp.d20.s1	In primary primate macrophages, the main cell type implicated in HIV and SIV infection in the CNS, specific miRNAs reduce, whereas miRNA inhibitors enhance, IFN-beta protein production.  	miRNA-corp.d20.s1.e3	Diseases	HIV and SIV infection 	4
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e3	Genes/Proteins	IFN-beta 	4
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e4	Relation_Trigger	increased expression 	5
miRNA-corp.d20.s2	The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta.  	miRNA-corp.d20.s2.e5	Relation_Trigger	regulation 	6
miRNA-corp.d20.s3	Thus, miRNAs may contribute significantly to the regulation of IFN-beta in innate immune responses.    	miRNA-corp.d20.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d20.s3	Thus, miRNAs may contribute significantly to the regulation of IFN-beta in innate immune responses.    	miRNA-corp.d20.s3.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s3	Thus, miRNAs may contribute significantly to the regulation of IFN-beta in innate immune responses.    	miRNA-corp.d20.s3.e2	Relation_Trigger	regulation 	3
miRNA-corp.d20.s4	IFN-beta production is an inaugural event in the innate immune response to viral infections, with relatively small fold changes in IFN-beta expression resulting in the activation of important antiviral signaling cascades.  	miRNA-corp.d20.s4.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d20.s4	IFN-beta production is an inaugural event in the innate immune response to viral infections, with relatively small fold changes in IFN-beta expression resulting in the activation of important antiviral signaling cascades.  	miRNA-corp.d20.s4.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s4	IFN-beta production is an inaugural event in the innate immune response to viral infections, with relatively small fold changes in IFN-beta expression resulting in the activation of important antiviral signaling cascades.  	miRNA-corp.d20.s4.e2	Relation_Trigger	activation 	3
miRNA-corp.d20.s4	IFN-beta production is an inaugural event in the innate immune response to viral infections, with relatively small fold changes in IFN-beta expression resulting in the activation of important antiviral signaling cascades.  	miRNA-corp.d20.s4.e3	Diseases	viral infections 	4
miRNA-corp.d20.s5	In our rapid SIV/macaque model of HIV encephalitis, the virus enters the CNS within 4 d of infection, accompanied by a marked IFN-beta response that wanes as SIV replication is controlled.  	miRNA-corp.d20.s5.e0	Diseases	HIV encephalitis 	1
miRNA-corp.d20.s5	In our rapid SIV/macaque model of HIV encephalitis, the virus enters the CNS within 4 d of infection, accompanied by a marked IFN-beta response that wanes as SIV replication is controlled.  	miRNA-corp.d20.s5.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s5	In our rapid SIV/macaque model of HIV encephalitis, the virus enters the CNS within 4 d of infection, accompanied by a marked IFN-beta response that wanes as SIV replication is controlled.  	miRNA-corp.d20.s5.e2	Diseases	infection 	3
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e2	Relation_Trigger	associated 	3
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e3	Relation_Trigger	activation 	4
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e4	Relation_Trigger	regulatory 	5
miRNA-corp.d20.s6	The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation.  	miRNA-corp.d20.s6.e5	Relation_Trigger	regulation 	6
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e0	Specific_miRNAs	let-7b 	1
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e4	Relation_Trigger	regulate 	5
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e5	Specific_miRNAs	miR-26a, -34a, -145 	6
miRNA-corp.d20.s7	In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells.  	miRNA-corp.d20.s7.e6	Species	human 	7
miRNA-corp.d21.s0	Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways.   	miRNA-corp.d21.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d21.s0	Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways.   	miRNA-corp.d21.s0.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d21.s1	MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown.  	miRNA-corp.d21.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d21.s1	MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown.  	miRNA-corp.d21.s1.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d21.s1	MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown.  	miRNA-corp.d21.s1.e2	Diseases	AD 	3
miRNA-corp.d21.s1	MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown.  	miRNA-corp.d21.s1.e3	Diseases	neurodegenerative diseases 	4
miRNA-corp.d21.s2	Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains.  	miRNA-corp.d21.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d21.s2	Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains.  	miRNA-corp.d21.s2.e1	Diseases	AD 	2
miRNA-corp.d21.s2	Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains.  	miRNA-corp.d21.s2.e2	Relation_Trigger	deregulation of miRNA expression 	3
miRNA-corp.d21.s2	Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains.  	miRNA-corp.d21.s2.e3	Species	patient 	4
miRNA-corp.d21.s3	We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.  	miRNA-corp.d21.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d21.s3	We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.  	miRNA-corp.d21.s3.e1	Diseases	AD 	2
miRNA-corp.d21.s3	We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.  	miRNA-corp.d21.s3.e2	Diseases	insulin resistance 	3
miRNA-corp.d21.s3	We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.  	miRNA-corp.d21.s3.e3	Genes/Proteins	insulin 	4
miRNA-corp.d21.s3	We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.  	miRNA-corp.d21.s3.e4	Relation_Trigger	deregulated 	5
miRNA-corp.d21.s4	We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease.    	miRNA-corp.d21.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d21.s4	We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease.    	miRNA-corp.d21.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d21.s4	We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease.    	miRNA-corp.d21.s4.e2	Diseases	AD 	3
miRNA-corp.d22.s0	In sum, our results suggest that specific miRNAs are involved in the fine-tuning of APP alternative splicing in neurons.  	miRNA-corp.d22.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d22.s0	In sum, our results suggest that specific miRNAs are involved in the fine-tuning of APP alternative splicing in neurons.  	miRNA-corp.d22.s0.e1	Genes/Proteins	APP 	2
miRNA-corp.d22.s1	Finally, we show that miR-124 is down-regulated in AD brain.  	miRNA-corp.d22.s1.e0	Relation_Trigger	down-regulated 	1
miRNA-corp.d22.s1	Finally, we show that miR-124 is down-regulated in AD brain.  	miRNA-corp.d22.s1.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d22.s1	Finally, we show that miR-124 is down-regulated in AD brain.  	miRNA-corp.d22.s1.e2	Diseases	AD 	3
miRNA-corp.d22.s2	Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation.  	miRNA-corp.d22.s2.e0	Relation_Trigger	levels correlate 	1
miRNA-corp.d22.s2	Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation.  	miRNA-corp.d22.s2.e1	Relation_Trigger	levels correlate 	2
miRNA-corp.d22.s2	Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation.  	miRNA-corp.d22.s2.e2	Genes/Proteins	APP 	3
miRNA-corp.d22.s2	Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation.  	miRNA-corp.d22.s2.e3	Genes/Proteins	PTBP2 	4
miRNA-corp.d22.s2	Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation.  	miRNA-corp.d22.s2.e4	Genes/Proteins	PTBP1 	5
miRNA-corp.d22.s3	Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene.  	miRNA-corp.d22.s3.e0	Genes/Proteins	polypyrimidine tract binding protein 	1
miRNA-corp.d22.s3	Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene.  	miRNA-corp.d22.s3.e1	Genes/Proteins	PTBP1 	2
miRNA-corp.d22.s3	Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene.  	miRNA-corp.d22.s3.e2	Specific_miRNAs	miR-124 	3
miRNA-corp.d22.s3	Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene.  	miRNA-corp.d22.s3.e3	Relation_Trigger	target 	4
miRNA-corp.d22.s4	In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs.   	miRNA-corp.d22.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d22.s4	In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs.   	miRNA-corp.d22.s4.e1	Genes/Proteins	amyloid precursor protein 	2
miRNA-corp.d22.s4	In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs.   	miRNA-corp.d22.s4.e2	Relation_Trigger	regulation 	3
miRNA-corp.d22.s5	The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP).  	miRNA-corp.d22.s5.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d22.s5	The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP).  	miRNA-corp.d22.s5.e1	Diseases	AD 	2
miRNA-corp.d22.s5	The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP).  	miRNA-corp.d22.s5.e2	Genes/Proteins	amyloid precursor protein 	3
miRNA-corp.d22.s5	The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP).  	miRNA-corp.d22.s5.e3	Genes/Proteins	APP 	4
miRNA-corp.d22.s5	The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP).  	miRNA-corp.d22.s5.e4	Genes/Proteins	β-amyloid peptide 	5
miRNA-corp.d22.s6	Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing.  	miRNA-corp.d22.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d22.s6	Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing.  	miRNA-corp.d22.s6.e1	Relation_Trigger	expression regulation 	2
miRNA-corp.d22.s6	Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing.  	miRNA-corp.d22.s6.e2	Relation_Trigger	regulation 	3
miRNA-corp.d22.s6	Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing.  	miRNA-corp.d22.s6.e3	Genes/Proteins	APP 	4
miRNA-corp.d22.s6	Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing.  	miRNA-corp.d22.s6.e4	Genes/Proteins	APP 	5
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e2	Relation_Trigger	ectopic expression 	3
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e3	Genes/Proteins	APP 	4
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e4	Specific_miRNAs	miR-124 	5
miRNA-corp.d22.s7	Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons.  	miRNA-corp.d22.s7.e5	Relation_Trigger	associated 	6
miRNA-corp.d22.s8	Recent evidence suggest that microRNAs (miRNAs) participate in the post-transcriptional regulation of APP expression.  	miRNA-corp.d22.s8.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d22.s8	Recent evidence suggest that microRNAs (miRNAs) participate in the post-transcriptional regulation of APP expression.  	miRNA-corp.d22.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d22.s8	Recent evidence suggest that microRNAs (miRNAs) participate in the post-transcriptional regulation of APP expression.  	miRNA-corp.d22.s8.e2	Relation_Trigger	regulation of APP expression 	3
miRNA-corp.d22.s8	Recent evidence suggest that microRNAs (miRNAs) participate in the post-transcriptional regulation of APP expression.  	miRNA-corp.d22.s8.e3	Genes/Proteins	APP 	4
miRNA-corp.d22.s9	Because gene dosage effects of the APP gene can cause genetic AD, dysregulation of the miRNA network could contribute significantly to disease.  	miRNA-corp.d22.s9.e0	Relation_Trigger	dysregulation 	1
miRNA-corp.d22.s9	Because gene dosage effects of the APP gene can cause genetic AD, dysregulation of the miRNA network could contribute significantly to disease.  	miRNA-corp.d22.s9.e1	Genes/Proteins	APP 	2
miRNA-corp.d22.s9	Because gene dosage effects of the APP gene can cause genetic AD, dysregulation of the miRNA network could contribute significantly to disease.  	miRNA-corp.d22.s9.e2	Diseases	AD 	3
miRNA-corp.d22.s9	Because gene dosage effects of the APP gene can cause genetic AD, dysregulation of the miRNA network could contribute significantly to disease.  	miRNA-corp.d22.s9.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d22.s10	Since abnormal neuronal splicing of APP affects β-amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.    	miRNA-corp.d22.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d22.s10	Since abnormal neuronal splicing of APP affects β-amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.    	miRNA-corp.d22.s10.e1	Genes/Proteins	APP 	2
miRNA-corp.d22.s10	Since abnormal neuronal splicing of APP affects β-amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.    	miRNA-corp.d22.s10.e2	Genes/Proteins	amyloid peptide 	3
miRNA-corp.d23.s0	A greater understanding of aberrant miRNA expression in pediatric brain tumors may aid in the development of novel therapies.  	miRNA-corp.d23.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d23.s0	A greater understanding of aberrant miRNA expression in pediatric brain tumors may aid in the development of novel therapies.  	miRNA-corp.d23.s0.e1	Diseases	brain tumors 	2
miRNA-corp.d23.s0	A greater understanding of aberrant miRNA expression in pediatric brain tumors may aid in the development of novel therapies.  	miRNA-corp.d23.s0.e2	Relation_Trigger	aberrant miRNA expression 	3
miRNA-corp.d23.s1	The characterization of tumor-specific miRNA signatures may aid in the discovery of biomarkers with diagnostic or prognostic utility.    	miRNA-corp.d23.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d23.s1	The characterization of tumor-specific miRNA signatures may aid in the discovery of biomarkers with diagnostic or prognostic utility.    	miRNA-corp.d23.s1.e1	Diseases	tumor 	2
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e1	Diseases	ependymoma 	2
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e2	Diseases	glioblastoma 	3
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e3	Diseases	medulloblastoma 	4
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e4	Diseases	pilocytic astrocytoma 	5
miRNA-corp.d23.s2	The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma.  	miRNA-corp.d23.s2.e5	Diseases	rhabdoid tumor 	6
miRNA-corp.d23.s3	PROCEDURE: MicroRNA expression in pediatric brain tumors and normal tissue controls was examined by microarray.  	miRNA-corp.d23.s3.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d23.s3	PROCEDURE: MicroRNA expression in pediatric brain tumors and normal tissue controls was examined by microarray.  	miRNA-corp.d23.s3.e1	Diseases	brain tumors 	2
miRNA-corp.d23.s4	BACKGROUND: A better understanding of pediatric brain tumor biology is needed to assist in the development of less toxic therapies and to provide better markers for disease stratification.  	miRNA-corp.d23.s4.e0	Diseases	brain tumor 	1
miRNA-corp.d23.s5	MicroRNAs (miRNA) may play a significant role in brain tumor biology.  	miRNA-corp.d23.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d23.s5	MicroRNAs (miRNA) may play a significant role in brain tumor biology.  	miRNA-corp.d23.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d23.s5	MicroRNAs (miRNA) may play a significant role in brain tumor biology.  	miRNA-corp.d23.s5.e2	Diseases	brain tumor 	3
miRNA-corp.d23.s6	When further examined by qRT-PCR, these miRNAs demonstrated differential expression that significantly correlated with the microarray findings.  	miRNA-corp.d23.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d23.s6	When further examined by qRT-PCR, these miRNAs demonstrated differential expression that significantly correlated with the microarray findings.  	miRNA-corp.d23.s6.e1	Relation_Trigger	differential expression 	2
miRNA-corp.d23.s6	When further examined by qRT-PCR, these miRNAs demonstrated differential expression that significantly correlated with the microarray findings.  	miRNA-corp.d23.s6.e2	Relation_Trigger	expression that significantly correlated 	3
miRNA-corp.d23.s7	Distinctive miRNA expression profiles were also observed in the different pediatric brain tumor types.  	miRNA-corp.d23.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d23.s7	Distinctive miRNA expression profiles were also observed in the different pediatric brain tumor types.  	miRNA-corp.d23.s7.e1	Diseases	brain tumor 	2
miRNA-corp.d23.s8	Three aberrantly expressed miRNAs were further studied in a larger cohort by quantitative real-time PCR (qRT-PCR).  	miRNA-corp.d23.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d23.s8	Three aberrantly expressed miRNAs were further studied in a larger cohort by quantitative real-time PCR (qRT-PCR).  	miRNA-corp.d23.s8.e1	Relation_Trigger	aberrantly expressed 	2
miRNA-corp.d23.s9	RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.  	miRNA-corp.d23.s9.e0	Diseases	brain tumor 	1
miRNA-corp.d23.s9	RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.  	miRNA-corp.d23.s9.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d23.s9	RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.  	miRNA-corp.d23.s9.e2	Specific_miRNAs	MicroRNA-129 	3
miRNA-corp.d23.s9	RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.  	miRNA-corp.d23.s9.e3	Specific_miRNAs	miR-142-5p 	4
miRNA-corp.d23.s9	RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.  	miRNA-corp.d23.s9.e4	Specific_miRNAs	miR-25 	5
miRNA-corp.d23.s10	CONCLUSIONS: MicroRNAs are differentially expressed between pediatric CNS neoplasms and normal tissue suggesting that they may play a significant role in oncogenesis.  	miRNA-corp.d23.s10.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d23.s10	CONCLUSIONS: MicroRNAs are differentially expressed between pediatric CNS neoplasms and normal tissue suggesting that they may play a significant role in oncogenesis.  	miRNA-corp.d23.s10.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d23.s10	CONCLUSIONS: MicroRNAs are differentially expressed between pediatric CNS neoplasms and normal tissue suggesting that they may play a significant role in oncogenesis.  	miRNA-corp.d23.s10.e2	Diseases	neoplasms 	3
miRNA-corp.d23.s11	Survey of MicroRNA expression in pediatric brain tumors.   	miRNA-corp.d23.s11.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d23.s11	Survey of MicroRNA expression in pediatric brain tumors.   	miRNA-corp.d23.s11.e1	Diseases	brain tumors 	2
miRNA-corp.d24.s0	The authors reviewed the records of nineteen consecutive children with newly diagnosed IIH in order to compare demographic characteristics, clinical pictures and ophthalmologic aspects as optic disc evaluation and visual field evaluation, as well as treatment modalities and follow up.  	miRNA-corp.d24.s0.e0	Species	children 	1
miRNA-corp.d24.s1	Beside obesity and female gender, potential alternative risk factors remains to be investigated, which need a good collaboration between neuro-ophthalmologists and pediatric neurologists.    	miRNA-corp.d24.s1.e0	Diseases	obesity 	1
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e0	Diseases	elevated intracranial pressure 	1
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e1	Diseases	Idiopathic intracranial hypertension 	2
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e2	Diseases	IIH 	3
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e3	Diseases	hydrocephalus 	4
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e4	Diseases	lesion 	5
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e5	Diseases	vascular malformation 	6
miRNA-corp.d24.s2	Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus.  	miRNA-corp.d24.s2.e6	Diseases	central nervous system infection 	7
miRNA-corp.d24.s4	Pediatric idiopathic intracranial hypertension: clinical and demographic features.   	miRNA-corp.d24.s4.e0	Diseases	idiopathic intracranial hypertension 	1
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e1	Relation_Trigger	targets 	2
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e2	Relation_Trigger	therapeutic target 	3
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e3	Relation_Trigger	regulation 	4
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e4	Diseases	cancers 	5
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e5	Species	human 	6
miRNA-corp.d25.s0	In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.    	miRNA-corp.d25.s0.e6	Species	human 	7
miRNA-corp.d25.s1	However, an miR-21 knockout mouse has not yet been generated, and the data about miR-21 functions in normal cells are still very limited.  	miRNA-corp.d25.s1.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d25.s1	However, an miR-21 knockout mouse has not yet been generated, and the data about miR-21 functions in normal cells are still very limited.  	miRNA-corp.d25.s1.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d25.s1	However, an miR-21 knockout mouse has not yet been generated, and the data about miR-21 functions in normal cells are still very limited.  	miRNA-corp.d25.s1.e2	Species	mouse 	3
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e1	Specific_miRNAs	miR-17-92 	2
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e2	Specific_miRNAs	let-7 	3
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e3	Specific_miRNAs	miR-155 	4
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e4	Specific_miRNAs	oncomir-1 	5
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e5	Non-Specific_miRNAs	miRNA 	6
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e6	Non-Specific_miRNAs	miRNAs 	7
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e7	Diseases	brain tumour glioblastoma 	8
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e8	Relation_Trigger	up-regulated 	9
miRNA-corp.d25.s2	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others.  	miRNA-corp.d25.s2.e9	Species	human 	10
miRNA-corp.d25.s3	Particular miRNAs emerge as principal regulators that control major cell functions in various physiological and pathophysiological settings.  	miRNA-corp.d25.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d25.s3	Particular miRNAs emerge as principal regulators that control major cell functions in various physiological and pathophysiological settings.  	miRNA-corp.d25.s3.e1	Relation_Trigger	regulators 	2
miRNA-corp.d25.s4	miR-21: a small multi-faceted RNA.   	miRNA-corp.d25.s4.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d25.s5	More than 1000 microRNAs (miRNAs) are expressed in human cells, some tissue or cell type specific, others considered as house-keeping molecules.  	miRNA-corp.d25.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d25.s5	More than 1000 microRNAs (miRNAs) are expressed in human cells, some tissue or cell type specific, others considered as house-keeping molecules.  	miRNA-corp.d25.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d25.s5	More than 1000 microRNAs (miRNAs) are expressed in human cells, some tissue or cell type specific, others considered as house-keeping molecules.  	miRNA-corp.d25.s5.e2	Species	human 	3
miRNA-corp.d25.s6	Functions and direct mRNA targets for some miRNAs have been relatively well studied over the last years.  	miRNA-corp.d25.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d25.s6	Functions and direct mRNA targets for some miRNAs have been relatively well studied over the last years.  	miRNA-corp.d25.s6.e1	Relation_Trigger	targets 	2
miRNA-corp.d25.s7	Every miRNA potentially regulates the expression of numerous protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are equally important; diverse high-throughput screenings of various systems have identified a limited number of key functional miRNAs over and over again.  	miRNA-corp.d25.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d25.s7	Every miRNA potentially regulates the expression of numerous protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are equally important; diverse high-throughput screenings of various systems have identified a limited number of key functional miRNAs over and over again.  	miRNA-corp.d25.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d25.s7	Every miRNA potentially regulates the expression of numerous protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are equally important; diverse high-throughput screenings of various systems have identified a limited number of key functional miRNAs over and over again.  	miRNA-corp.d25.s7.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d25.s7	Every miRNA potentially regulates the expression of numerous protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are equally important; diverse high-throughput screenings of various systems have identified a limited number of key functional miRNAs over and over again.  	miRNA-corp.d25.s7.e3	Relation_Trigger	regulates the expression 	4
miRNA-corp.d26.s0	Expression levels of select protein-coding genes and miRNAs could classify an independent set of medulloblastomas.  	miRNA-corp.d26.s0.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s0	Expression levels of select protein-coding genes and miRNAs could classify an independent set of medulloblastomas.  	miRNA-corp.d26.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d26.s1	Twelve of 31 medulloblastomas were found to overexpress genes belonging to the canonical WNT signaling pathway and carry a mutation in CTNNB1 gene.  	miRNA-corp.d26.s1.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s1	Twelve of 31 medulloblastomas were found to overexpress genes belonging to the canonical WNT signaling pathway and carry a mutation in CTNNB1 gene.  	miRNA-corp.d26.s1.e1	Genes/Proteins	CTNNB1 	2
miRNA-corp.d26.s1	Twelve of 31 medulloblastomas were found to overexpress genes belonging to the canonical WNT signaling pathway and carry a mutation in CTNNB1 gene.  	miRNA-corp.d26.s1.e2	Relation_Trigger	overexpress 	3
miRNA-corp.d26.s2	In order to get a better understanding of medulloblastoma biology, miRNA profiling of medulloblastomas was carried out in parallel with expression profiling of protein-coding genes.  	miRNA-corp.d26.s2.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s2	In order to get a better understanding of medulloblastoma biology, miRNA profiling of medulloblastomas was carried out in parallel with expression profiling of protein-coding genes.  	miRNA-corp.d26.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d26.s2	In order to get a better understanding of medulloblastoma biology, miRNA profiling of medulloblastomas was carried out in parallel with expression profiling of protein-coding genes.  	miRNA-corp.d26.s2.e2	Diseases	medulloblastoma 	3
miRNA-corp.d26.s3	MATERIALS AND METHODS: miRNA profiling of medulloblastomas was carried out using Taqman Low Density Array v 1.0 having 365 human microRNAs.  	miRNA-corp.d26.s3.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s3	MATERIALS AND METHODS: miRNA profiling of medulloblastomas was carried out using Taqman Low Density Array v 1.0 having 365 human microRNAs.  	miRNA-corp.d26.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d26.s3	MATERIALS AND METHODS: miRNA profiling of medulloblastomas was carried out using Taqman Low Density Array v 1.0 having 365 human microRNAs.  	miRNA-corp.d26.s3.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d26.s3	MATERIALS AND METHODS: miRNA profiling of medulloblastomas was carried out using Taqman Low Density Array v 1.0 having 365 human microRNAs.  	miRNA-corp.d26.s3.e3	Species	human 	4
miRNA-corp.d26.s5	RESULTS: Both the profiling studies identified four molecular subtypes of medulloblastomas.  	miRNA-corp.d26.s5.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s6	Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway.   	miRNA-corp.d26.s6.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s6	Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway.   	miRNA-corp.d26.s6.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d26.s6	Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway.   	miRNA-corp.d26.s6.e2	Relation_Trigger	associated 	3
miRNA-corp.d26.s7	AIM: Medulloblastoma is a malignant brain tumor that occurs predominantly in children.  	miRNA-corp.d26.s7.e0	Diseases	brain tumor 	1
miRNA-corp.d26.s7	AIM: Medulloblastoma is a malignant brain tumor that occurs predominantly in children.  	miRNA-corp.d26.s7.e1	Diseases	Medulloblastoma 	2
miRNA-corp.d26.s7	AIM: Medulloblastoma is a malignant brain tumor that occurs predominantly in children.  	miRNA-corp.d26.s7.e2	Species	children 	3
miRNA-corp.d26.s9	MicroRNA expression is known to be deregulated in various cancers and has been found to be useful in predicting tumor behavior.  	miRNA-corp.d26.s9.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d26.s9	MicroRNA expression is known to be deregulated in various cancers and has been found to be useful in predicting tumor behavior.  	miRNA-corp.d26.s9.e1	Relation_Trigger	deregulated 	2
miRNA-corp.d26.s9	MicroRNA expression is known to be deregulated in various cancers and has been found to be useful in predicting tumor behavior.  	miRNA-corp.d26.s9.e2	Diseases	cancers 	3
miRNA-corp.d26.s9	MicroRNA expression is known to be deregulated in various cancers and has been found to be useful in predicting tumor behavior.  	miRNA-corp.d26.s9.e3	Diseases	tumor 	4
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e2	Relation_Trigger	overexpressed 	3
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e3	Specific_miRNAs	miR-193a 	4
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e4	Specific_miRNAs	miR-224 	5
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e5	Specific_miRNAs	miR-452 	6
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e6	Specific_miRNAs	miR-182 	7
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e7	Specific_miRNAs	miR-183 	8
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e8	Specific_miRNAs	miR-96 	9
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e9	Specific_miRNAs	miR-148a 	10
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e10	Relation_Trigger	associated 	11
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e11	Relation_Trigger	suppressive 	12
miRNA-corp.d26.s10	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.  	miRNA-corp.d26.s10.e12	Diseases	tumor 	13
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e0	Diseases	medulloblastomas 	1
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e1	Diseases	medulloblastomas 	2
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e4	Relation_Trigger	associated 	5
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e5	Relation_Trigger	associated 	6
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e6	Relation_Trigger	suppressive 	7
miRNA-corp.d26.s11	CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.    	miRNA-corp.d26.s11.e7	Diseases	tumor 	8
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e1	Relation_Trigger	upregulation 	2
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e2	Specific_miRNAs	miR-193a 	3
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e3	Specific_miRNAs	miR-224 	4
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e4	Diseases	medulloblastoma 	5
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e5	Relation_Trigger	Exogenous expression 	6
miRNA-corp.d26.s12	Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells.  	miRNA-corp.d26.s12.e6	Relation_Trigger	inhibit 	7
miRNA-corp.d27.s0	We now report clinical and genetic findings in nine additional European families with myoclonus-dystonia syndrome.  	miRNA-corp.d27.s0.e0	Diseases	myoclonus-dystonia syndrome 	1
miRNA-corp.d27.s1	Mutations in the gene for epsilon-sarcoglycan (SGCE) have been found to cause myoclonus-dystonia syndrome.  	miRNA-corp.d27.s1.e0	Genes/Proteins	epsilon-sarcoglycan 	1
miRNA-corp.d27.s1	Mutations in the gene for epsilon-sarcoglycan (SGCE) have been found to cause myoclonus-dystonia syndrome.  	miRNA-corp.d27.s1.e1	Genes/Proteins	SGCE 	2
miRNA-corp.d27.s1	Mutations in the gene for epsilon-sarcoglycan (SGCE) have been found to cause myoclonus-dystonia syndrome.  	miRNA-corp.d27.s1.e2	Diseases	myoclonus-dystonia syndrome 	3
miRNA-corp.d27.s2	Six novel and one previously known heterozygous SGCE mutations were identified.  	miRNA-corp.d27.s2.e0	Genes/Proteins	SGCE 	1
miRNA-corp.d27.s3	The clinical presentation in 24 affecteds was homogeneous with myoclonus predominantly of neck and upper limbs in 23 of them and dystonia, presenting as cervical dystonia and/or writer's cramp, in 13 cases.  	miRNA-corp.d27.s3.e0	Diseases	dystonia 	1
miRNA-corp.d27.s3	The clinical presentation in 24 affecteds was homogeneous with myoclonus predominantly of neck and upper limbs in 23 of them and dystonia, presenting as cervical dystonia and/or writer's cramp, in 13 cases.  	miRNA-corp.d27.s3.e1	Diseases	myoclonus 	2
miRNA-corp.d27.s3	The clinical presentation in 24 affecteds was homogeneous with myoclonus predominantly of neck and upper limbs in 23 of them and dystonia, presenting as cervical dystonia and/or writer's cramp, in 13 cases.  	miRNA-corp.d27.s3.e2	Diseases	cervical dystonia 	3
miRNA-corp.d27.s3	The clinical presentation in 24 affecteds was homogeneous with myoclonus predominantly of neck and upper limbs in 23 of them and dystonia, presenting as cervical dystonia and/or writer's cramp, in 13 cases.  	miRNA-corp.d27.s3.e3	Diseases	writer's cramp 	4
miRNA-corp.d27.s4	SGCE deficiency seems to be the common pathogenetic mechanism in myoclonus-dystonia syndrome.    	miRNA-corp.d27.s4.e0	Genes/Proteins	SGCE 	1
miRNA-corp.d27.s4	SGCE deficiency seems to be the common pathogenetic mechanism in myoclonus-dystonia syndrome.    	miRNA-corp.d27.s4.e1	Diseases	myoclonus-dystonia syndrome 	2
miRNA-corp.d27.s5	Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype.   	miRNA-corp.d27.s5.e0	Diseases	Myoclonus-dystonia syndrome 	1
miRNA-corp.d27.s5	Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype.   	miRNA-corp.d27.s5.e1	Genes/Proteins	epsilon-sarcoglycan 	2
miRNA-corp.d28.s0	This review summarizes recent findings of miRNA study in brain tumors.    	miRNA-corp.d28.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d28.s0	This review summarizes recent findings of miRNA study in brain tumors.    	miRNA-corp.d28.s0.e1	Diseases	brain tumors 	2
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e1	Diseases	glioblastomas 	2
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e2	Diseases	medulloblastomas 	3
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e3	Relation_Trigger	targets 	4
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e4	Relation_Trigger	deregulated 	5
miRNA-corp.d28.s1	Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified.  	miRNA-corp.d28.s1.e5	Relation_Trigger	associated 	6
miRNA-corp.d28.s2	Moreover, specific miRNA subsets may have potential diagnostic and prognostic values in some brain tumors.  	miRNA-corp.d28.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d28.s2	Moreover, specific miRNA subsets may have potential diagnostic and prognostic values in some brain tumors.  	miRNA-corp.d28.s2.e1	Diseases	brain tumors 	2
miRNA-corp.d28.s3	Expression profiling has unveiled miRNA signatures that not only distinguish brain tumors from normal tissues, but can also differentiate histotypes or molecular subtypes with altered genetic pathways.  	miRNA-corp.d28.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d28.s3	Expression profiling has unveiled miRNA signatures that not only distinguish brain tumors from normal tissues, but can also differentiate histotypes or molecular subtypes with altered genetic pathways.  	miRNA-corp.d28.s3.e1	Diseases	brain tumors 	2
miRNA-corp.d28.s4	Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions.  	miRNA-corp.d28.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d28.s4	Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions.  	miRNA-corp.d28.s4.e1	Diseases	brain tumors 	2
miRNA-corp.d28.s4	Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions.  	miRNA-corp.d28.s4.e2	Diseases	glioblastomas 	3
miRNA-corp.d28.s4	Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions.  	miRNA-corp.d28.s4.e3	Diseases	medulloblastomas 	4
miRNA-corp.d28.s4	Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions.  	miRNA-corp.d28.s4.e4	Diseases	malignant lesions 	5
miRNA-corp.d28.s5	Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules.  	miRNA-corp.d28.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d28.s5	Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules.  	miRNA-corp.d28.s5.e1	Diseases	cancers 	2
miRNA-corp.d28.s5	Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules.  	miRNA-corp.d28.s5.e2	Relation_Trigger	deregulation 	3
miRNA-corp.d28.s5	Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules.  	miRNA-corp.d28.s5.e3	Relation_Trigger	tumor suppressors 	4
miRNA-corp.d28.s5	Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules.  	miRNA-corp.d28.s5.e4	Species	human 	5
miRNA-corp.d28.s6	MicroRNAs (miRNAs) are short non-protein-coding RNAs that function as key regulators of diverse biological processes through negative control on gene expression at the post-transcriptional level.  	miRNA-corp.d28.s6.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d28.s6	MicroRNAs (miRNAs) are short non-protein-coding RNAs that function as key regulators of diverse biological processes through negative control on gene expression at the post-transcriptional level.  	miRNA-corp.d28.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d28.s6	MicroRNAs (miRNAs) are short non-protein-coding RNAs that function as key regulators of diverse biological processes through negative control on gene expression at the post-transcriptional level.  	miRNA-corp.d28.s6.e2	Relation_Trigger	regulators 	3
miRNA-corp.d28.s7	Oncogenic role of microRNAs in brain tumors.   	miRNA-corp.d28.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d28.s7	Oncogenic role of microRNAs in brain tumors.   	miRNA-corp.d28.s7.e1	Diseases	brain tumors 	2
miRNA-corp.d29.s0	Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression.  	miRNA-corp.d29.s0.e0	Relation_Trigger	reduce HDh mRNA expression 	1
miRNA-corp.d29.s1	Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA.  	miRNA-corp.d29.s1.e0	Relation_Trigger	higher antisense RNA levels 	1
miRNA-corp.d29.s2	These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain.  	miRNA-corp.d29.s2.e0	Species	mouse 	1
miRNA-corp.d29.s3	Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy.  	miRNA-corp.d29.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d29.s3	Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy.  	miRNA-corp.d29.s3.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d29.s3	Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy.  	miRNA-corp.d29.s3.e2	Relation_Trigger	attenuated 	3
miRNA-corp.d29.s3	Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy.  	miRNA-corp.d29.s3.e3	Species	mouse 	4
miRNA-corp.d29.s4	Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.   	miRNA-corp.d29.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d29.s5	Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein.  	miRNA-corp.d29.s5.e0	Diseases	Huntington's disease 	1
miRNA-corp.d29.s5	Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein.  	miRNA-corp.d29.s5.e1	Diseases	HD 	2
miRNA-corp.d29.s5	Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein.  	miRNA-corp.d29.s5.e2	Genes/Proteins	huntingtin 	3
miRNA-corp.d29.s5	Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein.  	miRNA-corp.d29.s5.e3	Diseases	dominant neurodegenerative disease 	4
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e0	Diseases	HD 	1
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e1	Relation_Trigger	inhibitory 	2
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e2	Relation_Trigger	targeting 	3
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e3	Diseases	HD 	4
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e4	Species	human 	5
miRNA-corp.d29.s6	We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models.  	miRNA-corp.d29.s6.e5	Species	mouse 	6
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e0	Diseases	HD 	1
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e1	Diseases	HD 	2
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e2	Diseases	HD 	3
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e3	Relation_Trigger	targeting 	4
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e4	Species	human 	5
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e5	Species	mouse 	6
miRNA-corp.d29.s7	Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.  	miRNA-corp.d29.s7.e6	Species	mouse 	7
miRNA-corp.d29.s9	Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three.  	miRNA-corp.d29.s9.e0	Relation_Trigger	expression was reduced 	1
miRNA-corp.d29.s9	Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three.  	miRNA-corp.d29.s9.e1	Relation_Trigger	reduced to similar levels 	2
miRNA-corp.d29.s9	Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three.  	miRNA-corp.d29.s9.e2	Species	mouse 	3
miRNA-corp.d29.s10	Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.    	miRNA-corp.d29.s10.e0	Relation_Trigger	inhibitory 	1
miRNA-corp.d29.s10	Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.    	miRNA-corp.d29.s10.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d30.s0	These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.    	miRNA-corp.d30.s0.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s0	These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.    	miRNA-corp.d30.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d30.s0	These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.    	miRNA-corp.d30.s0.e2	Relation_Trigger	regulated 	3
miRNA-corp.d30.s0	These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.    	miRNA-corp.d30.s0.e3	Species	human 	4
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e1	Genes/Proteins	APP 	2
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e4	Relation_Trigger	Over-expression 	5
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e5	Relation_Trigger	translational repression 	6
miRNA-corp.d30.s1	Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels.  	miRNA-corp.d30.s1.e6	Relation_Trigger	reduces APP protein levels 	7
miRNA-corp.d30.s2	Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression.  	miRNA-corp.d30.s2.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s2	Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression.  	miRNA-corp.d30.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d30.s2	Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression.  	miRNA-corp.d30.s2.e2	Relation_Trigger	levels can be regulated 	3
miRNA-corp.d30.s2	Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression.  	miRNA-corp.d30.s2.e3	Relation_Trigger	regulating gene expression 	4
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e1	Specific_miRNAs	hsa-mir-106a 	2
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e2	Specific_miRNAs	hsa-mir-520c 	3
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e4	Relation_Trigger	bind 	5
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e5	Relation_Trigger	regulate reporter gene expression 	6
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e6	Relation_Trigger	target 	7
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e7	Relation_Trigger	negatively regulate 	8
miRNA-corp.d30.s3	Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression.  	miRNA-corp.d30.s3.e8	Species	human 	9
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e1	Diseases	dementias 	2
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e3	Diseases	AD 	4
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e4	Relation_Trigger	increased APP levels 	5
miRNA-corp.d30.s4	ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD).  	miRNA-corp.d30.s4.e5	Relation_Trigger	regulatory 	6
miRNA-corp.d30.s5	Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD.  	miRNA-corp.d30.s5.e0	Diseases	AD 	1
miRNA-corp.d30.s5	Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD.  	miRNA-corp.d30.s5.e1	Diseases	AD 	2
miRNA-corp.d30.s5	Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD.  	miRNA-corp.d30.s5.e2	Genes/Proteins	APP 	3
miRNA-corp.d30.s5	Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD.  	miRNA-corp.d30.s5.e3	Relation_Trigger	levels are regulated 	4
miRNA-corp.d30.s6	MicroRNAs can regulate human APP levels.   	miRNA-corp.d30.s6.e0	Genes/Proteins	APP 	1
miRNA-corp.d30.s6	MicroRNAs can regulate human APP levels.   	miRNA-corp.d30.s6.e1	Non-Specific_miRNAs	MicroRNAs 	2
miRNA-corp.d30.s6	MicroRNAs can regulate human APP levels.   	miRNA-corp.d30.s6.e2	Relation_Trigger	regulate human APP levels 	3
miRNA-corp.d30.s6	MicroRNAs can regulate human APP levels.   	miRNA-corp.d30.s6.e3	Species	human 	4
miRNA-corp.d31.s0	Predictive miRNAs could be potentially useful diagnostic markers, improving the classification of pituitary adenomas.    	miRNA-corp.d31.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d31.s0	Predictive miRNAs could be potentially useful diagnostic markers, improving the classification of pituitary adenomas.    	miRNA-corp.d31.s0.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d31.s1	Several of the identified miRNAs are involved in cell proliferation and apoptosis, suggesting that their deregulated expression may be involved in pituitary tumorigenesis.  	miRNA-corp.d31.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d31.s1	Several of the identified miRNAs are involved in cell proliferation and apoptosis, suggesting that their deregulated expression may be involved in pituitary tumorigenesis.  	miRNA-corp.d31.s1.e1	Relation_Trigger	deregulated expression 	2
miRNA-corp.d31.s2	Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.   	miRNA-corp.d31.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d31.s2	Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.   	miRNA-corp.d31.s2.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d31.s2	Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.   	miRNA-corp.d31.s2.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d31.s2	Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.   	miRNA-corp.d31.s2.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d31.s3	MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression by targeting mRNA.  	miRNA-corp.d31.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d31.s3	MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression by targeting mRNA.  	miRNA-corp.d31.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d31.s3	MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression by targeting mRNA.  	miRNA-corp.d31.s3.e2	Relation_Trigger	targeting 	3
miRNA-corp.d31.s4	It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.  	miRNA-corp.d31.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d31.s4	It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.  	miRNA-corp.d31.s4.e1	Relation_Trigger	expression is altered 	2
miRNA-corp.d31.s4	It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.  	miRNA-corp.d31.s4.e2	Diseases	cancers 	3
miRNA-corp.d31.s4	It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.  	miRNA-corp.d31.s4.e3	Species	human 	4
miRNA-corp.d31.s4	It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia.  	miRNA-corp.d31.s4.e4	Species	human 	5
miRNA-corp.d31.s5	To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR.  	miRNA-corp.d31.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d31.s5	To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR.  	miRNA-corp.d31.s5.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d31.s5	To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR.  	miRNA-corp.d31.s5.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d31.s5	To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR.  	miRNA-corp.d31.s5.e3	Relation_Trigger	expression is altered 	4
miRNA-corp.d31.s6	Here, we show that 30 miRNAs are differentially expressed between normal pituitary and pituitary adenomas.  	miRNA-corp.d31.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d31.s6	Here, we show that 30 miRNAs are differentially expressed between normal pituitary and pituitary adenomas.  	miRNA-corp.d31.s6.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d31.s6	Here, we show that 30 miRNAs are differentially expressed between normal pituitary and pituitary adenomas.  	miRNA-corp.d31.s6.e2	Relation_Trigger	differentially expressed 	3
miRNA-corp.d31.s7	Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype.  	miRNA-corp.d31.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d31.s7	Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype.  	miRNA-corp.d31.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d31.s7	Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype.  	miRNA-corp.d31.s7.e2	Diseases	pituitary adenoma 	3
miRNA-corp.d31.s7	Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype.  	miRNA-corp.d31.s7.e3	Diseases	pituitary adenoma 	4
miRNA-corp.d31.s8	miRNA expression could differentiate micro- from macro-adenomas and treated from non-treated patient samples.  	miRNA-corp.d31.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d31.s8	miRNA expression could differentiate micro- from macro-adenomas and treated from non-treated patient samples.  	miRNA-corp.d31.s8.e1	Diseases	adenomas 	2
miRNA-corp.d31.s8	miRNA expression could differentiate micro- from macro-adenomas and treated from non-treated patient samples.  	miRNA-corp.d31.s8.e2	Species	patient 	3
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e0	Diseases	medulloblastoma 	1
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e1	Diseases	brain tumors 	2
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e5	Non-Specific_miRNAs	miRNA 	6
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e6	Relation_Trigger	target 	7
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e7	Relation_Trigger	loss of these miRNAs 	8
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e8	Relation_Trigger	co-expression 	9
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e9	Relation_Trigger	expression increases 	10
miRNA-corp.d32.s0	Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors.  	miRNA-corp.d32.s0.e10	Species	mouse 	11
miRNA-corp.d32.s1	These findings demonstrate the context-dependence of miRNA-mRNA co-expression.    	miRNA-corp.d32.s1.e0	Relation_Trigger	co-expression 	1
miRNA-corp.d32.s1	These findings demonstrate the context-dependence of miRNA-mRNA co-expression.    	miRNA-corp.d32.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e2	Relation_Trigger	suppress 	3
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e3	Relation_Trigger	target 	4
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e4	Relation_Trigger	targets 	5
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e5	Relation_Trigger	co-expression 	6
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e6	Relation_Trigger	higher level 	7
miRNA-corp.d32.s2	Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum.  	miRNA-corp.d32.s2.e7	Relation_Trigger	target 	8
miRNA-corp.d32.s4	Towards that goal, we examined miRNA-mRNA interactions by measuring miRNA and mRNA in the same tissue during development and also in malignant conditions.  	miRNA-corp.d32.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d32.s4	Towards that goal, we examined miRNA-mRNA interactions by measuring miRNA and mRNA in the same tissue during development and also in malignant conditions.  	miRNA-corp.d32.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d32.s5	We identified significant miRNA-mediated biological process categories in developing mouse cerebellum and lung using non-targeted mRNA expression as the negative control.  	miRNA-corp.d32.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d32.s5	We identified significant miRNA-mediated biological process categories in developing mouse cerebellum and lung using non-targeted mRNA expression as the negative control.  	miRNA-corp.d32.s5.e1	Species	mouse 	2
miRNA-corp.d32.s6	Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy.   	miRNA-corp.d32.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d32.s6	Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy.   	miRNA-corp.d32.s6.e1	Relation_Trigger	co-expression 	2
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e3	Relation_Trigger	binding sites 	4
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e4	Relation_Trigger	regulations 	5
miRNA-corp.d32.s7	An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated.  	miRNA-corp.d32.s7.e5	Relation_Trigger	association 	6
miRNA-corp.d33.s0	The transcription factor REST silences neuronal gene expression in non-neuronal cells.  	miRNA-corp.d33.s0.e0	Genes/Proteins	REST 	1
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e0	Specific_miRNAs	miR-9 	1
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e1	Genes/Proteins	REST 	2
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e2	Genes/Proteins	CoREST 	3
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e3	Diseases	Huntington's disease 	4
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e4	Specific_miRNAs	miR-9 	5
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e5	Non-Specific_miRNAs	microRNA 	6
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e6	Relation_Trigger	regulates 	7
miRNA-corp.d33.s1	The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.   	miRNA-corp.d33.s1.e7	Relation_Trigger	downregulated 	8
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e0	Diseases	Huntington's disease 	1
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e1	Diseases	HD 	2
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e2	Genes/Proteins	REST 	3
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e3	Genes/Proteins	huntingtin 	4
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e4	Genes/Proteins	huntingtin 	5
miRNA-corp.d33.s2	Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding.  	miRNA-corp.d33.s2.e5	Relation_Trigger	binding 	6
miRNA-corp.d33.s3	In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin.  	miRNA-corp.d33.s3.e0	Genes/Proteins	huntingtin 	1
miRNA-corp.d33.s3	In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin.  	miRNA-corp.d33.s3.e1	Relation_Trigger	binding 	2
miRNA-corp.d33.s4	In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls.  	miRNA-corp.d33.s4.e0	Diseases	HD 	1
miRNA-corp.d33.s4	In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls.  	miRNA-corp.d33.s4.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d33.s4	In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls.  	miRNA-corp.d33.s4.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d33.s4	In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls.  	miRNA-corp.d33.s4.e3	Relation_Trigger	levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased 	4
miRNA-corp.d33.s4	In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls.  	miRNA-corp.d33.s4.e4	Species	patient 	5
miRNA-corp.d33.s5	Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression.  	miRNA-corp.d33.s5.e0	Genes/Proteins	REST 	1
miRNA-corp.d33.s5	Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression.  	miRNA-corp.d33.s5.e1	Relation_Trigger	repressor 	2
miRNA-corp.d33.s5	Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression.  	miRNA-corp.d33.s5.e2	Relation_Trigger	decreases neuronal gene expression 	3
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e0	Genes/Proteins	CoREST 	1
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e1	Specific_miRNAs	miR-9 	2
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e2	Specific_miRNAs	miR-9 	3
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e3	Specific_miRNAs	miR-9 	4
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e4	Specific_miRNAs	miR-9 	5
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e5	Relation_Trigger	targets 	6
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e6	Relation_Trigger	targets 	7
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e7	Relation_Trigger	targets 	8
miRNA-corp.d33.s6	Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST.  	miRNA-corp.d33.s6.e8	Genes/Proteins	REST 	9
miRNA-corp.d33.s7	These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates.    	miRNA-corp.d33.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d33.s7	These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates.    	miRNA-corp.d33.s7.e1	Relation_Trigger	regulates 	2
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e0	Diseases	stroke 	1
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e1	Non-Specific_miRNAs	MiRNAs 	2
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e2	Diseases	atherosclerosis 	3
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e3	Relation_Trigger	therapeutic target 	4
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e4	Diseases	vascular diseases 	5
miRNA-corp.d34.s0	MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.    	miRNA-corp.d34.s0.e5	Diseases	arteriopathy 	6
miRNA-corp.d34.s1	The results suggest that miRNAs are novel regulatory RNAs for neointimal lesion formation.  	miRNA-corp.d34.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d34.s1	The results suggest that miRNAs are novel regulatory RNAs for neointimal lesion formation.  	miRNA-corp.d34.s1.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d34.s1	The results suggest that miRNAs are novel regulatory RNAs for neointimal lesion formation.  	miRNA-corp.d34.s1.e2	Diseases	neointimal lesion 	3
miRNA-corp.d34.s2	MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate about 30% of the encoding genes of the human genome.  	miRNA-corp.d34.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d34.s2	MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate about 30% of the encoding genes of the human genome.  	miRNA-corp.d34.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d34.s2	MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate about 30% of the encoding genes of the human genome.  	miRNA-corp.d34.s2.e2	Relation_Trigger	regulate 	3
miRNA-corp.d34.s2	MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate about 30% of the encoding genes of the human genome.  	miRNA-corp.d34.s2.e3	Species	human 	4
miRNA-corp.d34.s3	MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation.   	miRNA-corp.d34.s3.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d34.s3	MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation.   	miRNA-corp.d34.s3.e1	Non-Specific_miRNAs	MicroRNA 	2
miRNA-corp.d34.s3	MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation.   	miRNA-corp.d34.s3.e2	Diseases	vascular neointimal lesion 	3
miRNA-corp.d34.s4	Western blot analysis demonstrated that PTEN and Bcl-2 were involved in miR-21-mediated cellular effects.  	miRNA-corp.d34.s4.e0	Genes/Proteins	PTEN 	1
miRNA-corp.d34.s4	Western blot analysis demonstrated that PTEN and Bcl-2 were involved in miR-21-mediated cellular effects.  	miRNA-corp.d34.s4.e1	Genes/Proteins	Bcl-2 	2
miRNA-corp.d34.s4	Western blot analysis demonstrated that PTEN and Bcl-2 were involved in miR-21-mediated cellular effects.  	miRNA-corp.d34.s4.e2	Specific_miRNAs	miR-21 	3
miRNA-corp.d34.s5	MiR-21-mediated cellular effects were further confirmed in vivo in balloon-injured rat carotid arteries.  	miRNA-corp.d34.s5.e0	Specific_miRNAs	MiR-21 	1
miRNA-corp.d34.s5	MiR-21-mediated cellular effects were further confirmed in vivo in balloon-injured rat carotid arteries.  	miRNA-corp.d34.s5.e1	Species	rat 	2
miRNA-corp.d34.s6	Depletion of miR-21 resulted in decreased cell proliferation and increased cell apoptosis in a dose-dependent manner.  	miRNA-corp.d34.s6.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d34.s7	In vitro, the expression level of miR-21 in dedifferentiated vascular smooth muscle cells was significantly higher than that in fresh isolated differentiated cells.  	miRNA-corp.d34.s7.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d34.s8	Modulating an aberrantly overexpressed miRNA, miR-21, via antisense-mediated depletion (knock-down) had a significant negative effect on neointimal lesion formation.  	miRNA-corp.d34.s8.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d34.s8	Modulating an aberrantly overexpressed miRNA, miR-21, via antisense-mediated depletion (knock-down) had a significant negative effect on neointimal lesion formation.  	miRNA-corp.d34.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d34.s8	Modulating an aberrantly overexpressed miRNA, miR-21, via antisense-mediated depletion (knock-down) had a significant negative effect on neointimal lesion formation.  	miRNA-corp.d34.s8.e2	Relation_Trigger	aberrantly overexpressed 	3
miRNA-corp.d34.s8	Modulating an aberrantly overexpressed miRNA, miR-21, via antisense-mediated depletion (knock-down) had a significant negative effect on neointimal lesion formation.  	miRNA-corp.d34.s8.e3	Diseases	neointimal lesion 	4
miRNA-corp.d34.s9	The aberrantly expressed miRNAs were further confirmed by Northern blot and quantitative real-time polymerase chain reaction.  	miRNA-corp.d34.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d34.s9	The aberrantly expressed miRNAs were further confirmed by Northern blot and quantitative real-time polymerase chain reaction.  	miRNA-corp.d34.s9.e1	Relation_Trigger	aberrantly expressed 	2
miRNA-corp.d34.s10	Using microarray analysis, we demonstrated for the first time that miRNAs are aberrantly expressed in the vascular walls after balloon injury.  	miRNA-corp.d34.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d34.s10	Using microarray analysis, we demonstrated for the first time that miRNAs are aberrantly expressed in the vascular walls after balloon injury.  	miRNA-corp.d34.s10.e1	Diseases	balloon injury 	2
miRNA-corp.d34.s10	Using microarray analysis, we demonstrated for the first time that miRNAs are aberrantly expressed in the vascular walls after balloon injury.  	miRNA-corp.d34.s10.e2	Relation_Trigger	aberrantly expressed 	3
miRNA-corp.d34.s11	However, the role of miRNAs in vascular disease is currently completely unknown.  	miRNA-corp.d34.s11.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d34.s11	However, the role of miRNAs in vascular disease is currently completely unknown.  	miRNA-corp.d34.s11.e1	Diseases	vascular disease 	2
miRNA-corp.d35.s0	Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease.      	miRNA-corp.d35.s0.e0	Diseases	familial Parkinson's disease 	1
miRNA-corp.d35.s0	Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease.      	miRNA-corp.d35.s0.e1	Genes/Proteins	NR4A2 	2
miRNA-corp.d36.s0	In a pilot study we could show that hsa-miR-342-3p was also upregulated in brain samples of human type 1 and type 2 sporadic CJD.  	miRNA-corp.d36.s0.e0	Specific_miRNAs	hsa-miR-342-3p 	1
miRNA-corp.d36.s0	In a pilot study we could show that hsa-miR-342-3p was also upregulated in brain samples of human type 1 and type 2 sporadic CJD.  	miRNA-corp.d36.s0.e1	Relation_Trigger	upregulated 	2
miRNA-corp.d36.s0	In a pilot study we could show that hsa-miR-342-3p was also upregulated in brain samples of human type 1 and type 2 sporadic CJD.  	miRNA-corp.d36.s0.e2	Diseases	type 2 sporadic CJD 	3
miRNA-corp.d36.s0	In a pilot study we could show that hsa-miR-342-3p was also upregulated in brain samples of human type 1 and type 2 sporadic CJD.  	miRNA-corp.d36.s0.e3	Species	human 	4
miRNA-corp.d36.s1	Our study revealed significant upregulation of hsa-miR-342-3p and hsa-miR-494 in the brains of BSE-infected macaques compared to non-infected animals.  	miRNA-corp.d36.s1.e0	Specific_miRNAs	hsa-miR-342-3p 	1
miRNA-corp.d36.s1	Our study revealed significant upregulation of hsa-miR-342-3p and hsa-miR-494 in the brains of BSE-infected macaques compared to non-infected animals.  	miRNA-corp.d36.s1.e1	Specific_miRNAs	hsa-miR-494 	2
miRNA-corp.d36.s1	Our study revealed significant upregulation of hsa-miR-342-3p and hsa-miR-494 in the brains of BSE-infected macaques compared to non-infected animals.  	miRNA-corp.d36.s1.e2	Relation_Trigger	upregulation 	3
miRNA-corp.d36.s2	Shock-frozen brain sections of six BSE-infected and five non-infected macaques were used to validate regulated miRNA candidates by two independent qRT-PCR-based methods.  	miRNA-corp.d36.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d36.s2	Shock-frozen brain sections of six BSE-infected and five non-infected macaques were used to validate regulated miRNA candidates by two independent qRT-PCR-based methods.  	miRNA-corp.d36.s2.e1	Relation_Trigger	regulated 	2
miRNA-corp.d36.s3	We have applied miRNA-microarrays to identify deregulated miRNA candidates in brains of BSE-infected macaques.  	miRNA-corp.d36.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d36.s3	We have applied miRNA-microarrays to identify deregulated miRNA candidates in brains of BSE-infected macaques.  	miRNA-corp.d36.s3.e1	Relation_Trigger	deregulated 	2
miRNA-corp.d36.s3	We have applied miRNA-microarrays to identify deregulated miRNA candidates in brains of BSE-infected macaques.  	miRNA-corp.d36.s3.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d36.s4	Therefore, we hypothesized that miRNAs are also regulated in response to human prion disease.  	miRNA-corp.d36.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d36.s4	Therefore, we hypothesized that miRNAs are also regulated in response to human prion disease.  	miRNA-corp.d36.s4.e1	Relation_Trigger	regulated 	2
miRNA-corp.d36.s4	Therefore, we hypothesized that miRNAs are also regulated in response to human prion disease.  	miRNA-corp.d36.s4.e2	Diseases	prion disease 	3
miRNA-corp.d36.s4	Therefore, we hypothesized that miRNAs are also regulated in response to human prion disease.  	miRNA-corp.d36.s4.e3	Species	human 	4
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e2	Diseases	Scrapie 	3
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e3	Relation_Trigger	deregulation 	4
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e4	Relation_Trigger	associated 	5
miRNA-corp.d36.s6	Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice.  	miRNA-corp.d36.s6.e5	Species	mice 	6
miRNA-corp.d36.s7	ABSTRACT: The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD).  	miRNA-corp.d36.s7.e0	Diseases	Creutzfeldt-Jakob disease 	1
miRNA-corp.d36.s7	ABSTRACT: The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD).  	miRNA-corp.d36.s7.e1	Diseases	CJD 	2
miRNA-corp.d36.s7	ABSTRACT: The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD).  	miRNA-corp.d36.s7.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d36.s7	ABSTRACT: The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD).  	miRNA-corp.d36.s7.e3	Relation_Trigger	differential expression 	4
miRNA-corp.d36.s8	MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting.  	miRNA-corp.d36.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d36.s8	MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting.  	miRNA-corp.d36.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d36.s8	MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting.  	miRNA-corp.d36.s8.e2	Relation_Trigger	regulating gene expression 	3
miRNA-corp.d36.s8	MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting.  	miRNA-corp.d36.s8.e3	Relation_Trigger	targeting 	4
miRNA-corp.d36.s9	Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.   	miRNA-corp.d36.s9.e0	Specific_miRNAs	hsa-miR-342-3p 	1
miRNA-corp.d36.s9	Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.   	miRNA-corp.d36.s9.e1	Diseases	prion disease 	2
miRNA-corp.d36.s9	Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.   	miRNA-corp.d36.s9.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d36.s9	Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.   	miRNA-corp.d36.s9.e3	Relation_Trigger	Upregulation 	4
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e0	Specific_miRNAs	hsa-miR-342-3p 	1
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e2	Diseases	prion disease 	3
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e3	Diseases	Scrapie 	4
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e4	Relation_Trigger	upregulation 	5
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e5	Relation_Trigger	regulation 	6
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e6	Diseases	TSEs 	7
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e7	Species	human 	8
miRNA-corp.d36.s10	With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.    	miRNA-corp.d36.s10.e8	Species	mice 	9
miRNA-corp.d37.s0	Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.   	miRNA-corp.d37.s0.e0	Specific_miRNAs	miR-146a 	1
miRNA-corp.d37.s0	Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.   	miRNA-corp.d37.s0.e1	Genes/Proteins	TBP 	2
miRNA-corp.d37.s0	Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.   	miRNA-corp.d37.s0.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d37.s0	Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.   	miRNA-corp.d37.s0.e3	Relation_Trigger	targets 	4
miRNA-corp.d37.s1	We studied expression of 90 miRNAs in STHdh(Q111)/Hdh(Q111) cells, a model for Huntington's disease and compared with that obtained in STHdh(Q7)/Hdh(Q7) cells.  	miRNA-corp.d37.s1.e0	Diseases	Huntington's disease 	1
miRNA-corp.d37.s1	We studied expression of 90 miRNAs in STHdh(Q111)/Hdh(Q111) cells, a model for Huntington's disease and compared with that obtained in STHdh(Q7)/Hdh(Q7) cells.  	miRNA-corp.d37.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d37.s2	Fifteen miRNAs were down regulated and 12 miRNAs were up regulated more than 2-fold.  	miRNA-corp.d37.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d37.s2	Fifteen miRNAs were down regulated and 12 miRNAs were up regulated more than 2-fold.  	miRNA-corp.d37.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d37.s2	Fifteen miRNAs were down regulated and 12 miRNAs were up regulated more than 2-fold.  	miRNA-corp.d37.s2.e2	Relation_Trigger	down regulated 	3
miRNA-corp.d37.s2	Fifteen miRNAs were down regulated and 12 miRNAs were up regulated more than 2-fold.  	miRNA-corp.d37.s2.e3	Relation_Trigger	up regulated 	4
miRNA-corp.d37.s4	One hundred and forty-two genes are experimentally known targets of these altered miRNAs.  	miRNA-corp.d37.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d37.s4	One hundred and forty-two genes are experimentally known targets of these altered miRNAs.  	miRNA-corp.d37.s4.e1	Relation_Trigger	altered miRNAs 	2
miRNA-corp.d37.s4	One hundred and forty-two genes are experimentally known targets of these altered miRNAs.  	miRNA-corp.d37.s4.e2	Relation_Trigger	targets 	3
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e0	Genes/Proteins	TBP 	1
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e1	Specific_miRNAs	miR-146a 	2
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e3	Genes/Proteins	TBP 	4
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e4	Relation_Trigger	targets 	5
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e5	Relation_Trigger	over-expression 	6
miRNA-corp.d37.s5	Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP.  	miRNA-corp.d37.s5.e6	Relation_Trigger	inhibition 	7
miRNA-corp.d37.s6	It has been predicted that miR-146a may target Tata Binding Protein (TBP).  	miRNA-corp.d37.s6.e0	Genes/Proteins	Tata Binding Protein 	1
miRNA-corp.d37.s6	It has been predicted that miR-146a may target Tata Binding Protein (TBP).  	miRNA-corp.d37.s6.e1	Genes/Proteins	TBP 	2
miRNA-corp.d37.s6	It has been predicted that miR-146a may target Tata Binding Protein (TBP).  	miRNA-corp.d37.s6.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d37.s6	It has been predicted that miR-146a may target Tata Binding Protein (TBP).  	miRNA-corp.d37.s6.e3	Relation_Trigger	predicted that miR-146a may target 	4
miRNA-corp.d37.s7	Regulation of TBP by miR-146a may contribute to HD pathogenesis.    	miRNA-corp.d37.s7.e0	Genes/Proteins	TBP 	1
miRNA-corp.d37.s7	Regulation of TBP by miR-146a may contribute to HD pathogenesis.    	miRNA-corp.d37.s7.e1	Specific_miRNAs	miR-146a 	2
miRNA-corp.d37.s7	Regulation of TBP by miR-146a may contribute to HD pathogenesis.    	miRNA-corp.d37.s7.e2	Diseases	HD 	3
miRNA-corp.d37.s7	Regulation of TBP by miR-146a may contribute to HD pathogenesis.    	miRNA-corp.d37.s7.e3	Relation_Trigger	Regulation 	4
miRNA-corp.d38.s0	This is, to our knowledge, the first case of this kind found in Argentina and is additional evidence that HAM/TSP solely related to HTLV-II infection occurs in HTLV-I-negative subjects.    	miRNA-corp.d38.s0.e0	Diseases	HAM 	1
miRNA-corp.d38.s0	This is, to our knowledge, the first case of this kind found in Argentina and is additional evidence that HAM/TSP solely related to HTLV-II infection occurs in HTLV-I-negative subjects.    	miRNA-corp.d38.s0.e1	Diseases	TSP 	2
miRNA-corp.d38.s0	This is, to our knowledge, the first case of this kind found in Argentina and is additional evidence that HAM/TSP solely related to HTLV-II infection occurs in HTLV-I-negative subjects.    	miRNA-corp.d38.s0.e2	Diseases	HTLV-II infection 	3
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e0	Species	human 	1
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e1	Diseases	human T lymphocyte virus-associated myelopathy 	2
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e2	Diseases	tropical spastic paraparesis 	3
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e3	Diseases	HAM 	4
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e4	Diseases	TSP 	5
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e5	Diseases	human T lymphocyte virus (HTLV)-II infection 	6
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e6	Diseases	neurological disease 	7
miRNA-corp.d38.s1	A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection.  	miRNA-corp.d38.s1.e7	Species	human 	8
miRNA-corp.d38.s2	A possible case of myelopathy/tropical spastic paraparesis in an Argentinian woman with human T lymphocyte virus type II.   	miRNA-corp.d38.s2.e0	Diseases	myelopathy 	1
miRNA-corp.d38.s2	A possible case of myelopathy/tropical spastic paraparesis in an Argentinian woman with human T lymphocyte virus type II.   	miRNA-corp.d38.s2.e1	Diseases	tropical spastic paraparesis 	2
miRNA-corp.d38.s2	A possible case of myelopathy/tropical spastic paraparesis in an Argentinian woman with human T lymphocyte virus type II.   	miRNA-corp.d38.s2.e2	Species	woman 	3
miRNA-corp.d38.s2	A possible case of myelopathy/tropical spastic paraparesis in an Argentinian woman with human T lymphocyte virus type II.   	miRNA-corp.d38.s2.e3	Species	human 	4
miRNA-corp.d39.s0	Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death.  	miRNA-corp.d39.s0.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d39.s0	Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death.  	miRNA-corp.d39.s0.e1	Relation_Trigger	triggers activation 	2
miRNA-corp.d39.s0	Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death.  	miRNA-corp.d39.s0.e2	Diseases	glioblastoma 	3
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e1	Relation_Trigger	elevated miR-21 levels 	2
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e2	Diseases	early-passage glioblastoma 	3
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e3	Diseases	human glioblastoma tumor 	4
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e4	Diseases	glioblastoma 	5
miRNA-corp.d39.s1	Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells.  	miRNA-corp.d39.s1.e5	Species	human 	6
miRNA-corp.d39.s2	Our data suggest that aberrantly expressed miR-21 may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.    	miRNA-corp.d39.s2.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d39.s2	Our data suggest that aberrantly expressed miR-21 may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.    	miRNA-corp.d39.s2.e1	Relation_Trigger	aberrantly expressed 	2
miRNA-corp.d39.s2	Our data suggest that aberrantly expressed miR-21 may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.    	miRNA-corp.d39.s2.e2	Relation_Trigger	blocking expression 	3
miRNA-corp.d39.s3	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation.  	miRNA-corp.d39.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d39.s3	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation.  	miRNA-corp.d39.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d39.s3	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation.  	miRNA-corp.d39.s3.e2	Relation_Trigger	repression of translation 	3
miRNA-corp.d39.s3	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation.  	miRNA-corp.d39.s3.e3	Relation_Trigger	regulate protein expression 	4
miRNA-corp.d39.s3	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation.  	miRNA-corp.d39.s3.e4	Relation_Trigger	targeting 	5
miRNA-corp.d39.s4	MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.   	miRNA-corp.d39.s4.e0	Specific_miRNAs	MicroRNA-21 	1
miRNA-corp.d39.s4	MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.   	miRNA-corp.d39.s4.e1	Relation_Trigger	antiapoptotic factor 	2
miRNA-corp.d39.s4	MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.   	miRNA-corp.d39.s4.e2	Diseases	glioblastoma 	3
miRNA-corp.d39.s4	MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.   	miRNA-corp.d39.s4.e3	Species	human 	4
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e1	Diseases	glioblastoma 	2
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e3	Relation_Trigger	over-expresses 	4
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e4	Diseases	human brain tumor 	5
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e5	Diseases	glioblastoma 	6
miRNA-corp.d39.s5	Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21.  	miRNA-corp.d39.s5.e6	Species	human 	7
miRNA-corp.d39.s6	The roles of miRNAs in lineage determination and proliferation as well as the location of several miRNA genes at sites of translocation breakpoints or deletions has led to the speculation that miRNAs could be important factors in the development or maintenance of the neoplastic state.  	miRNA-corp.d39.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d39.s6	The roles of miRNAs in lineage determination and proliferation as well as the location of several miRNA genes at sites of translocation breakpoints or deletions has led to the speculation that miRNAs could be important factors in the development or maintenance of the neoplastic state.  	miRNA-corp.d39.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d39.s6	The roles of miRNAs in lineage determination and proliferation as well as the location of several miRNA genes at sites of translocation breakpoints or deletions has led to the speculation that miRNAs could be important factors in the development or maintenance of the neoplastic state.  	miRNA-corp.d39.s6.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d40.s0	Key microRNAs have been identified as essential for a variety of cellular events including cell lineage determination, proliferation, apoptosis, DNA repair, and cytoskeletal organization; most, if not all, acting to fine-tune gene expression at the post-transcriptional level in a host of cellular signaling networks.  	miRNA-corp.d40.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d40.s1	Their discovery has evoked great excitement in biomedical research for their promise as potential disease biomarkers and therapeutic targets.  	miRNA-corp.d40.s1.e0	Relation_Trigger	therapeutic targets 	1
miRNA-corp.d40.s2	MicroRNAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via translational inhibition or message degradation.  	miRNA-corp.d40.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d40.s2	MicroRNAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via translational inhibition or message degradation.  	miRNA-corp.d40.s2.e1	Relation_Trigger	suppress gene expression 	2
miRNA-corp.d40.s2	MicroRNAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via translational inhibition or message degradation.  	miRNA-corp.d40.s2.e2	Relation_Trigger	translational inhibition 	3
miRNA-corp.d40.s2	MicroRNAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via translational inhibition or message degradation.  	miRNA-corp.d40.s2.e3	Relation_Trigger	negative regulators 	4
miRNA-corp.d40.s3	Unlike the familial forms of AD, the genetic and environmental risks factors identified for sporadic AD are extensive.  	miRNA-corp.d40.s3.e0	Diseases	AD 	1
miRNA-corp.d40.s3	Unlike the familial forms of AD, the genetic and environmental risks factors identified for sporadic AD are extensive.  	miRNA-corp.d40.s3.e1	Diseases	AD 	2
miRNA-corp.d40.s4	Understanding complex diseases such as sporadic Alzheimer disease (AD) has been a major challenge.  	miRNA-corp.d40.s4.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d40.s4	Understanding complex diseases such as sporadic Alzheimer disease (AD) has been a major challenge.  	miRNA-corp.d40.s4.e1	Diseases	AD 	2
miRNA-corp.d40.s5	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.   	miRNA-corp.d40.s5.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d40.s5	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.   	miRNA-corp.d40.s5.e1	Diseases	Alzheimer Disease 	2
miRNA-corp.d40.s5	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.   	miRNA-corp.d40.s5.e2	Diseases	CNS Disorders 	3
miRNA-corp.d40.s5	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.   	miRNA-corp.d40.s5.e3	Species	Human 	4
miRNA-corp.d40.s6	Here, the current understanding of the role of miRNAs in the central nervous system is reviewed with emphasis on their impact on the etiopathogenesis of sporadic AD.    	miRNA-corp.d40.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d40.s6	Here, the current understanding of the role of miRNAs in the central nervous system is reviewed with emphasis on their impact on the etiopathogenesis of sporadic AD.    	miRNA-corp.d40.s6.e1	Diseases	sporadic AD 	2
miRNA-corp.d40.s7	Dysfunctional microRNA-mediated regulation has been implicated in the pathogenesis of many disease states.  	miRNA-corp.d40.s7.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d40.s7	Dysfunctional microRNA-mediated regulation has been implicated in the pathogenesis of many disease states.  	miRNA-corp.d40.s7.e1	Relation_Trigger	regulation 	2
miRNA-corp.d40.s7	Dysfunctional microRNA-mediated regulation has been implicated in the pathogenesis of many disease states.  	miRNA-corp.d40.s7.e2	Relation_Trigger	Dysfunctional 	3
miRNA-corp.d41.s0	MicroRNAs (miRNAs) in neurodegenerative diseases.   	miRNA-corp.d41.s0.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d41.s0	MicroRNAs (miRNAs) in neurodegenerative diseases.   	miRNA-corp.d41.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d41.s0	MicroRNAs (miRNAs) in neurodegenerative diseases.   	miRNA-corp.d41.s0.e2	Diseases	neurodegenerative diseases 	3
miRNA-corp.d41.s1	Prior studies have shown that RNAs are pathologically altered during the inexorable course of some NDs.  	miRNA-corp.d41.s1.e0	Diseases	NDs 	1
miRNA-corp.d41.s2	Aging-related neurodegenerative diseases (NDs) are the culmination of many different genetic and environmental influences.  	miRNA-corp.d41.s2.e0	Diseases	neurodegenerative diseases 	1
miRNA-corp.d41.s2	Aging-related neurodegenerative diseases (NDs) are the culmination of many different genetic and environmental influences.  	miRNA-corp.d41.s2.e1	Diseases	NDs 	2
miRNA-corp.d41.s3	miRNAs are brain-enriched, small ( approximately 22 nucleotides) non-coding RNAs that participate in mRNA translational regulation.  	miRNA-corp.d41.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d41.s3	miRNAs are brain-enriched, small ( approximately 22 nucleotides) non-coding RNAs that participate in mRNA translational regulation.  	miRNA-corp.d41.s3.e1	Relation_Trigger	translational regulation 	2
miRNA-corp.d41.s4	Recent evidence suggests that microRNAs (miRNAs) may be a contributing factor in neurodegeneration.  	miRNA-corp.d41.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d41.s4	Recent evidence suggests that microRNAs (miRNAs) may be a contributing factor in neurodegeneration.  	miRNA-corp.d41.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d41.s5	Research about miRNAs in the context of neurodegeneration is accumulating rapidly, and the goal of this review is to provide perspective for these new data that may be helpful to specialists in either field.  	miRNA-corp.d41.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d41.s6	Although discovered in the framework of worm development, miRNAs are now appreciated to play a dynamic role in many mammalian brain-related biochemical pathways, including neuroplasticity and stress responses.  	miRNA-corp.d41.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d41.s7	Recently published studies pertaining to the roles of miRNAs in NDs--including Alzheimer's disease, Parkinson's disease and triplet repeat disorders-are described.  	miRNA-corp.d41.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d41.s7	Recently published studies pertaining to the roles of miRNAs in NDs--including Alzheimer's disease, Parkinson's disease and triplet repeat disorders-are described.  	miRNA-corp.d41.s7.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d41.s7	Recently published studies pertaining to the roles of miRNAs in NDs--including Alzheimer's disease, Parkinson's disease and triplet repeat disorders-are described.  	miRNA-corp.d41.s7.e2	Diseases	Parkinson's disease 	3
miRNA-corp.d41.s7	Recently published studies pertaining to the roles of miRNAs in NDs--including Alzheimer's disease, Parkinson's disease and triplet repeat disorders-are described.  	miRNA-corp.d41.s7.e3	Diseases	NDs 	4
miRNA-corp.d41.s8	An overview is provided about the normal functions for miRNAs, including some of the newer concepts related to the human brain.  	miRNA-corp.d41.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d41.s8	An overview is provided about the normal functions for miRNAs, including some of the newer concepts related to the human brain.  	miRNA-corp.d41.s8.e1	Species	human 	2
miRNA-corp.d41.s9	Finally, a discussion is included with theoretical syntheses and possible future directions in exploring the nexus between miRNA and ND research.    	miRNA-corp.d41.s9.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d41.s9	Finally, a discussion is included with theoretical syntheses and possible future directions in exploring the nexus between miRNA and ND research.    	miRNA-corp.d41.s9.e1	Diseases	ND 	2
miRNA-corp.d42.s0	Traumatic brain injury (TBI) initiates many different signaling cascades throughout the brain that impact both pathophysiological and neuroprotective processes.  	miRNA-corp.d42.s0.e0	Diseases	Traumatic brain injury 	1
miRNA-corp.d42.s0	Traumatic brain injury (TBI) initiates many different signaling cascades throughout the brain that impact both pathophysiological and neuroprotective processes.  	miRNA-corp.d42.s0.e1	Diseases	TBI 	2
miRNA-corp.d42.s1	Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury.   	miRNA-corp.d42.s1.e0	Relation_Trigger	Altered expression 	1
miRNA-corp.d42.s1	Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury.   	miRNA-corp.d42.s1.e1	Specific_miRNAs	miRNA-21 	2
miRNA-corp.d42.s1	Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury.   	miRNA-corp.d42.s1.e2	Diseases	traumatic brain injury 	3
miRNA-corp.d42.s1	Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury.   	miRNA-corp.d42.s1.e3	Relation_Trigger	targets 	4
miRNA-corp.d42.s2	In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer.  	miRNA-corp.d42.s2.e0	Relation_Trigger	increase in expression 	1
miRNA-corp.d42.s2	In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer.  	miRNA-corp.d42.s2.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d42.s2	In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer.  	miRNA-corp.d42.s2.e2	Diseases	TBI 	3
miRNA-corp.d42.s3	We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury.  	miRNA-corp.d42.s3.e0	Relation_Trigger	expression is significantly up-regulated 	1
miRNA-corp.d42.s3	We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury.  	miRNA-corp.d42.s3.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d42.s3	We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury.  	miRNA-corp.d42.s3.e2	Diseases	TBI 	3
miRNA-corp.d42.s3	We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury.  	miRNA-corp.d42.s3.e3	Relation_Trigger	expression levels peaking 	4
miRNA-corp.d42.s4	MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes.  	miRNA-corp.d42.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d42.s4	MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes.  	miRNA-corp.d42.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d42.s4	MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes.  	miRNA-corp.d42.s4.e2	Relation_Trigger	regulation of protein expression 	3
miRNA-corp.d42.s4	MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes.  	miRNA-corp.d42.s4.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d42.s4	MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes.  	miRNA-corp.d42.s4.e4	Relation_Trigger	target 	5
miRNA-corp.d42.s5	Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury.  	miRNA-corp.d42.s5.e0	Diseases	TBI 	1
miRNA-corp.d42.s5	Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury.  	miRNA-corp.d42.s5.e1	Relation_Trigger	modulate 	2
miRNA-corp.d42.s5	Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury.  	miRNA-corp.d42.s5.e2	Diseases	injury 	3
miRNA-corp.d42.s6	These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology.    	miRNA-corp.d42.s6.e0	Diseases	TBI 	1
miRNA-corp.d42.s6	These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology.    	miRNA-corp.d42.s6.e1	Relation_Trigger	increased miR-21 expression 	2
miRNA-corp.d42.s6	These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology.    	miRNA-corp.d42.s6.e2	Specific_miRNAs	miR-21 	3
miRNA-corp.d42.s7	Analysis of these genes' annotated Gene Ontology molecular function and biological process terms revealed an overrepresentation of genes involved in enzyme-linked receptor signaling, transcriptional regulation, and developmental processes.  	miRNA-corp.d42.s7.e0	Relation_Trigger	transcriptional regulation 	1
miRNA-corp.d42.s8	We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions.  	miRNA-corp.d42.s8.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d42.s8	We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions.  	miRNA-corp.d42.s8.e1	Relation_Trigger	binding sites 	2
miRNA-corp.d42.s8	We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions.  	miRNA-corp.d42.s8.e2	Relation_Trigger	potential target 	3
miRNA-corp.d43.s0	MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment.  	miRNA-corp.d43.s0.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d43.s0	MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment.  	miRNA-corp.d43.s0.e1	Diseases	tumors 	2
miRNA-corp.d43.s0	MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment.  	miRNA-corp.d43.s0.e2	Diseases	tumor 	3
miRNA-corp.d43.s0	MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment.  	miRNA-corp.d43.s0.e3	Relation_Trigger	correlated 	4
miRNA-corp.d43.s0	MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment.  	miRNA-corp.d43.s0.e4	Species	human 	5
miRNA-corp.d43.s1	MiRNA fingerprinting can therefore be added to the diagnostic and prognostic tools used by medical oncologists.  	miRNA-corp.d43.s1.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d43.s2	Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors.    	miRNA-corp.d43.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d43.s2	Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors.    	miRNA-corp.d43.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d43.s2	Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors.    	miRNA-corp.d43.s2.e2	Diseases	brain tumors 	3
miRNA-corp.d43.s2	Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors.    	miRNA-corp.d43.s2.e3	Relation_Trigger	tumor suppressors 	4
miRNA-corp.d43.s3	MicroRNA involvement in brain tumors: from bench to bedside.   	miRNA-corp.d43.s3.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d43.s3	MicroRNA involvement in brain tumors: from bench to bedside.   	miRNA-corp.d43.s3.e1	Diseases	brain tumors 	2
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e2	Relation_Trigger	regulators of gene expression 	3
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e3	Relation_Trigger	tumor suppressive 	4
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e4	Diseases	tumors 	5
miRNA-corp.d43.s4	MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential.  	miRNA-corp.d43.s4.e5	Species	human 	6
miRNA-corp.d43.s5	Recently, miRNA involvement in the pathophysiology of brain cancer has been assessed.  	miRNA-corp.d43.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d43.s5	Recently, miRNA involvement in the pathophysiology of brain cancer has been assessed.  	miRNA-corp.d43.s5.e1	Diseases	brain cancer 	2
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e2	Relation_Trigger	Aberrant gene expression 	3
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e3	Relation_Trigger	abnormal expression levels 	4
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e4	Relation_Trigger	dysfunction 	5
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e5	Diseases	cancer 	6
miRNA-corp.d43.s6	Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal.  	miRNA-corp.d43.s6.e6	Diseases	tumor 	7
miRNA-corp.d43.s7	MiRNA germline and somatic mutations or polymorphisms in the protein coding messenger RNA targeted by miRNAs may also occur, contributing to cancer predisposition, initiation and/or progression.  	miRNA-corp.d43.s7.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d43.s7	MiRNA germline and somatic mutations or polymorphisms in the protein coding messenger RNA targeted by miRNAs may also occur, contributing to cancer predisposition, initiation and/or progression.  	miRNA-corp.d43.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d43.s7	MiRNA germline and somatic mutations or polymorphisms in the protein coding messenger RNA targeted by miRNAs may also occur, contributing to cancer predisposition, initiation and/or progression.  	miRNA-corp.d43.s7.e2	Relation_Trigger	targeted 	3
miRNA-corp.d43.s7	MiRNA germline and somatic mutations or polymorphisms in the protein coding messenger RNA targeted by miRNAs may also occur, contributing to cancer predisposition, initiation and/or progression.  	miRNA-corp.d43.s7.e3	Diseases	cancer 	4
miRNA-corp.d43.s8	If present in somatic cells, miRNA alterations may play a role in tumor initiation, while if present in germ line cells they could constitute a cancer predisposing event.  	miRNA-corp.d43.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d43.s8	If present in somatic cells, miRNA alterations may play a role in tumor initiation, while if present in germ line cells they could constitute a cancer predisposing event.  	miRNA-corp.d43.s8.e1	Diseases	tumor 	2
miRNA-corp.d43.s8	If present in somatic cells, miRNA alterations may play a role in tumor initiation, while if present in germ line cells they could constitute a cancer predisposing event.  	miRNA-corp.d43.s8.e2	Diseases	cancer 	3
miRNA-corp.d44.s0	RESULTS: We detected a total of 360 miRNAs.  	miRNA-corp.d44.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d44.s1	Selective miRNAs then were synthesized and transfected into Neuro-2a cells before oxygen-glucose deprivation.  	miRNA-corp.d44.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d44.s2	Transfections of some of these were neuroprotective in in vitro ischemia.  	miRNA-corp.d44.s2.e0	Diseases	ischemia 	1
miRNA-corp.d44.s3	Two miRNA families, miR-200 and miR-182, were selectively upregulated at 3 hours after ischemic preconditioning.  	miRNA-corp.d44.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d44.s3	Two miRNA families, miR-200 and miR-182, were selectively upregulated at 3 hours after ischemic preconditioning.  	miRNA-corp.d44.s3.e1	Specific_miRNAs	miR-200 	2
miRNA-corp.d44.s3	Two miRNA families, miR-200 and miR-182, were selectively upregulated at 3 hours after ischemic preconditioning.  	miRNA-corp.d44.s3.e2	Specific_miRNAs	miR-182 	3
miRNA-corp.d44.s3	Two miRNA families, miR-200 and miR-182, were selectively upregulated at 3 hours after ischemic preconditioning.  	miRNA-corp.d44.s3.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d44.s4	Although miRNAs control a number of conditions and diseases, few neuroprotective miRNAs have been described.  	miRNA-corp.d44.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d44.s4	Although miRNAs control a number of conditions and diseases, few neuroprotective miRNAs have been described.  	miRNA-corp.d44.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d44.s5	In this study, we investigated neuroprotective miRNAs induced early in ischemic preconditioning.  	miRNA-corp.d44.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d44.s6	METHODS: Ischemic preconditioning or focal cerebral ischemia was induced in mice by transient occlusion of the middle cerebral artery for 15 or 120 minutes.  	miRNA-corp.d44.s6.e0	Diseases	focal cerebral ischemia 	1
miRNA-corp.d44.s6	METHODS: Ischemic preconditioning or focal cerebral ischemia was induced in mice by transient occlusion of the middle cerebral artery for 15 or 120 minutes.  	miRNA-corp.d44.s6.e1	Species	mice 	2
miRNA-corp.d44.s7	We prepared RNA samples from the ischemic cortex at 3 or 24 hours after the onset of ischemia.  	miRNA-corp.d44.s7.e0	Diseases	ischemia 	1
miRNA-corp.d44.s8	MicroRNAs induced during ischemic preconditioning.   	miRNA-corp.d44.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d44.s9	BACKGROUND AND PURPOSE: MicroRNAs (miRNA) are single-stranded short RNA molecules that regulate gene expression by either degradation or translational repression of mRNA.  	miRNA-corp.d44.s9.e0	Relation_Trigger	translational repression 	1
miRNA-corp.d44.s9	BACKGROUND AND PURPOSE: MicroRNAs (miRNA) are single-stranded short RNA molecules that regulate gene expression by either degradation or translational repression of mRNA.  	miRNA-corp.d44.s9.e1	Non-Specific_miRNAs	MicroRNAs 	2
miRNA-corp.d44.s9	BACKGROUND AND PURPOSE: MicroRNAs (miRNA) are single-stranded short RNA molecules that regulate gene expression by either degradation or translational repression of mRNA.  	miRNA-corp.d44.s9.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d44.s9	BACKGROUND AND PURPOSE: MicroRNAs (miRNA) are single-stranded short RNA molecules that regulate gene expression by either degradation or translational repression of mRNA.  	miRNA-corp.d44.s9.e3	Relation_Trigger	regulate gene expression 	4
miRNA-corp.d44.s10	Among them, miR-200b, miR-200c, and miR-429 targeted prolyl hydroxylase 2 and had the best neuroprotective effect.  	miRNA-corp.d44.s10.e0	Specific_miRNAs	miR-200b 	1
miRNA-corp.d44.s10	Among them, miR-200b, miR-200c, and miR-429 targeted prolyl hydroxylase 2 and had the best neuroprotective effect.  	miRNA-corp.d44.s10.e1	Specific_miRNAs	miR-200c 	2
miRNA-corp.d44.s10	Among them, miR-200b, miR-200c, and miR-429 targeted prolyl hydroxylase 2 and had the best neuroprotective effect.  	miRNA-corp.d44.s10.e2	Specific_miRNAs	miR-429 	3
miRNA-corp.d44.s10	Among them, miR-200b, miR-200c, and miR-429 targeted prolyl hydroxylase 2 and had the best neuroprotective effect.  	miRNA-corp.d44.s10.e3	Relation_Trigger	targeted 	4
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e1	Specific_miRNAs	miR-200 	2
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e2	Specific_miRNAs	miR-182 	3
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e4	Relation_Trigger	downregulating 	5
miRNA-corp.d44.s11	CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels.  	miRNA-corp.d44.s11.e5	Specific_miRNAs	miR-200 	6
miRNA-corp.d44.s12	These miRNAs may be useful in future research and therapeutic applications.    	miRNA-corp.d44.s12.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d45.s0	A significant association with death was found for major adverse events, medical adverse events, and nosocomial infections, with adjusted odds ratio estimates of 3.74 [95% confidence interval (CI) 1.64-8.54], 3.71 (95% CI 1.61-8.53), and 3.22 (95% CI 1.21-8.59), respectively.  	miRNA-corp.d45.s0.e0	Diseases	nosocomial infections 	1
miRNA-corp.d45.s0	A significant association with death was found for major adverse events, medical adverse events, and nosocomial infections, with adjusted odds ratio estimates of 3.74 [95% confidence interval (CI) 1.64-8.54], 3.71 (95% CI 1.61-8.53), and 3.22 (95% CI 1.21-8.59), respectively.  	miRNA-corp.d45.s0.e1	Relation_Trigger	association 	2
miRNA-corp.d45.s1	CONCLUSION: Adverse events, mostly severe, predominated among deceased patients, resulting mainly from diagnostic or therapeutic procedures and nursing activities.  	miRNA-corp.d45.s1.e0	Species	patients 	1
miRNA-corp.d45.s2	In spite of limitations concerning the observational retrospective nature of this study, we found that severe adverse events, medical adverse events, and nosocomial infections were significantly associated with death in stroke patients.    	miRNA-corp.d45.s2.e0	Species	patients 	1
miRNA-corp.d45.s2	In spite of limitations concerning the observational retrospective nature of this study, we found that severe adverse events, medical adverse events, and nosocomial infections were significantly associated with death in stroke patients.    	miRNA-corp.d45.s2.e1	Diseases	nosocomial infections 	2
miRNA-corp.d45.s2	In spite of limitations concerning the observational retrospective nature of this study, we found that severe adverse events, medical adverse events, and nosocomial infections were significantly associated with death in stroke patients.    	miRNA-corp.d45.s2.e2	Diseases	stroke 	3
miRNA-corp.d45.s2	In spite of limitations concerning the observational retrospective nature of this study, we found that severe adverse events, medical adverse events, and nosocomial infections were significantly associated with death in stroke patients.    	miRNA-corp.d45.s2.e3	Relation_Trigger	associated 	4
miRNA-corp.d45.s3	OBJECTIVES: To identify the occurrence of adverse events in stroke patients presenting to the emergency department of a tertiary university facility, and to disclose the categories of adverse events associated with death.  	miRNA-corp.d45.s3.e0	Species	patients 	1
miRNA-corp.d45.s3	OBJECTIVES: To identify the occurrence of adverse events in stroke patients presenting to the emergency department of a tertiary university facility, and to disclose the categories of adverse events associated with death.  	miRNA-corp.d45.s3.e1	Diseases	stroke 	2
miRNA-corp.d45.s3	OBJECTIVES: To identify the occurrence of adverse events in stroke patients presenting to the emergency department of a tertiary university facility, and to disclose the categories of adverse events associated with death.  	miRNA-corp.d45.s3.e2	Relation_Trigger	associated 	3
miRNA-corp.d45.s4	Adverse events and death in stroke patients admitted to the emergency department of a tertiary university hospital.   	miRNA-corp.d45.s4.e0	Species	patients 	1
miRNA-corp.d45.s4	Adverse events and death in stroke patients admitted to the emergency department of a tertiary university hospital.   	miRNA-corp.d45.s4.e1	Diseases	stroke 	2
miRNA-corp.d45.s6	RESULTS: Adverse events totaled 1218 and occurred in 295 patients: 932 events (76.5%) in 170 cases and 286 (23.5%) in 125 controls.  	miRNA-corp.d45.s6.e0	Species	patients 	1
miRNA-corp.d45.s9	The cases comprised 234 consecutive deaths and the controls 234 discharged patients, matched for primary diagnosis and admission period.  	miRNA-corp.d45.s9.e0	Species	patients 	1
miRNA-corp.d45.s10	METHODS: This matched case-control study enrolled 468 patients admitted with stroke to the emergency department from March 1996 to September 1999.  	miRNA-corp.d45.s10.e0	Species	patients 	1
miRNA-corp.d45.s10	METHODS: This matched case-control study enrolled 468 patients admitted with stroke to the emergency department from March 1996 to September 1999.  	miRNA-corp.d45.s10.e1	Diseases	stroke 	2
miRNA-corp.d45.s11	The association with death was analysed by conditional logistic regression.  	miRNA-corp.d45.s11.e0	Relation_Trigger	association 	1
miRNA-corp.d46.s0	These findings reveal a novel mechanism of targeted intercellular protein regulation between brain tumor cells.    	miRNA-corp.d46.s0.e0	Diseases	brain tumor 	1
miRNA-corp.d46.s0	These findings reveal a novel mechanism of targeted intercellular protein regulation between brain tumor cells.    	miRNA-corp.d46.s0.e1	Relation_Trigger	targeted 	2
miRNA-corp.d46.s0	These findings reveal a novel mechanism of targeted intercellular protein regulation between brain tumor cells.    	miRNA-corp.d46.s0.e2	Relation_Trigger	regulation 	3
miRNA-corp.d46.s1	Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat.  	miRNA-corp.d46.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d46.s1	Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat.  	miRNA-corp.d46.s1.e1	Specific_miRNAs	cel-miR-67 	2
miRNA-corp.d46.s1	Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat.  	miRNA-corp.d46.s1.e2	Diseases	gliosarcoma 	3
miRNA-corp.d46.s1	Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat.  	miRNA-corp.d46.s1.e3	Species	rat 	4
miRNA-corp.d46.s1	Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat.  	miRNA-corp.d46.s1.e4	Species	rat 	5
miRNA-corp.d46.s2	Coculture of these cells with cells that expressed a luciferase reporter that contained a complementary sequence to cel-miR-67 resulted in significant suppression of luciferase expression.  	miRNA-corp.d46.s2.e0	Specific_miRNAs	cel-miR-67 	1
miRNA-corp.d46.s2	Coculture of these cells with cells that expressed a luciferase reporter that contained a complementary sequence to cel-miR-67 resulted in significant suppression of luciferase expression.  	miRNA-corp.d46.s2.e1	Relation_Trigger	suppression of luciferase expression 	2
miRNA-corp.d46.s3	Functional microRNA is transferred between glioma cells.   	miRNA-corp.d46.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d46.s3	Functional microRNA is transferred between glioma cells.   	miRNA-corp.d46.s3.e1	Diseases	glioma 	2
miRNA-corp.d46.s4	MicroRNAs (miRNA) are single-stranded 17- to 27-nucleotide RNA molecules that regulate gene expression by posttranscriptional silencing of target mRNAs.  	miRNA-corp.d46.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d46.s4	MicroRNAs (miRNA) are single-stranded 17- to 27-nucleotide RNA molecules that regulate gene expression by posttranscriptional silencing of target mRNAs.  	miRNA-corp.d46.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d46.s4	MicroRNAs (miRNA) are single-stranded 17- to 27-nucleotide RNA molecules that regulate gene expression by posttranscriptional silencing of target mRNAs.  	miRNA-corp.d46.s4.e2	Relation_Trigger	regulate gene expression 	3
miRNA-corp.d46.s4	MicroRNAs (miRNA) are single-stranded 17- to 27-nucleotide RNA molecules that regulate gene expression by posttranscriptional silencing of target mRNAs.  	miRNA-corp.d46.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d46.s5	Finally, in situ hybridization revealed the presence of cel-miR-67 in cel-miR-67-null 9L cells after coculture with cel-miR-67-expressing cells.  	miRNA-corp.d46.s5.e0	Specific_miRNAs	cel-miR-67 	1
miRNA-corp.d46.s5	Finally, in situ hybridization revealed the presence of cel-miR-67 in cel-miR-67-null 9L cells after coculture with cel-miR-67-expressing cells.  	miRNA-corp.d46.s5.e1	Specific_miRNAs	cel-miR-67 	2
miRNA-corp.d46.s5	Finally, in situ hybridization revealed the presence of cel-miR-67 in cel-miR-67-null 9L cells after coculture with cel-miR-67-expressing cells.  	miRNA-corp.d46.s5.e2	Specific_miRNAs	cel-miR-67 	3
miRNA-corp.d46.s6	Our data show that miRNA transcribed in glioma cells can be transferred to adjacent cells and induces targeted inhibition of protein expression in the acceptor cells.  	miRNA-corp.d46.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d46.s6	Our data show that miRNA transcribed in glioma cells can be transferred to adjacent cells and induces targeted inhibition of protein expression in the acceptor cells.  	miRNA-corp.d46.s6.e1	Diseases	glioma 	2
miRNA-corp.d46.s6	Our data show that miRNA transcribed in glioma cells can be transferred to adjacent cells and induces targeted inhibition of protein expression in the acceptor cells.  	miRNA-corp.d46.s6.e2	Relation_Trigger	targeted 	3
miRNA-corp.d46.s6	Our data show that miRNA transcribed in glioma cells can be transferred to adjacent cells and induces targeted inhibition of protein expression in the acceptor cells.  	miRNA-corp.d46.s6.e3	Relation_Trigger	inhibition of protein expression 	4
miRNA-corp.d46.s7	This effect was also observed in the U87-MG human glioma cell line.  	miRNA-corp.d46.s7.e0	Diseases	glioma 	1
miRNA-corp.d46.s7	This effect was also observed in the U87-MG human glioma cell line.  	miRNA-corp.d46.s7.e1	Species	human 	2
miRNA-corp.d46.s8	Moreover, luciferase suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junction communication regulates intercellular transfer of miRNA.  	miRNA-corp.d46.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d46.s8	Moreover, luciferase suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junction communication regulates intercellular transfer of miRNA.  	miRNA-corp.d46.s8.e1	Relation_Trigger	suppression 	2
miRNA-corp.d46.s8	Moreover, luciferase suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junction communication regulates intercellular transfer of miRNA.  	miRNA-corp.d46.s8.e2	Relation_Trigger	inhibited 	3
miRNA-corp.d46.s8	Moreover, luciferase suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junction communication regulates intercellular transfer of miRNA.  	miRNA-corp.d46.s8.e3	Relation_Trigger	regulates 	4
miRNA-corp.d47.s0	Moreover, bioinformatics analyses revealed a theoretical basis for many other potential interactions between natural antisense transcripts and miRNAs at the binding sites of the latter.    	miRNA-corp.d47.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d47.s0	Moreover, bioinformatics analyses revealed a theoretical basis for many other potential interactions between natural antisense transcripts and miRNAs at the binding sites of the latter.    	miRNA-corp.d47.s0.e1	Relation_Trigger	binding sites 	2
miRNA-corp.d47.s2	BACKGROUND: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets.  	miRNA-corp.d47.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d47.s2	BACKGROUND: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets.  	miRNA-corp.d47.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d47.s2	BACKGROUND: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets.  	miRNA-corp.d47.s2.e2	Relation_Trigger	regulate 	3
miRNA-corp.d47.s2	BACKGROUND: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets.  	miRNA-corp.d47.s2.e3	Relation_Trigger	targets 	4
miRNA-corp.d47.s3	Evidence for natural antisense transcript-mediated inhibition of microRNA function.   	miRNA-corp.d47.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d47.s3	Evidence for natural antisense transcript-mediated inhibition of microRNA function.   	miRNA-corp.d47.s3.e1	Relation_Trigger	inhibition 	2
miRNA-corp.d47.s4	Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA.  	miRNA-corp.d47.s4.e0	Specific_miRNAs	miR-485-5p 	1
miRNA-corp.d47.s4	Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA.  	miRNA-corp.d47.s4.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d47.s4	Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA.  	miRNA-corp.d47.s4.e2	Relation_Trigger	binding 	3
miRNA-corp.d47.s5	RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p.  	miRNA-corp.d47.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d47.s5	RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p.  	miRNA-corp.d47.s5.e1	Relation_Trigger	binding site 	2
miRNA-corp.d47.s5	RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p.  	miRNA-corp.d47.s5.e2	Genes/Proteins	BACE1 	3
miRNA-corp.d47.s5	RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p.  	miRNA-corp.d47.s5.e3	Specific_miRNAs	miR-485-5p 	4
miRNA-corp.d47.s5	RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p.  	miRNA-corp.d47.s5.e4	Relation_Trigger	repression 	5
miRNA-corp.d47.s6	The BACE1-antisense transcript is markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) BACE1 transcript.  	miRNA-corp.d47.s6.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d47.s6	The BACE1-antisense transcript is markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) BACE1 transcript.  	miRNA-corp.d47.s6.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d47.s6	The BACE1-antisense transcript is markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) BACE1 transcript.  	miRNA-corp.d47.s6.e2	Relation_Trigger	up-regulated 	3
miRNA-corp.d47.s6	The BACE1-antisense transcript is markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) BACE1 transcript.  	miRNA-corp.d47.s6.e3	Species	patients 	4
miRNA-corp.d47.s7	We have recently identified and characterized a highly conserved non-coding antisense transcript for beta-secretase-1 (BACE1), a critical enzyme in Alzheimer's disease pathophysiology.  	miRNA-corp.d47.s7.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d47.s7	We have recently identified and characterized a highly conserved non-coding antisense transcript for beta-secretase-1 (BACE1), a critical enzyme in Alzheimer's disease pathophysiology.  	miRNA-corp.d47.s7.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d47.s7	We have recently identified and characterized a highly conserved non-coding antisense transcript for beta-secretase-1 (BACE1), a critical enzyme in Alzheimer's disease pathophysiology.  	miRNA-corp.d47.s7.e2	Genes/Proteins	beta-secretase-1 	3
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e0	Relation_Trigger	suppression 	1
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e2	Specific_miRNAs	miR-485-5p 	3
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e3	Specific_miRNAs	miR-485-5p 	4
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e4	Relation_Trigger	over-expression 	5
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e5	Non-Specific_miRNAs	miRNA 	6
miRNA-corp.d47.s8	We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression.  	miRNA-corp.d47.s8.e6	Genes/Proteins	BACE1 	7
miRNA-corp.d47.s9	We found that the expression of BACE1-antisense as well as miR-485-5p are dysregulated in RNA samples from Alzheimer's disease subjects compared to control individuals.  	miRNA-corp.d47.s9.e0	Relation_Trigger	dysregulated 	1
miRNA-corp.d47.s9	We found that the expression of BACE1-antisense as well as miR-485-5p are dysregulated in RNA samples from Alzheimer's disease subjects compared to control individuals.  	miRNA-corp.d47.s9.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d47.s9	We found that the expression of BACE1-antisense as well as miR-485-5p are dysregulated in RNA samples from Alzheimer's disease subjects compared to control individuals.  	miRNA-corp.d47.s9.e2	Specific_miRNAs	miR-485-5p 	3
miRNA-corp.d47.s10	CONCLUSIONS: Our data demonstrate an interface between two distinct groups of regulatory RNAs in the computation of BACE1 gene expression.  	miRNA-corp.d47.s10.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d47.s10	CONCLUSIONS: Our data demonstrate an interface between two distinct groups of regulatory RNAs in the computation of BACE1 gene expression.  	miRNA-corp.d47.s10.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e0	Genes/Proteins	Drosha 	1
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e1	Genes/Proteins	Dicer 	2
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e2	Diseases	cerebral artery occlusion 	3
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e4	Genes/Proteins	exportin-5 	5
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e5	Relation_Trigger	modulate 	6
miRNA-corp.d48.s0	The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s0.e6	Non-Specific_miRNAs	miRNA 	7
miRNA-corp.d48.s1	Thus, the present studies indicate a critical role of miRNAs in controlling mRNA transcription and translation in the postischemic brain.    	miRNA-corp.d48.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d48.s2	Bioinformatics analysis indicated a correlation between miRNAs altered to several mRNAs known to mediate inflammation, transcription, neuroprotection, receptors function, and ionic homeostasis.  	miRNA-corp.d48.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d48.s2	Bioinformatics analysis indicated a correlation between miRNAs altered to several mRNAs known to mediate inflammation, transcription, neuroprotection, receptors function, and ionic homeostasis.  	miRNA-corp.d48.s2.e1	Relation_Trigger	correlation 	2
miRNA-corp.d48.s2	Bioinformatics analysis indicated a correlation between miRNAs altered to several mRNAs known to mediate inflammation, transcription, neuroprotection, receptors function, and ionic homeostasis.  	miRNA-corp.d48.s2.e2	Diseases	inflammation 	3
miRNA-corp.d48.s4	In silico analysis showed sequence complementarity of eight miRNAs induced after focal ischemia to 877 promoters indicating the possibility of noncoding RNA-induced activation of gene expression.  	miRNA-corp.d48.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d48.s4	In silico analysis showed sequence complementarity of eight miRNAs induced after focal ischemia to 877 promoters indicating the possibility of noncoding RNA-induced activation of gene expression.  	miRNA-corp.d48.s4.e1	Diseases	focal ischemia 	2
miRNA-corp.d48.s4	In silico analysis showed sequence complementarity of eight miRNAs induced after focal ischemia to 877 promoters indicating the possibility of noncoding RNA-induced activation of gene expression.  	miRNA-corp.d48.s4.e2	Relation_Trigger	activation 	3
miRNA-corp.d48.s5	Antagomir-mediated prevention of mir-145 expression led to an increased protein expression of its downstream target superoxide dismutase-2 in the postischemic brain.  	miRNA-corp.d48.s5.e0	Specific_miRNAs	mir-145 	1
miRNA-corp.d48.s5	Antagomir-mediated prevention of mir-145 expression led to an increased protein expression of its downstream target superoxide dismutase-2 in the postischemic brain.  	miRNA-corp.d48.s5.e1	Genes/Proteins	superoxide dismutase-2 	2
miRNA-corp.d48.s5	Antagomir-mediated prevention of mir-145 expression led to an increased protein expression of its downstream target superoxide dismutase-2 in the postischemic brain.  	miRNA-corp.d48.s5.e2	Relation_Trigger	increased protein expression 	3
miRNA-corp.d48.s5	Antagomir-mediated prevention of mir-145 expression led to an increased protein expression of its downstream target superoxide dismutase-2 in the postischemic brain.  	miRNA-corp.d48.s5.e3	Relation_Trigger	target 	4
miRNA-corp.d48.s6	MicroRNAs (miRNAs) are approximately 22 nucleotides long, noncoding RNAs that control cellular function by either degrading mRNAs or arresting their translation.  	miRNA-corp.d48.s6.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d48.s6	MicroRNAs (miRNAs) are approximately 22 nucleotides long, noncoding RNAs that control cellular function by either degrading mRNAs or arresting their translation.  	miRNA-corp.d48.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d48.s7	Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome.   	miRNA-corp.d48.s7.e0	Diseases	Transient focal ischemia 	1
miRNA-corp.d48.s7	Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome.   	miRNA-corp.d48.s7.e1	Species	rat 	2
miRNA-corp.d48.s8	Of the 238 miRNAs evaluated, 8 showed increased and 12 showed decreased expression at least at 4 out of 5 reperfusion time points studied between 3 h and 3 days compared with sham.  	miRNA-corp.d48.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d48.s8	Of the 238 miRNAs evaluated, 8 showed increased and 12 showed decreased expression at least at 4 out of 5 reperfusion time points studied between 3 h and 3 days compared with sham.  	miRNA-corp.d48.s8.e1	Relation_Trigger	decreased expression 	2
miRNA-corp.d48.s9	To understand their functional significance in ischemic pathophysiology, we profiled miRNAs in adult rat brain as a function of reperfusion time after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d48.s9	To understand their functional significance in ischemic pathophysiology, we profiled miRNAs in adult rat brain as a function of reperfusion time after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s9.e1	Diseases	middle cerebral artery occlusion 	2
miRNA-corp.d48.s9	To understand their functional significance in ischemic pathophysiology, we profiled miRNAs in adult rat brain as a function of reperfusion time after transient middle cerebral artery occlusion.  	miRNA-corp.d48.s9.e2	Species	rat 	3
miRNA-corp.d49.s0	The possible use of RNAi in the treatment of spinocerebellar ataxia or amyotrophic lateral sclerosis, with its advantages and pitfalls and possible extensions to other diseases are discussed.    	miRNA-corp.d49.s0.e0	Diseases	spinocerebellar ataxia 	1
miRNA-corp.d49.s0	The possible use of RNAi in the treatment of spinocerebellar ataxia or amyotrophic lateral sclerosis, with its advantages and pitfalls and possible extensions to other diseases are discussed.    	miRNA-corp.d49.s0.e1	Diseases	amyotrophic lateral sclerosis 	2
miRNA-corp.d49.s2	RNAi utilises cellular machinery associated with the processing of naturally occurring micro RNA (miRNAs).  	miRNA-corp.d49.s2.e0	Non-Specific_miRNAs	micro RNA 	1
miRNA-corp.d49.s2	RNAi utilises cellular machinery associated with the processing of naturally occurring micro RNA (miRNAs).  	miRNA-corp.d49.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d49.s2	RNAi utilises cellular machinery associated with the processing of naturally occurring micro RNA (miRNAs).  	miRNA-corp.d49.s2.e2	Relation_Trigger	associated 	3
miRNA-corp.d49.s4	RNA interference has become the tool of choice to analyse the loss-of-function of individual genes and has been exploited to identify complex regulatory pathways following genomic screening.  	miRNA-corp.d49.s4.e0	Relation_Trigger	regulatory 	1
miRNA-corp.d49.s5	Design of shRNAs for RNAi-A lesson from pre-miRNA processing: possible clinical applications.   	miRNA-corp.d49.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d49.s6	The cellular processing of shRNAs shares common features with the biogenesis of naturally occurring miRNA such as cleavage by nuclear RNase Drosha, export from the nucleus, processing by a cytoplasmic RNase Dicer, and incorporation into the RNA-induced silencing complex (RISC).  	miRNA-corp.d49.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d49.s6	The cellular processing of shRNAs shares common features with the biogenesis of naturally occurring miRNA such as cleavage by nuclear RNase Drosha, export from the nucleus, processing by a cytoplasmic RNase Dicer, and incorporation into the RNA-induced silencing complex (RISC).  	miRNA-corp.d49.s6.e1	Genes/Proteins	Drosha 	2
miRNA-corp.d49.s6	The cellular processing of shRNAs shares common features with the biogenesis of naturally occurring miRNA such as cleavage by nuclear RNase Drosha, export from the nucleus, processing by a cytoplasmic RNase Dicer, and incorporation into the RNA-induced silencing complex (RISC).  	miRNA-corp.d49.s6.e2	Genes/Proteins	Dicer 	3
miRNA-corp.d49.s10	Effective use of RNAi requires detailed knowledge of the individual steps and the proteins involved, as well as the similarities and distinctions between miRNA and siRNA pathways.  	miRNA-corp.d49.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e1	Diseases	traumatic brain injury 	2
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e2	Diseases	TBI 	3
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e4	Non-Specific_miRNAs	microRNA 	5
miRNA-corp.d50.s0	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.    	miRNA-corp.d50.s0.e5	Species	rat 	6
miRNA-corp.d50.s1	Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury.  	miRNA-corp.d50.s1.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d50.s1	Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury.  	miRNA-corp.d50.s1.e1	Diseases	injury 	2
miRNA-corp.d50.s1	Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury.  	miRNA-corp.d50.s1.e2	Relation_Trigger	up-regulation 	3
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e5	Non-Specific_miRNAs	miRNAs 	6
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e6	Non-Specific_miRNAs	miRNAs 	7
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e7	Non-Specific_miRNAs	miRNAs 	8
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e8	Non-Specific_miRNAs	miRNAs 	9
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e9	Non-Specific_miRNAs	miRNAs 	10
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e10	Non-Specific_miRNAs	miRNAs 	11
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e11	Non-Specific_miRNAs	miRNAs 	12
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e12	Relation_Trigger	up-regulated 	13
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e13	Relation_Trigger	down-regulated 	14
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e14	Diseases	injury 	15
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e15	Diseases	injury 	16
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e16	Diseases	injury 	17
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e17	Diseases	injury 	18
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e18	Relation_Trigger	up-regulated 	19
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e19	Relation_Trigger	down-regulated 	20
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e20	Relation_Trigger	up-regulated 	21
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e21	Relation_Trigger	down-regulated 	22
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e22	Relation_Trigger	up-regulated 	23
miRNA-corp.d50.s2	Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated.  	miRNA-corp.d50.s2.e23	Relation_Trigger	down-regulated 	24
miRNA-corp.d50.s5	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation.  	miRNA-corp.d50.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d50.s5	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation.  	miRNA-corp.d50.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d50.s5	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation.  	miRNA-corp.d50.s5.e2	Relation_Trigger	regulators 	3
miRNA-corp.d50.s5	MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation.  	miRNA-corp.d50.s5.e3	Diseases	tumor 	4
miRNA-corp.d50.s6	MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs.  	miRNA-corp.d50.s6.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d50.s6	MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs.  	miRNA-corp.d50.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d50.s6	MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs.  	miRNA-corp.d50.s6.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d50.s6	MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs.  	miRNA-corp.d50.s6.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d50.s7	In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method.  	miRNA-corp.d50.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d50.s7	In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method.  	miRNA-corp.d50.s7.e1	Diseases	traumatic brain injury 	2
miRNA-corp.d50.s7	In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method.  	miRNA-corp.d50.s7.e2	Species	rat 	3
miRNA-corp.d50.s8	We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups.  	miRNA-corp.d50.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d50.s8	We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups.  	miRNA-corp.d50.s8.e1	Diseases	brain injury 	2
miRNA-corp.d50.s8	We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups.  	miRNA-corp.d50.s8.e2	Relation_Trigger	differential expression 	3
miRNA-corp.d50.s8	We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups.  	miRNA-corp.d50.s8.e3	Species	rat 	4
miRNA-corp.d50.s9	Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury.   	miRNA-corp.d50.s9.e0	Diseases	traumatic brain injury 	1
miRNA-corp.d50.s9	Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury.   	miRNA-corp.d50.s9.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d50.s9	Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury.   	miRNA-corp.d50.s9.e2	Species	rat 	3
miRNA-corp.d51.s0	MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study.   	miRNA-corp.d51.s0.e0	Specific_miRNAs	MiR-107 	1
miRNA-corp.d51.s0	MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study.   	miRNA-corp.d51.s0.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e2	Relation_Trigger	decreased expression 	3
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e3	Diseases	Alzheimer's disease 	4
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e4	Diseases	AD 	5
miRNA-corp.d51.s1	MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD).  	miRNA-corp.d51.s1.e5	Specific_miRNAs	MiR-107 	6
miRNA-corp.d51.s2	Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue.  	miRNA-corp.d51.s2.e0	Relation_Trigger	decreased miR-107 expression 	1
miRNA-corp.d51.s2	Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue.  	miRNA-corp.d51.s2.e1	Specific_miRNAs	miR-107 	2
miRNA-corp.d51.s2	Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue.  	miRNA-corp.d51.s2.e2	Relation_Trigger	Correlation 	3
miRNA-corp.d51.s2	Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P< 0.05) and neurofibrillary tangle counts (P< 0.02) in adjacent brain tissue.  	miRNA-corp.d51.s2.e3	Diseases	neuritic plaque 	4
miRNA-corp.d51.s3	Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P< 0.07).  	miRNA-corp.d51.s3.e0	Relation_Trigger	correlate negatively 	1
miRNA-corp.d51.s3	Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P< 0.07).  	miRNA-corp.d51.s3.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d51.s3	Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P< 0.07).  	miRNA-corp.d51.s3.e2	Specific_miRNAs	miR-107 	3
miRNA-corp.d51.s4	Here we study a new group of well-characterized human temporal cortex samples (N=19).  	miRNA-corp.d51.s4.e0	Species	human 	1
miRNA-corp.d51.s5	MiR-107 expression was assessed, normalized to miR-124 and let-7a.  	miRNA-corp.d51.s5.e0	Specific_miRNAs	MiR-107 	1
miRNA-corp.d51.s5	MiR-107 expression was assessed, normalized to miR-124 and let-7a.  	miRNA-corp.d51.s5.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d51.s5	MiR-107 expression was assessed, normalized to miR-124 and let-7a.  	miRNA-corp.d51.s5.e2	Specific_miRNAs	let-7a 	3
miRNA-corp.d51.s6	In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.    	miRNA-corp.d51.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d51.s6	In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.    	miRNA-corp.d51.s6.e1	Relation_Trigger	expression tends to be lower 	2
miRNA-corp.d51.s6	In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.    	miRNA-corp.d51.s6.e2	Diseases	AD 	3
miRNA-corp.d51.s6	In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.    	miRNA-corp.d51.s6.e3	Specific_miRNAs	miR-107 	4
miRNA-corp.d52.s0	Small RNAs are short (approximately 18 to 30 nucleotides), non-coding RNA molecules that can regulate gene expression in both the cytoplasm and the nucleus via post-transcriptional gene silencing (PTGS), chromatin-dependent gene silencing (CDGS) or RNA activation (RNAa).  	miRNA-corp.d52.s0.e0	Relation_Trigger	regulate gene expression 	1
miRNA-corp.d52.s3	Three classes of small RNAs have been defined: microRNAs (miRNAs), siRNAs and Piwi-interacting RNAs (piRNAs).  	miRNA-corp.d52.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d52.s3	Three classes of small RNAs have been defined: microRNAs (miRNAs), siRNAs and Piwi-interacting RNAs (piRNAs).  	miRNA-corp.d52.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e0	Diseases	cardiovascular disease 	1
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e1	Diseases	stroke 	2
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e3	Diseases	diabetes 	4
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e4	Diseases	liver disease 	5
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e5	Diseases	kidney disease 	6
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e6	Diseases	infectious disease 	7
miRNA-corp.d52.s4	More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease.  	miRNA-corp.d52.s4.e7	Diseases	cancer 	8
miRNA-corp.d52.s5	Accordingly, small RNAs are critical regulators of normal development and physiology.  	miRNA-corp.d52.s5.e0	Relation_Trigger	regulators 	1
miRNA-corp.d52.s6	Additionally, small RNAs may serve as novel biomarkers and therapeutic targets for the majority of diseases.    	miRNA-corp.d52.s6.e0	Relation_Trigger	therapeutic targets 	1
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e1	Diseases	cerebral malaria 	2
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e2	Diseases	malaria 	3
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e3	Diseases	CM 	4
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e4	Diseases	infection 	5
miRNA-corp.d53.s0	We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM.  	miRNA-corp.d53.s0.e5	Species	mice 	6
miRNA-corp.d53.s1	MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown.  	miRNA-corp.d53.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d53.s1	MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown.  	miRNA-corp.d53.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d53.s1	MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown.  	miRNA-corp.d53.s1.e2	Relation_Trigger	regulation 	3
miRNA-corp.d53.s1	MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown.  	miRNA-corp.d53.s1.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d53.s1	MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown.  	miRNA-corp.d53.s1.e4	Diseases	Plasmodium infection 	5
miRNA-corp.d53.s2	Differential MicroRNA Expression in Experimental Cerebral and Noncerebral Malaria.   	miRNA-corp.d53.s2.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d53.s2	Differential MicroRNA Expression in Experimental Cerebral and Noncerebral Malaria.   	miRNA-corp.d53.s2.e1	Diseases	Malaria 	2
miRNA-corp.d53.s2	Differential MicroRNA Expression in Experimental Cerebral and Noncerebral Malaria.   	miRNA-corp.d53.s2.e2	Relation_Trigger	Differential MicroRNA Expression 	3
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e0	Diseases	CM 	1
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e1	Genes/Proteins	IFN 	2
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e2	Specific_miRNAs	miR-27a 	3
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e3	Specific_miRNAs	miR-150 	4
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e4	Specific_miRNAs	let-7i 	5
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e5	Genes/Proteins	gamma interferon 	6
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e6	Species	mice 	7
miRNA-corp.d53.s3	To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background.  	miRNA-corp.d53.s3.e7	Species	mice 	8
miRNA-corp.d53.s4	In contrast, no miRNA changes were detected in the heart, an organ with no known pathology during acute malaria.  	miRNA-corp.d53.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d53.s4	In contrast, no miRNA changes were detected in the heart, an organ with no known pathology during acute malaria.  	miRNA-corp.d53.s4.e1	Diseases	acute malaria 	2
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e2	Specific_miRNAs	let7i 	3
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e3	Specific_miRNAs	miR-27a 	4
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e4	Specific_miRNAs	miR-150 	5
miRNA-corp.d53.s5	We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.  	miRNA-corp.d53.s5.e5	Species	mice 	6
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e1	Relation_Trigger	differential expression 	2
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e2	Specific_miRNAs	let-7i 	3
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e3	Specific_miRNAs	miR-27a 	4
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e4	Specific_miRNAs	miR-150 	5
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e5	Specific_miRNAs	miR-126 	6
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e6	Specific_miRNAs	miR-210 	7
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e7	Specific_miRNAs	miR-155 	8
miRNA-corp.d53.s6	The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR).  	miRNA-corp.d53.s6.e8	Species	mouse 	9
miRNA-corp.d53.s7	Our data suggest that in the CBA mouse at least, miRNA may have a regulatory role in the pathogenesis of severe malaria.    	miRNA-corp.d53.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d53.s7	Our data suggest that in the CBA mouse at least, miRNA may have a regulatory role in the pathogenesis of severe malaria.    	miRNA-corp.d53.s7.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d53.s7	Our data suggest that in the CBA mouse at least, miRNA may have a regulatory role in the pathogenesis of severe malaria.    	miRNA-corp.d53.s7.e2	Diseases	malaria 	3
miRNA-corp.d53.s7	Our data suggest that in the CBA mouse at least, miRNA may have a regulatory role in the pathogenesis of severe malaria.    	miRNA-corp.d53.s7.e3	Species	mouse 	4
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e1	Relation_Trigger	targets 	2
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e2	Relation_Trigger	Overexpression 	3
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e3	Relation_Trigger	regulation 	4
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e4	Diseases	infection 	5
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e5	Diseases	neurological syndrome 	6
miRNA-corp.d53.s8	Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets.  	miRNA-corp.d53.s8.e6	Species	mice 	7
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e0	Genes/Proteins	IFN 	1
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e1	Specific_miRNAs	let-7i 	2
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e2	Specific_miRNAs	miR-27a 	3
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e3	Specific_miRNAs	miR-150 	4
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e4	Diseases	infection 	5
miRNA-corp.d53.s9	The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection.  	miRNA-corp.d53.s9.e5	Species	mice 	6
miRNA-corp.d54.s0	We also discuss the implications of these findings with respect to the involvement of miRNAs in the etiopathology of brain disorders and pinpoint the emerging therapeutic potential of miRNAs for the treatment of human diseases.    	miRNA-corp.d54.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d54.s0	We also discuss the implications of these findings with respect to the involvement of miRNAs in the etiopathology of brain disorders and pinpoint the emerging therapeutic potential of miRNAs for the treatment of human diseases.    	miRNA-corp.d54.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d54.s0	We also discuss the implications of these findings with respect to the involvement of miRNAs in the etiopathology of brain disorders and pinpoint the emerging therapeutic potential of miRNAs for the treatment of human diseases.    	miRNA-corp.d54.s0.e2	Diseases	brain disorders 	3
miRNA-corp.d54.s0	We also discuss the implications of these findings with respect to the involvement of miRNAs in the etiopathology of brain disorders and pinpoint the emerging therapeutic potential of miRNAs for the treatment of human diseases.    	miRNA-corp.d54.s0.e3	Species	human 	4
miRNA-corp.d54.s2	We focus on the role of the miRNA pathway in brain development, function, and disease by highlighting recent observations with respect to miRNA-mediated gene regulation in neuronal differentiation, synaptic plasticity, and the circadian clock.  	miRNA-corp.d54.s2.e0	Relation_Trigger	regulation 	1
miRNA-corp.d54.s2	We focus on the role of the miRNA pathway in brain development, function, and disease by highlighting recent observations with respect to miRNA-mediated gene regulation in neuronal differentiation, synaptic plasticity, and the circadian clock.  	miRNA-corp.d54.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d54.s2	We focus on the role of the miRNA pathway in brain development, function, and disease by highlighting recent observations with respect to miRNA-mediated gene regulation in neuronal differentiation, synaptic plasticity, and the circadian clock.  	miRNA-corp.d54.s2.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d54.s3	MicroRNAs in brain function and disease.   	miRNA-corp.d54.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d54.s4	MicroRNAs (miRNAs), a class of small, non-protein-coding transcripts about 21 nucleotides long, have recently entered center stage in the study of posttranscriptional gene regulation.  	miRNA-corp.d54.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d54.s4	MicroRNAs (miRNAs), a class of small, non-protein-coding transcripts about 21 nucleotides long, have recently entered center stage in the study of posttranscriptional gene regulation.  	miRNA-corp.d54.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d54.s4	MicroRNAs (miRNAs), a class of small, non-protein-coding transcripts about 21 nucleotides long, have recently entered center stage in the study of posttranscriptional gene regulation.  	miRNA-corp.d54.s4.e2	Relation_Trigger	regulation 	3
miRNA-corp.d55.s0	In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the Tet-On system for p53 in the LN-Z308 glioblastoma cell line.  	miRNA-corp.d55.s0.e0	Diseases	glioblastoma 	1
miRNA-corp.d55.s0	In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the Tet-On system for p53 in the LN-Z308 glioblastoma cell line.  	miRNA-corp.d55.s0.e1	Genes/Proteins	p53 	2
miRNA-corp.d55.s0	In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the Tet-On system for p53 in the LN-Z308 glioblastoma cell line.  	miRNA-corp.d55.s0.e2	Diseases	gliomas 	3
miRNA-corp.d55.s0	In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the Tet-On system for p53 in the LN-Z308 glioblastoma cell line.  	miRNA-corp.d55.s0.e3	Genes/Proteins	p53 	4
miRNA-corp.d55.s1	p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis.  	miRNA-corp.d55.s1.e0	Relation_Trigger	activated 	1
miRNA-corp.d55.s1	p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis.  	miRNA-corp.d55.s1.e1	Genes/Proteins	p53 	2
miRNA-corp.d55.s1	p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis.  	miRNA-corp.d55.s1.e2	Relation_Trigger	inhibition 	3
miRNA-corp.d55.s2	Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines.  	miRNA-corp.d55.s2.e0	Diseases	glioblastoma 	1
miRNA-corp.d55.s2	Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines.  	miRNA-corp.d55.s2.e1	Genes/Proteins	MIC-1 	2
miRNA-corp.d55.s2	Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines.  	miRNA-corp.d55.s2.e2	Diseases	anoxia 	3
miRNA-corp.d55.s3	The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling.  	miRNA-corp.d55.s3.e0	Relation_Trigger	target 	1
miRNA-corp.d55.s3	The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling.  	miRNA-corp.d55.s3.e1	Genes/Proteins	macrophage inhibitory cytokine-1 	2
miRNA-corp.d55.s3	The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling.  	miRNA-corp.d55.s3.e2	Genes/Proteins	MIC-1 	3
miRNA-corp.d55.s3	The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling.  	miRNA-corp.d55.s3.e3	Genes/Proteins	p53 	4
miRNA-corp.d55.s4	Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected.  	miRNA-corp.d55.s4.e0	Genes/Proteins	MIC-1 	1
miRNA-corp.d55.s4	Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected.  	miRNA-corp.d55.s4.e1	Relation_Trigger	ectopic expression 	2
miRNA-corp.d55.s4	Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected.  	miRNA-corp.d55.s4.e2	Species	nude mice 	3
miRNA-corp.d55.s5	MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway.  	miRNA-corp.d55.s5.e0	Genes/Proteins	p53 	1
miRNA-corp.d55.s5	MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway.  	miRNA-corp.d55.s5.e1	Genes/Proteins	MIC-1 	2
miRNA-corp.d55.s5	MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway.  	miRNA-corp.d55.s5.e2	Diseases	anoxia 	3
miRNA-corp.d55.s5	MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway.  	miRNA-corp.d55.s5.e3	Relation_Trigger	up-regulation 	4
miRNA-corp.d55.s6	Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.    	miRNA-corp.d55.s6.e0	Genes/Proteins	p53 	1
miRNA-corp.d55.s6	Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.    	miRNA-corp.d55.s6.e1	Genes/Proteins	MIC-1 	2
miRNA-corp.d55.s7	In the present experimental model MIC-1 may exert its anti-tumorigenic properties via a paracrine mechanism mediated by host cells in vivo.  	miRNA-corp.d55.s7.e0	Genes/Proteins	MIC-1 	1
miRNA-corp.d55.s8	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression.  	miRNA-corp.d55.s8.e0	Relation_Trigger	tumor suppressor 	1
miRNA-corp.d55.s8	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression.  	miRNA-corp.d55.s8.e1	Diseases	astrocytic brain tumors 	2
miRNA-corp.d55.s8	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression.  	miRNA-corp.d55.s8.e2	Genes/Proteins	p53 	3
miRNA-corp.d55.s8	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression.  	miRNA-corp.d55.s8.e3	Species	Human 	4
miRNA-corp.d55.s9	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.   	miRNA-corp.d55.s9.e0	Genes/Proteins	p53 	1
miRNA-corp.d55.s9	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.   	miRNA-corp.d55.s9.e1	Genes/Proteins	macrophage inhibitory cytokine-1 	2
miRNA-corp.d55.s9	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.   	miRNA-corp.d55.s9.e2	Genes/Proteins	MIC-1 	3
miRNA-corp.d55.s9	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.   	miRNA-corp.d55.s9.e3	Diseases	Anoxia 	4
miRNA-corp.d55.s9	Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.   	miRNA-corp.d55.s9.e4	Diseases	glioblastoma 	5
miRNA-corp.d56.s0	This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.    	miRNA-corp.d56.s0.e0	Genes/Proteins	GALC 	1
miRNA-corp.d56.s0	This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.    	miRNA-corp.d56.s0.e1	Diseases	GLD 	2
miRNA-corp.d56.s0	This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.    	miRNA-corp.d56.s0.e2	Diseases	GLD 	3
miRNA-corp.d56.s0	This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.    	miRNA-corp.d56.s0.e3	Species	mouse 	4
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e0	Diseases	Globoid cell leukodystrophy 	1
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e1	Diseases	GLD 	2
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e2	Diseases	Krabbe disease 	3
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e3	Genes/Proteins	galactocerebrosidase 	4
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e4	Genes/Proteins	GALC 	5
miRNA-corp.d56.s1	Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene.  	miRNA-corp.d56.s1.e5	Diseases	fatal lysosomal storage disorder 	6
miRNA-corp.d56.s2	Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression.  	miRNA-corp.d56.s2.e0	Genes/Proteins	GALC 	1
miRNA-corp.d56.s2	Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression.  	miRNA-corp.d56.s2.e1	Diseases	GLD 	2
miRNA-corp.d56.s2	Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression.  	miRNA-corp.d56.s2.e2	Relation_Trigger	regulation of vector expression 	3
miRNA-corp.d56.s3	Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy.   	miRNA-corp.d56.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d56.s3	Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy.   	miRNA-corp.d56.s3.e1	Diseases	globoid cell leukodystrophy 	2
miRNA-corp.d56.s4	Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation.  	miRNA-corp.d56.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d56.s4	Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation.  	miRNA-corp.d56.s4.e1	Species	human 	2
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e0	Relation_Trigger	suppressed GALC expression 	1
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e1	Specific_miRNAs	miR-126 	2
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e2	Genes/Proteins	GALC 	3
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e3	Relation_Trigger	target 	4
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e4	Genes/Proteins	GALC 	5
miRNA-corp.d56.s5	By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells.  	miRNA-corp.d56.s5.e5	Genes/Proteins	GALC 	6
miRNA-corp.d56.s6	We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution.  	miRNA-corp.d56.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d56.s7	We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny.  	miRNA-corp.d56.s7.e0	Specific_miRNAs	miR-126 	1
miRNA-corp.d56.s7	We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny.  	miRNA-corp.d56.s7.e1	Specific_miRNAs	miR-130a 	2
miRNA-corp.d56.s7	We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny.  	miRNA-corp.d56.s7.e2	Species	mice 	3
miRNA-corp.d56.s7	We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny.  	miRNA-corp.d56.s7.e3	Species	humans 	4
miRNA-corp.d57.s0	The genomic sequences predict that miRNAs are likely to be derived from larger precursors that have the capacity to form stem-loop structures.   	miRNA-corp.d57.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d57.s1	Here we report that Gemin3 and Gemin4 are also in a separate complex that contains eIF2C2, a member of the Argonaute protein family.  	miRNA-corp.d57.s1.e0	Genes/Proteins	Gemin3 	1
miRNA-corp.d57.s1	Here we report that Gemin3 and Gemin4 are also in a separate complex that contains eIF2C2, a member of the Argonaute protein family.  	miRNA-corp.d57.s1.e1	Genes/Proteins	Gemin4 	2
miRNA-corp.d57.s1	Here we report that Gemin3 and Gemin4 are also in a separate complex that contains eIF2C2, a member of the Argonaute protein family.  	miRNA-corp.d57.s1.e2	Genes/Proteins	eIF2C2 	3
miRNA-corp.d57.s3	We describe 40 miRNAs, a few of which are identical to recently described human miRNAs, a class of small endogenous RNAs.  	miRNA-corp.d57.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d57.s3	We describe 40 miRNAs, a few of which are identical to recently described human miRNAs, a class of small endogenous RNAs.  	miRNA-corp.d57.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d57.s3	We describe 40 miRNAs, a few of which are identical to recently described human miRNAs, a class of small endogenous RNAs.  	miRNA-corp.d57.s3.e2	Species	human 	3
miRNA-corp.d57.s4	This novel complex is a large approximately 15S RNP that contains numerous microRNAs (miRNAs).  	miRNA-corp.d57.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d57.s4	This novel complex is a large approximately 15S RNP that contains numerous microRNAs (miRNAs).  	miRNA-corp.d57.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d57.s5	miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs.   	miRNA-corp.d57.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d57.s6	Reduction in SMN protein results in Spinal muscular atrophy (SMA), a common neurodegenerative disease.  	miRNA-corp.d57.s6.e0	Diseases	Spinal muscular atrophy 	1
miRNA-corp.d57.s6	Reduction in SMN protein results in Spinal muscular atrophy (SMA), a common neurodegenerative disease.  	miRNA-corp.d57.s6.e1	Diseases	SMA 	2
miRNA-corp.d57.s6	Reduction in SMN protein results in Spinal muscular atrophy (SMA), a common neurodegenerative disease.  	miRNA-corp.d57.s6.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d57.s6	Reduction in SMN protein results in Spinal muscular atrophy (SMA), a common neurodegenerative disease.  	miRNA-corp.d57.s6.e3	Relation_Trigger	Reduction in SMN protein 	4
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e0	Genes/Proteins	Gemin2 	1
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e1	Genes/Proteins	Gemin4 	2
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e2	Genes/Proteins	Gemin5 	3
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e3	Genes/Proteins	Gemin6 	4
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e4	Genes/Proteins	DEAD-box RNA helicase 	5
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e5	Genes/Proteins	Gemin3 	6
miRNA-corp.d57.s7	Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6.  	miRNA-corp.d57.s7.e6	Relation_Trigger	binds 	7
miRNA-corp.d58.s0	Defective RNA metabolism is an emerging mechanism involved in ALS pathogenesis and possibly in other neurodegenerative disorders.  	miRNA-corp.d58.s0.e0	Diseases	ALS 	1
miRNA-corp.d58.s0	Defective RNA metabolism is an emerging mechanism involved in ALS pathogenesis and possibly in other neurodegenerative disorders.  	miRNA-corp.d58.s0.e1	Diseases	neurodegenerative disorders 	2
miRNA-corp.d58.s1	miRNA malfunction causes spinal motor neuron disease.   	miRNA-corp.d58.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d58.s1	miRNA malfunction causes spinal motor neuron disease.   	miRNA-corp.d58.s1.e1	Diseases	spinal motor neuron disease 	2
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e0	Diseases	spinal muscular atrophy 	1
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e1	Diseases	SMA 	2
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e3	Diseases	sclerosis of the spinal cord ventral horns 	4
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e4	Diseases	atrophy 	5
miRNA-corp.d58.s2	Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation.  	miRNA-corp.d58.s2.e5	Species	mice 	6
miRNA-corp.d58.s3	Here, we show that microRNA (miRNA) activity is essential for long-term survival of postmitotic spinal motor neurons (SMNs) in vivo.  	miRNA-corp.d58.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d58.s3	Here, we show that microRNA (miRNA) activity is essential for long-term survival of postmitotic spinal motor neurons (SMNs) in vivo.  	miRNA-corp.d58.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d58.s4	We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.  	miRNA-corp.d58.s4.e0	Specific_miRNAs	miR-9 	1
miRNA-corp.d58.s4	We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.  	miRNA-corp.d58.s4.e1	Diseases	SMA 	2
miRNA-corp.d58.s4	We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.  	miRNA-corp.d58.s4.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d58.s4	We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.  	miRNA-corp.d58.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d58.s4	We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.  	miRNA-corp.d58.s4.e4	Relation_Trigger	down-regulated 	5
miRNA-corp.d58.s5	Furthermore, a neurofilament heavy subunit previously implicated in motor neuron degeneration is specifically up-regulated in miRNA-deficient SMNs.  	miRNA-corp.d58.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d58.s5	Furthermore, a neurofilament heavy subunit previously implicated in motor neuron degeneration is specifically up-regulated in miRNA-deficient SMNs.  	miRNA-corp.d58.s5.e1	Relation_Trigger	up-regulated 	2
miRNA-corp.d58.s5	Furthermore, a neurofilament heavy subunit previously implicated in motor neuron degeneration is specifically up-regulated in miRNA-deficient SMNs.  	miRNA-corp.d58.s5.e2	Diseases	motor neuron degeneration 	3
miRNA-corp.d58.s6	These data provide evidence for miRNA function in SMN diseases and emphasize the potential role of miR-9-based regulatory mechanisms in adult neurons and neurodegenerative states.    	miRNA-corp.d58.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d58.s6	These data provide evidence for miRNA function in SMN diseases and emphasize the potential role of miR-9-based regulatory mechanisms in adult neurons and neurodegenerative states.    	miRNA-corp.d58.s6.e1	Specific_miRNAs	miR-9 	2
miRNA-corp.d58.s6	These data provide evidence for miRNA function in SMN diseases and emphasize the potential role of miR-9-based regulatory mechanisms in adult neurons and neurodegenerative states.    	miRNA-corp.d58.s6.e2	Diseases	SMN diseases 	3
miRNA-corp.d58.s6	These data provide evidence for miRNA function in SMN diseases and emphasize the potential role of miR-9-based regulatory mechanisms in adult neurons and neurodegenerative states.    	miRNA-corp.d58.s6.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d59.s0	Novel animal models for studying complex brain disorders: BAC-driven miRNA-mediated in vivo silencing of gene expression.   	miRNA-corp.d59.s0.e0	Diseases	brain disorders 	1
miRNA-corp.d59.s0	Novel animal models for studying complex brain disorders: BAC-driven miRNA-mediated in vivo silencing of gene expression.   	miRNA-corp.d59.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d59.s1	In schizophrenia, glutamic acid decarboxylase 1 (GAD1) disturbances are robust, consistently observed, cell-type specific and represent a core feature of the disease.  	miRNA-corp.d59.s1.e0	Diseases	schizophrenia 	1
miRNA-corp.d59.s1	In schizophrenia, glutamic acid decarboxylase 1 (GAD1) disturbances are robust, consistently observed, cell-type specific and represent a core feature of the disease.  	miRNA-corp.d59.s1.e1	Genes/Proteins	glutamic acid decarboxylase 1 	2
miRNA-corp.d59.s1	In schizophrenia, glutamic acid decarboxylase 1 (GAD1) disturbances are robust, consistently observed, cell-type specific and represent a core feature of the disease.  	miRNA-corp.d59.s1.e2	Genes/Proteins	GAD1 	3
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e0	Diseases	schizophrenia 	1
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e1	Genes/Proteins	GAD1 	2
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e2	Relation_Trigger	reduced expression 	3
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e3	Relation_Trigger	dysfunction 	4
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e4	Genes/Proteins	neuropeptide Y 	5
miRNA-corp.d59.s2	In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder.  	miRNA-corp.d59.s2.e5	Genes/Proteins	NPY 	6
miRNA-corp.d59.s3	However, modeling gene expression disturbances in schizophrenia in a cell type-specific manner has been extremely challenging.  	miRNA-corp.d59.s3.e0	Diseases	schizophrenia 	1
miRNA-corp.d59.s4	To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons.  	miRNA-corp.d59.s4.e0	Genes/Proteins	GAD1 	1
miRNA-corp.d59.s4	To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons.  	miRNA-corp.d59.s4.e1	Relation_Trigger	downregulated GAD1 mRNA expression 	2
miRNA-corp.d59.s4	To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons.  	miRNA-corp.d59.s4.e2	Genes/Proteins	NPY 	3
miRNA-corp.d59.s4	To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons.  	miRNA-corp.d59.s4.e3	Species	human 	4
miRNA-corp.d59.s4	To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons.  	miRNA-corp.d59.s4.e4	Species	transgenic mouse 	5
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e2	Genes/Proteins	GAD1 	3
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e3	Relation_Trigger	reducing gene expression 	4
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e4	Genes/Proteins	NPY 	5
miRNA-corp.d59.s5	This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1.  	miRNA-corp.d59.s5.e5	Relation_Trigger	targeted 	6
miRNA-corp.d59.s6	The animals of isogenic strains are generated rapidly, providing a new tool for better understanding the molecular disturbances in the GABAergic system observed in complex neuropsychiatric disorders such as schizophrenia.  	miRNA-corp.d59.s6.e0	Diseases	neuropsychiatric disorders 	1
miRNA-corp.d59.s6	The animals of isogenic strains are generated rapidly, providing a new tool for better understanding the molecular disturbances in the GABAergic system observed in complex neuropsychiatric disorders such as schizophrenia.  	miRNA-corp.d59.s6.e1	Diseases	schizophrenia 	2
miRNA-corp.d59.s7	In the future, because of the small size of the silencing miRNAs combined with our BAC strategy, this method may be modified to allow generation of mice with simultaneous silencing of multiple genes in the same cells with a single construct, and production of splice-variant-specific knockdown animals.    	miRNA-corp.d59.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d59.s7	In the future, because of the small size of the silencing miRNAs combined with our BAC strategy, this method may be modified to allow generation of mice with simultaneous silencing of multiple genes in the same cells with a single construct, and production of splice-variant-specific knockdown animals.    	miRNA-corp.d59.s7.e1	Species	mice 	2
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e1	Specific_miRNAs	miR-328 	2
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e2	Genes/Proteins	BACE1 	3
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e3	Specific_miRNAs	miR-298 	4
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e4	Relation_Trigger	regulatory effects on BACE1 protein expression 	5
miRNA-corp.d60.s0	Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells.  	miRNA-corp.d60.s0.e5	Relation_Trigger	recognize specific binding sites in the 3'-UTR 	6
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e0	Diseases	AD 	1
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e4	Relation_Trigger	loss of correlation 	5
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e5	Relation_Trigger	regulation of BACE1 expression 	6
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e6	Relation_Trigger	regulatory 	7
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e7	Genes/Proteins	BACE1 	8
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e8	Genes/Proteins	BACE1 	9
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e9	Relation_Trigger	impairment 	10
miRNA-corp.d60.s1	Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells.  	miRNA-corp.d60.s1.e10	Species	mouse 	11
miRNA-corp.d60.s2	Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder.    	miRNA-corp.d60.s2.e0	Diseases	AD 	1
miRNA-corp.d60.s2	Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder.    	miRNA-corp.d60.s2.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d60.s2	Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder.    	miRNA-corp.d60.s2.e2	Relation_Trigger	deregulation 	3
miRNA-corp.d60.s2	Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder.    	miRNA-corp.d60.s2.e3	Diseases	neurological disorder 	4
miRNA-corp.d60.s3	MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR).  	miRNA-corp.d60.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d60.s3	MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR).  	miRNA-corp.d60.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d60.s3	MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR).  	miRNA-corp.d60.s3.e2	Relation_Trigger	repress mRNA translation 	3
miRNA-corp.d60.s3	MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR).  	miRNA-corp.d60.s3.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d60.s3	MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR).  	miRNA-corp.d60.s3.e4	Relation_Trigger	binding sites 	5
miRNA-corp.d60.s4	MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.   	miRNA-corp.d60.s4.e0	Specific_miRNAs	MicroRNA-298 	1
miRNA-corp.d60.s4	MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.   	miRNA-corp.d60.s4.e1	Specific_miRNAs	microRNA-328 	2
miRNA-corp.d60.s4	MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.   	miRNA-corp.d60.s4.e2	Relation_Trigger	regulate expression 	3
miRNA-corp.d60.s4	MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.   	miRNA-corp.d60.s4.e3	Species	mouse 	4
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e1	Diseases	AD 	2
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e2	Relation_Trigger	higher beta-amyloid precursor protein-converting enzyme (BACE) protein 	3
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e3	Genes/Proteins	beta-amyloid precursor protein-converting enzyme (BACE) protein 	4
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e4	Genes/Proteins	BACE 	5
miRNA-corp.d60.s5	Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD).  	miRNA-corp.d60.s5.e5	Species	patients 	6
miRNA-corp.d60.s6	Loss of specific miRNA control of gene expression is thus expected to underlie serious genetic diseases.  	miRNA-corp.d60.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d60.s6	Loss of specific miRNA control of gene expression is thus expected to underlie serious genetic diseases.  	miRNA-corp.d60.s6.e1	Relation_Trigger	Loss of specific miRNA 	2
miRNA-corp.d61.s0	MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats.  	miRNA-corp.d61.s0.e0	Non-Specific_miRNAs	MiRNAs 	1
miRNA-corp.d61.s0	MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats.  	miRNA-corp.d61.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d61.s0	MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats.  	miRNA-corp.d61.s0.e2	Diseases	TLE 	3
miRNA-corp.d61.s0	MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats.  	miRNA-corp.d61.s0.e3	Species	rats 	4
miRNA-corp.d61.s0	MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats.  	miRNA-corp.d61.s0.e4	Species	rats 	5
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e3	Diseases	temporal lobe epilepsy 	4
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e4	Diseases	TLE 	5
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e5	Diseases	TLE 	6
miRNA-corp.d61.s1	To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models.  	miRNA-corp.d61.s1.e6	Species	rat 	7
miRNA-corp.d61.s2	Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.   	miRNA-corp.d61.s2.e0	Specific_miRNAs	miR-23a/b 	1
miRNA-corp.d61.s2	Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.   	miRNA-corp.d61.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d61.s2	Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.   	miRNA-corp.d61.s2.e2	Diseases	Temporal lobe epilepsy 	3
miRNA-corp.d61.s2	Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.   	miRNA-corp.d61.s2.e3	Specific_miRNAs	let-7e 	4
miRNA-corp.d61.s2	Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.   	miRNA-corp.d61.s2.e4	Relation_Trigger	induces differential expression 	5
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e0	Specific_miRNAs	let-7e 	1
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e1	Relation_Trigger	down-regulated expression 	2
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e2	Relation_Trigger	up-regulated expression 	3
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e3	Diseases	SE 	4
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e4	Diseases	SE 	5
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e5	Diseases	SE 	6
miRNA-corp.d61.s3	let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P<0.01).  	miRNA-corp.d61.s3.e6	Relation_Trigger	up-regulated expression 	7
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e0	Specific_miRNAs	miR-23a/b 	1
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e3	Diseases	epilepsy 	4
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e4	Relation_Trigger	down-regulated 	5
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e5	Relation_Trigger	alters the expression levels 	6
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e6	Relation_Trigger	deregulated 	7
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e7	Diseases	TLE 	8
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e8	Diseases	SE 	9
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e9	Diseases	SE 	10
miRNA-corp.d61.s4	miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P<0.01), 50d (2.4 folds, P<0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly.  	miRNA-corp.d61.s4.e10	Relation_Trigger	up-regulated 	11
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e0	Specific_miRNAs	miR-23a/b 	1
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e4	Relation_Trigger	expressed differentially 	5
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e5	Relation_Trigger	down-regulated 	6
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e6	Relation_Trigger	up-regulated 	7
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e7	Specific_miRNAs	let-7e 	8
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e8	Diseases	TLE 	9
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e9	Species	rats 	10
miRNA-corp.d61.s5	Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included).  	miRNA-corp.d61.s5.e10	Species	rats 	11
miRNA-corp.d61.s6	Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE).  	miRNA-corp.d61.s6.e0	Specific_miRNAs	miR-23a/b 	1
miRNA-corp.d61.s6	Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE).  	miRNA-corp.d61.s6.e1	Diseases	status epilepticus 	2
miRNA-corp.d61.s6	Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE).  	miRNA-corp.d61.s6.e2	Diseases	SE 	3
miRNA-corp.d61.s6	Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE).  	miRNA-corp.d61.s6.e3	Specific_miRNAs	let-7e 	4
miRNA-corp.d61.s6	Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE).  	miRNA-corp.d61.s6.e4	Species	rat 	5
miRNA-corp.d61.s7	Also the temporal change of the let-7e and miR-23a/b expression in the epileptogenesis indicated their underlying functions on TLE.    	miRNA-corp.d61.s7.e0	Specific_miRNAs	let-7e 	1
miRNA-corp.d61.s7	Also the temporal change of the let-7e and miR-23a/b expression in the epileptogenesis indicated their underlying functions on TLE.    	miRNA-corp.d61.s7.e1	Specific_miRNAs	miR-23a/b 	2
miRNA-corp.d61.s7	Also the temporal change of the let-7e and miR-23a/b expression in the epileptogenesis indicated their underlying functions on TLE.    	miRNA-corp.d61.s7.e2	Diseases	TLE 	3
miRNA-corp.d61.s7	Also the temporal change of the let-7e and miR-23a/b expression in the epileptogenesis indicated their underlying functions on TLE.    	miRNA-corp.d61.s7.e3	Relation_Trigger	change of the let-7e and miR-23a/b expression 	4
miRNA-corp.d62.s5	By using scrAAV, we could increase expression efficiency and reduce immune response caused by vectors themselves.  	miRNA-corp.d62.s5.e0	Relation_Trigger	increase expression 	1
miRNA-corp.d62.s7	So far, it has been used in the treatment of hepatic diseases, central nervous system diseases, and eye diseases.  	miRNA-corp.d62.s7.e0	Diseases	central nervous system diseases 	1
miRNA-corp.d62.s7	So far, it has been used in the treatment of hepatic diseases, central nervous system diseases, and eye diseases.  	miRNA-corp.d62.s7.e1	Diseases	hepatic diseases 	2
miRNA-corp.d62.s7	So far, it has been used in the treatment of hepatic diseases, central nervous system diseases, and eye diseases.  	miRNA-corp.d62.s7.e2	Diseases	eye diseases 	3
miRNA-corp.d62.s8	It has also been used in the modifications of stem cells and as vectors for siRNA/miRNA and ribozymes.  	miRNA-corp.d62.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d62.s10	We mainly introduced the recent progress of scrAAV based therapy of Hemophilia B, in order to elucidate the potential and prospects of scrAAV in gene therapy.    	miRNA-corp.d62.s10.e0	Diseases	Hemophilia B 	1
miRNA-corp.d63.s0	Learning, retention and generalization of a mirror tracing skill in Alzheimer's disease.   	miRNA-corp.d63.s0.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d63.s1	The present study examined the ability of 12 patients with probable Alzheimer's disease (AD) and 12 age- and education-matched normal control (NC) subjects to learn and retain the visuomotor skills necessary to efficiently trace a pattern (e.g., a 4- or 6-pointed star) seen only in mirror-reversed view.  	miRNA-corp.d63.s1.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d63.s1	The present study examined the ability of 12 patients with probable Alzheimer's disease (AD) and 12 age- and education-matched normal control (NC) subjects to learn and retain the visuomotor skills necessary to efficiently trace a pattern (e.g., a 4- or 6-pointed star) seen only in mirror-reversed view.  	miRNA-corp.d63.s1.e1	Diseases	AD 	2
miRNA-corp.d63.s1	The present study examined the ability of 12 patients with probable Alzheimer's disease (AD) and 12 age- and education-matched normal control (NC) subjects to learn and retain the visuomotor skills necessary to efficiently trace a pattern (e.g., a 4- or 6-pointed star) seen only in mirror-reversed view.  	miRNA-corp.d63.s1.e2	Species	patients 	3
miRNA-corp.d63.s2	Those AD (N=6) and NC (N=7) subjects who were able to initially perform the basic mirror tracing task did not differ significantly in initial level of performance, learning over trials, retention of the skill over a 30-min delay interval, and generalization of the skill to a new figure or to the opposite direction of tracing.  	miRNA-corp.d63.s2.e0	Diseases	AD 	1
miRNA-corp.d63.s3	The AD patients who were unable to initially perform the mirror tracing task were significantly worse than those who could perform the task on several neuropsychological measures sensitive to deficits in problem solving and executive functions, but not on tests of global cognitive decline, memory, language, or visuoperceptual functioning.  	miRNA-corp.d63.s3.e0	Diseases	AD 	1
miRNA-corp.d63.s3	The AD patients who were unable to initially perform the mirror tracing task were significantly worse than those who could perform the task on several neuropsychological measures sensitive to deficits in problem solving and executive functions, but not on tests of global cognitive decline, memory, language, or visuoperceptual functioning.  	miRNA-corp.d63.s3.e1	Species	patients 	2
miRNA-corp.d63.s4	These results indicate that acquisition and retention of a complex visuomotor skill can proceed normally in the early stages of AD in those individuals who can initially perform the basic task, and that inability to perform the basic task may be related to the frontal lobe dysfunction that is often prominent in the disorder.    	miRNA-corp.d63.s4.e0	Diseases	frontal lobe dysfunction 	1
miRNA-corp.d63.s4	These results indicate that acquisition and retention of a complex visuomotor skill can proceed normally in the early stages of AD in those individuals who can initially perform the basic task, and that inability to perform the basic task may be related to the frontal lobe dysfunction that is often prominent in the disorder.    	miRNA-corp.d63.s4.e1	Diseases	AD 	2
miRNA-corp.d64.s0	This review reports the current knowledge of microRNA (miRNA) expression in pituitary adenomas, focusing on recent microarray data.  	miRNA-corp.d64.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d64.s0	This review reports the current knowledge of microRNA (miRNA) expression in pituitary adenomas, focusing on recent microarray data.  	miRNA-corp.d64.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d64.s0	This review reports the current knowledge of microRNA (miRNA) expression in pituitary adenomas, focusing on recent microarray data.  	miRNA-corp.d64.s0.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d64.s1	Moreover, a discussion is provided concerning the possible role of validated and putative targets of the most dysregulated miRNA in pituitary adenoma pathogenesis.    	miRNA-corp.d64.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d64.s1	Moreover, a discussion is provided concerning the possible role of validated and putative targets of the most dysregulated miRNA in pituitary adenoma pathogenesis.    	miRNA-corp.d64.s1.e1	Diseases	pituitary adenoma 	2
miRNA-corp.d64.s1	Moreover, a discussion is provided concerning the possible role of validated and putative targets of the most dysregulated miRNA in pituitary adenoma pathogenesis.    	miRNA-corp.d64.s1.e2	Relation_Trigger	dysregulated 	3
miRNA-corp.d64.s1	Moreover, a discussion is provided concerning the possible role of validated and putative targets of the most dysregulated miRNA in pituitary adenoma pathogenesis.    	miRNA-corp.d64.s1.e3	Relation_Trigger	putative targets 	4
miRNA-corp.d64.s2	MicroRNAs and possible role in pituitary adenoma.   	miRNA-corp.d64.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d64.s2	MicroRNAs and possible role in pituitary adenoma.   	miRNA-corp.d64.s2.e1	Diseases	pituitary adenoma 	2
miRNA-corp.d65.s0	Expression profile of MicroRNAs in young stroke patients.   	miRNA-corp.d65.s0.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d65.s0	Expression profile of MicroRNAs in young stroke patients.   	miRNA-corp.d65.s0.e1	Diseases	stroke 	2
miRNA-corp.d65.s0	Expression profile of MicroRNAs in young stroke patients.   	miRNA-corp.d65.s0.e2	Species	patients 	3
miRNA-corp.d65.s1	BACKGROUND: The methods currently available for diagnosis and prognosis of cerebral ischaemia still require further improvements.  	miRNA-corp.d65.s1.e0	Diseases	cerebral ischaemia 	1
miRNA-corp.d65.s3	Total RNA extracted from whole blood was subjected to miroRNA profiling and real-time PCR analysis.  	miRNA-corp.d65.s3.e0	Non-Specific_miRNAs	miroRNA 	1
miRNA-corp.d65.s4	miRNAs that are implicated in the endothelial/vascular function, erythropoiesis, angiogenesis and neural function showed differential expression profile as compared to the normal control.  	miRNA-corp.d65.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d65.s4	miRNAs that are implicated in the endothelial/vascular function, erythropoiesis, angiogenesis and neural function showed differential expression profile as compared to the normal control.  	miRNA-corp.d65.s4.e1	Relation_Trigger	differential expression 	2
miRNA-corp.d65.s5	Interestingly, miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles.  	miRNA-corp.d65.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d65.s5	Interestingly, miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles.  	miRNA-corp.d65.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d65.s5	Interestingly, miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles.  	miRNA-corp.d65.s5.e2	Diseases	hypoxic 	3
miRNA-corp.d65.s6	Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as cancer and diabetes.  	miRNA-corp.d65.s6.e0	Non-Specific_miRNAs	Micro-RNAs 	1
miRNA-corp.d65.s6	Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as cancer and diabetes.  	miRNA-corp.d65.s6.e1	Diseases	diabetes 	2
miRNA-corp.d65.s6	Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as cancer and diabetes.  	miRNA-corp.d65.s6.e2	Diseases	cancer 	3
miRNA-corp.d65.s7	We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify characteristic patterns in ischaemic stroke.  	miRNA-corp.d65.s7.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d65.s7	We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify characteristic patterns in ischaemic stroke.  	miRNA-corp.d65.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d65.s7	We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify characteristic patterns in ischaemic stroke.  	miRNA-corp.d65.s7.e2	Diseases	ischaemic stroke 	3
miRNA-corp.d65.s8	METHODS/PRINCIPAL FINDINGS: The ischaemic stroke patients aged between 18-49 years, characterized based on World Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis [n=8] b) Small-vessel disease [n=3] c) Cardioembolism [n=5] d) Undetermined cause [n=3].  	miRNA-corp.d65.s8.e0	Diseases	ischaemic stroke 	1
miRNA-corp.d65.s8	METHODS/PRINCIPAL FINDINGS: The ischaemic stroke patients aged between 18-49 years, characterized based on World Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis [n=8] b) Small-vessel disease [n=3] c) Cardioembolism [n=5] d) Undetermined cause [n=3].  	miRNA-corp.d65.s8.e1	Diseases	atherosclerosis 	2
miRNA-corp.d65.s8	METHODS/PRINCIPAL FINDINGS: The ischaemic stroke patients aged between 18-49 years, characterized based on World Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis [n=8] b) Small-vessel disease [n=3] c) Cardioembolism [n=5] d) Undetermined cause [n=3].  	miRNA-corp.d65.s8.e2	Species	patients 	3
miRNA-corp.d65.s9	The patients' functional status at the time of blood sampling (at the outpatient clinics) was evaluated with the modified Rankin Scale (mRS).  	miRNA-corp.d65.s9.e0	Species	patients 	1
miRNA-corp.d65.s10	CONCLUSION: We demonstrate that the peripheral blood miRNAs and their profiles can be developed as biomarkers in diagnosis and prognosis of cerebral ischaemic stroke.  	miRNA-corp.d65.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d65.s10	CONCLUSION: We demonstrate that the peripheral blood miRNAs and their profiles can be developed as biomarkers in diagnosis and prognosis of cerebral ischaemic stroke.  	miRNA-corp.d65.s10.e1	Diseases	cerebral ischaemic stroke 	2
miRNA-corp.d65.s11	The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.    	miRNA-corp.d65.s11.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d65.s11	The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.    	miRNA-corp.d65.s11.e1	Diseases	stroke 	2
miRNA-corp.d65.s11	The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.    	miRNA-corp.d65.s11.e2	Relation_Trigger	dysregulated 	3
miRNA-corp.d65.s11	The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.    	miRNA-corp.d65.s11.e3	Species	patients 	4
miRNA-corp.d66.s0	We also indentified 97 differentially expressed microRNAs among 240 tumor and 10 normal samples.  	miRNA-corp.d66.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d66.s0	We also indentified 97 differentially expressed microRNAs among 240 tumor and 10 normal samples.  	miRNA-corp.d66.s0.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d66.s0	We also indentified 97 differentially expressed microRNAs among 240 tumor and 10 normal samples.  	miRNA-corp.d66.s0.e2	Diseases	tumor 	3
miRNA-corp.d66.s1	22 of which have been reported to affect glioblastoma and 50 of which were implicated in other cancers and brain diseases.  	miRNA-corp.d66.s1.e0	Diseases	glioblastoma 	1
miRNA-corp.d66.s1	22 of which have been reported to affect glioblastoma and 50 of which were implicated in other cancers and brain diseases.  	miRNA-corp.d66.s1.e1	Diseases	brain diseases 	2
miRNA-corp.d66.s1	22 of which have been reported to affect glioblastoma and 50 of which were implicated in other cancers and brain diseases.  	miRNA-corp.d66.s1.e2	Diseases	cancers 	3
miRNA-corp.d66.s2	Though a lot of research has been focused on this disease, the causes and pathogenesis of glioblastoma have not been indentified clearly.  	miRNA-corp.d66.s2.e0	Diseases	glioblastoma 	1
miRNA-corp.d66.s3	RESULTS: We indentified 1,236 significantly differentially expressed genes, and 30 pathways enriched in the set of differentially expressed genes among 243 tumor and 11 normal samples.  	miRNA-corp.d66.s3.e0	Relation_Trigger	differentially expressed 	1
miRNA-corp.d66.s3	RESULTS: We indentified 1,236 significantly differentially expressed genes, and 30 pathways enriched in the set of differentially expressed genes among 243 tumor and 11 normal samples.  	miRNA-corp.d66.s3.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d66.s3	RESULTS: We indentified 1,236 significantly differentially expressed genes, and 30 pathways enriched in the set of differentially expressed genes among 243 tumor and 11 normal samples.  	miRNA-corp.d66.s3.e2	Diseases	tumor 	3
miRNA-corp.d66.s4	Investigation gene and microRNA expression in glioblastoma.   	miRNA-corp.d66.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d66.s4	Investigation gene and microRNA expression in glioblastoma.   	miRNA-corp.d66.s4.e1	Diseases	glioblastoma 	2
miRNA-corp.d66.s5	BACKGROUND: Glioblastoma is the most common primary brain tumor in adults.  	miRNA-corp.d66.s5.e0	Diseases	Glioblastoma 	1
miRNA-corp.d66.s5	BACKGROUND: Glioblastoma is the most common primary brain tumor in adults.  	miRNA-corp.d66.s5.e1	Diseases	brain tumor 	2
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e2	Diseases	glioblastoma 	3
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e3	Relation_Trigger	differential expressed 	4
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e4	Diseases	Glioblastoma 	5
miRNA-corp.d66.s6	CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients.  	miRNA-corp.d66.s6.e5	Species	patients 	6
miRNA-corp.d66.s7	Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated with Cell Signalling and Nervous System.  	miRNA-corp.d66.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d66.s7	Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated with Cell Signalling and Nervous System.  	miRNA-corp.d66.s7.e1	Relation_Trigger	targeted 	2
miRNA-corp.d66.s7	Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated with Cell Signalling and Nervous System.  	miRNA-corp.d66.s7.e2	Relation_Trigger	associated 	3
miRNA-corp.d66.s7	Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated with Cell Signalling and Nervous System.  	miRNA-corp.d66.s7.e3	Relation_Trigger	target 	4
miRNA-corp.d66.s8	We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.  	miRNA-corp.d66.s8.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d66.s8	We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.  	miRNA-corp.d66.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d66.s8	We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.  	miRNA-corp.d66.s8.e2	Relation_Trigger	targets 	3
miRNA-corp.d66.s8	We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.  	miRNA-corp.d66.s8.e3	Relation_Trigger	tumor suppressor 	4
miRNA-corp.d66.s8	We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.  	miRNA-corp.d66.s8.e4	Relation_Trigger	target 	5
miRNA-corp.d66.s9	We regressed gene expression on microRNA expression in 237 tumor tissues and 10 normal tissues comprehensively.  	miRNA-corp.d66.s9.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d66.s9	We regressed gene expression on microRNA expression in 237 tumor tissues and 10 normal tissues comprehensively.  	miRNA-corp.d66.s9.e1	Diseases	tumor 	2
miRNA-corp.d66.s10	These findings gave important clues to study of the carcinogenic process in glioblastomas.    	miRNA-corp.d66.s10.e0	Diseases	glioblastomas 	1
miRNA-corp.d67.s0	CONCLUSION: Our results indicate a time-dependent expression pattern of miR-223 and miR-124a in a mouse model of SCI.  	miRNA-corp.d67.s0.e0	Specific_miRNAs	miR-223 	1
miRNA-corp.d67.s0	CONCLUSION: Our results indicate a time-dependent expression pattern of miR-223 and miR-124a in a mouse model of SCI.  	miRNA-corp.d67.s0.e1	Specific_miRNAs	miR-124a 	2
miRNA-corp.d67.s0	CONCLUSION: Our results indicate a time-dependent expression pattern of miR-223 and miR-124a in a mouse model of SCI.  	miRNA-corp.d67.s0.e2	Diseases	SCI 	3
miRNA-corp.d67.s0	CONCLUSION: Our results indicate a time-dependent expression pattern of miR-223 and miR-124a in a mouse model of SCI.  	miRNA-corp.d67.s0.e3	Species	mouse 	4
miRNA-corp.d67.s1	In this study, the time course of miRNA-223 expression may be related to inflammatory responses after SCI, and the time course of decreased miR-124a expression may reflect cell death.    	miRNA-corp.d67.s1.e0	Specific_miRNAs	miRNA-223 	1
miRNA-corp.d67.s1	In this study, the time course of miRNA-223 expression may be related to inflammatory responses after SCI, and the time course of decreased miR-124a expression may reflect cell death.    	miRNA-corp.d67.s1.e1	Specific_miRNAs	miR-124a 	2
miRNA-corp.d67.s1	In this study, the time course of miRNA-223 expression may be related to inflammatory responses after SCI, and the time course of decreased miR-124a expression may reflect cell death.    	miRNA-corp.d67.s1.e2	Diseases	SCI 	3
miRNA-corp.d67.s1	In this study, the time course of miRNA-223 expression may be related to inflammatory responses after SCI, and the time course of decreased miR-124a expression may reflect cell death.    	miRNA-corp.d67.s1.e3	Relation_Trigger	decreased miR-124a expression 	4
miRNA-corp.d67.s2	However, miR-124a, which was present in the normal spinal cord, was not observed at the injured site.  	miRNA-corp.d67.s2.e0	Specific_miRNAs	miR-124a 	1
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e0	Specific_miRNAs	miR-223 	1
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e1	Specific_miRNAs	MiR-124a 	2
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e2	Diseases	SCI 	3
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e3	Diseases	SCI 	4
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e4	Relation_Trigger	expression decreased 	5
miRNA-corp.d67.s3	RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI.  	miRNA-corp.d67.s3.e5	Relation_Trigger	decreased significantly 	6
miRNA-corp.d67.s4	In situ hybridization demonstrated the presence of miR-223 around the injured site.  	miRNA-corp.d67.s4.e0	Specific_miRNAs	miR-223 	1
miRNA-corp.d67.s5	METHODS: We examined the expression of miRNA (miR)-223 and miR-124a in a mouse model at 6 h, 12 h, 1 day, 3 days and 7 days after SCI using quantitative PCR.  	miRNA-corp.d67.s5.e0	Specific_miRNAs	miRNA (miR)-223 	1
miRNA-corp.d67.s5	METHODS: We examined the expression of miRNA (miR)-223 and miR-124a in a mouse model at 6 h, 12 h, 1 day, 3 days and 7 days after SCI using quantitative PCR.  	miRNA-corp.d67.s5.e1	Specific_miRNAs	miR-124a 	2
miRNA-corp.d67.s5	METHODS: We examined the expression of miRNA (miR)-223 and miR-124a in a mouse model at 6 h, 12 h, 1 day, 3 days and 7 days after SCI using quantitative PCR.  	miRNA-corp.d67.s5.e2	Diseases	SCI 	3
miRNA-corp.d67.s5	METHODS: We examined the expression of miRNA (miR)-223 and miR-124a in a mouse model at 6 h, 12 h, 1 day, 3 days and 7 days after SCI using quantitative PCR.  	miRNA-corp.d67.s5.e3	Species	mouse 	4
miRNA-corp.d67.s6	The miRNA expression was confirmed by in situ hybridization.  	miRNA-corp.d67.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d67.s7	MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease.  	miRNA-corp.d67.s7.e0	Non-Specific_miRNAs	MiRNAs 	1
miRNA-corp.d67.s7	MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease.  	miRNA-corp.d67.s7.e1	Relation_Trigger	target 	2
miRNA-corp.d67.s7	MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease.  	miRNA-corp.d67.s7.e2	Relation_Trigger	binding 	3
miRNA-corp.d67.s7	MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease.  	miRNA-corp.d67.s7.e3	Relation_Trigger	suppress 	4
miRNA-corp.d67.s7	MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease.  	miRNA-corp.d67.s7.e4	Relation_Trigger	regulation 	5
miRNA-corp.d67.s8	The purpose of this study was to examine miRNA expression after SCI. SETTING: Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University.  	miRNA-corp.d67.s8.e0	Diseases	SCI 	1
miRNA-corp.d67.s8	The purpose of this study was to examine miRNA expression after SCI. SETTING: Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University.  	miRNA-corp.d67.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d67.s9	STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice.  	miRNA-corp.d67.s9.e0	Diseases	spinal cord injury 	1
miRNA-corp.d67.s9	STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice.  	miRNA-corp.d67.s9.e1	Diseases	SCI 	2
miRNA-corp.d67.s9	STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice.  	miRNA-corp.d67.s9.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d67.s9	STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice.  	miRNA-corp.d67.s9.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d67.s9	STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice.  	miRNA-corp.d67.s9.e4	Species	mice 	5
miRNA-corp.d67.s10	OBJECTIVES: The recent discovery of miRNAs suggests a novel regulatory control over gene expression during plant and animal development.  	miRNA-corp.d67.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d67.s10	OBJECTIVES: The recent discovery of miRNAs suggests a novel regulatory control over gene expression during plant and animal development.  	miRNA-corp.d67.s10.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d67.s11	Responses of microRNAs 124a and 223 following spinal cord injury in mice.   	miRNA-corp.d67.s11.e0	Specific_miRNAs	microRNAs 124a and 223 	1
miRNA-corp.d67.s11	Responses of microRNAs 124a and 223 following spinal cord injury in mice.   	miRNA-corp.d67.s11.e1	Diseases	spinal cord injury 	2
miRNA-corp.d67.s11	Responses of microRNAs 124a and 223 following spinal cord injury in mice.   	miRNA-corp.d67.s11.e2	Species	mice 	3
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e3	Relation_Trigger	Aberrant microRNA expression 	4
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e4	Relation_Trigger	targets 	5
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e5	Specific_miRNAs	miR-29a 	6
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e6	Diseases	Alzheimer disease 	7
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e7	Genes/Proteins	neurone navigator 3 	8
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e8	Relation_Trigger	target 	9
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e9	Relation_Trigger	translational repression 	10
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e10	Relation_Trigger	regulate 	11
miRNA-corp.d68.s0	Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs.  	miRNA-corp.d68.s0.e11	Diseases	neurodegenerative diseases 	12
miRNA-corp.d68.s1	MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay.  	miRNA-corp.d68.s1.e0	Specific_miRNAs	MiR-29a 	1
miRNA-corp.d68.s1	MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay.  	miRNA-corp.d68.s1.e1	Relation_Trigger	down-regulation 	2
miRNA-corp.d68.s1	MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay.  	miRNA-corp.d68.s1.e2	Genes/Proteins	NAV3 	3
miRNA-corp.d68.s2	However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains.  	miRNA-corp.d68.s2.e0	Relation_Trigger	down-regulation 	1
miRNA-corp.d68.s2	However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains.  	miRNA-corp.d68.s2.e1	Specific_miRNAs	miR-29a 	2
miRNA-corp.d68.s2	However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains.  	miRNA-corp.d68.s2.e2	Diseases	Alzheimer disease 	3
miRNA-corp.d68.s2	However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains.  	miRNA-corp.d68.s2.e3	Diseases	AD 	4
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e0	Relation_Trigger	principal target 	1
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e1	Genes/Proteins	neurone navigator 3 	2
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e2	Genes/Proteins	NAV3 	3
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e3	Genes/Proteins	NAV3 	4
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e4	Specific_miRNAs	miR-29a 	5
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e5	Diseases	AD 	6
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e6	Relation_Trigger	Target 	7
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e7	Relation_Trigger	regulator 	8
miRNA-corp.d68.s3	The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains.  	miRNA-corp.d68.s3.e8	Relation_Trigger	levels were elevated 	9
miRNA-corp.d68.s5	RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR.  	miRNA-corp.d68.s5.e0	Diseases	amyotrophic lateral sclerosis 	1
miRNA-corp.d68.s5	RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR.  	miRNA-corp.d68.s5.e1	Relation_Trigger	up-regulation 	2
miRNA-corp.d68.s5	RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR.  	miRNA-corp.d68.s5.e2	Specific_miRNAs	miR-29a 	3
miRNA-corp.d68.s5	RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR.  	miRNA-corp.d68.s5.e3	Specific_miRNAs	miR-29b 	4
miRNA-corp.d68.s5	RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR.  	miRNA-corp.d68.s5.e4	Specific_miRNAs	miR-338-3p 	5
miRNA-corp.d68.s6	To identify miRNAs closely associated with neurodegeneration, we performed miRNA expression profiling of brain tissues of various neurodegenerative diseases.  	miRNA-corp.d68.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d68.s6	To identify miRNAs closely associated with neurodegeneration, we performed miRNA expression profiling of brain tissues of various neurodegenerative diseases.  	miRNA-corp.d68.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d68.s6	To identify miRNAs closely associated with neurodegeneration, we performed miRNA expression profiling of brain tissues of various neurodegenerative diseases.  	miRNA-corp.d68.s6.e2	Relation_Trigger	associated 	3
miRNA-corp.d68.s6	To identify miRNAs closely associated with neurodegeneration, we performed miRNA expression profiling of brain tissues of various neurodegenerative diseases.  	miRNA-corp.d68.s6.e3	Diseases	neurodegenerative diseases 	4
miRNA-corp.d68.s7	METHODS: We initially studied the frontal cortex derived from three amyotrophic lateral sclerosis patients by using a microarray of 723 human miRNAs.  	miRNA-corp.d68.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d68.s7	METHODS: We initially studied the frontal cortex derived from three amyotrophic lateral sclerosis patients by using a microarray of 723 human miRNAs.  	miRNA-corp.d68.s7.e1	Species	patients 	2
miRNA-corp.d68.s7	METHODS: We initially studied the frontal cortex derived from three amyotrophic lateral sclerosis patients by using a microarray of 723 human miRNAs.  	miRNA-corp.d68.s7.e2	Species	human 	3
miRNA-corp.d68.s7	METHODS: We initially studied the frontal cortex derived from three amyotrophic lateral sclerosis patients by using a microarray of 723 human miRNAs.  	miRNA-corp.d68.s7.e3	Diseases	amyotrophic lateral sclerosis 	4
miRNA-corp.d68.s8	Accumulating evidence indicates that various miRNAs, expressed in a spatially and temporally controlled that manner in the brain plays a key role in neuronal development.  	miRNA-corp.d68.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d68.s9	However, at present, the pathological implication of aberrant miRNA expression in neurodegenerative events remains largely unknown.  	miRNA-corp.d68.s9.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d68.s9	However, at present, the pathological implication of aberrant miRNA expression in neurodegenerative events remains largely unknown.  	miRNA-corp.d68.s9.e1	Relation_Trigger	aberrant miRNA expression 	2
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e0	Relation_Trigger	underexpression 	1
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e1	Relation_Trigger	enhancing neuronal NAV3 expression 	2
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e2	Genes/Proteins	NAV3 	3
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e3	Diseases	AD 	4
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e4	Diseases	AD 	5
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e5	Specific_miRNAs	miR-29a 	6
miRNA-corp.d68.s10	By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.    	miRNA-corp.d68.s10.e6	Genes/Proteins	NAV3 	7
miRNA-corp.d69.s0	Many miRNA targets have been computationally predicted but only a limited number of these were experimentally validated.  	miRNA-corp.d69.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s0	Many miRNA targets have been computationally predicted but only a limited number of these were experimentally validated.  	miRNA-corp.d69.s0.e1	Relation_Trigger	targets 	2
miRNA-corp.d69.s1	However, interactions between miRNAs and their targets are complex and very often there are numerous putative miRNA recognition sites in mRNAs.  	miRNA-corp.d69.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d69.s1	However, interactions between miRNAs and their targets are complex and very often there are numerous putative miRNA recognition sites in mRNAs.  	miRNA-corp.d69.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d69.s1	However, interactions between miRNAs and their targets are complex and very often there are numerous putative miRNA recognition sites in mRNAs.  	miRNA-corp.d69.s1.e2	Relation_Trigger	targets 	3
miRNA-corp.d69.s2	Therefore, it is of particular interest to reliably predict potential miRNA targets which might be involved in these diseases.  	miRNA-corp.d69.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s2	Therefore, it is of particular interest to reliably predict potential miRNA targets which might be involved in these diseases.  	miRNA-corp.d69.s2.e1	Relation_Trigger	potential miRNA targets 	2
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e2	Relation_Trigger	altered miRNA expression 	3
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e3	Diseases	cancer 	4
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e4	Diseases	neurodegenerative diseases 	5
miRNA-corp.d69.s3	Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases.  	miRNA-corp.d69.s3.e5	Relation_Trigger	deregulation 	6
miRNA-corp.d69.s4	In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed.  	miRNA-corp.d69.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s4	In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed.  	miRNA-corp.d69.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d69.s4	In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed.  	miRNA-corp.d69.s4.e2	Relation_Trigger	target 	3
miRNA-corp.d69.s4	In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed.  	miRNA-corp.d69.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d69.s5	Hence, finding a functional miRNA target is still a challenging task.  	miRNA-corp.d69.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s5	Hence, finding a functional miRNA target is still a challenging task.  	miRNA-corp.d69.s5.e1	Relation_Trigger	functional miRNA target 	2
miRNA-corp.d69.s6	Although a variety of miRNA target prediction algorithms are available, results of their application are often inconsistent.  	miRNA-corp.d69.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s6	Although a variety of miRNA target prediction algorithms are available, results of their application are often inconsistent.  	miRNA-corp.d69.s6.e1	Relation_Trigger	target 	2
miRNA-corp.d69.s7	microRNAs (miRNAs) are endogenous non-coding RNAs that control gene expression at the posttranscriptional level.  	miRNA-corp.d69.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d69.s7	microRNAs (miRNAs) are endogenous non-coding RNAs that control gene expression at the posttranscriptional level.  	miRNA-corp.d69.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d69.s8	These small regulatory molecules play a key role in the majority of biological processes and their expression is also tightly regulated.  	miRNA-corp.d69.s8.e0	Relation_Trigger	expression is also tightly regulated 	1
miRNA-corp.d69.s8	These small regulatory molecules play a key role in the majority of biological processes and their expression is also tightly regulated.  	miRNA-corp.d69.s8.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d69.s9	Practical Aspects of microRNA Target Prediction.   	miRNA-corp.d69.s9.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d69.s9	Practical Aspects of microRNA Target Prediction.   	miRNA-corp.d69.s9.e1	Relation_Trigger	Target 	2
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e1	Diseases	trinucleotide repeat expansion diseases 	2
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e2	Diseases	TREDs 	3
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e3	Diseases	Huntington's disease 	4
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e4	Diseases	HD 	5
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e5	Diseases	spinocerebellar ataxias 	6
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e6	Diseases	SCAs 	7
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e7	Diseases	myotonic dystrophy type 1 	8
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e8	Diseases	DM1 	9
miRNA-corp.d69.s10	Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).    	miRNA-corp.d69.s10.e9	Diseases	neurological disorders 	10
miRNA-corp.d70.s0	CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA.  	miRNA-corp.d70.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s0	CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA.  	miRNA-corp.d70.s0.e1	Relation_Trigger	altered miRNAs expression 	2
miRNA-corp.d70.s0	CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA.  	miRNA-corp.d70.s0.e2	Diseases	acromegaly 	3
miRNA-corp.d70.s0	CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA.  	miRNA-corp.d70.s0.e3	Diseases	pituitary adenomas 	4
miRNA-corp.d70.s1	Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.    	miRNA-corp.d70.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s1	Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.    	miRNA-corp.d70.s1.e1	Diseases	pituitary adenoma 	2
miRNA-corp.d70.s1	Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.    	miRNA-corp.d70.s1.e2	Relation_Trigger	targets 	3
miRNA-corp.d70.s1	Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.    	miRNA-corp.d70.s1.e3	Diseases	adenoma 	4
miRNA-corp.d70.s2	Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression.  	miRNA-corp.d70.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s2	Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression.  	miRNA-corp.d70.s2.e1	Diseases	cancer 	2
miRNA-corp.d70.s3	Seven miRNAs were differentially expressed between SSA responders or GH nonresponders.  	miRNA-corp.d70.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s3	Seven miRNAs were differentially expressed between SSA responders or GH nonresponders.  	miRNA-corp.d70.s3.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d70.s4	RESULTS: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries.  	miRNA-corp.d70.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s4	RESULTS: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries.  	miRNA-corp.d70.s4.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d70.s4	RESULTS: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries.  	miRNA-corp.d70.s4.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d70.s5	We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.  	miRNA-corp.d70.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s5	We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.  	miRNA-corp.d70.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d70.s5	We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.  	miRNA-corp.d70.s5.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d70.s5	We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.  	miRNA-corp.d70.s5.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d70.s6	Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients.  	miRNA-corp.d70.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s6	Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients.  	miRNA-corp.d70.s6.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d70.s6	Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients.  	miRNA-corp.d70.s6.e2	Diseases	tumor 	3
miRNA-corp.d70.s6	Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients.  	miRNA-corp.d70.s6.e3	Species	patients 	4
miRNA-corp.d70.s6	Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients.  	miRNA-corp.d70.s6.e4	Species	patients 	5
miRNA-corp.d70.s7	Differential expression of 9 miRNAs was observed between micro- and macro-adenomas.  	miRNA-corp.d70.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s7	Differential expression of 9 miRNAs was observed between micro- and macro-adenomas.  	miRNA-corp.d70.s7.e1	Diseases	macro-adenomas 	2
miRNA-corp.d70.s7	Differential expression of 9 miRNAs was observed between micro- and macro-adenomas.  	miRNA-corp.d70.s7.e2	Relation_Trigger	Differential expression 	3
miRNA-corp.d70.s8	Differential expression of microRNAs in GH-secreting pituitary adenomas.   	miRNA-corp.d70.s8.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d70.s8	Differential expression of microRNAs in GH-secreting pituitary adenomas.   	miRNA-corp.d70.s8.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d70.s8	Differential expression of microRNAs in GH-secreting pituitary adenomas.   	miRNA-corp.d70.s8.e2	Relation_Trigger	Differential expression 	3
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e3	Genes/Proteins	somatostatin 	4
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e4	Genes/Proteins	somatostatin 	5
miRNA-corp.d70.s9	BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA).  	miRNA-corp.d70.s9.e5	Diseases	tumor 	6
miRNA-corp.d70.s10	METHODS: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery.  	miRNA-corp.d70.s10.e0	Diseases	adenomas 	1
miRNA-corp.d70.s10	METHODS: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery.  	miRNA-corp.d70.s10.e1	Species	patients 	2
miRNA-corp.d70.s11	Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders.  	miRNA-corp.d70.s11.e0	Species	Patients 	1
miRNA-corp.d70.s11	Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders.  	miRNA-corp.d70.s11.e1	Species	patients 	2
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e0	Genes/Proteins	Gemin3 	1
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e1	Genes/Proteins	Gemin4 	2
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e2	Genes/Proteins	eIF2C2 	3
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e3	Relation_Trigger	associate 	4
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e4	Non-Specific_miRNAs	microRNAs 	5
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e5	Non-Specific_miRNAs	miRNAs 	6
miRNA-corp.d71.s0	We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs.  	miRNA-corp.d71.s0.e6	Genes/Proteins	SMN 	7
miRNA-corp.d71.s1	SMN is part of a large complex that functions in the assembly/restructuring of ribonucleoprotein (RNP) complexes.  	miRNA-corp.d71.s1.e0	Genes/Proteins	SMN 	1
miRNA-corp.d71.s2	Spinal muscular atrophy (SMA) is a common neurodegenerative disease that is caused by deletions or loss-of-function mutations in the Survival of Motor Neuron (SMN) protein.  	miRNA-corp.d71.s2.e0	Diseases	Spinal muscular atrophy 	1
miRNA-corp.d71.s2	Spinal muscular atrophy (SMA) is a common neurodegenerative disease that is caused by deletions or loss-of-function mutations in the Survival of Motor Neuron (SMN) protein.  	miRNA-corp.d71.s2.e1	Diseases	SMA 	2
miRNA-corp.d71.s2	Spinal muscular atrophy (SMA) is a common neurodegenerative disease that is caused by deletions or loss-of-function mutations in the Survival of Motor Neuron (SMN) protein.  	miRNA-corp.d71.s2.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d71.s2	Spinal muscular atrophy (SMA) is a common neurodegenerative disease that is caused by deletions or loss-of-function mutations in the Survival of Motor Neuron (SMN) protein.  	miRNA-corp.d71.s2.e3	Genes/Proteins	Survival of Motor Neuron (SMN) protein 	4
miRNA-corp.d71.s3	Numerous microRNPs in neuronal cells containing novel microRNAs.   	miRNA-corp.d71.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d71.s4	The chromosomal locations of most of the novel miRNAs were identified and indicate some phylogenetic conservation of the likely precursor structures.  	miRNA-corp.d71.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e0	Relation_Trigger	candidate region 	1
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e1	Diseases	early-onset parkinsonism 	2
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e2	Diseases	X-linked mental retardation 	3
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e3	Specific_miRNAs	miR-175 	4
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e5	Diseases	Waisman syndrome 	6
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e6	Diseases	MRX3 	7
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e7	Genes/Proteins	Waisman syndrome 	8
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e8	Genes/Proteins	MRX3 	9
miRNA-corp.d71.s5	Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3).  	miRNA-corp.d71.s5.e9	Diseases	neurologic diseases 	10
miRNA-corp.d71.s6	Here we report on miRNPs isolated from neuronal cell lines of mouse and human, and describe 53 novel miRNAs.  	miRNA-corp.d71.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d71.s6	Here we report on miRNPs isolated from neuronal cell lines of mouse and human, and describe 53 novel miRNAs.  	miRNA-corp.d71.s6.e1	Species	mouse 	2
miRNA-corp.d71.s6	Here we report on miRNPs isolated from neuronal cell lines of mouse and human, and describe 53 novel miRNAs.  	miRNA-corp.d71.s6.e2	Species	human 	3
miRNA-corp.d71.s7	Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans.  	miRNA-corp.d71.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d71.s7	Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans.  	miRNA-corp.d71.s7.e1	Species	nematode 	2
miRNA-corp.d71.s7	Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans.  	miRNA-corp.d71.s7.e2	Species	rat 	3
miRNA-corp.d71.s7	Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans.  	miRNA-corp.d71.s7.e3	Species	zebrafish 	4
miRNA-corp.d71.s7	Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans.  	miRNA-corp.d71.s7.e4	Species	Caenorhabditis elegans 	5
miRNA-corp.d71.s8	Also, several miRNAs identified as part of miRNPs in these cells appear to constitute two distinct subfamilies.  	miRNA-corp.d71.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d71.s9	These subfamilies comprise multiple copies of miRNAs on different chromosomes, suggesting an important function in the regulation of gene expression.    	miRNA-corp.d71.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d71.s9	These subfamilies comprise multiple copies of miRNAs on different chromosomes, suggesting an important function in the regulation of gene expression.    	miRNA-corp.d71.s9.e1	Relation_Trigger	regulation of gene expression 	2
miRNA-corp.d72.s0	Here we show that human platelets harbor an abundant and diverse array of microRNAs (miRNAs), which are known as key regulators of mRNA translation in other cell types.  	miRNA-corp.d72.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d72.s0	Here we show that human platelets harbor an abundant and diverse array of microRNAs (miRNAs), which are known as key regulators of mRNA translation in other cell types.  	miRNA-corp.d72.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d72.s0	Here we show that human platelets harbor an abundant and diverse array of microRNAs (miRNAs), which are known as key regulators of mRNA translation in other cell types.  	miRNA-corp.d72.s0.e2	Relation_Trigger	regulators of mRNA translation 	3
miRNA-corp.d72.s0	Here we show that human platelets harbor an abundant and diverse array of microRNAs (miRNAs), which are known as key regulators of mRNA translation in other cell types.  	miRNA-corp.d72.s0.e3	Species	human 	4
miRNA-corp.d72.s1	Further analyses revealed that platelets contain the Dicer and Argonaute 2 (Ago2) complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts, respectively.  	miRNA-corp.d72.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d72.s1	Further analyses revealed that platelets contain the Dicer and Argonaute 2 (Ago2) complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts, respectively.  	miRNA-corp.d72.s1.e1	Genes/Proteins	Dicer 	2
miRNA-corp.d72.s1	Further analyses revealed that platelets contain the Dicer and Argonaute 2 (Ago2) complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts, respectively.  	miRNA-corp.d72.s1.e2	Genes/Proteins	Argonaute 2 	3
miRNA-corp.d72.s1	Further analyses revealed that platelets contain the Dicer and Argonaute 2 (Ago2) complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts, respectively.  	miRNA-corp.d72.s1.e3	Genes/Proteins	Ago2 	4
miRNA-corp.d72.s2	Detection of the receptor P2Y(12) mRNA in Ago2 immunoprecipitates suggests that P2Y(12) expression may be subjected to miRNA control in human platelets.  	miRNA-corp.d72.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d72.s2	Detection of the receptor P2Y(12) mRNA in Ago2 immunoprecipitates suggests that P2Y(12) expression may be subjected to miRNA control in human platelets.  	miRNA-corp.d72.s2.e1	Genes/Proteins	Ago2 	2
miRNA-corp.d72.s2	Detection of the receptor P2Y(12) mRNA in Ago2 immunoprecipitates suggests that P2Y(12) expression may be subjected to miRNA control in human platelets.  	miRNA-corp.d72.s2.e2	Species	human 	3
miRNA-corp.d72.s4	Existence of a microRNA pathway in anucleate platelets.   	miRNA-corp.d72.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d72.s5	Platelets have a crucial role in the maintenance of hemostasis as well as in thrombosis and vessel occlusion, which underlie stroke and acute coronary syndromes.  	miRNA-corp.d72.s5.e0	Diseases	acute coronary syndromes 	1
miRNA-corp.d72.s5	Platelets have a crucial role in the maintenance of hemostasis as well as in thrombosis and vessel occlusion, which underlie stroke and acute coronary syndromes.  	miRNA-corp.d72.s5.e1	Diseases	stroke 	2
miRNA-corp.d72.s5	Platelets have a crucial role in the maintenance of hemostasis as well as in thrombosis and vessel occlusion, which underlie stroke and acute coronary syndromes.  	miRNA-corp.d72.s5.e2	Diseases	thrombosis 	3
miRNA-corp.d72.s6	Anucleate platelets contain mRNAs and are capable of protein synthesis, raising the issue of how these mRNAs are regulated.  	miRNA-corp.d72.s6.e0	Relation_Trigger	regulated 	1
miRNA-corp.d73.s0	miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.   	miRNA-corp.d73.s0.e0	Specific_miRNAs	miR-16-1 	1
miRNA-corp.d73.s0	miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.   	miRNA-corp.d73.s0.e1	Specific_miRNAs	miR-15a 	2
miRNA-corp.d73.s0	miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.   	miRNA-corp.d73.s0.e2	Diseases	cancer 	3
miRNA-corp.d73.s1	Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, and suppresses tumorigenicity both in vitro and in vivo.  	miRNA-corp.d73.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d73.s1	Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, and suppresses tumorigenicity both in vitro and in vivo.  	miRNA-corp.d73.s1.e1	Relation_Trigger	suppresses 	2
miRNA-corp.d73.s1	Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, and suppresses tumorigenicity both in vitro and in vivo.  	miRNA-corp.d73.s1.e2	Relation_Trigger	inhibits 	3
miRNA-corp.d73.s1	Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, and suppresses tumorigenicity both in vitro and in vivo.  	miRNA-corp.d73.s1.e3	Diseases	cancer 	4
miRNA-corp.d73.s2	MicroRNAs (miRNAs) encoded by the miR-15/16 cluster are known to act as tumor suppressors.  	miRNA-corp.d73.s2.e0	Specific_miRNAs	miR-15/16 	1
miRNA-corp.d73.s2	MicroRNAs (miRNAs) encoded by the miR-15/16 cluster are known to act as tumor suppressors.  	miRNA-corp.d73.s2.e1	Non-Specific_miRNAs	MicroRNAs 	2
miRNA-corp.d73.s2	MicroRNAs (miRNAs) encoded by the miR-15/16 cluster are known to act as tumor suppressors.  	miRNA-corp.d73.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d73.s2	MicroRNAs (miRNAs) encoded by the miR-15/16 cluster are known to act as tumor suppressors.  	miRNA-corp.d73.s2.e3	Relation_Trigger	tumor suppressors 	4
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e0	Diseases	chronic lymphocytic lymphoma 	1
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e1	Diseases	CLL 	2
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e3	Diseases	pituitary adenomas 	4
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e4	Diseases	prostate carcinoma 	5
miRNA-corp.d73.s3	Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.  	miRNA-corp.d73.s3.e5	Relation_Trigger	Down-regulation 	6
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e0	Specific_miRNAs	miR-15a 	1
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e1	Specific_miRNAs	miR-16-1 	2
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e2	Genes/Proteins	BCL2 	3
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e3	Genes/Proteins	MCL1 	4
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e4	Genes/Proteins	CCND1 	5
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e5	Genes/Proteins	WNT3A 	6
miRNA-corp.d73.s4	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A.  	miRNA-corp.d73.s4.e6	Relation_Trigger	targeting 	7
miRNA-corp.d73.s5	This review summarizes the discovery, functions, and clinical relevance of these miRNAs in cancer, particularly CLL.    	miRNA-corp.d73.s5.e0	Diseases	CLL 	1
miRNA-corp.d73.s5	This review summarizes the discovery, functions, and clinical relevance of these miRNAs in cancer, particularly CLL.    	miRNA-corp.d73.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d73.s5	This review summarizes the discovery, functions, and clinical relevance of these miRNAs in cancer, particularly CLL.    	miRNA-corp.d73.s5.e2	Diseases	cancer 	3
miRNA-corp.d74.s0	Molecular and cellular neurobiological studies of the miRNAs in neurodegeneration represent the exploration of a new Frontier of miRNAs biology and the potential development of new diagnostic tests and genetic therapies for neurodegenerative diseases.    	miRNA-corp.d74.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d74.s0	Molecular and cellular neurobiological studies of the miRNAs in neurodegeneration represent the exploration of a new Frontier of miRNAs biology and the potential development of new diagnostic tests and genetic therapies for neurodegenerative diseases.    	miRNA-corp.d74.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d74.s0	Molecular and cellular neurobiological studies of the miRNAs in neurodegeneration represent the exploration of a new Frontier of miRNAs biology and the potential development of new diagnostic tests and genetic therapies for neurodegenerative diseases.    	miRNA-corp.d74.s0.e2	Diseases	neurodegenerative diseases 	3
miRNA-corp.d74.s1	MiRNA studies in neurobiology showed their involvement in synaptic plasticity and brain diseases.  	miRNA-corp.d74.s1.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d74.s1	MiRNA studies in neurobiology showed their involvement in synaptic plasticity and brain diseases.  	miRNA-corp.d74.s1.e1	Diseases	brain diseases 	2
miRNA-corp.d74.s2	In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed.  	miRNA-corp.d74.s2.e0	Diseases	Alzheimer's 	1
miRNA-corp.d74.s2	In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed.  	miRNA-corp.d74.s2.e1	Diseases	Parkinson's 	2
miRNA-corp.d74.s2	In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed.  	miRNA-corp.d74.s2.e2	Relation_Trigger	correlations 	3
miRNA-corp.d74.s2	In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed.  	miRNA-corp.d74.s2.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d74.s2	In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed.  	miRNA-corp.d74.s2.e4	Diseases	neurodegenerative diseases 	5
miRNA-corp.d74.s3	In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded.  	miRNA-corp.d74.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d74.s3	In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded.  	miRNA-corp.d74.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d74.s3	In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded.  	miRNA-corp.d74.s3.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d74.s3	In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded.  	miRNA-corp.d74.s3.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d74.s3	In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded.  	miRNA-corp.d74.s3.e4	Relation_Trigger	regulate gene expression 	5
miRNA-corp.d74.s4	Interestingly, numerous miRNAs are expressed in a spatially and temporally controlled manner in the nervous system, suggesting that their posttrascriptional regulation may be particularly relevant in neural development and function.  	miRNA-corp.d74.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d74.s4	Interestingly, numerous miRNAs are expressed in a spatially and temporally controlled manner in the nervous system, suggesting that their posttrascriptional regulation may be particularly relevant in neural development and function.  	miRNA-corp.d74.s4.e1	Relation_Trigger	regulation 	2
miRNA-corp.d74.s5	Searching for MIND: microRNAs in neurodegenerative diseases.   	miRNA-corp.d74.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d74.s5	Searching for MIND: microRNAs in neurodegenerative diseases.   	miRNA-corp.d74.s5.e1	Diseases	neurodegenerative diseases 	2
miRNA-corp.d75.s4	As examples, a detailed description is given on the regeneration of functional sweat glands on burned skin as well as neural cells in middle cerebral artery occlusion (MCAO) animals upon MSC transplantation.  	miRNA-corp.d75.s4.e0	Diseases	middle cerebral artery occlusion 	1
miRNA-corp.d75.s4	As examples, a detailed description is given on the regeneration of functional sweat glands on burned skin as well as neural cells in middle cerebral artery occlusion (MCAO) animals upon MSC transplantation.  	miRNA-corp.d75.s4.e1	Diseases	MCAO 	2
miRNA-corp.d75.s5	The mechanisms of therapeutic effects of MSCs are attributed to their ability to migrate along chemokine gradients, differentiate into tissue-specific cells, enhance angiogenesis of wound tissue and regulate immune response.  	miRNA-corp.d75.s5.e0	Relation_Trigger	regulate 	1
miRNA-corp.d75.s5	The mechanisms of therapeutic effects of MSCs are attributed to their ability to migrate along chemokine gradients, differentiate into tissue-specific cells, enhance angiogenesis of wound tissue and regulate immune response.  	miRNA-corp.d75.s5.e1	Diseases	wound 	2
miRNA-corp.d75.s6	Special attention is given to miRNA expression and its relationship with the characteristics of MSCs.  	miRNA-corp.d75.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d75.s7	WHAT THE READER WILL GAIN: The gene expression profiles for mRNA, protein, microRNA and cell surface marker of MSCs are summarized.  	miRNA-corp.d75.s7.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d76.s0	MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.   	miRNA-corp.d76.s0.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d76.s0	MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.   	miRNA-corp.d76.s0.e1	Diseases	ischemia 	2
miRNA-corp.d76.s0	MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.   	miRNA-corp.d76.s0.e2	Diseases	middle cerebral artery occlusion 	3
miRNA-corp.d76.s0	MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.   	miRNA-corp.d76.s0.e3	Species	rats 	4
miRNA-corp.d76.s1	BACKGROUND AND PURPOSE: Several hundred small RNAs called microRNAs (miRNAs) have been identified and characterized from various organisms, including humans.  	miRNA-corp.d76.s1.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d76.s1	BACKGROUND AND PURPOSE: Several hundred small RNAs called microRNAs (miRNAs) have been identified and characterized from various organisms, including humans.  	miRNA-corp.d76.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d76.s1	BACKGROUND AND PURPOSE: Several hundred small RNAs called microRNAs (miRNAs) have been identified and characterized from various organisms, including humans.  	miRNA-corp.d76.s1.e2	Species	humans 	3
miRNA-corp.d76.s2	In humans, some of these miRNAs have been found to regulate (patho)physiologic conditions such as tumor progression/regression, cholesterol and glucose homeostasis, etc.  	miRNA-corp.d76.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d76.s2	In humans, some of these miRNAs have been found to regulate (patho)physiologic conditions such as tumor progression/regression, cholesterol and glucose homeostasis, etc.  	miRNA-corp.d76.s2.e1	Relation_Trigger	regulate 	2
miRNA-corp.d76.s2	In humans, some of these miRNAs have been found to regulate (patho)physiologic conditions such as tumor progression/regression, cholesterol and glucose homeostasis, etc.  	miRNA-corp.d76.s2.e2	Diseases	tumor progression 	3
miRNA-corp.d76.s2	In humans, some of these miRNAs have been found to regulate (patho)physiologic conditions such as tumor progression/regression, cholesterol and glucose homeostasis, etc.  	miRNA-corp.d76.s2.e3	Species	humans 	4
miRNA-corp.d76.s3	In this report, we present data on the miRNAs expressed under ischemic conditions in both the brain and blood of rats subjected to middle cerebral artery occlusion (MCAo).  	miRNA-corp.d76.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d76.s3	In this report, we present data on the miRNAs expressed under ischemic conditions in both the brain and blood of rats subjected to middle cerebral artery occlusion (MCAo).  	miRNA-corp.d76.s3.e1	Diseases	middle cerebral artery occlusion 	2
miRNA-corp.d76.s3	In this report, we present data on the miRNAs expressed under ischemic conditions in both the brain and blood of rats subjected to middle cerebral artery occlusion (MCAo).  	miRNA-corp.d76.s3.e2	Diseases	MCAo 	3
miRNA-corp.d76.s3	In this report, we present data on the miRNAs expressed under ischemic conditions in both the brain and blood of rats subjected to middle cerebral artery occlusion (MCAo).  	miRNA-corp.d76.s3.e3	Species	rats 	4
miRNA-corp.d76.s4	METHODS: Sprague-Dawley rats subjected to MCAo were reperfused for either 24 or 48 hours, and both blood and brain samples were harvested.  	miRNA-corp.d76.s4.e0	Diseases	MCAo 	1
miRNA-corp.d76.s4	METHODS: Sprague-Dawley rats subjected to MCAo were reperfused for either 24 or 48 hours, and both blood and brain samples were harvested.  	miRNA-corp.d76.s4.e1	Species	rats 	2
miRNA-corp.d76.s5	miRNA expression profiling and oligonucleotide microarray were carried out, and the data were validated by quantitative real-time polymerase chain reaction and correlated with published data on protein and gene expression in MCAo rats.  	miRNA-corp.d76.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d76.s5	miRNA expression profiling and oligonucleotide microarray were carried out, and the data were validated by quantitative real-time polymerase chain reaction and correlated with published data on protein and gene expression in MCAo rats.  	miRNA-corp.d76.s5.e1	Diseases	MCAo 	2
miRNA-corp.d76.s5	miRNA expression profiling and oligonucleotide microarray were carried out, and the data were validated by quantitative real-time polymerase chain reaction and correlated with published data on protein and gene expression in MCAo rats.  	miRNA-corp.d76.s5.e2	Species	rats 	3
miRNA-corp.d76.s5	miRNA expression profiling and oligonucleotide microarray were carried out, and the data were validated by quantitative real-time polymerase chain reaction and correlated with published data on protein and gene expression in MCAo rats.  	miRNA-corp.d76.s5.e3	Relation_Trigger	correlated 	4
miRNA-corp.d76.s6	RESULTS: We report here for the first time the involvement of miRNA regulation in brain pathogenesis associated with MCAo.  	miRNA-corp.d76.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d76.s6	RESULTS: We report here for the first time the involvement of miRNA regulation in brain pathogenesis associated with MCAo.  	miRNA-corp.d76.s6.e1	Diseases	MCAo 	2
miRNA-corp.d76.s6	RESULTS: We report here for the first time the involvement of miRNA regulation in brain pathogenesis associated with MCAo.  	miRNA-corp.d76.s6.e2	Relation_Trigger	regulation 	3
miRNA-corp.d76.s6	RESULTS: We report here for the first time the involvement of miRNA regulation in brain pathogenesis associated with MCAo.  	miRNA-corp.d76.s6.e3	Relation_Trigger	associated 	4
miRNA-corp.d76.s7	Comparison with the corresponding DNA microarray data revealed that the target mRNA expression is correlated with the regulation of miRNA.  	miRNA-corp.d76.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d76.s7	Comparison with the corresponding DNA microarray data revealed that the target mRNA expression is correlated with the regulation of miRNA.  	miRNA-corp.d76.s7.e1	Relation_Trigger	target 	2
miRNA-corp.d76.s7	Comparison with the corresponding DNA microarray data revealed that the target mRNA expression is correlated with the regulation of miRNA.  	miRNA-corp.d76.s7.e2	Relation_Trigger	regulation 	3
miRNA-corp.d76.s7	Comparison with the corresponding DNA microarray data revealed that the target mRNA expression is correlated with the regulation of miRNA.  	miRNA-corp.d76.s7.e3	Relation_Trigger	expression is correlated 	4
miRNA-corp.d76.s8	We have also provided evidence that some of the miRNAs that are highly expressed in the ischemic brain can be detected in blood samples.  	miRNA-corp.d76.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d76.s8	We have also provided evidence that some of the miRNAs that are highly expressed in the ischemic brain can be detected in blood samples.  	miRNA-corp.d76.s8.e1	Relation_Trigger	highly expressed 	2
miRNA-corp.d76.s9	CONCLUSIONS: Further studies are needed to evaluate the possible use of miRNAs as biomarkers in stroke and related pathologies.    	miRNA-corp.d76.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d76.s9	CONCLUSIONS: Further studies are needed to evaluate the possible use of miRNAs as biomarkers in stroke and related pathologies.    	miRNA-corp.d76.s9.e1	Diseases	stroke 	2
miRNA-corp.d77.s0	[A study on miRNA alternation after H2O2-induced PC12 cell apoptosis using microarray technique].   	miRNA-corp.d77.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d77.s2	OBJECTIVE: To screen the differentially expressed microRNAs(miRNA) between H2O2-induced PC12 cell apoptosis and normal PC12 cells with microarray chips.  	miRNA-corp.d77.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d77.s2	OBJECTIVE: To screen the differentially expressed microRNAs(miRNA) between H2O2-induced PC12 cell apoptosis and normal PC12 cells with microarray chips.  	miRNA-corp.d77.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d77.s2	OBJECTIVE: To screen the differentially expressed microRNAs(miRNA) between H2O2-induced PC12 cell apoptosis and normal PC12 cells with microarray chips.  	miRNA-corp.d77.s2.e2	Relation_Trigger	differentially expressed 	3
miRNA-corp.d77.s3	Of the 46 miRNAs in the H2O2 treated groups, 39 were similar to that of the control group and 6 were significantly down-regulated.  	miRNA-corp.d77.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d77.s3	Of the 46 miRNAs in the H2O2 treated groups, 39 were similar to that of the control group and 6 were significantly down-regulated.  	miRNA-corp.d77.s3.e1	Relation_Trigger	down-regulated 	2
miRNA-corp.d77.s4	CONCLUSION: Our preliminary data may provide a new potential foundation for further study of pathogenesis and its treatment of nerve cell apoptosis caused by cerebral ischemia reperfusion.    	miRNA-corp.d77.s4.e0	Diseases	cerebral ischemia reperfusion 	1
miRNA-corp.d77.s6	Expression of 68 miRNAs and 46 miRNAs were detected in both control group and the H2O2 treated groups.  	miRNA-corp.d77.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d77.s6	Expression of 68 miRNAs and 46 miRNAs were detected in both control group and the H2O2 treated groups.  	miRNA-corp.d77.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d77.s7	miRNAs were isolated from control (0 nmol/L H2O2) and H2O2 treated (at concentrations of 50, 100, 200, and 400 nmol/L H2O2, respectively) groups of the PC12 cells, respectively, and were then detected and analyzed by microarray chips.  	miRNA-corp.d77.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d78.s0	CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition.  	miRNA-corp.d78.s0.e0	Diseases	hypothalamic dysfunction 	1
miRNA-corp.d78.s0	CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition.  	miRNA-corp.d78.s0.e1	Genes/Proteins	prolactin 	2
miRNA-corp.d78.s0	CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition.  	miRNA-corp.d78.s0.e2	Diseases	pituitary tumour 	3
miRNA-corp.d78.s0	CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition.  	miRNA-corp.d78.s0.e3	Diseases	NPG 	4
miRNA-corp.d78.s0	CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition.  	miRNA-corp.d78.s0.e4	Species	patients 	5
miRNA-corp.d78.s1	An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.    	miRNA-corp.d78.s1.e0	Diseases	NPG 	1
miRNA-corp.d78.s1	An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.    	miRNA-corp.d78.s1.e1	Diseases	infertility 	2
miRNA-corp.d78.s1	An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.    	miRNA-corp.d78.s1.e2	Diseases	galactorrhea 	3
miRNA-corp.d78.s1	An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.    	miRNA-corp.d78.s1.e3	Genes/Proteins	prolactin 	4
miRNA-corp.d78.s1	An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.    	miRNA-corp.d78.s1.e4	Species	patients 	5
miRNA-corp.d78.s2	BACKGROUND: Abnormal frequency and pulse amplitud of prolactin secretion in micro and macroprolactinomas has been atributed to a dysfunctional tumoral lactotrope.  	miRNA-corp.d78.s2.e0	Genes/Proteins	prolactin 	1
miRNA-corp.d78.s2	BACKGROUND: Abnormal frequency and pulse amplitud of prolactin secretion in micro and macroprolactinomas has been atributed to a dysfunctional tumoral lactotrope.  	miRNA-corp.d78.s2.e1	Diseases	macroprolactinomas 	2
miRNA-corp.d78.s3	[Irregular secretion of prolactin in infertile women with normoprolactinemic galactorrhea].   	miRNA-corp.d78.s3.e0	Genes/Proteins	prolactin 	1
miRNA-corp.d78.s3	[Irregular secretion of prolactin in infertile women with normoprolactinemic galactorrhea].   	miRNA-corp.d78.s3.e1	Diseases	normoprolactinemic galactorrhea 	2
miRNA-corp.d78.s3	[Irregular secretion of prolactin in infertile women with normoprolactinemic galactorrhea].   	miRNA-corp.d78.s3.e2	Species	women 	3
miRNA-corp.d78.s4	The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia.  	miRNA-corp.d78.s4.e0	Diseases	tumoral hyperprolactinemia 	1
miRNA-corp.d78.s4	The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia.  	miRNA-corp.d78.s4.e1	Diseases	normoprolactinemic galactorrhea 	2
miRNA-corp.d78.s4	The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia.  	miRNA-corp.d78.s4.e2	Diseases	NPG 	3
miRNA-corp.d78.s4	The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia.  	miRNA-corp.d78.s4.e3	Genes/Proteins	prolactin 	4
miRNA-corp.d78.s4	The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia.  	miRNA-corp.d78.s4.e4	Species	patients 	5
miRNA-corp.d78.s5	Previous evidence suggests that non tumoral hyperprolactinemia is caused by a hypothalamic dysfunction.  	miRNA-corp.d78.s5.e0	Diseases	hypothalamic dysfunction 	1
miRNA-corp.d78.s5	Previous evidence suggests that non tumoral hyperprolactinemia is caused by a hypothalamic dysfunction.  	miRNA-corp.d78.s5.e1	Diseases	non tumoral hyperprolactinemia 	2
miRNA-corp.d78.s6	PATIENTS AND METHODS: A transversal-comparative study was carried out in 6 infertile women with normoprolactinemic galactorrhea and 4 healthy women as controls.  	miRNA-corp.d78.s6.e0	Diseases	normoprolactinemic galactorrhea 	1
miRNA-corp.d78.s6	PATIENTS AND METHODS: A transversal-comparative study was carried out in 6 infertile women with normoprolactinemic galactorrhea and 4 healthy women as controls.  	miRNA-corp.d78.s6.e1	Species	women 	2
miRNA-corp.d78.s6	PATIENTS AND METHODS: A transversal-comparative study was carried out in 6 infertile women with normoprolactinemic galactorrhea and 4 healthy women as controls.  	miRNA-corp.d78.s6.e2	Species	women 	3
miRNA-corp.d78.s6	PATIENTS AND METHODS: A transversal-comparative study was carried out in 6 infertile women with normoprolactinemic galactorrhea and 4 healthy women as controls.  	miRNA-corp.d78.s6.e3	Species	PATIENTS 	4
miRNA-corp.d78.s7	Objective: To analyze the 24-hour prolactin secretion pattern and its secretion regularity in a group of infertile women with normoprolactinemic galatorea.  	miRNA-corp.d78.s7.e0	Genes/Proteins	prolactin 	1
miRNA-corp.d78.s7	Objective: To analyze the 24-hour prolactin secretion pattern and its secretion regularity in a group of infertile women with normoprolactinemic galatorea.  	miRNA-corp.d78.s7.e1	Species	women 	2
miRNA-corp.d78.s8	RESULTS: Blunting of the nyctohemeral rythm and nocturn hyperprolactinaemia occurred in patients with normoprolactinemic galactorrhea (NPG).  	miRNA-corp.d78.s8.e0	Diseases	nocturn hyperprolactinaemia 	1
miRNA-corp.d78.s8	RESULTS: Blunting of the nyctohemeral rythm and nocturn hyperprolactinaemia occurred in patients with normoprolactinemic galactorrhea (NPG).  	miRNA-corp.d78.s8.e1	Diseases	normoprolactinemic galactorrhea 	2
miRNA-corp.d78.s8	RESULTS: Blunting of the nyctohemeral rythm and nocturn hyperprolactinaemia occurred in patients with normoprolactinemic galactorrhea (NPG).  	miRNA-corp.d78.s8.e2	Diseases	NPG 	3
miRNA-corp.d78.s8	RESULTS: Blunting of the nyctohemeral rythm and nocturn hyperprolactinaemia occurred in patients with normoprolactinemic galactorrhea (NPG).  	miRNA-corp.d78.s8.e3	Species	patients 	4
miRNA-corp.d78.s9	The 24 hour prolactin profile, the ratio night time mean concentration/daytime mean concentrattion (NM/DM ratio) and apparent entropy (Ap En, Ap En ratio) were compared in the two groups.  	miRNA-corp.d78.s9.e0	Genes/Proteins	prolactin 	1
miRNA-corp.d78.s10	Higher irregularity of prolactin secretion was found in patients with NPG (ApEn: 0.853 +/- 0.158 vs 0.608 +/- 0.171, p=0.04; Ap En ratio: 0.839 +/- 0.11 vs 0.661 +/- 0.14; p=0.04).  	miRNA-corp.d78.s10.e0	Diseases	NPG 	1
miRNA-corp.d78.s10	Higher irregularity of prolactin secretion was found in patients with NPG (ApEn: 0.853 +/- 0.158 vs 0.608 +/- 0.171, p=0.04; Ap En ratio: 0.839 +/- 0.11 vs 0.661 +/- 0.14; p=0.04).  	miRNA-corp.d78.s10.e1	Genes/Proteins	prolactin 	2
miRNA-corp.d78.s10	Higher irregularity of prolactin secretion was found in patients with NPG (ApEn: 0.853 +/- 0.158 vs 0.608 +/- 0.171, p=0.04; Ap En ratio: 0.839 +/- 0.11 vs 0.661 +/- 0.14; p=0.04).  	miRNA-corp.d78.s10.e2	Species	patients 	3
miRNA-corp.d78.s11	NM/DM ratio was lower in patients with NPG than in controls (1.28 +/- 0.25 vs. 1.75 +/- 0.05; p= 0.01).  	miRNA-corp.d78.s11.e0	Diseases	NPG 	1
miRNA-corp.d78.s11	NM/DM ratio was lower in patients with NPG than in controls (1.28 +/- 0.25 vs. 1.75 +/- 0.05; p= 0.01).  	miRNA-corp.d78.s11.e1	Species	patients 	2
miRNA-corp.d79.s0	Alteration of miRNA expression by disease and insult also holds the potential for improved diagnostic tools.  	miRNA-corp.d79.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d79.s0	Alteration of miRNA expression by disease and insult also holds the potential for improved diagnostic tools.  	miRNA-corp.d79.s0.e1	Relation_Trigger	Alteration of miRNA expression 	2
miRNA-corp.d79.s1	Finally, miRNAs have been shown to control cellular proliferation and specification, suggesting that manipulation of miRNAs in cultured cells could result in more convenient generation of pure cell populations for transplantation.    	miRNA-corp.d79.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d79.s1	Finally, miRNAs have been shown to control cellular proliferation and specification, suggesting that manipulation of miRNAs in cultured cells could result in more convenient generation of pure cell populations for transplantation.    	miRNA-corp.d79.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d79.s2	miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke.  	miRNA-corp.d79.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d79.s2	miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke.  	miRNA-corp.d79.s2.e1	Diseases	stroke 	2
miRNA-corp.d79.s2	miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke.  	miRNA-corp.d79.s2.e2	Diseases	developmental disorders 	3
miRNA-corp.d79.s2	miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke.  	miRNA-corp.d79.s2.e3	Relation_Trigger	dysregulated 	4
miRNA-corp.d79.s2	miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke.  	miRNA-corp.d79.s2.e4	Diseases	neurodegenerative diseases 	5
miRNA-corp.d79.s3	MicroRNAS (miRNAs) have been suggested to play important roles in the central nervous system during development as well as disease.  	miRNA-corp.d79.s3.e0	Non-Specific_miRNAs	MicroRNAS 	1
miRNA-corp.d79.s3	MicroRNAS (miRNAs) have been suggested to play important roles in the central nervous system during development as well as disease.  	miRNA-corp.d79.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d79.s4	The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair.   	miRNA-corp.d79.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d79.s5	Artificial miRNAs have also been generated for the repression of specific transcripts.  	miRNA-corp.d79.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d79.s5	Artificial miRNAs have also been generated for the repression of specific transcripts.  	miRNA-corp.d79.s5.e1	Relation_Trigger	repression 	2
miRNA-corp.d79.s6	Both viral delivery and administration of modified oligonucleotides mimicking or inhibiting specific miRNAs have been effective in model systems.  	miRNA-corp.d79.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d79.s6	Both viral delivery and administration of modified oligonucleotides mimicking or inhibiting specific miRNAs have been effective in model systems.  	miRNA-corp.d79.s6.e1	Relation_Trigger	inhibiting 	2
miRNA-corp.d79.s7	Recent findings suggest that it may eventually be possible to treat some neurological disorders by restoring or inhibiting miRNAs altered by disease pathology.  	miRNA-corp.d79.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d79.s7	Recent findings suggest that it may eventually be possible to treat some neurological disorders by restoring or inhibiting miRNAs altered by disease pathology.  	miRNA-corp.d79.s7.e1	Relation_Trigger	inhibiting 	2
miRNA-corp.d79.s7	Recent findings suggest that it may eventually be possible to treat some neurological disorders by restoring or inhibiting miRNAs altered by disease pathology.  	miRNA-corp.d79.s7.e2	Diseases	neurological disorders 	3
miRNA-corp.d79.s8	Each miRNA has the ability to regulate hundreds of messenger RNA transcripts, both by causing degradation of the mRNA and by inhibition of protein translation.  	miRNA-corp.d79.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d79.s8	Each miRNA has the ability to regulate hundreds of messenger RNA transcripts, both by causing degradation of the mRNA and by inhibition of protein translation.  	miRNA-corp.d79.s8.e1	Relation_Trigger	regulate 	2
miRNA-corp.d79.s8	Each miRNA has the ability to regulate hundreds of messenger RNA transcripts, both by causing degradation of the mRNA and by inhibition of protein translation.  	miRNA-corp.d79.s8.e2	Relation_Trigger	inhibition of protein translation 	3
miRNA-corp.d80.s8	METHODS: A controlled study of patients with left (LTLE) or right (RTLE) TLE.  	miRNA-corp.d80.s8.e0	Diseases	TLE 	1
miRNA-corp.d80.s8	METHODS: A controlled study of patients with left (LTLE) or right (RTLE) TLE.  	miRNA-corp.d80.s8.e1	Species	patients 	2
miRNA-corp.d80.s9	AIM: To assess the hippocampal function in remote orientation and visuospatial memory in patients with refractory temporal epilepsy.  	miRNA-corp.d80.s9.e0	Diseases	refractory temporal epilepsy 	1
miRNA-corp.d80.s9	AIM: To assess the hippocampal function in remote orientation and visuospatial memory in patients with refractory temporal epilepsy.  	miRNA-corp.d80.s9.e1	Species	patients 	2
miRNA-corp.d80.s10	INTRODUCTION: In temporal lobe epilepsy (TLE), about 30% of the patients do not achieve adequate pharmacologic control of refractory crises, and surgery becomes an alternative.  	miRNA-corp.d80.s10.e0	Diseases	temporal lobe epilepsy 	1
miRNA-corp.d80.s10	INTRODUCTION: In temporal lobe epilepsy (TLE), about 30% of the patients do not achieve adequate pharmacologic control of refractory crises, and surgery becomes an alternative.  	miRNA-corp.d80.s10.e1	Diseases	TLE 	2
miRNA-corp.d80.s10	INTRODUCTION: In temporal lobe epilepsy (TLE), about 30% of the patients do not achieve adequate pharmacologic control of refractory crises, and surgery becomes an alternative.  	miRNA-corp.d80.s10.e2	Species	patients 	3
miRNA-corp.d81.s0	Yet, genetic testing for CADASIL is associated with a nameable proportion of false-negative results.  	miRNA-corp.d81.s0.e0	Diseases	CADASIL 	1
miRNA-corp.d81.s0	Yet, genetic testing for CADASIL is associated with a nameable proportion of false-negative results.  	miRNA-corp.d81.s0.e1	Relation_Trigger	associated 	2
miRNA-corp.d81.s5	In 5 patients (4.0%), no mutation was identified.  	miRNA-corp.d81.s5.e0	Species	patients 	1
miRNA-corp.d81.s7	RESULTS: We detected 54 distinct mutations (117 missense mutations and 3 in-frame deletions) in 120 (96.0%) of the 125 patients.  	miRNA-corp.d81.s7.e0	Species	patients 	1
miRNA-corp.d81.s8	BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults.  	miRNA-corp.d81.s8.e0	Diseases	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 	1
miRNA-corp.d81.s8	BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults.  	miRNA-corp.d81.s8.e1	Diseases	CADASIL 	2
miRNA-corp.d81.s8	BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults.  	miRNA-corp.d81.s8.e2	Diseases	stroke 	3
miRNA-corp.d81.s8	BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults.  	miRNA-corp.d81.s8.e3	Genes/Proteins	NOTCH3 	4
miRNA-corp.d81.s9	Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies.   	miRNA-corp.d81.s9.e0	Diseases	CADASIL 	1
miRNA-corp.d81.s10	DESIGN: Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor-like repeats.  	miRNA-corp.d81.s10.e0	Genes/Proteins	NOTCH3 	1
miRNA-corp.d81.s10	DESIGN: Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor-like repeats.  	miRNA-corp.d81.s10.e1	Diseases	CADASIL 	2
miRNA-corp.d81.s10	DESIGN: Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor-like repeats.  	miRNA-corp.d81.s10.e2	Species	patients 	3
miRNA-corp.d81.s11	OBJECTIVES: To identify the spectrum of NOTCH3 mutations in CADASIL and to discuss the implications for diagnostic strategies.  	miRNA-corp.d81.s11.e0	Genes/Proteins	NOTCH3 	1
miRNA-corp.d81.s11	OBJECTIVES: To identify the spectrum of NOTCH3 mutations in CADASIL and to discuss the implications for diagnostic strategies.  	miRNA-corp.d81.s11.e1	Diseases	CADASIL 	2
miRNA-corp.d81.s13	Mutations are typically located within epidermal growth factor-like repeat domains in the extracellular part of the Notch3 receptor.  	miRNA-corp.d81.s13.e0	Genes/Proteins	Notch3 receptor 	1
miRNA-corp.d82.s0	Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.   	miRNA-corp.d82.s0.e0	Genes/Proteins	ABHD12 	1
miRNA-corp.d82.s0	Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.   	miRNA-corp.d82.s0.e1	Diseases	PHARC 	2
miRNA-corp.d82.s0	Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.   	miRNA-corp.d82.s0.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e0	Diseases	Polyneuropathy 	1
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e1	Diseases	hearing loss 	2
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e2	Diseases	ataxia 	3
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e3	Diseases	retinitis pigmentosa 	4
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e4	Diseases	cataract 	5
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e5	Diseases	PHARC 	6
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e6	Diseases	cataract 	7
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e7	Diseases	cerebellar ataxia 	8
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e8	Diseases	hearing loss 	9
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e9	Diseases	retinitis pigmentosa 	10
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e10	Diseases	polyneuropathy 	11
miRNA-corp.d82.s2	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia.  	miRNA-corp.d82.s2.e11	Diseases	neurodegenerative disease 	12
miRNA-corp.d82.s3	Our findings show that ABHD12 performs essential functions in both the central and peripheral nervous systems and the eye.  	miRNA-corp.d82.s3.e0	Genes/Proteins	ABHD12 	1
miRNA-corp.d82.s5	Here we report that mutations in the ABHD12 gene cause PHARC disease and we describe the clinical manifestations in a total of 19 patients from four different countries.  	miRNA-corp.d82.s5.e0	Genes/Proteins	ABHD12 	1
miRNA-corp.d82.s5	Here we report that mutations in the ABHD12 gene cause PHARC disease and we describe the clinical manifestations in a total of 19 patients from four different countries.  	miRNA-corp.d82.s5.e1	Diseases	PHARC 	2
miRNA-corp.d82.s5	Here we report that mutations in the ABHD12 gene cause PHARC disease and we describe the clinical manifestations in a total of 19 patients from four different countries.  	miRNA-corp.d82.s5.e2	Species	patients 	3
miRNA-corp.d82.s6	The ABHD12 enzyme was recently shown to hydrolyze 2-arachidonoyl glycerol (2-AG), the main endocannabinoid lipid transmitter that acts on cannabinoid receptors CB1 and CB2.  	miRNA-corp.d82.s6.e0	Genes/Proteins	ABHD12 	1
miRNA-corp.d82.s6	The ABHD12 enzyme was recently shown to hydrolyze 2-arachidonoyl glycerol (2-AG), the main endocannabinoid lipid transmitter that acts on cannabinoid receptors CB1 and CB2.  	miRNA-corp.d82.s6.e1	Genes/Proteins	CB1 	2
miRNA-corp.d82.s6	The ABHD12 enzyme was recently shown to hydrolyze 2-arachidonoyl glycerol (2-AG), the main endocannabinoid lipid transmitter that acts on cannabinoid receptors CB1 and CB2.  	miRNA-corp.d82.s6.e2	Genes/Proteins	CB2 	3
miRNA-corp.d82.s8	The endocannabinoid system is involved in a wide range of physiological processes including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation, and several potential drugs targeting these pathways are in development for clinical applications.  	miRNA-corp.d82.s8.e0	Relation_Trigger	targeting 	1
miRNA-corp.d82.s8	The endocannabinoid system is involved in a wide range of physiological processes including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation, and several potential drugs targeting these pathways are in development for clinical applications.  	miRNA-corp.d82.s8.e1	Diseases	inflammation 	2
miRNA-corp.d82.s8	The endocannabinoid system is involved in a wide range of physiological processes including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation, and several potential drugs targeting these pathways are in development for clinical applications.  	miRNA-corp.d82.s8.e2	Diseases	pain 	3
miRNA-corp.d83.s0	HIV-1-infected opiate abusers often exhibit an accelerated form of HIV-1-associated dementia and enhanced neurological dysfunction.  	miRNA-corp.d83.s0.e0	Diseases	dementia 	1
miRNA-corp.d83.s0	HIV-1-infected opiate abusers often exhibit an accelerated form of HIV-1-associated dementia and enhanced neurological dysfunction.  	miRNA-corp.d83.s0.e1	Species	HIV-1 	2
miRNA-corp.d83.s0	HIV-1-infected opiate abusers often exhibit an accelerated form of HIV-1-associated dementia and enhanced neurological dysfunction.  	miRNA-corp.d83.s0.e2	Species	HIV-1 	3
miRNA-corp.d83.s0	HIV-1-infected opiate abusers often exhibit an accelerated form of HIV-1-associated dementia and enhanced neurological dysfunction.  	miRNA-corp.d83.s0.e3	Diseases	neurological dysfunction 	4
miRNA-corp.d83.s1	Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system.   	miRNA-corp.d83.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d83.s1	Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system.   	miRNA-corp.d83.s1.e1	Diseases	inflammation 	2
miRNA-corp.d83.s1	Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system.   	miRNA-corp.d83.s1.e2	Species	human 	3
miRNA-corp.d83.s2	In order to understand the role of morphine in this process, we performed a genome-wide association study at the micro RNA (miRNA) and protein levels in human monocyte-derived macrophages (h-mdms).  	miRNA-corp.d83.s2.e0	Non-Specific_miRNAs	micro RNA 	1
miRNA-corp.d83.s2	In order to understand the role of morphine in this process, we performed a genome-wide association study at the micro RNA (miRNA) and protein levels in human monocyte-derived macrophages (h-mdms).  	miRNA-corp.d83.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d83.s2	In order to understand the role of morphine in this process, we performed a genome-wide association study at the micro RNA (miRNA) and protein levels in human monocyte-derived macrophages (h-mdms).  	miRNA-corp.d83.s2.e2	Species	human 	3
miRNA-corp.d83.s3	Productive HIV-1 infection of microglia and perivascular macrophages and the resultant secretion of neurotoxic molecules by these cells contribute to this phenomenon.  	miRNA-corp.d83.s3.e0	Species	HIV-1 	1
miRNA-corp.d83.s3	Productive HIV-1 infection of microglia and perivascular macrophages and the resultant secretion of neurotoxic molecules by these cells contribute to this phenomenon.  	miRNA-corp.d83.s3.e1	Diseases	HIV-1 infection 	2
miRNA-corp.d83.s4	Computational analysis predicted fibroblast growth factor-2 (FGF-2) as the strongest target gene for hsa-miR15b.  	miRNA-corp.d83.s4.e0	Genes/Proteins	fibroblast growth factor-2 	1
miRNA-corp.d83.s4	Computational analysis predicted fibroblast growth factor-2 (FGF-2) as the strongest target gene for hsa-miR15b.  	miRNA-corp.d83.s4.e1	Genes/Proteins	FGF-2 	2
miRNA-corp.d83.s4	Computational analysis predicted fibroblast growth factor-2 (FGF-2) as the strongest target gene for hsa-miR15b.  	miRNA-corp.d83.s4.e2	Specific_miRNAs	hsa-miR15b 	3
miRNA-corp.d83.s4	Computational analysis predicted fibroblast growth factor-2 (FGF-2) as the strongest target gene for hsa-miR15b.  	miRNA-corp.d83.s4.e3	Relation_Trigger	target 	4
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e0	Specific_miRNAs	hsa-miR-15b 	1
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e1	Specific_miRNAs	hsa-miR-181b 	2
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e4	Relation_Trigger	increase and decrease in expression levels 	5
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e5	Relation_Trigger	decrease in expression levels 	6
miRNA-corp.d83.s5	A total of 26 differentially expressed miRNA were identified (P < 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively.  	miRNA-corp.d83.s5.e6	Relation_Trigger	decrease in expression levels 	7
miRNA-corp.d83.s6	Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways.  	miRNA-corp.d83.s6.e0	Specific_miRNAs	hsa-miR-15b 	1
miRNA-corp.d83.s6	Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways.  	miRNA-corp.d83.s6.e1	Specific_miRNAs	hsa-miR-181b 	2
miRNA-corp.d83.s6	Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways.  	miRNA-corp.d83.s6.e2	Relation_Trigger	predicted gene targets 	3
miRNA-corp.d83.s6	Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways.  	miRNA-corp.d83.s6.e3	Relation_Trigger	activation 	4
miRNA-corp.d83.s6	Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways.  	miRNA-corp.d83.s6.e4	Diseases	inflammation 	5
miRNA-corp.d83.s7	Of note, we observed a decrease in FGF-2 protein expression in response to morphine.  	miRNA-corp.d83.s7.e0	Genes/Proteins	FGF-2 	1
miRNA-corp.d83.s7	Of note, we observed a decrease in FGF-2 protein expression in response to morphine.  	miRNA-corp.d83.s7.e1	Relation_Trigger	decrease in FGF-2 protein expression 	2
miRNA-corp.d83.s9	In this context, we observed induction of MCP-2 and IL-6 by morphine.  	miRNA-corp.d83.s9.e0	Genes/Proteins	MCP-2 	1
miRNA-corp.d83.s9	In this context, we observed induction of MCP-2 and IL-6 by morphine.  	miRNA-corp.d83.s9.e1	Genes/Proteins	IL-6 	2
miRNA-corp.d83.s10	Of note, differentially expressed miRNAs (hsa-miR-15b and 181-b) may have a potential role in regulating these processes.    	miRNA-corp.d83.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d83.s10	Of note, differentially expressed miRNAs (hsa-miR-15b and 181-b) may have a potential role in regulating these processes.    	miRNA-corp.d83.s10.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d83.s10	Of note, differentially expressed miRNAs (hsa-miR-15b and 181-b) may have a potential role in regulating these processes.    	miRNA-corp.d83.s10.e2	Relation_Trigger	regulating 	3
miRNA-corp.d83.s10	Of note, differentially expressed miRNAs (hsa-miR-15b and 181-b) may have a potential role in regulating these processes.    	miRNA-corp.d83.s10.e3	Specific_miRNAs	hsa-miR-15b and 181-b 	4
miRNA-corp.d83.s11	Collectively, these observations demonstrate that morphine induces inflammation and oxidative stress in h-mdms thereby contributing to expansion of HIV-1 CNS reservoir expansion and disease progression.  	miRNA-corp.d83.s11.e0	Species	HIV-1 	1
miRNA-corp.d83.s11	Collectively, these observations demonstrate that morphine induces inflammation and oxidative stress in h-mdms thereby contributing to expansion of HIV-1 CNS reservoir expansion and disease progression.  	miRNA-corp.d83.s11.e1	Diseases	inflammation 	2
miRNA-corp.d83.s12	HIV-1 infection did not induce mitochondrial superoxide dismutase.  	miRNA-corp.d83.s12.e0	Species	HIV-1 	1
miRNA-corp.d83.s12	HIV-1 infection did not induce mitochondrial superoxide dismutase.  	miRNA-corp.d83.s12.e1	Diseases	HIV-1 infection 	2
miRNA-corp.d84.s0	MRI scan showed an area of encephalomalacia in the left temporal lobe, as well as post-surgical changes in the left frontal area.  	miRNA-corp.d84.s0.e0	Diseases	encephalomalacia 	1
miRNA-corp.d84.s1	He presented with status epilepticus every two or three months, and required long periods of hospitalization on each occasion for post-ictal confusion and aphasia.  	miRNA-corp.d84.s1.e0	Diseases	status epilepticus 	1
miRNA-corp.d84.s1	He presented with status epilepticus every two or three months, and required long periods of hospitalization on each occasion for post-ictal confusion and aphasia.  	miRNA-corp.d84.s1.e1	Diseases	aphasia 	2
miRNA-corp.d84.s1	He presented with status epilepticus every two or three months, and required long periods of hospitalization on each occasion for post-ictal confusion and aphasia.  	miRNA-corp.d84.s1.e2	Diseases	post-ictal confusion 	3
miRNA-corp.d84.s2	He continued to have frequent seizures despite treatment with multiple combinations of antiepileptic medications.  	miRNA-corp.d84.s2.e0	Diseases	seizures 	1
miRNA-corp.d84.s3	EEG telemetry recorded multiple seizures, all with a clear focus in the left temporal area.  	miRNA-corp.d84.s3.e0	Diseases	multiple seizures 	1
miRNA-corp.d84.s5	CASE REPORT: We report a case of a 75-year-old right-handed man who underwent a left fronto-temporal craniotomy for resection of a suprasellar meningioma in 2002.  	miRNA-corp.d84.s5.e0	Diseases	suprasellar meningioma 	1
miRNA-corp.d84.s5	CASE REPORT: We report a case of a 75-year-old right-handed man who underwent a left fronto-temporal craniotomy for resection of a suprasellar meningioma in 2002.  	miRNA-corp.d84.s5.e1	Species	man 	2
miRNA-corp.d84.s6	Immediately following hospital discharge, he began to experience complex partial seizures.  	miRNA-corp.d84.s6.e0	Diseases	seizures 	1
miRNA-corp.d84.s7	BACKGROUND: Epilepsy surgery is increasingly well-supported as an effective treatment for patients with intractable epilepsy.  	miRNA-corp.d84.s7.e0	Diseases	Epilepsy 	1
miRNA-corp.d84.s7	BACKGROUND: Epilepsy surgery is increasingly well-supported as an effective treatment for patients with intractable epilepsy.  	miRNA-corp.d84.s7.e1	Diseases	epilepsy 	2
miRNA-corp.d84.s7	BACKGROUND: Epilepsy surgery is increasingly well-supported as an effective treatment for patients with intractable epilepsy.  	miRNA-corp.d84.s7.e2	Species	patients 	3
miRNA-corp.d84.s8	It is most often performed on younger patients and the safety and efficacy of epilepsy surgery in elderly patients are not frequently described.  	miRNA-corp.d84.s8.e0	Diseases	epilepsy 	1
miRNA-corp.d84.s8	It is most often performed on younger patients and the safety and efficacy of epilepsy surgery in elderly patients are not frequently described.  	miRNA-corp.d84.s8.e1	Species	patients 	2
miRNA-corp.d84.s8	It is most often performed on younger patients and the safety and efficacy of epilepsy surgery in elderly patients are not frequently described.  	miRNA-corp.d84.s8.e2	Species	patients 	3
miRNA-corp.d84.s9	Epilepsy surgery in the elderly: an unusual case of a 75-year-old man with recurrent status epilepticus.   	miRNA-corp.d84.s9.e0	Diseases	status epilepticus 	1
miRNA-corp.d84.s9	Epilepsy surgery in the elderly: an unusual case of a 75-year-old man with recurrent status epilepticus.   	miRNA-corp.d84.s9.e1	Diseases	Epilepsy 	2
miRNA-corp.d84.s9	Epilepsy surgery in the elderly: an unusual case of a 75-year-old man with recurrent status epilepticus.   	miRNA-corp.d84.s9.e2	Species	man 	3
miRNA-corp.d84.s10	In addition, few cases with such a malignant evolution of temporal lobe epilepsy have been described in this age group.    	miRNA-corp.d84.s10.e0	Diseases	temporal lobe epilepsy 	1
miRNA-corp.d84.s12	Neuropsychological testing showed bilateral memory impairment with no significant cognitive decline expected after unilateral temporal lobe resection.  	miRNA-corp.d84.s12.e0	Diseases	bilateral memory impairment 	1
miRNA-corp.d84.s13	CONCLUSIONS: This is one of the oldest patients reported in the literature with epilepsy surgery and supports the possibility of epilepsy surgery in elderly patients for particular cases.  	miRNA-corp.d84.s13.e0	Diseases	epilepsy 	1
miRNA-corp.d84.s13	CONCLUSIONS: This is one of the oldest patients reported in the literature with epilepsy surgery and supports the possibility of epilepsy surgery in elderly patients for particular cases.  	miRNA-corp.d84.s13.e1	Diseases	epilepsy 	2
miRNA-corp.d84.s13	CONCLUSIONS: This is one of the oldest patients reported in the literature with epilepsy surgery and supports the possibility of epilepsy surgery in elderly patients for particular cases.  	miRNA-corp.d84.s13.e2	Species	patients 	3
miRNA-corp.d84.s13	CONCLUSIONS: This is one of the oldest patients reported in the literature with epilepsy surgery and supports the possibility of epilepsy surgery in elderly patients for particular cases.  	miRNA-corp.d84.s13.e3	Species	patients 	4
miRNA-corp.d84.s14	Since surgery, the patient was not seizure-free (Engel class II-b), but had no further episodes of status epilepticus in one year and two months of follow-up.  	miRNA-corp.d84.s14.e0	Diseases	seizure 	1
miRNA-corp.d84.s14	Since surgery, the patient was not seizure-free (Engel class II-b), but had no further episodes of status epilepticus in one year and two months of follow-up.  	miRNA-corp.d84.s14.e1	Diseases	status epilepticus 	2
miRNA-corp.d84.s14	Since surgery, the patient was not seizure-free (Engel class II-b), but had no further episodes of status epilepticus in one year and two months of follow-up.  	miRNA-corp.d84.s14.e2	Species	patient 	3
miRNA-corp.d85.s0	Aberrant expression of miRNAs can lead to diseases, including cancer.  	miRNA-corp.d85.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d85.s0	Aberrant expression of miRNAs can lead to diseases, including cancer.  	miRNA-corp.d85.s0.e1	Relation_Trigger	Aberrant expression 	2
miRNA-corp.d85.s0	Aberrant expression of miRNAs can lead to diseases, including cancer.  	miRNA-corp.d85.s0.e2	Diseases	cancer 	3
miRNA-corp.d85.s1	Expression of many miRNAs in the de-differentiated brain tumor cancer stem cells resembles that of neural stem cells.  	miRNA-corp.d85.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d85.s1	Expression of many miRNAs in the de-differentiated brain tumor cancer stem cells resembles that of neural stem cells.  	miRNA-corp.d85.s1.e1	Diseases	de-differentiated brain tumor 	2
miRNA-corp.d85.s1	Expression of many miRNAs in the de-differentiated brain tumor cancer stem cells resembles that of neural stem cells.  	miRNA-corp.d85.s1.e2	Diseases	cancer 	3
miRNA-corp.d85.s2	MicroRNAs: regulators of oncogenesis and stemness.   	miRNA-corp.d85.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d85.s2	MicroRNAs: regulators of oncogenesis and stemness.   	miRNA-corp.d85.s2.e1	Relation_Trigger	regulators 	2
miRNA-corp.d85.s3	MicroRNAs (miRNAs) are essential post-transcriptional regulators that determine cell identity and fate.  	miRNA-corp.d85.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d85.s3	MicroRNAs (miRNAs) are essential post-transcriptional regulators that determine cell identity and fate.  	miRNA-corp.d85.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d85.s3	MicroRNAs (miRNAs) are essential post-transcriptional regulators that determine cell identity and fate.  	miRNA-corp.d85.s3.e2	Relation_Trigger	regulators 	3
miRNA-corp.d85.s4	In this issue of BMC Medicine, Silber et al provide evidence of the expression of such miRNAs and their potential to mediate differentiation in both stem cell populations.  	miRNA-corp.d85.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e0	Specific_miRNAs	miR-124 	1
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e1	Specific_miRNAs	miR-137 	2
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e2	Diseases	glioblastomas 	3
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e3	Relation_Trigger	dysregulation 	4
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d85.s5	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.    	miRNA-corp.d85.s5.e5	Diseases	cancer 	6
miRNA-corp.d86.s0	RESULTS: We hypothesized that schizophrenia might be associated with altered miRNA profiles.  	miRNA-corp.d86.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d86.s0	RESULTS: We hypothesized that schizophrenia might be associated with altered miRNA profiles.  	miRNA-corp.d86.s0.e1	Relation_Trigger	associated 	2
miRNA-corp.d86.s0	RESULTS: We hypothesized that schizophrenia might be associated with altered miRNA profiles.  	miRNA-corp.d86.s0.e2	Relation_Trigger	altered miRNA profiles 	3
miRNA-corp.d86.s0	RESULTS: We hypothesized that schizophrenia might be associated with altered miRNA profiles.  	miRNA-corp.d86.s0.e3	Diseases	schizophrenia 	4
miRNA-corp.d86.s1	To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray.  	miRNA-corp.d86.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d86.s1	To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray.  	miRNA-corp.d86.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d86.s1	To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray.  	miRNA-corp.d86.s1.e2	Diseases	schizoaffective disorder 	3
miRNA-corp.d86.s1	To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray.  	miRNA-corp.d86.s1.e3	Diseases	schizophrenia 	4
miRNA-corp.d86.s1	To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray.  	miRNA-corp.d86.s1.e4	Species	human 	5
miRNA-corp.d86.s2	Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects.  	miRNA-corp.d86.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d86.s2	Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects.  	miRNA-corp.d86.s2.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d86.s2	Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects.  	miRNA-corp.d86.s2.e2	Relation_Trigger	higher level 	3
miRNA-corp.d86.s2	Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects.  	miRNA-corp.d86.s2.e3	Relation_Trigger	expressed at lower levels 	4
miRNA-corp.d86.s2	Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects.  	miRNA-corp.d86.s2.e4	Species	patient 	5
miRNA-corp.d86.s3	The expression levels of 12 selected miRNAs were also determined by quantitative RT-PCR in our lab.  	miRNA-corp.d86.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d86.s4	For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR.  	miRNA-corp.d86.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d86.s4	For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR.  	miRNA-corp.d86.s4.e1	Relation_Trigger	expressed at lower levels 	2
miRNA-corp.d86.s4	For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR.  	miRNA-corp.d86.s4.e2	Diseases	schizophrenia 	3
miRNA-corp.d86.s4	For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR.  	miRNA-corp.d86.s4.e3	Relation_Trigger	expressed at lower microarray levels 	4
miRNA-corp.d86.s5	CONCLUSION: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.    	miRNA-corp.d86.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d86.s5	CONCLUSION: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.    	miRNA-corp.d86.s5.e1	Diseases	schizophrenia 	2
miRNA-corp.d86.s5	CONCLUSION: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.    	miRNA-corp.d86.s5.e2	Relation_Trigger	altered miRNA profiles 	3
miRNA-corp.d86.s5	CONCLUSION: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.    	miRNA-corp.d86.s5.e3	Species	patients 	4
miRNA-corp.d86.s6	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.   	miRNA-corp.d86.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d86.s6	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.   	miRNA-corp.d86.s6.e1	Diseases	schizophrenia 	2
miRNA-corp.d86.s6	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.   	miRNA-corp.d86.s6.e2	Diseases	schizoaffective disorder 	3
miRNA-corp.d86.s7	BACKGROUND: microRNAs (miRNAs) are small, noncoding RNA molecules that are now thought to regulate the expression of many mRNAs.  	miRNA-corp.d86.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d86.s7	BACKGROUND: microRNAs (miRNAs) are small, noncoding RNA molecules that are now thought to regulate the expression of many mRNAs.  	miRNA-corp.d86.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d86.s7	BACKGROUND: microRNAs (miRNAs) are small, noncoding RNA molecules that are now thought to regulate the expression of many mRNAs.  	miRNA-corp.d86.s7.e2	Relation_Trigger	regulate the expression 	3
miRNA-corp.d86.s8	They have been implicated in the etiology of a variety of complex diseases, including Tourette's syndrome, Fragile x syndrome, and several types of cancer.  	miRNA-corp.d86.s8.e0	Diseases	Tourette's syndrome 	1
miRNA-corp.d86.s8	They have been implicated in the etiology of a variety of complex diseases, including Tourette's syndrome, Fragile x syndrome, and several types of cancer.  	miRNA-corp.d86.s8.e1	Diseases	Fragile x syndrome 	2
miRNA-corp.d86.s8	They have been implicated in the etiology of a variety of complex diseases, including Tourette's syndrome, Fragile x syndrome, and several types of cancer.  	miRNA-corp.d86.s8.e2	Diseases	cancer 	3
miRNA-corp.d87.s0	We explored to what extent abnormalities of echogenicity of the periventricular crossroads correlate with changes in size of the corpus callosum.  	miRNA-corp.d87.s0.e0	Relation_Trigger	correlate 	1
miRNA-corp.d87.s3	Our study included nine infants (gestation from 26-41 weeks; birth weight between 938-4450 grams) with perinatal brain injury.  	miRNA-corp.d87.s3.e0	Diseases	perinatal brain injury 	1
miRNA-corp.d87.s4	We found a statistically significant correlation between the increased echogenicity in the crossroad areas and the decrease of the corpus callosum midsagittal area (p < 0.05).  	miRNA-corp.d87.s4.e0	Relation_Trigger	correlation 	1
miRNA-corp.d87.s7	Changes of the corpus callosum in children who suffered perinatal injury of the periventricular crossroads of pathways.   	miRNA-corp.d87.s7.e0	Species	children 	1
miRNA-corp.d87.s7	Changes of the corpus callosum in children who suffered perinatal injury of the periventricular crossroads of pathways.   	miRNA-corp.d87.s7.e1	Diseases	perinatal injury 	2
miRNA-corp.d87.s8	There is a high incidence of periventricular leukomalacia, caused by hypoxia-ischemia, in preterm infants.  	miRNA-corp.d87.s8.e0	Diseases	periventricular leukomalacia 	1
miRNA-corp.d87.s8	There is a high incidence of periventricular leukomalacia, caused by hypoxia-ischemia, in preterm infants.  	miRNA-corp.d87.s8.e1	Diseases	hypoxia-ischemia 	2
miRNA-corp.d88.s0	These results confirm those of other studies with animals and humans using novel imaging techniques, suggesting that the motor homunculus may not always be considered a definite and absolute representation of M1.    	miRNA-corp.d88.s0.e0	Species	humans 	1
miRNA-corp.d88.s1	The results of this study challenge the notion of orderly topographic relationships between the human sensorimotor functions and their representation in the primary motor cortex.  	miRNA-corp.d88.s1.e0	Species	human 	1
miRNA-corp.d88.s3	A total of 43 maps from 36 patients were analyzed.  	miRNA-corp.d88.s3.e0	Species	patients 	1
miRNA-corp.d88.s4	The authors found variations in the organization of M1 (primary motor cortex) in seven patients (19.4%).  	miRNA-corp.d88.s4.e0	Species	patients 	1
miRNA-corp.d88.s5	Four patients (11.1%) presented mosaicism (overlapping of functional areas), two (5.6%) presented variability (inverted disposition of M1 functional areas), and one (2.8%) had both.  	miRNA-corp.d88.s5.e0	Diseases	mosaicism 	1
miRNA-corp.d88.s5	Four patients (11.1%) presented mosaicism (overlapping of functional areas), two (5.6%) presented variability (inverted disposition of M1 functional areas), and one (2.8%) had both.  	miRNA-corp.d88.s5.e1	Species	patients 	2
miRNA-corp.d88.s6	Functional variability of the human cortical motor map: electrical stimulation findings in perirolandic epilepsy surgery.   	miRNA-corp.d88.s6.e0	Diseases	perirolandic epilepsy 	1
miRNA-corp.d88.s6	Functional variability of the human cortical motor map: electrical stimulation findings in perirolandic epilepsy surgery.   	miRNA-corp.d88.s6.e1	Species	human 	2
miRNA-corp.d88.s7	The purpose of this study was to assess the cortical representation of sensorimotor functions in patients undergoing perirolandic epilepsy surgery, focusing on somatotopy, mosaicism, and variability of function in relation to the classic motor homunculus.  	miRNA-corp.d88.s7.e0	Diseases	perirolandic epilepsy 	1
miRNA-corp.d88.s7	The purpose of this study was to assess the cortical representation of sensorimotor functions in patients undergoing perirolandic epilepsy surgery, focusing on somatotopy, mosaicism, and variability of function in relation to the classic motor homunculus.  	miRNA-corp.d88.s7.e1	Diseases	mosaicism 	2
miRNA-corp.d88.s7	The purpose of this study was to assess the cortical representation of sensorimotor functions in patients undergoing perirolandic epilepsy surgery, focusing on somatotopy, mosaicism, and variability of function in relation to the classic motor homunculus.  	miRNA-corp.d88.s7.e2	Species	patients 	3
miRNA-corp.d88.s8	The authors studied 36 patients in whom intraoperative or extraoperative electrical cortical stimulation to map motor functions was performed.  	miRNA-corp.d88.s8.e0	Species	patients 	1
miRNA-corp.d89.s0	These results indicate that miRNAs are differentially expressed in C. elegans PD models and suggest a role for these molecules in disease pathogenesis.    	miRNA-corp.d89.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d89.s0	These results indicate that miRNAs are differentially expressed in C. elegans PD models and suggest a role for these molecules in disease pathogenesis.    	miRNA-corp.d89.s0.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d89.s0	These results indicate that miRNAs are differentially expressed in C. elegans PD models and suggest a role for these molecules in disease pathogenesis.    	miRNA-corp.d89.s0.e2	Diseases	PD 	3
miRNA-corp.d89.s0	These results indicate that miRNAs are differentially expressed in C. elegans PD models and suggest a role for these molecules in disease pathogenesis.    	miRNA-corp.d89.s0.e3	Species	C. elegans 	4
miRNA-corp.d89.s1	Here, we show that 12 specific miRNAs are differentially regulated in the animals overexpressing alpha-synuclein, five in cat-1, and three in the pdr-1 mutants.  	miRNA-corp.d89.s1.e0	Genes/Proteins	alpha-synuclein 	1
miRNA-corp.d89.s1	Here, we show that 12 specific miRNAs are differentially regulated in the animals overexpressing alpha-synuclein, five in cat-1, and three in the pdr-1 mutants.  	miRNA-corp.d89.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d89.s1	Here, we show that 12 specific miRNAs are differentially regulated in the animals overexpressing alpha-synuclein, five in cat-1, and three in the pdr-1 mutants.  	miRNA-corp.d89.s1.e2	Relation_Trigger	differentially regulated 	3
miRNA-corp.d89.s1	Here, we show that 12 specific miRNAs are differentially regulated in the animals overexpressing alpha-synuclein, five in cat-1, and three in the pdr-1 mutants.  	miRNA-corp.d89.s1.e3	Relation_Trigger	overexpressing 	4
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e0	Specific_miRNAs	miR-64 	1
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e1	Specific_miRNAs	miR-65 	2
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e2	Genes/Proteins	mdl-1 	3
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e3	Genes/Proteins	alpha-synuclein 	4
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e4	Specific_miRNAs	miR-64 	5
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e5	Specific_miRNAs	miR-65 	6
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e6	Genes/Proteins	alpha-synuclein 	7
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e7	Genes/Proteins	ptc-1 	8
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e8	Genes/Proteins	alpha-synuclein 	9
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e9	Relation_Trigger	co-underexpressed 	10
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e10	Relation_Trigger	co-underexpressed 	11
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e11	Relation_Trigger	target candidates 	12
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e12	Relation_Trigger	overexpressed 	13
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e13	Specific_miRNAs	let-7 	14
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e14	Specific_miRNAs	miR 	15
miRNA-corp.d89.s2	The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals.  	miRNA-corp.d89.s2.e15	Specific_miRNAs	miR-64/65 	16
miRNA-corp.d89.s3	MicroRNAs (miRNAs) play an important role in human brain development and maintenance.  	miRNA-corp.d89.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d89.s3	MicroRNAs (miRNAs) play an important role in human brain development and maintenance.  	miRNA-corp.d89.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d89.s3	MicroRNAs (miRNAs) play an important role in human brain development and maintenance.  	miRNA-corp.d89.s3.e2	Species	human 	3
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e0	Diseases	Parkinsons disease 	1
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e1	Diseases	PD 	2
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e2	Genes/Proteins	A53T alpha-synuclein 	3
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e5	Non-Specific_miRNAs	miRNAs 	6
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e6	Diseases	PD 	7
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e7	Relation_Trigger	overexpress 	8
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e8	Relation_Trigger	expression changes 	9
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e9	Species	Caenorhabditis elegans 	10
miRNA-corp.d89.s4	To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog.  	miRNA-corp.d89.s4.e10	Species	human 	11
miRNA-corp.d89.s5	Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.   	miRNA-corp.d89.s5.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d89.s5	Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.   	miRNA-corp.d89.s5.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d89.s5	Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.   	miRNA-corp.d89.s5.e2	Species	Caenorhabditis elegans 	3
miRNA-corp.d90.s0	Glioma angiogenesis: Towards novel RNA therapeutics.   	miRNA-corp.d90.s0.e0	Diseases	Glioma 	1
miRNA-corp.d90.s1	Brain tumors exhibit marked and aberrant blood vessel formation indicating angiogenic endothelial cells as a potential target for brain tumor treatment.  	miRNA-corp.d90.s1.e0	Diseases	Brain tumors 	1
miRNA-corp.d90.s1	Brain tumors exhibit marked and aberrant blood vessel formation indicating angiogenic endothelial cells as a potential target for brain tumor treatment.  	miRNA-corp.d90.s1.e1	Relation_Trigger	potential target 	2
miRNA-corp.d90.s1	Brain tumors exhibit marked and aberrant blood vessel formation indicating angiogenic endothelial cells as a potential target for brain tumor treatment.  	miRNA-corp.d90.s1.e2	Diseases	brain tumor 	3
miRNA-corp.d90.s2	The brain tumor blood vessels are used for nutrient delivery, and possibly for cancer cell migration.  	miRNA-corp.d90.s2.e0	Diseases	brain tumor 	1
miRNA-corp.d90.s2	The brain tumor blood vessels are used for nutrient delivery, and possibly for cancer cell migration.  	miRNA-corp.d90.s2.e1	Diseases	cancer 	2
miRNA-corp.d90.s4	The current angiogenesis inhibitors used in clinical trials mostly target single angiogenic proteins and so far show limited effects on tumor growth.  	miRNA-corp.d90.s4.e0	Relation_Trigger	inhibitors 	1
miRNA-corp.d90.s4	The current angiogenesis inhibitors used in clinical trials mostly target single angiogenic proteins and so far show limited effects on tumor growth.  	miRNA-corp.d90.s4.e1	Relation_Trigger	target 	2
miRNA-corp.d90.s4	The current angiogenesis inhibitors used in clinical trials mostly target single angiogenic proteins and so far show limited effects on tumor growth.  	miRNA-corp.d90.s4.e2	Diseases	tumor 	3
miRNA-corp.d90.s5	Besides the conventional angiogenesis inhibitors, RNA-based inhibitors such as small-interfering RNAs (siRNAs) are being analyzed for their capacity to silence the message of proteins involved in neovascularization.  	miRNA-corp.d90.s5.e0	Relation_Trigger	inhibitors 	1
miRNA-corp.d90.s5	Besides the conventional angiogenesis inhibitors, RNA-based inhibitors such as small-interfering RNAs (siRNAs) are being analyzed for their capacity to silence the message of proteins involved in neovascularization.  	miRNA-corp.d90.s5.e1	Relation_Trigger	inhibitors 	2
miRNA-corp.d90.s6	More recently, a new family of non-coding RNAs, named angiomirs [microRNAs (miRNAs) involved in angiogenesis] has emerged.  	miRNA-corp.d90.s6.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d90.s6	More recently, a new family of non-coding RNAs, named angiomirs [microRNAs (miRNAs) involved in angiogenesis] has emerged.  	miRNA-corp.d90.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d90.s6	More recently, a new family of non-coding RNAs, named angiomirs [microRNAs (miRNAs) involved in angiogenesis] has emerged.  	miRNA-corp.d90.s6.e2	Non-Specific_miRNAs	angiomirs 	3
miRNA-corp.d90.s7	These small RNAs have the advantage over siRNAs in that they have the potential of silencing multiple messages at the same time and therefore they might become therapeutically relevant in a "one-hit multiple-target" context against brain tumor angiogenesis.  	miRNA-corp.d90.s7.e0	Diseases	brain tumor 	1
miRNA-corp.d91.s0	RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.  	miRNA-corp.d91.s0.e0	Relation_Trigger	regulation of gene expression 	1
miRNA-corp.d91.s1	Gene regulation through RNA editing.   	miRNA-corp.d91.s1.e0	Relation_Trigger	regulation 	1
miRNA-corp.d91.s3	Widespread A-to-I modification of repeat sequences in the human transcriptome suggests additional roles for RNA editing and links it to other processes of gene regulation, such as RNA splicing as well as siRNA mediated gene silencing and miRNA function.  	miRNA-corp.d91.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d91.s3	Widespread A-to-I modification of repeat sequences in the human transcriptome suggests additional roles for RNA editing and links it to other processes of gene regulation, such as RNA splicing as well as siRNA mediated gene silencing and miRNA function.  	miRNA-corp.d91.s3.e1	Relation_Trigger	regulation 	2
miRNA-corp.d91.s3	Widespread A-to-I modification of repeat sequences in the human transcriptome suggests additional roles for RNA editing and links it to other processes of gene regulation, such as RNA splicing as well as siRNA mediated gene silencing and miRNA function.  	miRNA-corp.d91.s3.e2	Species	human 	3
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e0	Diseases	neurological diseases 	1
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e1	Diseases	epilepsy 	2
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e2	Diseases	amyotrophic lateral sclerosis 	3
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e3	Diseases	ALS 	4
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e4	Diseases	depression 	5
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e5	Diseases	tumor 	6
miRNA-corp.d91.s4	The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression.  	miRNA-corp.d91.s4.e6	Relation_Trigger	misregulation 	7
miRNA-corp.d91.s5	Also, it regulates important functional properties of neurotransmitter receptor genes in the central nervous system by changing single codons in pre-mRNA.  	miRNA-corp.d91.s5.e0	Relation_Trigger	regulates 	1
miRNA-corp.d92.s0	New insights into the roles of microRNAs in drug addiction and neuroplasticity.   	miRNA-corp.d92.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d92.s0	New insights into the roles of microRNAs in drug addiction and neuroplasticity.   	miRNA-corp.d92.s0.e1	Diseases	drug addiction 	2
miRNA-corp.d92.s1	In this review, the aim is to provide an overview of the emerging role of miRNAs in addiction.    	miRNA-corp.d92.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d92.s2	miRNAs are small non-coding RNAs, particularly abundant in the nervous system, that play key roles as regulatory molecules in processes such as neurogenesis, synapse development and plasticity in the brain.  	miRNA-corp.d92.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d92.s2	miRNAs are small non-coding RNAs, particularly abundant in the nervous system, that play key roles as regulatory molecules in processes such as neurogenesis, synapse development and plasticity in the brain.  	miRNA-corp.d92.s2.e1	Relation_Trigger	regulatory molecules 	2
miRNA-corp.d92.s3	They also act as key spatiotemporal regulators during dendritic morphogenesis, controlling the expression of hundreds of genes involved in neuroplasticity and in the function of synapses.  	miRNA-corp.d92.s3.e0	Relation_Trigger	regulators 	1
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e2	Diseases	brain disorders 	3
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e3	Specific_miRNAs	miR-16 	4
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e4	Specific_miRNAs	miR-212 	5
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e5	Specific_miRNAs	miR-133b 	6
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e6	Relation_Trigger	specifically expressed 	7
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e7	Relation_Trigger	regulates 	8
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e8	Relation_Trigger	targets 	9
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e9	Genes/Proteins	brain-derived neurotrophic factor 	10
miRNA-corp.d92.s4	Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine.  	miRNA-corp.d92.s4.e10	Genes/Proteins	tyrosine hydroxylase 	11
miRNA-corp.d92.s5	Clearly, specific miRNAs have emerged as key regulators leading to addiction, and could serve as valuable targets for more efficient therapies.  	miRNA-corp.d92.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d92.s5	Clearly, specific miRNAs have emerged as key regulators leading to addiction, and could serve as valuable targets for more efficient therapies.  	miRNA-corp.d92.s5.e1	Relation_Trigger	regulators 	2
miRNA-corp.d92.s5	Clearly, specific miRNAs have emerged as key regulators leading to addiction, and could serve as valuable targets for more efficient therapies.  	miRNA-corp.d92.s5.e2	Relation_Trigger	targets 	3
miRNA-corp.d92.s6	ABSTRACT : Drug addiction is a major public health issue.  	miRNA-corp.d92.s6.e0	Diseases	Drug addiction 	1
miRNA-corp.d92.s7	It is typically a multigenetic brain disorder, implying combined changes of expression of several hundred genes.  	miRNA-corp.d92.s7.e0	Diseases	brain disorder 	1
miRNA-corp.d92.s7	It is typically a multigenetic brain disorder, implying combined changes of expression of several hundred genes.  	miRNA-corp.d92.s7.e1	Relation_Trigger	changes of expression 	2
miRNA-corp.d92.s8	Psychostimulants (such as cocaine, heroin and amphetamines) induce strong and persistent neuroadaptive changes through a surfeit of gene regulatory mechanisms leading to addiction.  	miRNA-corp.d92.s8.e0	Relation_Trigger	regulatory 	1
miRNA-corp.d92.s9	Activity-dependent synaptic plasticity of the mesolimbic dopaminergic system, known as the 'reward pathway', plays a crucial role in the development of drug dependence.  	miRNA-corp.d92.s9.e0	Diseases	drug dependence 	1
miRNA-corp.d93.s0	The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.    	miRNA-corp.d93.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d93.s0	The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.    	miRNA-corp.d93.s0.e1	Diseases	medulloblastomas 	2
miRNA-corp.d93.s0	The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.    	miRNA-corp.d93.s0.e2	Diseases	gliomas 	3
miRNA-corp.d93.s0	The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.    	miRNA-corp.d93.s0.e3	Relation_Trigger	inhibitors 	4
miRNA-corp.d93.s1	In addition to the established role of miRNAs as developmental regulators of normal cellular function, they have recently been shown to be important players in pathological states such as cancer.  	miRNA-corp.d93.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d93.s1	In addition to the established role of miRNAs as developmental regulators of normal cellular function, they have recently been shown to be important players in pathological states such as cancer.  	miRNA-corp.d93.s1.e1	Relation_Trigger	regulators 	2
miRNA-corp.d93.s1	In addition to the established role of miRNAs as developmental regulators of normal cellular function, they have recently been shown to be important players in pathological states such as cancer.  	miRNA-corp.d93.s1.e2	Diseases	cancer 	3
miRNA-corp.d93.s2	The many roles of microRNAs in brain tumor biology.   	miRNA-corp.d93.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d93.s2	The many roles of microRNAs in brain tumor biology.   	miRNA-corp.d93.s2.e1	Diseases	brain tumor 	2
miRNA-corp.d93.s3	MicroRNAs (miRNAs) are now recognized as the primary RNAs involved in the purposeful silencing of the cell's own message.  	miRNA-corp.d93.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d93.s3	MicroRNAs (miRNAs) are now recognized as the primary RNAs involved in the purposeful silencing of the cell's own message.  	miRNA-corp.d93.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d94.s0	Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs).  	miRNA-corp.d94.s0.e0	Non-Specific_miRNAs	Micro RNAs 	1
miRNA-corp.d94.s0	Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs).  	miRNA-corp.d94.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d94.s0	Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs).  	miRNA-corp.d94.s0.e2	Relation_Trigger	regulate 	3
miRNA-corp.d94.s0	Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs).  	miRNA-corp.d94.s0.e3	Relation_Trigger	modulators of gene expression 	4
miRNA-corp.d94.s0	Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs).  	miRNA-corp.d94.s0.e4	Relation_Trigger	target 	5
miRNA-corp.d94.s1	Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation.   	miRNA-corp.d94.s1.e0	Specific_miRNAs	Micro RNA-125b 	1
miRNA-corp.d94.s1	Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation.   	miRNA-corp.d94.s1.e1	Specific_miRNAs	miRNA-125b 	2
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e0	Genes/Proteins	IL-6 	1
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e1	Relation_Trigger	target 	2
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e2	Relation_Trigger	increased the expression 	3
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e3	Specific_miRNAs	miRNA-125b 	4
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e4	Genes/Proteins	cyclin-dependent kinase inhibitor 2A 	5
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e5	Genes/Proteins	CDKN2A 	6
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e6	Relation_Trigger	attenuated 	7
miRNA-corp.d94.s2	In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth.  	miRNA-corp.d94.s2.e7	Relation_Trigger	negative regulator 	8
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e0	Relation_Trigger	up-regulated 	1
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e1	Specific_miRNAs	miRNA-125b 	2
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e2	Genes/Proteins	interleukin-6 	3
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e3	Genes/Proteins	IL-6 	4
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e4	Species	human 	5
miRNA-corp.d94.s3	Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis.  	miRNA-corp.d94.s3.e5	Species	human 	6
miRNA-corp.d94.s4	The results suggest that miRNA-125b up-regulation contributes to astrogliosis and to defects in the cell cycle that are characteristic of degenerating brain tissues.    	miRNA-corp.d94.s4.e0	Relation_Trigger	up-regulation 	1
miRNA-corp.d94.s4	The results suggest that miRNA-125b up-regulation contributes to astrogliosis and to defects in the cell cycle that are characteristic of degenerating brain tissues.    	miRNA-corp.d94.s4.e1	Specific_miRNAs	miRNA-125b 	2
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e0	Genes/Proteins	vimentin 	1
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e1	Relation_Trigger	positive correlation 	2
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e3	Diseases	AD 	4
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e4	Diseases	Down's syndrome 	5
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e5	Diseases	DS 	6
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e6	Genes/Proteins	glial fibrillary acidic protein 	7
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e7	Genes/Proteins	GFAP 	8
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e8	Genes/Proteins	CDKN2A 	9
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e9	Specific_miRNAs	miRNA-125b 	10
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e10	Relation_Trigger	down-regulation 	11
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e11	Relation_Trigger	associated 	12
miRNA-corp.d94.s5	A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis.  	miRNA-corp.d94.s5.e12	Diseases	neurological disorders 	13
miRNA-corp.d95.s0	PURPOSE Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children.  	miRNA-corp.d95.s0.e0	Diseases	brain tumor 	1
miRNA-corp.d95.s0	PURPOSE Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children.  	miRNA-corp.d95.s0.e1	Diseases	Medulloblastomas 	2
miRNA-corp.d95.s0	PURPOSE Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children.  	miRNA-corp.d95.s0.e2	Diseases	tumors 	3
miRNA-corp.d95.s0	PURPOSE Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children.  	miRNA-corp.d95.s0.e3	Species	children 	4
miRNA-corp.d95.s1	Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.   	miRNA-corp.d95.s1.e0	Diseases	medulloblastoma 	1
miRNA-corp.d95.s2	We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals.  	miRNA-corp.d95.s2.e0	Genes/Proteins	MYC 	1
miRNA-corp.d95.s2	We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals.  	miRNA-corp.d95.s2.e1	Specific_miRNAs	miR-183∼96∼182 	2
miRNA-corp.d95.s2	We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals.  	miRNA-corp.d95.s2.e2	Relation_Trigger	associated 	3
miRNA-corp.d95.s2	We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals.  	miRNA-corp.d95.s2.e3	Relation_Trigger	increased miR-183∼96∼182 expression 	4
miRNA-corp.d95.s3	Results Identified are six molecular subgroups of medulloblastoma, each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression.  	miRNA-corp.d95.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d95.s3	Results Identified are six molecular subgroups of medulloblastoma, each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression.  	miRNA-corp.d95.s3.e1	Diseases	medulloblastoma 	2
miRNA-corp.d95.s3	Results Identified are six molecular subgroups of medulloblastoma, each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression.  	miRNA-corp.d95.s3.e2	Diseases	chromosomal aberrations 	3
miRNA-corp.d95.s4	CONCLUSION Our results detail the complex genomic heterogeneity of medulloblastomas and identify a previously unrecognized molecular subgroup with poor clinical outcome for which more effective therapeutic strategies should be developed.    	miRNA-corp.d95.s4.e0	Diseases	medulloblastomas 	1
miRNA-corp.d95.s5	PATIENTS AND METHODS We profiled the mRNA transcriptome of 194 medulloblastomas and performed high-density single nucleotide polymorphism array and miRNA analysis on 115 and 98 of these, respectively.  	miRNA-corp.d95.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d95.s5	PATIENTS AND METHODS We profiled the mRNA transcriptome of 194 medulloblastomas and performed high-density single nucleotide polymorphism array and miRNA analysis on 115 and 98 of these, respectively.  	miRNA-corp.d95.s5.e1	Diseases	medulloblastomas 	2
miRNA-corp.d95.s5	PATIENTS AND METHODS We profiled the mRNA transcriptome of 194 medulloblastomas and performed high-density single nucleotide polymorphism array and miRNA analysis on 115 and 98 of these, respectively.  	miRNA-corp.d95.s5.e2	Species	PATIENTS 	3
miRNA-corp.d95.s6	To understand the molecular characteristics underlying their heterogeneity and to identify whether such characteristics represent risk factors for patients with this disease, we performed an integrated genomic analysis of a large series of primary tumors.  	miRNA-corp.d95.s6.e0	Diseases	tumors 	1
miRNA-corp.d95.s6	To understand the molecular characteristics underlying their heterogeneity and to identify whether such characteristics represent risk factors for patients with this disease, we performed an integrated genomic analysis of a large series of primary tumors.  	miRNA-corp.d95.s6.e1	Species	patients 	2
miRNA-corp.d95.s7	We additionally validated our findings in three previously published independent medulloblastoma data sets.  	miRNA-corp.d95.s7.e0	Diseases	medulloblastoma 	1
miRNA-corp.d95.s8	Non-negative matrix factorization-based clustering of mRNA expression data was used to identify molecular subgroups of medulloblastoma; DNA copy number, miRNA profiles, and clinical outcomes were analyzed for each.  	miRNA-corp.d95.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d95.s8	Non-negative matrix factorization-based clustering of mRNA expression data was used to identify molecular subgroups of medulloblastoma; DNA copy number, miRNA profiles, and clinical outcomes were analyzed for each.  	miRNA-corp.d95.s8.e1	Diseases	medulloblastoma 	2
miRNA-corp.d96.s0	MicroRNAs and apoptosis: implications in the molecular therapy of human disease.   	miRNA-corp.d96.s0.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d96.s0	MicroRNAs and apoptosis: implications in the molecular therapy of human disease.   	miRNA-corp.d96.s0.e1	Species	human 	2
miRNA-corp.d96.s1	1. MicroRNAs (miRNAs), the small non-coding RNAs of approximately 22 nucleotides, are now recognized as a very large family present throughout the genomes of plants and metazoans.  	miRNA-corp.d96.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d96.s1	1. MicroRNAs (miRNAs), the small non-coding RNAs of approximately 22 nucleotides, are now recognized as a very large family present throughout the genomes of plants and metazoans.  	miRNA-corp.d96.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d96.s2	These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition.  	miRNA-corp.d96.s2.e0	Relation_Trigger	target 	1
miRNA-corp.d96.s2	These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition.  	miRNA-corp.d96.s2.e1	Relation_Trigger	targeting 	2
miRNA-corp.d96.s2	These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition.  	miRNA-corp.d96.s2.e2	Relation_Trigger	translational inhibition 	3
miRNA-corp.d96.s2	These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition.  	miRNA-corp.d96.s2.e3	Relation_Trigger	modulate protein expression 	4
miRNA-corp.d96.s2	These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition.  	miRNA-corp.d96.s2.e4	Relation_Trigger	binding to 	5
miRNA-corp.d96.s3	2. The discovery of miRNAs has revolutionized our understanding of the mechanisms that regulate gene expression, with the addition of an entirely novel level of regulatory control.  	miRNA-corp.d96.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d96.s3	2. The discovery of miRNAs has revolutionized our understanding of the mechanisms that regulate gene expression, with the addition of an entirely novel level of regulatory control.  	miRNA-corp.d96.s3.e1	Relation_Trigger	regulate gene expression 	2
miRNA-corp.d96.s3	2. The discovery of miRNAs has revolutionized our understanding of the mechanisms that regulate gene expression, with the addition of an entirely novel level of regulatory control.  	miRNA-corp.d96.s3.e2	Relation_Trigger	level of regulatory 	3
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e3	Diseases	hypertrophy 	4
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e4	Diseases	heart failure 	5
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e5	Relation_Trigger	regulation 	6
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e6	Diseases	cancer 	7
miRNA-corp.d96.s4	3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure.  	miRNA-corp.d96.s4.e7	Species	human 	8
miRNA-corp.d96.s5	Indeed, aberrant miRNA expression has been documented in human disease as well as in animal models, with evidence for a causative role in tumourigenesis.  	miRNA-corp.d96.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d96.s5	Indeed, aberrant miRNA expression has been documented in human disease as well as in animal models, with evidence for a causative role in tumourigenesis.  	miRNA-corp.d96.s5.e1	Relation_Trigger	aberrant miRNA expression 	2
miRNA-corp.d96.s5	Indeed, aberrant miRNA expression has been documented in human disease as well as in animal models, with evidence for a causative role in tumourigenesis.  	miRNA-corp.d96.s5.e2	Species	human 	3
miRNA-corp.d96.s6	We now know that miRNAs play pivotal roles in diverse processes, such as development and differentiation, control of cell proliferation and death, stress response and metabolism.  	miRNA-corp.d96.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d96.s7	Considerable information on miRNAs has been accumulated in this rapidly evolving research field.  	miRNA-corp.d96.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d96.s8	4. The present review provides a comprehensive summary and analysis of the currently available data, focusing on the transcriptional controls, target genes and signalling pathways linking the apoptosis-regulating miRNAs and apoptotic cell death.    	miRNA-corp.d96.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d96.s8	4. The present review provides a comprehensive summary and analysis of the currently available data, focusing on the transcriptional controls, target genes and signalling pathways linking the apoptosis-regulating miRNAs and apoptotic cell death.    	miRNA-corp.d96.s8.e1	Relation_Trigger	target 	2
miRNA-corp.d96.s9	Thus far, nearly 30 of 500 human miRNAs have been validated experimentally to regulate apoptosis; this number is likely to increase with future studies.  	miRNA-corp.d96.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d96.s9	Thus far, nearly 30 of 500 human miRNAs have been validated experimentally to regulate apoptosis; this number is likely to increase with future studies.  	miRNA-corp.d96.s9.e1	Relation_Trigger	regulate 	2
miRNA-corp.d96.s9	Thus far, nearly 30 of 500 human miRNAs have been validated experimentally to regulate apoptosis; this number is likely to increase with future studies.  	miRNA-corp.d96.s9.e2	Species	human 	3
miRNA-corp.d97.s0	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.  	miRNA-corp.d97.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d97.s0	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.  	miRNA-corp.d97.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d97.s0	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.  	miRNA-corp.d97.s0.e2	Relation_Trigger	modulate adenoviral protein expression 	3
miRNA-corp.d97.s0	Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity.  	miRNA-corp.d97.s0.e3	Diseases	tumor 	4
miRNA-corp.d97.s2	This review discusses three aspects of the use of oncolytic adenoviruses to treat cancer: (i) the induction of autophagy and autophagic cell death during adenoviral replication; (ii) the opportunities and strategies involved in the exploitation of miRNA specificity to generate tissue- and tumor-selective oncolytic viruses; and (iii) the rationale for combining oncolytic adenoviruses with chemotherapeutic agents.    	miRNA-corp.d97.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d97.s2	This review discusses three aspects of the use of oncolytic adenoviruses to treat cancer: (i) the induction of autophagy and autophagic cell death during adenoviral replication; (ii) the opportunities and strategies involved in the exploitation of miRNA specificity to generate tissue- and tumor-selective oncolytic viruses; and (iii) the rationale for combining oncolytic adenoviruses with chemotherapeutic agents.    	miRNA-corp.d97.s2.e1	Diseases	tumor 	2
miRNA-corp.d97.s2	This review discusses three aspects of the use of oncolytic adenoviruses to treat cancer: (i) the induction of autophagy and autophagic cell death during adenoviral replication; (ii) the opportunities and strategies involved in the exploitation of miRNA specificity to generate tissue- and tumor-selective oncolytic viruses; and (iii) the rationale for combining oncolytic adenoviruses with chemotherapeutic agents.    	miRNA-corp.d97.s2.e2	Diseases	cancer 	3
miRNA-corp.d97.s3	Furthermore, the capability of adenoviruses to inhibit the expression of the DNA repair enzyme MGMT and to chemosensitize glioma cells to temozolomide has been demonstrated.  	miRNA-corp.d97.s3.e0	Relation_Trigger	inhibit the expression 	1
miRNA-corp.d97.s3	Furthermore, the capability of adenoviruses to inhibit the expression of the DNA repair enzyme MGMT and to chemosensitize glioma cells to temozolomide has been demonstrated.  	miRNA-corp.d97.s3.e1	Diseases	glioma 	2
miRNA-corp.d97.s3	Furthermore, the capability of adenoviruses to inhibit the expression of the DNA repair enzyme MGMT and to chemosensitize glioma cells to temozolomide has been demonstrated.  	miRNA-corp.d97.s3.e2	Genes/Proteins	MGMT 	3
miRNA-corp.d97.s4	In recent years, oncolytic viruses have been genetically engineered to target cancer cells selectively.  	miRNA-corp.d97.s4.e0	Relation_Trigger	target 	1
miRNA-corp.d97.s4	In recent years, oncolytic viruses have been genetically engineered to target cancer cells selectively.  	miRNA-corp.d97.s4.e1	Diseases	cancer 	2
miRNA-corp.d97.s5	Oncolytic adenoviruses for the treatment of brain tumors.   	miRNA-corp.d97.s5.e0	Diseases	brain tumors 	1
miRNA-corp.d97.s7	Adenovirus is one such oncolytic virus that is being tested in clinical trials for the treatment of cancer.  	miRNA-corp.d97.s7.e0	Diseases	cancer 	1
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e1	Specific_miRNAs	miR-107 	2
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e2	Specific_miRNAs	miR-107 	3
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e3	Genes/Proteins	BACE1 	4
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e4	Genes/Proteins	BACE1 	5
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e5	Diseases	AD 	6
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e6	Relation_Trigger	levels tended to increase 	7
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e7	Relation_Trigger	levels decreased 	8
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e8	Relation_Trigger	binding sites 	9
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e9	Non-Specific_miRNAs	miRNA 	10
miRNA-corp.d98.s0	BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA.  	miRNA-corp.d98.s0.e10	Relation_Trigger	miRNA recognition sequence in the 3'-UTR 	11
miRNA-corp.d98.s1	Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107.  	miRNA-corp.d98.s1.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d98.s1	Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107.  	miRNA-corp.d98.s1.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d98.s1	Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107.  	miRNA-corp.d98.s1.e2	Genes/Proteins	beta-site amyloid precursor protein-cleaving enzyme 1 	3
miRNA-corp.d98.s1	Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107.  	miRNA-corp.d98.s1.e3	Relation_Trigger	3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted 	4
miRNA-corp.d98.s2	From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients.  	miRNA-corp.d98.s2.e0	Diseases	AD 	1
miRNA-corp.d98.s2	From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients.  	miRNA-corp.d98.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d98.s2	From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients.  	miRNA-corp.d98.s2.e2	Diseases	MCI 	3
miRNA-corp.d98.s2	From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients.  	miRNA-corp.d98.s2.e3	Species	patients 	4
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e1	Specific_miRNAs	miR-107 	2
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e3	Diseases	AD 	4
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e4	Relation_Trigger	expression changes 	5
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e5	Relation_Trigger	levels decreased 	6
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e6	Relation_Trigger	decreased significantly 	7
miRNA-corp.d98.s3	Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology.  	miRNA-corp.d98.s3.e7	Species	patients 	8
miRNA-corp.d98.s4	In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression.  	miRNA-corp.d98.s4.e0	Diseases	AD 	1
miRNA-corp.d98.s4	In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression.  	miRNA-corp.d98.s4.e1	Specific_miRNAs	miR-107 	2
miRNA-corp.d98.s4	In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression.  	miRNA-corp.d98.s4.e2	Relation_Trigger	diminished neuronal miR-107 expression 	3
miRNA-corp.d98.s5	We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation.  	miRNA-corp.d98.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d98.s5	We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation.  	miRNA-corp.d98.s5.e1	Diseases	Alzheimer's Disease 	2
miRNA-corp.d98.s5	We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation.  	miRNA-corp.d98.s5.e2	Relation_Trigger	correlation 	3
miRNA-corp.d98.s5	We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation.  	miRNA-corp.d98.s5.e3	Species	human 	4
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e0	Diseases	AD 	1
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e1	Diseases	AD 	2
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e2	Diseases	AD 	3
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e3	Diseases	MCI 	4
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e4	Diseases	mild cognitive impairment 	5
miRNA-corp.d98.s6	Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD.  	miRNA-corp.d98.s6.e5	Diseases	negligible AD 	6
miRNA-corp.d98.s7	MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.  	miRNA-corp.d98.s7.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d98.s7	MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.  	miRNA-corp.d98.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d98.s7	MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.  	miRNA-corp.d98.s7.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d98.s7	MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.  	miRNA-corp.d98.s7.e3	Relation_Trigger	regulation 	4
miRNA-corp.d98.s8	However, little is understood about the role(s) of miRNAs in Alzheimer's disease (AD).  	miRNA-corp.d98.s8.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d98.s8	However, little is understood about the role(s) of miRNAs in Alzheimer's disease (AD).  	miRNA-corp.d98.s8.e1	Diseases	AD 	2
miRNA-corp.d98.s8	However, little is understood about the role(s) of miRNAs in Alzheimer's disease (AD).  	miRNA-corp.d98.s8.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d98.s9	Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.    	miRNA-corp.d98.s9.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d98.s9	Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.    	miRNA-corp.d98.s9.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d98.s9	Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.    	miRNA-corp.d98.s9.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d98.s9	Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.    	miRNA-corp.d98.s9.e3	Relation_Trigger	regulation 	4
miRNA-corp.d98.s9	Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.    	miRNA-corp.d98.s9.e4	Relation_Trigger	accelerated 	5
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e2	Genes/Proteins	beta-site amyloid precursor protein-cleaving enzyme 1 	3
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e4	Relation_Trigger	expression of microRNA miR-107 decreases 	5
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e5	Relation_Trigger	regulation 	6
miRNA-corp.d98.s10	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.   	miRNA-corp.d98.s10.e6	Relation_Trigger	accelerate 	7
miRNA-corp.d99.s0	This opportunistic mycosis infection presented with clinically totally nonspecific signs and symptoms of CNS affection.  	miRNA-corp.d99.s0.e0	Diseases	mycosis infection 	1
miRNA-corp.d99.s1	Therefore, we suspected affection of CNS with SLE.  	miRNA-corp.d99.s1.e0	Diseases	SLE 	1
miRNA-corp.d99.s2	Even though all diagnostic procedures were made on time and that adequate antifungal and supportive agents were applied very early after the infection onset, the outcome was fatal.  	miRNA-corp.d99.s2.e0	Diseases	infection 	1
miRNA-corp.d99.s3	Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans.  	miRNA-corp.d99.s3.e0	Diseases	opportunistic infections 	1
miRNA-corp.d99.s3	Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans.  	miRNA-corp.d99.s3.e1	Diseases	infections 	2
miRNA-corp.d99.s3	Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans.  	miRNA-corp.d99.s3.e2	Diseases	infection 	3
miRNA-corp.d99.s3	Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans.  	miRNA-corp.d99.s3.e3	Diseases	SLE 	4
miRNA-corp.d99.s3	Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans.  	miRNA-corp.d99.s3.e4	Species	patients 	5
miRNA-corp.d99.s4	It was meningitis caused by C. neoformans.  	miRNA-corp.d99.s4.e0	Diseases	meningitis 	1
miRNA-corp.d99.s7	Systemic erythematosus lupus (SLE) is a disease with wide range of clinical manifestations, signs and symptoms.  	miRNA-corp.d99.s7.e0	Diseases	Systemic erythematosus lupus 	1
miRNA-corp.d99.s7	Systemic erythematosus lupus (SLE) is a disease with wide range of clinical manifestations, signs and symptoms.  	miRNA-corp.d99.s7.e1	Diseases	SLE 	2
miRNA-corp.d99.s8	[Cryptococcal meningitis as a diagnostic problem in a patient with SLE--case report].   	miRNA-corp.d99.s8.e0	Diseases	SLE 	1
miRNA-corp.d99.s8	[Cryptococcal meningitis as a diagnostic problem in a patient with SLE--case report].   	miRNA-corp.d99.s8.e1	Diseases	Cryptococcal meningitis 	2
miRNA-corp.d99.s8	[Cryptococcal meningitis as a diagnostic problem in a patient with SLE--case report].   	miRNA-corp.d99.s8.e2	Species	patient 	3
miRNA-corp.d99.s9	Very important cause of death in patients with SLE is infection.  	miRNA-corp.d99.s9.e0	Diseases	infection 	1
miRNA-corp.d99.s9	Very important cause of death in patients with SLE is infection.  	miRNA-corp.d99.s9.e1	Diseases	SLE 	2
miRNA-corp.d99.s9	Very important cause of death in patients with SLE is infection.  	miRNA-corp.d99.s9.e2	Species	patients 	3
miRNA-corp.d99.s11	During one of the disease flares the patient was hospitalized an opportunistic infection developed.  	miRNA-corp.d99.s11.e0	Diseases	infection 	1
miRNA-corp.d99.s11	During one of the disease flares the patient was hospitalized an opportunistic infection developed.  	miRNA-corp.d99.s11.e1	Species	patient 	2
miRNA-corp.d99.s12	As an outcome of the combined effect of disease and immunosuppressive agents used in the treatment of the disease, the patient had increased infective diathesis (repeated infections caused by S. enteritidis--urinary infections and sepsis).  	miRNA-corp.d99.s12.e0	Diseases	infections 	1
miRNA-corp.d99.s12	As an outcome of the combined effect of disease and immunosuppressive agents used in the treatment of the disease, the patient had increased infective diathesis (repeated infections caused by S. enteritidis--urinary infections and sepsis).  	miRNA-corp.d99.s12.e1	Diseases	sepsis 	2
miRNA-corp.d99.s12	As an outcome of the combined effect of disease and immunosuppressive agents used in the treatment of the disease, the patient had increased infective diathesis (repeated infections caused by S. enteritidis--urinary infections and sepsis).  	miRNA-corp.d99.s12.e2	Diseases	urinary infections 	3
miRNA-corp.d99.s12	As an outcome of the combined effect of disease and immunosuppressive agents used in the treatment of the disease, the patient had increased infective diathesis (repeated infections caused by S. enteritidis--urinary infections and sepsis).  	miRNA-corp.d99.s12.e3	Species	patient 	4
miRNA-corp.d99.s13	In this case report we have presented a patient with SLE who initially had severe renal affection, but also complications of immunosuppressive therapy that was administered.  	miRNA-corp.d99.s13.e0	Diseases	SLE 	1
miRNA-corp.d99.s13	In this case report we have presented a patient with SLE who initially had severe renal affection, but also complications of immunosuppressive therapy that was administered.  	miRNA-corp.d99.s13.e1	Species	patient 	2
miRNA-corp.d99.s14	Infections are very common among these patients due to aggressive immunosuppressive treatment that is needed for the disease inflammatory activity control.  	miRNA-corp.d99.s14.e0	Diseases	Infections 	1
miRNA-corp.d99.s14	Infections are very common among these patients due to aggressive immunosuppressive treatment that is needed for the disease inflammatory activity control.  	miRNA-corp.d99.s14.e1	Species	patients 	2
miRNA-corp.d99.s15	Because of lupus nephropathy, in the early phase of the disease we administered aggressive immunosuppressive therapy (combined parenteral therapy of glucocorticoides and cyclophosphamide).  	miRNA-corp.d99.s15.e0	Diseases	lupus nephropathy 	1
miRNA-corp.d100.s0	Specifically, we highlight the importance of unbiased association studies and follow-up functional experiments for providing a clearer picture of the extent to which microRNA target site variations are relevant in various human diseases.    	miRNA-corp.d100.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d100.s0	Specifically, we highlight the importance of unbiased association studies and follow-up functional experiments for providing a clearer picture of the extent to which microRNA target site variations are relevant in various human diseases.    	miRNA-corp.d100.s0.e1	Relation_Trigger	target 	2
miRNA-corp.d100.s0	Specifically, we highlight the importance of unbiased association studies and follow-up functional experiments for providing a clearer picture of the extent to which microRNA target site variations are relevant in various human diseases.    	miRNA-corp.d100.s0.e2	Relation_Trigger	association 	3
miRNA-corp.d100.s0	Specifically, we highlight the importance of unbiased association studies and follow-up functional experiments for providing a clearer picture of the extent to which microRNA target site variations are relevant in various human diseases.    	miRNA-corp.d100.s0.e3	Species	human 	4
miRNA-corp.d100.s3	Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer.  	miRNA-corp.d100.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d100.s3	Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer.  	miRNA-corp.d100.s3.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d100.s3	Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer.  	miRNA-corp.d100.s3.e2	Relation_Trigger	associated 	3
miRNA-corp.d100.s3	Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer.  	miRNA-corp.d100.s3.e3	Relation_Trigger	target 	4
miRNA-corp.d100.s3	Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer.  	miRNA-corp.d100.s3.e4	Diseases	cancer 	5
miRNA-corp.d100.s4	They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie more human diseases than currently appreciated.  	miRNA-corp.d100.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d100.s4	They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie more human diseases than currently appreciated.  	miRNA-corp.d100.s4.e1	Species	human 	2
miRNA-corp.d100.s5	MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression.  	miRNA-corp.d100.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d100.s5	MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression.  	miRNA-corp.d100.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d100.s5	MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression.  	miRNA-corp.d100.s5.e2	Relation_Trigger	regulators of eukaryotic gene expression 	3
miRNA-corp.d100.s6	MicroRNA target site polymorphisms and human disease.   	miRNA-corp.d100.s6.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d100.s6	MicroRNA target site polymorphisms and human disease.   	miRNA-corp.d100.s6.e1	Relation_Trigger	target 	2
miRNA-corp.d100.s6	MicroRNA target site polymorphisms and human disease.   	miRNA-corp.d100.s6.e2	Species	human 	3
miRNA-corp.d101.s0	Human traumatic brain injury alters plasma microRNA levels.   	miRNA-corp.d101.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d101.s0	Human traumatic brain injury alters plasma microRNA levels.   	miRNA-corp.d101.s0.e1	Diseases	brain injury 	2
miRNA-corp.d101.s0	Human traumatic brain injury alters plasma microRNA levels.   	miRNA-corp.d101.s0.e2	Relation_Trigger	alters plasma microRNA levels 	3
miRNA-corp.d101.s0	Human traumatic brain injury alters plasma microRNA levels.   	miRNA-corp.d101.s0.e3	Species	Human 	4
miRNA-corp.d101.s1	Circulating microRNAs (miRNAs) present in the serum/plasma are characteristically altered in many pathological conditions, and have been employed as diagnostic markers for specific diseases.  	miRNA-corp.d101.s1.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d101.s1	Circulating microRNAs (miRNAs) present in the serum/plasma are characteristically altered in many pathological conditions, and have been employed as diagnostic markers for specific diseases.  	miRNA-corp.d101.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e1	Relation_Trigger	levels are altered 	2
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e2	Diseases	TBI 	3
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e3	Diseases	traumatic brain injury 	4
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e4	Diseases	TBI 	5
miRNA-corp.d101.s2	We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers.  	miRNA-corp.d101.s2.e5	Species	patients 	6
miRNA-corp.d101.s3	The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score ≤8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis.  	miRNA-corp.d101.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d101.s3	The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score ≤8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis.  	miRNA-corp.d101.s3.e1	Diseases	TBI 	2
miRNA-corp.d101.s3	The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score ≤8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis.  	miRNA-corp.d101.s3.e2	Species	patients 	3
miRNA-corp.d101.s4	Of the 108 miRNAs identified in healthy volunteer plasma, 52 were altered after severe TBI, including 33 with decreased and 19 with increased relative abundance.  	miRNA-corp.d101.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d101.s4	Of the 108 miRNAs identified in healthy volunteer plasma, 52 were altered after severe TBI, including 33 with decreased and 19 with increased relative abundance.  	miRNA-corp.d101.s4.e1	Diseases	TBI 	2
miRNA-corp.d101.s5	An additional 8 miRNAs were detected only in the TBI plasma.  	miRNA-corp.d101.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d101.s5	An additional 8 miRNAs were detected only in the TBI plasma.  	miRNA-corp.d101.s5.e1	Diseases	TBI 	2
miRNA-corp.d101.s6	We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury.  	miRNA-corp.d101.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d101.s6	We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury.  	miRNA-corp.d101.s6.e1	Diseases	TBI 	2
miRNA-corp.d101.s6	We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury.  	miRNA-corp.d101.s6.e2	Diseases	injury 	3
miRNA-corp.d101.s6	We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury.  	miRNA-corp.d101.s6.e3	Species	patients 	4
miRNA-corp.d101.s7	Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively).  	miRNA-corp.d101.s7.e0	Diseases	TBI 	1
miRNA-corp.d101.s7	Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively).  	miRNA-corp.d101.s7.e1	Specific_miRNAs	miR-765 	2
miRNA-corp.d101.s7	Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively).  	miRNA-corp.d101.s7.e2	Specific_miRNAs	miR-92a 	3
miRNA-corp.d101.s7	Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively).  	miRNA-corp.d101.s7.e3	Specific_miRNAs	miR-16 	4
miRNA-corp.d101.s8	Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients.  	miRNA-corp.d101.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d101.s8	Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients.  	miRNA-corp.d101.s8.e1	Diseases	orthopedic injury 	2
miRNA-corp.d101.s8	Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients.  	miRNA-corp.d101.s8.e2	Species	patients 	3
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e0	Relation_Trigger	sma levels of miR-92a and miR-16 were significantly incre 	1
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e1	Diseases	TBI 	2
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e2	Specific_miRNAs	miR-16 	3
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e3	Specific_miRNAs	miR-92a 	4
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e4	Specific_miRNAs	miR-765 	5
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e5	Diseases	injury 	6
miRNA-corp.d101.s9	In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively.  	miRNA-corp.d101.s9.e6	Species	patients 	7
miRNA-corp.d101.s10	Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.    	miRNA-corp.d101.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d101.s10	Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.    	miRNA-corp.d101.s10.e1	Diseases	TBI 	2
miRNA-corp.d101.s10	Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.    	miRNA-corp.d101.s10.e2	Species	patient 	3
miRNA-corp.d101.s11	Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers.  	miRNA-corp.d101.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d101.s11	Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers.  	miRNA-corp.d101.s11.e1	Relation_Trigger	levels are altered 	2
miRNA-corp.d101.s11	Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers.  	miRNA-corp.d101.s11.e2	Diseases	TBI 	3
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e0	Specific_miRNAs	MicroRNA-205 	1
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e1	Genes/Proteins	Low-density lipoprotein receptor-related protein 1 	2
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e2	Genes/Proteins	LRP1 	3
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e3	Diseases	Alzheimer's disease 	4
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e4	Genes/Proteins	LDL receptor-related protein 1 	5
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e5	Relation_Trigger	down-regulating the expression 	6
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e6	Relation_Trigger	inhibits 	7
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e7	Diseases	tumor 	8
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e8	Diseases	tumor 	9
miRNA-corp.d102.s0	MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease.  	miRNA-corp.d102.s0.e9	Species	human 	10
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e0	Specific_miRNAs	miR-205 	1
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e1	Genes/Proteins	LRP1 	2
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e2	Genes/Proteins	LRP1 	3
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e3	Relation_Trigger	down-regulates the expression 	4
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e4	Relation_Trigger	targeting sequences in the 3'UTR 	5
miRNA-corp.d102.s1	In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA.  	miRNA-corp.d102.s1.e5	Species	human 	6
miRNA-corp.d102.s2	However, mechanisms that regulate LRP1 expression under physiological and pathophysiological conditions are not unclear.  	miRNA-corp.d102.s2.e0	Genes/Proteins	LRP1 	1
miRNA-corp.d102.s2	However, mechanisms that regulate LRP1 expression under physiological and pathophysiological conditions are not unclear.  	miRNA-corp.d102.s2.e1	Relation_Trigger	regulate LRP1 expression 	2
miRNA-corp.d102.s3	The ectopic expression of miR-205 also significantly mitigated migration of both U87 and SK-LU-1 cells.  	miRNA-corp.d102.s3.e0	Specific_miRNAs	miR-205 	1
miRNA-corp.d102.s3	The ectopic expression of miR-205 also significantly mitigated migration of both U87 and SK-LU-1 cells.  	miRNA-corp.d102.s3.e1	Relation_Trigger	ectopic expression 	2
miRNA-corp.d102.s4	This effect was abolished by deleting the miR-205 seed site in the 3'UTR of LRP1.  	miRNA-corp.d102.s4.e0	Specific_miRNAs	miR-205 	1
miRNA-corp.d102.s4	This effect was abolished by deleting the miR-205 seed site in the 3'UTR of LRP1.  	miRNA-corp.d102.s4.e1	Genes/Proteins	LRP1 	2
miRNA-corp.d102.s5	These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.    	miRNA-corp.d102.s5.e0	Genes/Proteins	LRP1 	1
miRNA-corp.d102.s5	These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.    	miRNA-corp.d102.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d102.s5	These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.    	miRNA-corp.d102.s5.e2	Relation_Trigger	expression of human LRP1 is regulated 	3
miRNA-corp.d102.s5	These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.    	miRNA-corp.d102.s5.e3	Diseases	tumor 	4
miRNA-corp.d102.s5	These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.    	miRNA-corp.d102.s5.e4	Species	human 	5
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e3	Diseases	AD 	4
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e4	Relation_Trigger	miRNA profiles are altered 	5
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e5	Relation_Trigger	dysfunction 	6
miRNA-corp.d103.s0	In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.  	miRNA-corp.d103.s0.e6	Diseases	neurodegenerative disorders 	7
miRNA-corp.d103.s1	These small non-coding RNA regulators are highly enriched in brain where they play key roles in neuronal development, plasticity and disease.  	miRNA-corp.d103.s1.e0	Relation_Trigger	regulators 	1
miRNA-corp.d103.s2	Normal brain development and function depends on microRNA (miRNA) networks to fine tune the balance between the transcriptome and proteome of the cell.  	miRNA-corp.d103.s2.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d103.s2	Normal brain development and function depends on microRNA (miRNA) networks to fine tune the balance between the transcriptome and proteome of the cell.  	miRNA-corp.d103.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d103.s3	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.   	miRNA-corp.d103.s3.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d103.s3	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.   	miRNA-corp.d103.s3.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d103.s3	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.   	miRNA-corp.d103.s3.e2	Genes/Proteins	amyloid-beta 	3
miRNA-corp.d103.s3	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.   	miRNA-corp.d103.s3.e3	Relation_Trigger	deregulation 	4
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e2	Diseases	AD 	3
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e3	Genes/Proteins	Abeta 	4
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e4	Relation_Trigger	deregulated 	5
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e5	Relation_Trigger	deregulation 	6
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e6	Relation_Trigger	deregulation 	7
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e7	Relation_Trigger	target 	8
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e8	Genes/Proteins	Abeta42 	9
miRNA-corp.d103.s4	Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation.  	miRNA-corp.d103.s4.e9	Species	mice 	10
miRNA-corp.d103.s5	Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid.  	miRNA-corp.d103.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d103.s5	Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid.  	miRNA-corp.d103.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d103.s5	Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid.  	miRNA-corp.d103.s5.e2	Genes/Proteins	Abeta 	3
miRNA-corp.d103.s5	Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid.  	miRNA-corp.d103.s5.e3	Genes/Proteins	Abeta 	4
miRNA-corp.d103.s5	Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid.  	miRNA-corp.d103.s5.e4	Relation_Trigger	regulator of miRNA levels 	5
miRNA-corp.d103.s6	We used sensitive TaqMan low density miRNA arrays (TLDA) on murine primary hippocampal cultures to show that about half of all miRNAs tested were down-regulated in response to Abeta peptides.  	miRNA-corp.d103.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d103.s6	We used sensitive TaqMan low density miRNA arrays (TLDA) on murine primary hippocampal cultures to show that about half of all miRNAs tested were down-regulated in response to Abeta peptides.  	miRNA-corp.d103.s6.e1	Genes/Proteins	Abeta 	2
miRNA-corp.d103.s6	We used sensitive TaqMan low density miRNA arrays (TLDA) on murine primary hippocampal cultures to show that about half of all miRNAs tested were down-regulated in response to Abeta peptides.  	miRNA-corp.d103.s6.e2	Relation_Trigger	down-regulated 	3
miRNA-corp.d103.s6	We used sensitive TaqMan low density miRNA arrays (TLDA) on murine primary hippocampal cultures to show that about half of all miRNAs tested were down-regulated in response to Abeta peptides.  	miRNA-corp.d103.s6.e3	Species	murine 	4
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e1	Diseases	AD 	2
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e2	Diseases	AD 	3
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e3	Diseases	AD 	4
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e4	Genes/Proteins	amyloid-beta 	5
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e5	Genes/Proteins	Abeta 	6
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e6	Relation_Trigger	deregulation 	7
miRNA-corp.d103.s7	Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD.  	miRNA-corp.d103.s7.e7	Species	human 	8
miRNA-corp.d103.s8	In addition, the miRNA deregulation in hippocampal cultures and APP23 hippocampus overlaps with those obtained in human AD studies.  	miRNA-corp.d103.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d103.s8	In addition, the miRNA deregulation in hippocampal cultures and APP23 hippocampus overlaps with those obtained in human AD studies.  	miRNA-corp.d103.s8.e1	Diseases	AD 	2
miRNA-corp.d103.s8	In addition, the miRNA deregulation in hippocampal cultures and APP23 hippocampus overlaps with those obtained in human AD studies.  	miRNA-corp.d103.s8.e2	Relation_Trigger	deregulation 	3
miRNA-corp.d103.s8	In addition, the miRNA deregulation in hippocampal cultures and APP23 hippocampus overlaps with those obtained in human AD studies.  	miRNA-corp.d103.s8.e3	Species	human 	4
miRNA-corp.d103.s9	Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD.    	miRNA-corp.d103.s9.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d103.s9	Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD.    	miRNA-corp.d103.s9.e1	Diseases	AD 	2
miRNA-corp.d103.s9	Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD.    	miRNA-corp.d103.s9.e2	Genes/Proteins	Abeta 	3
miRNA-corp.d103.s9	Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD.    	miRNA-corp.d103.s9.e3	Relation_Trigger	deregulation 	4
miRNA-corp.d104.s0	We report here on a patient who was treated for an atypical brain meningioma with multiple surgeries and multiple sessions of stereotactic radiosurgery with good control of his brain disease.  	miRNA-corp.d104.s0.e0	Diseases	meningioma 	1
miRNA-corp.d104.s0	We report here on a patient who was treated for an atypical brain meningioma with multiple surgeries and multiple sessions of stereotactic radiosurgery with good control of his brain disease.  	miRNA-corp.d104.s0.e1	Diseases	brain disease 	2
miRNA-corp.d104.s0	We report here on a patient who was treated for an atypical brain meningioma with multiple surgeries and multiple sessions of stereotactic radiosurgery with good control of his brain disease.  	miRNA-corp.d104.s0.e2	Species	patient 	3
miRNA-corp.d104.s2	Extracranial metastases from brain meningiomas is a rare, but well-documented entity.  	miRNA-corp.d104.s2.e0	Diseases	meningiomas 	1
miRNA-corp.d104.s4	Extraneural metastases from cranial meningioma: a case report.   	miRNA-corp.d104.s4.e0	Diseases	cranial meningioma 	1
miRNA-corp.d105.s0	The present review examines the various miRNAs that have been identified as being potentially involved in T2D, focusing on the insulin-sensitive organs: white adipose tissue, liver, skeletal muscle and the insulin-producing pancreatic β-cells.    	miRNA-corp.d105.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d105.s0	The present review examines the various miRNAs that have been identified as being potentially involved in T2D, focusing on the insulin-sensitive organs: white adipose tissue, liver, skeletal muscle and the insulin-producing pancreatic β-cells.    	miRNA-corp.d105.s0.e1	Diseases	T2D 	2
miRNA-corp.d105.s0	The present review examines the various miRNAs that have been identified as being potentially involved in T2D, focusing on the insulin-sensitive organs: white adipose tissue, liver, skeletal muscle and the insulin-producing pancreatic β-cells.    	miRNA-corp.d105.s0.e2	Genes/Proteins	insulin 	3
miRNA-corp.d105.s0	The present review examines the various miRNAs that have been identified as being potentially involved in T2D, focusing on the insulin-sensitive organs: white adipose tissue, liver, skeletal muscle and the insulin-producing pancreatic β-cells.    	miRNA-corp.d105.s0.e3	Genes/Proteins	insulin 	4
miRNA-corp.d105.s1	miRNAs are involved in a large number of biological functions such as development, metabolism, immunity and diseases such as cancer, cardiovascular diseases and diabetes.  	miRNA-corp.d105.s1.e0	Diseases	cardiovascular diseases 	1
miRNA-corp.d105.s1	miRNAs are involved in a large number of biological functions such as development, metabolism, immunity and diseases such as cancer, cardiovascular diseases and diabetes.  	miRNA-corp.d105.s1.e1	Diseases	diabetes 	2
miRNA-corp.d105.s1	miRNAs are involved in a large number of biological functions such as development, metabolism, immunity and diseases such as cancer, cardiovascular diseases and diabetes.  	miRNA-corp.d105.s1.e2	Diseases	cancer 	3
miRNA-corp.d105.s1	miRNAs are involved in a large number of biological functions such as development, metabolism, immunity and diseases such as cancer, cardiovascular diseases and diabetes.  	miRNA-corp.d105.s1.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d105.s2	miRNAs are small 22-25-nt-long untranslated RNAs that negatively regulate the translation of mRNAs.  	miRNA-corp.d105.s2.e0	Relation_Trigger	regulate the translation 	1
miRNA-corp.d105.s2	miRNAs are small 22-25-nt-long untranslated RNAs that negatively regulate the translation of mRNAs.  	miRNA-corp.d105.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d105.s3	Although T2D seems to be strongly linked to environmental factors such as nutrition and lifestyle, studies have shown that genetic factors, such as polymorphisms associated with metabolic genes, imprinting, fetal programming and miRNA (microRNA) expression, could also contribute to the development of this disease.  	miRNA-corp.d105.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d105.s3	Although T2D seems to be strongly linked to environmental factors such as nutrition and lifestyle, studies have shown that genetic factors, such as polymorphisms associated with metabolic genes, imprinting, fetal programming and miRNA (microRNA) expression, could also contribute to the development of this disease.  	miRNA-corp.d105.s3.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d105.s3	Although T2D seems to be strongly linked to environmental factors such as nutrition and lifestyle, studies have shown that genetic factors, such as polymorphisms associated with metabolic genes, imprinting, fetal programming and miRNA (microRNA) expression, could also contribute to the development of this disease.  	miRNA-corp.d105.s3.e2	Diseases	T2D 	3
miRNA-corp.d105.s3	Although T2D seems to be strongly linked to environmental factors such as nutrition and lifestyle, studies have shown that genetic factors, such as polymorphisms associated with metabolic genes, imprinting, fetal programming and miRNA (microRNA) expression, could also contribute to the development of this disease.  	miRNA-corp.d105.s3.e3	Relation_Trigger	associated 	4
miRNA-corp.d105.s4	The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance.  	miRNA-corp.d105.s4.e0	Diseases	T2D 	1
miRNA-corp.d105.s4	The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance.  	miRNA-corp.d105.s4.e1	Diseases	T2D 	2
miRNA-corp.d105.s4	The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance.  	miRNA-corp.d105.s4.e2	Diseases	obesity 	3
miRNA-corp.d105.s4	The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance.  	miRNA-corp.d105.s4.e3	Diseases	dyslipidaemia 	4
miRNA-corp.d105.s4	The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance.  	miRNA-corp.d105.s4.e4	Diseases	insulin resistance 	5
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e0	Diseases	TD2 	1
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e1	Diseases	heart disease 	2
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e2	Diseases	stroke 	3
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e3	Diseases	kidney failure 	4
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e4	Diseases	blindness 	5
miRNA-corp.d105.s5	Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage.  	miRNA-corp.d105.s5.e5	Diseases	nerve damage 	6
miRNA-corp.d105.s6	T2D is a progressive metabolic disorder characterized by reduced insulin sensitivity, insulin resistance and pancreatic β-cell dysfunction.  	miRNA-corp.d105.s6.e0	Diseases	T2D 	1
miRNA-corp.d105.s6	T2D is a progressive metabolic disorder characterized by reduced insulin sensitivity, insulin resistance and pancreatic β-cell dysfunction.  	miRNA-corp.d105.s6.e1	Genes/Proteins	insulin 	2
miRNA-corp.d105.s6	T2D is a progressive metabolic disorder characterized by reduced insulin sensitivity, insulin resistance and pancreatic β-cell dysfunction.  	miRNA-corp.d105.s6.e2	Diseases	insulin resistance 	3
miRNA-corp.d105.s6	T2D is a progressive metabolic disorder characterized by reduced insulin sensitivity, insulin resistance and pancreatic β-cell dysfunction.  	miRNA-corp.d105.s6.e3	Diseases	pancreatic β-cell dysfunction 	4
miRNA-corp.d105.s7	The involvement of microRNAs in Type 2 diabetes.   	miRNA-corp.d105.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d105.s7	The involvement of microRNAs in Type 2 diabetes.   	miRNA-corp.d105.s7.e1	Diseases	Type 2 diabetes 	2
miRNA-corp.d105.s8	T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide.  	miRNA-corp.d105.s8.e0	Diseases	T2D 	1
miRNA-corp.d105.s8	T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide.  	miRNA-corp.d105.s8.e1	Diseases	Type 2 diabetes mellitus 	2
miRNA-corp.d106.s0	Isolation and characterization of a novel pituitary tumor apoptosis gene.   	miRNA-corp.d106.s0.e0	Genes/Proteins	pituitary tumor apoptosis gene 	1
miRNA-corp.d106.s1	We report the isolation of a novel differentially methylated chromosome 22 CpG island-associated gene (C22orf3).  	miRNA-corp.d106.s1.e0	Genes/Proteins	C22orf3 	1
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e0	Relation_Trigger	failed to express 	1
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e1	Relation_Trigger	failed to express 	2
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e2	Genes/Proteins	pituitary tumor apoptosis gene 	3
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e3	Genes/Proteins	PTAG 	4
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e4	Diseases	tumors 	5
miRNA-corp.d106.s3	Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene.  	miRNA-corp.d106.s3.e5	Diseases	adenomas 	6
miRNA-corp.d106.s4	Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary.  	miRNA-corp.d106.s4.e0	Diseases	tumor 	1
miRNA-corp.d106.s4	Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary.  	miRNA-corp.d106.s4.e1	Relation_Trigger	failed to express 	2
miRNA-corp.d106.s4	Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary.  	miRNA-corp.d106.s4.e2	Diseases	adenomas 	3
miRNA-corp.d106.s4	Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary.  	miRNA-corp.d106.s4.e3	Diseases	adenoma 	4
miRNA-corp.d106.s5	Enforced expression of C22orf3 in AtT20 cells had no measurable effects on cell proliferation or viability; however, in response to bromocriptine challenge (10-40 microm) cells expressing this gene showed a significantly augmented apoptotic response as determined by both acridine orange staining and TUNEL labeling.  	miRNA-corp.d106.s5.e0	Genes/Proteins	C22orf3 	1
miRNA-corp.d106.s6	In those cases where the CpG island of these genes was methylated it was invariably associated with loss of transcript expression.  	miRNA-corp.d106.s6.e0	Relation_Trigger	loss of transcript expression 	1
miRNA-corp.d106.s6	In those cases where the CpG island of these genes was methylated it was invariably associated with loss of transcript expression.  	miRNA-corp.d106.s6.e1	Relation_Trigger	associated 	2
miRNA-corp.d106.s7	In addition, in time course experiments, direct measurement of active caspases by fluorochrome-labeled inhibition of caspases, showed an augmented increase (approximately 2.4 fold) in active caspases in response to bromocriptine challenge in cells expressing C22orf3 relative to those harboring an empty vector control.  	miRNA-corp.d106.s7.e0	Relation_Trigger	inhibition 	1
miRNA-corp.d106.s7	In addition, in time course experiments, direct measurement of active caspases by fluorochrome-labeled inhibition of caspases, showed an augmented increase (approximately 2.4 fold) in active caspases in response to bromocriptine challenge in cells expressing C22orf3 relative to those harboring an empty vector control.  	miRNA-corp.d106.s7.e1	Genes/Proteins	C22orf3 	2
miRNA-corp.d106.s8	The apoptotic response to bromocriptine challenge was inhibited in coincubation experiments with the general caspase inhibitor z-VAD-fmk.  	miRNA-corp.d106.s8.e0	Relation_Trigger	inhibited 	1
miRNA-corp.d106.s8	The apoptotic response to bromocriptine challenge was inhibited in coincubation experiments with the general caspase inhibitor z-VAD-fmk.  	miRNA-corp.d106.s8.e1	Relation_Trigger	inhibitor 	2
miRNA-corp.d106.s9	The pituitary tumor derivation and its role in apoptosis of this gene led us to assign the acronym PTAG to this gene and its protein product.  	miRNA-corp.d106.s9.e0	Genes/Proteins	PTAG 	1
miRNA-corp.d106.s9	The pituitary tumor derivation and its role in apoptosis of this gene led us to assign the acronym PTAG to this gene and its protein product.  	miRNA-corp.d106.s9.e1	Diseases	pituitary tumor 	2
miRNA-corp.d106.s10	The ability of cells, showing reduced expression of PTAG, to evade or show a blunted apoptotic response may underlie oncogenic transformation in both the pituitary and other tumor types.    	miRNA-corp.d106.s10.e0	Genes/Proteins	PTAG 	1
miRNA-corp.d106.s10	The ability of cells, showing reduced expression of PTAG, to evade or show a blunted apoptotic response may underlie oncogenic transformation in both the pituitary and other tumor types.    	miRNA-corp.d106.s10.e1	Diseases	tumor 	2
miRNA-corp.d106.s10	The ability of cells, showing reduced expression of PTAG, to evade or show a blunted apoptotic response may underlie oncogenic transformation in both the pituitary and other tumor types.    	miRNA-corp.d106.s10.e2	Relation_Trigger	reduced expression 	3
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e0	Specific_miRNAs	miR-29a/b-1 	1
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e3	Relation_Trigger	Loss of microRNA cluster 	4
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e4	Relation_Trigger	increased BACE1/beta-secretase expression 	5
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e5	Diseases	sporadic Alzheimer's disease 	6
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e6	Genes/Proteins	beta-secretase 	7
miRNA-corp.d107.s0	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.   	miRNA-corp.d107.s0.e7	Relation_Trigger	correlates 	8
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e0	Genes/Proteins	APP 	1
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e1	Diseases	AD 	2
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e2	Genes/Proteins	Abeta 	3
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e3	Genes/Proteins	Abeta 	4
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e4	Genes/Proteins	APP 	5
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e5	Genes/Proteins	BACE1 	6
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e6	Diseases	sporadic AD 	7
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e7	Diseases	genetic Alzheimer's disease 	8
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e8	Relation_Trigger	increased expression 	9
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e9	Relation_Trigger	associated 	10
miRNA-corp.d107.s1	Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease.  	miRNA-corp.d107.s1.e10	Genes/Proteins	beta-secretase 	11
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e0	Genes/Proteins	APP 	1
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e5	Diseases	sporadic AD 	6
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e6	Relation_Trigger	changes in microRNA (miRNA) expression 	7
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e7	Relation_Trigger	regulation 	8
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e8	Relation_Trigger	expression appeared to be decreased 	9
miRNA-corp.d107.s2	We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain.  	miRNA-corp.d107.s2.e9	Species	patients 	10
miRNA-corp.d107.s3	We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro.  	miRNA-corp.d107.s3.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d107.s3	We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro.  	miRNA-corp.d107.s3.e1	Relation_Trigger	regulate BACE1 expression 	2
miRNA-corp.d107.s3	We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro.  	miRNA-corp.d107.s3.e2	Specific_miRNAs	miR-29a, -29b-1, and -9 	3
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e1	Diseases	AD 	2
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e2	Specific_miRNAs	miR-29a/b-1 	3
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e3	Diseases	AD 	4
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e4	Diseases	dementia 	5
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e5	Relation_Trigger	significantly (and AD-dementia-specific) decreased 	6
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e6	Relation_Trigger	abnormally high BACE1 protein 	7
miRNA-corp.d107.s4	The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein.  	miRNA-corp.d107.s4.e7	Species	patients 	8
miRNA-corp.d107.s5	Similar correlations between expression of this cluster and BACE1 were found during brain development and in primary neuronal cultures.  	miRNA-corp.d107.s5.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d107.s5	Similar correlations between expression of this cluster and BACE1 were found during brain development and in primary neuronal cultures.  	miRNA-corp.d107.s5.e1	Relation_Trigger	correlations between expression 	2
miRNA-corp.d107.s6	Finally, we provide evidence for a potential causal relationship between miR-29a/b-1 expression and Abeta generation in a cell culture model.  	miRNA-corp.d107.s6.e0	Genes/Proteins	Abeta 	1
miRNA-corp.d107.s6	Finally, we provide evidence for a potential causal relationship between miR-29a/b-1 expression and Abeta generation in a cell culture model.  	miRNA-corp.d107.s6.e1	Specific_miRNAs	miR-29a/b-1 	2
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e1	Genes/Proteins	Abeta 	2
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e3	Relation_Trigger	loss of specific miRNAs 	4
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e4	Relation_Trigger	increased BACE1 and Abeta levels 	5
miRNA-corp.d107.s7	We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.    	miRNA-corp.d107.s7.e5	Diseases	sporadic AD 	6
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e0	Genes/Proteins	GRN 	1
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e1	Diseases	FTLD-U 	2
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e2	Genes/Proteins	GRN 	3
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e3	Specific_miRNAs	miR-659 	4
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e4	Diseases	FTLD-U 	5
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e5	Relation_Trigger	binding-site 	6
miRNA-corp.d108.s0	Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U.  	miRNA-corp.d108.s0.e6	Relation_Trigger	binding 	7
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e0	Genes/Proteins	GRN 	1
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e1	Diseases	frontotemporal dementia 	2
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e2	Diseases	FTLD-U 	3
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e3	Diseases	early-onset dementia 	4
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e4	Diseases	progressive neurodegenerative disease 	5
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e5	Genes/Proteins	progranulin 	6
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e6	Genes/Proteins	TAR DNA-binding protein 43 	7
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e7	Genes/Proteins	TDP-43 	8
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e8	Genes/Proteins	ubiquitin 	9
miRNA-corp.d108.s1	Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients.  	miRNA-corp.d108.s1.e9	Species	patients 	10
miRNA-corp.d108.s2	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.   	miRNA-corp.d108.s2.e0	Specific_miRNAs	miR-659 	1
miRNA-corp.d108.s2	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.   	miRNA-corp.d108.s2.e1	Genes/Proteins	GRN 	2
miRNA-corp.d108.s2	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.   	miRNA-corp.d108.s2.e2	Diseases	frontotemporal dementia 	3
miRNA-corp.d108.s2	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.   	miRNA-corp.d108.s2.e3	Genes/Proteins	TDP43 	4
miRNA-corp.d108.s2	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.   	miRNA-corp.d108.s2.e4	Relation_Trigger	binding-site 	5
miRNA-corp.d108.s3	In support of these findings, the neuropathology of homozygous rs5848 T-allele carriers frequently resembled the pathological FTLD-U subtype of GRN mutation carriers.  	miRNA-corp.d108.s3.e0	Diseases	FTLD-U 	1
miRNA-corp.d108.s3	In support of these findings, the neuropathology of homozygous rs5848 T-allele carriers frequently resembled the pathological FTLD-U subtype of GRN mutation carriers.  	miRNA-corp.d108.s3.e1	Genes/Proteins	GRN 	2
miRNA-corp.d108.s4	A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations.  	miRNA-corp.d108.s4.e0	Genes/Proteins	GRN 	1
miRNA-corp.d108.s4	A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations.  	miRNA-corp.d108.s4.e1	Genes/Proteins	GRN 	2
miRNA-corp.d108.s4	A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations.  	miRNA-corp.d108.s4.e2	Relation_Trigger	reduction in GRN protein 	3
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e0	Genes/Proteins	GRN 	1
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e1	Genes/Proteins	GRN 	2
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e2	Specific_miRNAs	miR-659 	3
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e3	Specific_miRNAs	miR-659 	4
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e4	Relation_Trigger	translational inhibition 	5
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e5	Relation_Trigger	regulate GRN expression 	6
miRNA-corp.d108.s5	We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN.  	miRNA-corp.d108.s5.e6	Relation_Trigger	binding 	7
miRNA-corp.d108.s6	In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73).  	miRNA-corp.d108.s6.e0	Diseases	FTLD-U 	1
miRNA-corp.d108.s6	In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73).  	miRNA-corp.d108.s6.e1	Diseases	FTLD-U 	2
miRNA-corp.d108.s6	In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73).  	miRNA-corp.d108.s6.e2	Genes/Proteins	GRN 	3
miRNA-corp.d108.s6	In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73).  	miRNA-corp.d108.s6.e3	Species	patients 	4
miRNA-corp.d108.s7	Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders.    	miRNA-corp.d108.s7.e0	Relation_Trigger	Translational regulation 	1
miRNA-corp.d108.s7	Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders.    	miRNA-corp.d108.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d108.s7	Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders.    	miRNA-corp.d108.s7.e2	Diseases	neurodegenerative disorders 	3
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e0	Diseases	FTLD-U 	1
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e1	Genes/Proteins	GRN 	2
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e4	Relation_Trigger	expression of GRN is regulated 	5
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e5	Relation_Trigger	significantly increase 	6
miRNA-corp.d108.s8	We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U.  	miRNA-corp.d108.s8.e6	Relation_Trigger	binding-site 	7
miRNA-corp.d109.s0	Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules.    	miRNA-corp.d109.s0.e0	Specific_miRNAs	miR-15b 	1
miRNA-corp.d109.s0	Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules.    	miRNA-corp.d109.s0.e1	Relation_Trigger	regulates 	2
miRNA-corp.d109.s0	Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules.    	miRNA-corp.d109.s0.e2	Relation_Trigger	targeting 	3
miRNA-corp.d109.s0	Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules.    	miRNA-corp.d109.s0.e3	Diseases	glioma 	4
miRNA-corp.d109.s1	Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase.  	miRNA-corp.d109.s1.e0	Specific_miRNAs	miR-15b 	1
miRNA-corp.d109.s1	Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase.  	miRNA-corp.d109.s1.e1	Specific_miRNAs	miR-15b 	2
miRNA-corp.d109.s1	Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase.  	miRNA-corp.d109.s1.e2	Relation_Trigger	Over-expression 	3
miRNA-corp.d109.s1	Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase.  	miRNA-corp.d109.s1.e3	Relation_Trigger	suppression of miR-15b expression 	4
miRNA-corp.d109.s2	We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b.  	miRNA-corp.d109.s2.e0	Specific_miRNAs	miR-15b 	1
miRNA-corp.d109.s2	We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b.  	miRNA-corp.d109.s2.e1	Genes/Proteins	CCNE1 	2
miRNA-corp.d109.s2	We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b.  	miRNA-corp.d109.s2.e2	Genes/Proteins	cyclin E1 	3
miRNA-corp.d109.s2	We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b.  	miRNA-corp.d109.s2.e3	Relation_Trigger	targets 	4
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e4	Diseases	glioma 	5
miRNA-corp.d109.s3	We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs.  	miRNA-corp.d109.s3.e5	Species	patients 	6
miRNA-corp.d109.s4	Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets.  	miRNA-corp.d109.s4.e0	Specific_miRNAs	miR-15b 	1
miRNA-corp.d109.s4	Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets.  	miRNA-corp.d109.s4.e1	Diseases	glioma 	2
miRNA-corp.d109.s4	Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets.  	miRNA-corp.d109.s4.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d109.s4	Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets.  	miRNA-corp.d109.s4.e3	Relation_Trigger	targets 	4
miRNA-corp.d109.s5	MicroRNAs (miRNAs) are non-protein-coding RNAs that function as post-transcriptional gene regulators.  	miRNA-corp.d109.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d109.s5	MicroRNAs (miRNAs) are non-protein-coding RNAs that function as post-transcriptional gene regulators.  	miRNA-corp.d109.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d109.s5	MicroRNAs (miRNAs) are non-protein-coding RNAs that function as post-transcriptional gene regulators.  	miRNA-corp.d109.s5.e2	Relation_Trigger	regulators 	3
miRNA-corp.d109.s6	Recent evidence has shown that miRNA plays a pivotal role in the development of many cancers including glioma, a lethal brain cancer.  	miRNA-corp.d109.s6.e0	Diseases	glioma 	1
miRNA-corp.d109.s6	Recent evidence has shown that miRNA plays a pivotal role in the development of many cancers including glioma, a lethal brain cancer.  	miRNA-corp.d109.s6.e1	Diseases	brain cancer 	2
miRNA-corp.d109.s6	Recent evidence has shown that miRNA plays a pivotal role in the development of many cancers including glioma, a lethal brain cancer.  	miRNA-corp.d109.s6.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d109.s6	Recent evidence has shown that miRNA plays a pivotal role in the development of many cancers including glioma, a lethal brain cancer.  	miRNA-corp.d109.s6.e3	Diseases	cancers 	4
miRNA-corp.d109.s7	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.   	miRNA-corp.d109.s7.e0	Specific_miRNAs	MicroRNA-15b 	1
miRNA-corp.d109.s7	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.   	miRNA-corp.d109.s7.e1	Relation_Trigger	regulates 	2
miRNA-corp.d109.s7	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.   	miRNA-corp.d109.s7.e2	Relation_Trigger	targeting 	3
miRNA-corp.d109.s7	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.   	miRNA-corp.d109.s7.e3	Diseases	glioma 	4
miRNA-corp.d110.s0	It has been recently demonstrated that herpesviruses encode miRNAs to control the post-transcriptional regulation of expression from their own genomes and possibly that of their host, thus adding an additional layer of complexity to the physiological cross-talk between host and pathogen.  	miRNA-corp.d110.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s0	It has been recently demonstrated that herpesviruses encode miRNAs to control the post-transcriptional regulation of expression from their own genomes and possibly that of their host, thus adding an additional layer of complexity to the physiological cross-talk between host and pathogen.  	miRNA-corp.d110.s0.e1	Relation_Trigger	regulation of expression 	2
miRNA-corp.d110.s1	MicroRNAs are small non-coding RNAs approximately 22 nt long that modulate gene expression in animals and plants.  	miRNA-corp.d110.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d110.s1	MicroRNAs are small non-coding RNAs approximately 22 nt long that modulate gene expression in animals and plants.  	miRNA-corp.d110.s1.e1	Relation_Trigger	modulate gene expression 	2
miRNA-corp.d110.s2	Co-expression of host and viral microRNAs in porcine dendritic cells infected by the pseudorabies virus.   	miRNA-corp.d110.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d110.s2	Co-expression of host and viral microRNAs in porcine dendritic cells infected by the pseudorabies virus.   	miRNA-corp.d110.s2.e1	Relation_Trigger	Co-expression 	2
miRNA-corp.d110.s2	Co-expression of host and viral microRNAs in porcine dendritic cells infected by the pseudorabies virus.   	miRNA-corp.d110.s2.e2	Species	porcine 	3
miRNA-corp.d110.s3	Almost 95% of reads mapped to the draft pig genome sequence and pig miRNAs previously annotated in dedicated databases were detected by sequence alignment.  	miRNA-corp.d110.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s3	Almost 95% of reads mapped to the draft pig genome sequence and pig miRNAs previously annotated in dedicated databases were detected by sequence alignment.  	miRNA-corp.d110.s3.e1	Species	pig 	2
miRNA-corp.d110.s3	Almost 95% of reads mapped to the draft pig genome sequence and pig miRNAs previously annotated in dedicated databases were detected by sequence alignment.  	miRNA-corp.d110.s3.e2	Species	pig 	3
miRNA-corp.d110.s5	A catalogue of porcine and viral miRNAs, expressed eight hours post-infection, was established by deep sequencing.  	miRNA-corp.d110.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s5	A catalogue of porcine and viral miRNAs, expressed eight hours post-infection, was established by deep sequencing.  	miRNA-corp.d110.s5.e1	Diseases	infection 	2
miRNA-corp.d110.s5	A catalogue of porcine and viral miRNAs, expressed eight hours post-infection, was established by deep sequencing.  	miRNA-corp.d110.s5.e2	Species	porcine 	3
miRNA-corp.d110.s6	The present study focussed on the interactions between porcine dendritic cells (DCs) and the Pseudorabies virus (PRV), an alpha-herpesvirus causing Aujeszky's disease in pigs.  	miRNA-corp.d110.s6.e0	Diseases	Aujeszky's disease 	1
miRNA-corp.d110.s6	The present study focussed on the interactions between porcine dendritic cells (DCs) and the Pseudorabies virus (PRV), an alpha-herpesvirus causing Aujeszky's disease in pigs.  	miRNA-corp.d110.s6.e1	Species	pigs 	2
miRNA-corp.d110.s6	The present study focussed on the interactions between porcine dendritic cells (DCs) and the Pseudorabies virus (PRV), an alpha-herpesvirus causing Aujeszky's disease in pigs.  	miRNA-corp.d110.s6.e2	Species	porcine 	3
miRNA-corp.d110.s7	In silico prediction allowed the identification of unknown porcine as well as of five miRNAs transcribed by the Large Latency Transcript (LLT) of PRV.  	miRNA-corp.d110.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s7	In silico prediction allowed the identification of unknown porcine as well as of five miRNAs transcribed by the Large Latency Transcript (LLT) of PRV.  	miRNA-corp.d110.s7.e1	Species	porcine 	2
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e2	Relation_Trigger	target 	3
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e4	Relation_Trigger	regulation of gene expression 	5
miRNA-corp.d110.s8	The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression.  	miRNA-corp.d110.s8.e5	Species	pig 	6
miRNA-corp.d110.s9	The results support a role for PRV miRNAs in the maintenance of the host cell latency state through the down-regulation of immediate-early viral genes which is similar to other herpesviruses.  	miRNA-corp.d110.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s9	The results support a role for PRV miRNAs in the maintenance of the host cell latency state through the down-regulation of immediate-early viral genes which is similar to other herpesviruses.  	miRNA-corp.d110.s9.e1	Relation_Trigger	down-regulation 	2
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e2	Relation_Trigger	target 	3
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e3	Relation_Trigger	differentially expressed 	4
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e4	Relation_Trigger	modulation 	5
miRNA-corp.d110.s10	The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.    	miRNA-corp.d110.s10.e5	Species	swine 	6
miRNA-corp.d111.s0	An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy.    	miRNA-corp.d111.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d111.s0	An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy.    	miRNA-corp.d111.s0.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d111.s0	An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy.    	miRNA-corp.d111.s0.e2	Relation_Trigger	affect the expression 	3
miRNA-corp.d111.s1	MicroRNAs (miRNAs) are short non-coding RNAs involved in post-transcriptional regulation of gene expression.  	miRNA-corp.d111.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d111.s1	MicroRNAs (miRNAs) are short non-coding RNAs involved in post-transcriptional regulation of gene expression.  	miRNA-corp.d111.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d111.s1	MicroRNAs (miRNAs) are short non-coding RNAs involved in post-transcriptional regulation of gene expression.  	miRNA-corp.d111.s1.e2	Relation_Trigger	regulation of gene expression 	3
miRNA-corp.d111.s2	Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing.  	miRNA-corp.d111.s2.e0	Specific_miRNAs	lin-4 	1
miRNA-corp.d111.s2	Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing.  	miRNA-corp.d111.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d111.s2	Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing.  	miRNA-corp.d111.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d111.s2	Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing.  	miRNA-corp.d111.s2.e3	Species	C. elegans 	4
miRNA-corp.d111.s2	Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing.  	miRNA-corp.d111.s2.e4	Species	humans 	5
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e2	Diseases	viral infections 	3
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e3	Diseases	diabetes 	4
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e4	Diseases	myopathies 	5
miRNA-corp.d111.s3	Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies.  	miRNA-corp.d111.s3.e5	Diseases	cancer 	6
miRNA-corp.d111.s4	In the present review we will summarize miRNA profiling studies in human diseases and discuss the newly discovered link between microRNAs and drug response.  	miRNA-corp.d111.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d111.s4	In the present review we will summarize miRNA profiling studies in human diseases and discuss the newly discovered link between microRNAs and drug response.  	miRNA-corp.d111.s4.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d111.s4	In the present review we will summarize miRNA profiling studies in human diseases and discuss the newly discovered link between microRNAs and drug response.  	miRNA-corp.d111.s4.e2	Species	human 	3
miRNA-corp.d111.s5	MicroRNAs in diseases and drug response.   	miRNA-corp.d111.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d112.s1	These cancers are thought to be linked to indirect radiation-induced bystander effect.  	miRNA-corp.d112.s1.e0	Diseases	cancers 	1
miRNA-corp.d112.s2	Radiation therapy is a primary treatment modality for brain tumors, yet it has been linked to the increased incidence of secondary, post-radiation therapy cancers.  	miRNA-corp.d112.s2.e0	Diseases	brain tumors 	1
miRNA-corp.d112.s2	Radiation therapy is a primary treatment modality for brain tumors, yet it has been linked to the increased incidence of secondary, post-radiation therapy cancers.  	miRNA-corp.d112.s2.e1	Diseases	cancers 	2
miRNA-corp.d112.s6	To investigate the possibility that localized X-ray irradiation induces persistent bystander effects in distant tissue, we monitored the induction of epigenetic changes (i.e. alterations in DNA methylation, histone methylation and microRNA (miRNA) expression) in the rat spleen tissue 24 h and 7 months after localized cranial exposure to 20 Gy of X-rays.  	miRNA-corp.d112.s6.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d112.s6	To investigate the possibility that localized X-ray irradiation induces persistent bystander effects in distant tissue, we monitored the induction of epigenetic changes (i.e. alterations in DNA methylation, histone methylation and microRNA (miRNA) expression) in the rat spleen tissue 24 h and 7 months after localized cranial exposure to 20 Gy of X-rays.  	miRNA-corp.d112.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d112.s6	To investigate the possibility that localized X-ray irradiation induces persistent bystander effects in distant tissue, we monitored the induction of epigenetic changes (i.e. alterations in DNA methylation, histone methylation and microRNA (miRNA) expression) in the rat spleen tissue 24 h and 7 months after localized cranial exposure to 20 Gy of X-rays.  	miRNA-corp.d112.s6.e2	Species	rat 	3
miRNA-corp.d112.s7	Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2.  	miRNA-corp.d112.s7.e0	Specific_miRNAs	miR-194 	1
miRNA-corp.d112.s7	Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2.  	miRNA-corp.d112.s7.e1	Genes/Proteins	MeCP2 	2
miRNA-corp.d112.s7	Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2.  	miRNA-corp.d112.s7.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d112.s7	Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2.  	miRNA-corp.d112.s7.e3	Relation_Trigger	targeting 	4
miRNA-corp.d112.s7	Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2.  	miRNA-corp.d112.s7.e4	Relation_Trigger	altered expression 	5
miRNA-corp.d112.s8	Specifically, this exposure caused the profound epigenetic dysregulation in the bystander spleen tissue that manifested as a significant loss of global DNA methylation, alterations in methylation of long interspersed nucleotide element-1 (LINE-1) retrotransposable elements and down-regulation of DNA methyltransferases and methyl-binding protein methyl CpG binding protein 2 (MeCP2).  	miRNA-corp.d112.s8.e0	Genes/Proteins	MeCP2 	1
miRNA-corp.d112.s8	Specifically, this exposure caused the profound epigenetic dysregulation in the bystander spleen tissue that manifested as a significant loss of global DNA methylation, alterations in methylation of long interspersed nucleotide element-1 (LINE-1) retrotransposable elements and down-regulation of DNA methyltransferases and methyl-binding protein methyl CpG binding protein 2 (MeCP2).  	miRNA-corp.d112.s8.e1	Relation_Trigger	dysregulation 	2
miRNA-corp.d112.s8	Specifically, this exposure caused the profound epigenetic dysregulation in the bystander spleen tissue that manifested as a significant loss of global DNA methylation, alterations in methylation of long interspersed nucleotide element-1 (LINE-1) retrotransposable elements and down-regulation of DNA methyltransferases and methyl-binding protein methyl CpG binding protein 2 (MeCP2).  	miRNA-corp.d112.s8.e2	Relation_Trigger	down-regulation 	3
miRNA-corp.d112.s8	Specifically, this exposure caused the profound epigenetic dysregulation in the bystander spleen tissue that manifested as a significant loss of global DNA methylation, alterations in methylation of long interspersed nucleotide element-1 (LINE-1) retrotransposable elements and down-regulation of DNA methyltransferases and methyl-binding protein methyl CpG binding protein 2 (MeCP2).  	miRNA-corp.d112.s8.e3	Genes/Proteins	methyl CpG binding protein 2 	4
miRNA-corp.d112.s9	This study is the first to report conclusive evidence of the long-term persistence of bystander effects in radiation carcinogenesis target organ (spleen) upon localized distant exposure using the doses comparable with those used for clinical brain tumor treatments.    	miRNA-corp.d112.s9.e0	Diseases	brain tumor 	1
miRNA-corp.d112.s9	This study is the first to report conclusive evidence of the long-term persistence of bystander effects in radiation carcinogenesis target organ (spleen) upon localized distant exposure using the doses comparable with those used for clinical brain tumor treatments.    	miRNA-corp.d112.s9.e1	Relation_Trigger	target 	2
miRNA-corp.d113.s1	Furthermore, we demonstrate that miRNAs can be isolated and profiled from formalin-fixed paraffin-embedded tissue, which opens up new opportunities for analyses of small RNAs from archival human tissue.  	miRNA-corp.d113.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d113.s1	Furthermore, we demonstrate that miRNAs can be isolated and profiled from formalin-fixed paraffin-embedded tissue, which opens up new opportunities for analyses of small RNAs from archival human tissue.  	miRNA-corp.d113.s1.e1	Species	human 	2
miRNA-corp.d113.s3	We show that the RAKE assay is sensitive and specific for miRNAs and is ideally suited for rapid expression profiling of all known miRNAs.  	miRNA-corp.d113.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d113.s3	We show that the RAKE assay is sensitive and specific for miRNAs and is ideally suited for rapid expression profiling of all known miRNAs.  	miRNA-corp.d113.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d113.s4	We used RAKE to study human cell lines and brain tumors.  	miRNA-corp.d113.s4.e0	Diseases	brain tumors 	1
miRNA-corp.d113.s4	We used RAKE to study human cell lines and brain tumors.  	miRNA-corp.d113.s4.e1	Species	human 	2
miRNA-corp.d113.s5	The technique is termed the RNA-primed, array-based Klenow enzyme (RAKE) assay, because it involves on-slide application of the Klenow fragment of DNA polymerase I to extend unmodified miRNAs hybridized to immobilized DNA probes.  	miRNA-corp.d113.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d113.s6	We describe a new method for high-throughput miRNA detection.  	miRNA-corp.d113.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d113.s7	MicroRNAs (miRNAs) are small regulatory RNAs that serve fundamental biological roles across eukaryotic species.  	miRNA-corp.d113.s7.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d113.s7	MicroRNAs (miRNAs) are small regulatory RNAs that serve fundamental biological roles across eukaryotic species.  	miRNA-corp.d113.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d113.s7	MicroRNAs (miRNAs) are small regulatory RNAs that serve fundamental biological roles across eukaryotic species.  	miRNA-corp.d113.s7.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d113.s8	Microarray-based, high-throughput gene expression profiling of microRNAs.   	miRNA-corp.d113.s8.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e1	Diseases	AD 	2
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e4	Relation_Trigger	significantly altered 	5
miRNA-corp.d114.s0	Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD).  	miRNA-corp.d114.s0.e5	Diseases	neurodegenerative disorders 	6
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e1	Genes/Proteins	complement factor H 	2
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e2	Genes/Proteins	CFH 	3
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e3	Relation_Trigger	up-regulation 	4
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e4	Relation_Trigger	repressor 	5
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e5	Relation_Trigger	down-regulates the expression 	6
miRNA-corp.d114.s1	Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation.  	miRNA-corp.d114.s1.e6	Species	human 	7
miRNA-corp.d114.s2	Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.   	miRNA-corp.d114.s2.e0	Genes/Proteins	complement factor H 	1
miRNA-corp.d114.s2	Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.   	miRNA-corp.d114.s2.e1	Genes/Proteins	CFH 	2
miRNA-corp.d114.s2	Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.   	miRNA-corp.d114.s2.e2	Specific_miRNAs	miRNA-146a 	3
miRNA-corp.d114.s2	Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.   	miRNA-corp.d114.s2.e3	Relation_Trigger	down-regulation 	4
miRNA-corp.d114.s2	Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.   	miRNA-corp.d114.s2.e4	Species	human 	5
miRNA-corp.d114.s3	Micro RNAs (miRNAs) represent a family of small ribonucleic acids (RNAs) that are post-transcriptional regulators of messenger RNA (mRNA) complexity.  	miRNA-corp.d114.s3.e0	Non-Specific_miRNAs	Micro RNAs 	1
miRNA-corp.d114.s3	Micro RNAs (miRNAs) represent a family of small ribonucleic acids (RNAs) that are post-transcriptional regulators of messenger RNA (mRNA) complexity.  	miRNA-corp.d114.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d114.s3	Micro RNAs (miRNAs) represent a family of small ribonucleic acids (RNAs) that are post-transcriptional regulators of messenger RNA (mRNA) complexity.  	miRNA-corp.d114.s3.e2	Relation_Trigger	regulators 	3
miRNA-corp.d114.s4	An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression.  	miRNA-corp.d114.s4.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d114.s4	An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression.  	miRNA-corp.d114.s4.e1	Genes/Proteins	CFH 	2
miRNA-corp.d114.s4	An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression.  	miRNA-corp.d114.s4.e2	Specific_miRNAs	miRNA-146a 	3
miRNA-corp.d114.s4	An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression.  	miRNA-corp.d114.s4.e3	Relation_Trigger	up-regulation 	4
miRNA-corp.d114.s4	An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression.  	miRNA-corp.d114.s4.e4	Relation_Trigger	decreased CFH gene expression 	5
miRNA-corp.d114.s5	These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.    	miRNA-corp.d114.s5.e0	Genes/Proteins	CFH 	1
miRNA-corp.d114.s5	These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.    	miRNA-corp.d114.s5.e1	Diseases	AD 	2
miRNA-corp.d114.s5	These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.    	miRNA-corp.d114.s5.e2	Specific_miRNAs	miRNA-146a 	3
miRNA-corp.d114.s5	These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.    	miRNA-corp.d114.s5.e3	Relation_Trigger	modulation of CFH gene expression 	4
miRNA-corp.d114.s5	These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.    	miRNA-corp.d114.s5.e4	Diseases	neurodegenerative disease 	5
miRNA-corp.d114.s6	This NF-kappaB-miRNA-146a-CFH signaling circuit is known to be similarly affected by Abeta42 peptides and in AD brain.  	miRNA-corp.d114.s6.e0	Diseases	AD 	1
miRNA-corp.d114.s6	This NF-kappaB-miRNA-146a-CFH signaling circuit is known to be similarly affected by Abeta42 peptides and in AD brain.  	miRNA-corp.d114.s6.e1	Genes/Proteins	Abeta42 	2
miRNA-corp.d114.s6	This NF-kappaB-miRNA-146a-CFH signaling circuit is known to be similarly affected by Abeta42 peptides and in AD brain.  	miRNA-corp.d114.s6.e2	Genes/Proteins	CFH 	3
miRNA-corp.d114.s6	This NF-kappaB-miRNA-146a-CFH signaling circuit is known to be similarly affected by Abeta42 peptides and in AD brain.  	miRNA-corp.d114.s6.e3	Specific_miRNAs	miRNA-146a 	4
miRNA-corp.d115.s0	Extensive modulation of a set of microRNAs in primary glioblastoma.   	miRNA-corp.d115.s0.e0	Relation_Trigger	modulation 	1
miRNA-corp.d115.s0	Extensive modulation of a set of microRNAs in primary glioblastoma.   	miRNA-corp.d115.s0.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d115.s0	Extensive modulation of a set of microRNAs in primary glioblastoma.   	miRNA-corp.d115.s0.e2	Diseases	primary glioblastoma 	3
miRNA-corp.d115.s1	MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles in animals and plants by repressing translation or cleaving RNA transcripts.  	miRNA-corp.d115.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d115.s1	MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles in animals and plants by repressing translation or cleaving RNA transcripts.  	miRNA-corp.d115.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d115.s1	MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles in animals and plants by repressing translation or cleaving RNA transcripts.  	miRNA-corp.d115.s1.e2	Relation_Trigger	repressing translation 	3
miRNA-corp.d115.s1	MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles in animals and plants by repressing translation or cleaving RNA transcripts.  	miRNA-corp.d115.s1.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d115.s2	The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis.  	miRNA-corp.d115.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d115.s2	The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis.  	miRNA-corp.d115.s2.e1	Relation_Trigger	modulation 	2
miRNA-corp.d115.s2	The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis.  	miRNA-corp.d115.s2.e2	Relation_Trigger	associated 	3
miRNA-corp.d115.s2	The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis.  	miRNA-corp.d115.s2.e3	Diseases	cancer 	4
miRNA-corp.d115.s2	The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis.  	miRNA-corp.d115.s2.e4	Species	human 	5
miRNA-corp.d115.s3	In our study, we examined by microarray the global expression levels of 245 microRNAs in glioblastoma multiforme, the most frequent and malignant of primary brain tumors.  	miRNA-corp.d115.s3.e0	Diseases	glioblastoma 	1
miRNA-corp.d115.s3	In our study, we examined by microarray the global expression levels of 245 microRNAs in glioblastoma multiforme, the most frequent and malignant of primary brain tumors.  	miRNA-corp.d115.s3.e1	Diseases	brain tumors 	2
miRNA-corp.d115.s3	In our study, we examined by microarray the global expression levels of 245 microRNAs in glioblastoma multiforme, the most frequent and malignant of primary brain tumors.  	miRNA-corp.d115.s3.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d115.s4	The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor.  	miRNA-corp.d115.s4.e0	Diseases	glioblastoma 	1
miRNA-corp.d115.s4	The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor.  	miRNA-corp.d115.s4.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d115.s4	The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor.  	miRNA-corp.d115.s4.e2	Relation_Trigger	expression is significantly altered 	3
miRNA-corp.d115.s4	The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor.  	miRNA-corp.d115.s4.e3	Diseases	glioblastoma 	4
miRNA-corp.d115.s4	The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor.  	miRNA-corp.d115.s4.e4	Diseases	tumor 	5
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e0	Specific_miRNAs	miR-221 	1
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e1	Specific_miRNAs	miR-128 	2
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e2	Specific_miRNAs	miR-181a 	3
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e3	Specific_miRNAs	miR-181b 	4
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e4	Specific_miRNAs	miR-181c 	5
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e5	Diseases	glioblastoma 	6
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e6	Diseases	glioblastoma 	7
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e7	Non-Specific_miRNAs	miRNAs 	8
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e8	Relation_Trigger	down-regulated 	9
miRNA-corp.d115.s5	The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.    	miRNA-corp.d115.s5.e9	Relation_Trigger	up-regulated 	10
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e0	Specific_miRNAs	miR-181a 	1
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e1	Specific_miRNAs	miR-630 	2
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e2	Genes/Proteins	p53 	3
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e3	Genes/Proteins	p53 	4
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e4	Relation_Trigger	inhibition 	5
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e5	Relation_Trigger	activation 	6
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e6	Relation_Trigger	blocks 	7
miRNA-corp.d116.s0	Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation.  	miRNA-corp.d116.s0.e7	Diseases	DNA damage 	8
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e0	Specific_miRNAs	miR-630 	1
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e1	Genes/Proteins	p27 	2
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e2	Genes/Proteins	Kip1 	3
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e3	Relation_Trigger	correlating 	4
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e4	Relation_Trigger	inhibitor 	5
miRNA-corp.d116.s1	Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP.  	miRNA-corp.d116.s1.e5	Relation_Trigger	increased levels 	6
miRNA-corp.d116.s2	Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.    	miRNA-corp.d116.s2.e0	Specific_miRNAs	miR-181a 	1
miRNA-corp.d116.s2	Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.    	miRNA-corp.d116.s2.e1	Specific_miRNAs	miR-630 	2
miRNA-corp.d116.s2	Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.    	miRNA-corp.d116.s2.e2	Diseases	NSCLC 	3
miRNA-corp.d116.s2	Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.    	miRNA-corp.d116.s2.e3	Relation_Trigger	modulators 	4
miRNA-corp.d116.s3	The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion.  	miRNA-corp.d116.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d116.s3	The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion.  	miRNA-corp.d116.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e0	Specific_miRNAs	miR-181a 	1
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e1	Specific_miRNAs	miR-630 	2
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e2	Specific_miRNAs	miR-181a 	3
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e3	Specific_miRNAs	miR-630 	4
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e4	Relation_Trigger	inhibitors 	5
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e5	Relation_Trigger	targeting 	6
miRNA-corp.d116.s4	Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively.  	miRNA-corp.d116.s4.e6	Relation_Trigger	modulate 	7
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e0	Specific_miRNAs	miR-181a 	1
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e1	Specific_miRNAs	miR-630 	2
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e2	Genes/Proteins	caspase-9 	3
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e3	Genes/Proteins	caspase-3 	4
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e4	Genes/Proteins	Bax 	5
miRNA-corp.d116.s5	Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3.  	miRNA-corp.d116.s5.e5	Relation_Trigger	modulated 	6
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e0	Specific_miRNAs	miR-630 	1
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e1	Genes/Proteins	ataxia-telangiectasia mutated 	2
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e2	Genes/Proteins	ATM 	3
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e3	Genes/Proteins	ATM 	4
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e4	Genes/Proteins	H2AX 	5
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e5	Genes/Proteins	p53 	6
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e6	Relation_Trigger	blocked 	7
miRNA-corp.d116.s6	In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53.  	miRNA-corp.d116.s6.e7	Diseases	DNA damage 	8
miRNA-corp.d116.s7	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.   	miRNA-corp.d116.s7.e0	Specific_miRNAs	miR-181a 	1
miRNA-corp.d116.s7	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.   	miRNA-corp.d116.s7.e1	Specific_miRNAs	miR-630 	2
miRNA-corp.d116.s7	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.   	miRNA-corp.d116.s7.e2	Relation_Trigger	regulate 	3
miRNA-corp.d116.s7	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.   	miRNA-corp.d116.s7.e3	Diseases	cancer 	4
miRNA-corp.d116.s8	MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis.  	miRNA-corp.d116.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d116.s8	MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis.  	miRNA-corp.d116.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d116.s8	MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis.  	miRNA-corp.d116.s8.e2	Relation_Trigger	regulate 	3
miRNA-corp.d116.s9	We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP).  	miRNA-corp.d116.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d116.s9	We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP).  	miRNA-corp.d116.s9.e1	Diseases	non-small cell lung cancer 	2
miRNA-corp.d116.s9	We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP).  	miRNA-corp.d116.s9.e2	Diseases	NSCLC 	3
miRNA-corp.d116.s9	We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP).  	miRNA-corp.d116.s9.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d117.s1	Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.  	miRNA-corp.d117.s1.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d117.s1	Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.  	miRNA-corp.d117.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d117.s1	Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.  	miRNA-corp.d117.s1.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d117.s1	Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.  	miRNA-corp.d117.s1.e3	Relation_Trigger	activated 	4
miRNA-corp.d117.s1	Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes.  	miRNA-corp.d117.s1.e4	Relation_Trigger	regulatory 	5
miRNA-corp.d117.s2	Finally, we suggest that the pathology of several conditions, including Huntington's disease, might be a consequence of the disruption of the control of RNA via endolysosomal membranes.    	miRNA-corp.d117.s2.e0	Diseases	Huntington's disease 	1
miRNA-corp.d117.s4	Recent advances in the cell biology of RNA silencing have unraveled an intriguing association of post-transcriptionally regulated RNA with endolysosomal membranes in several circumstances of mRNA localization, microRNA activity and viral RNA transport and packaging.  	miRNA-corp.d117.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d117.s4	Recent advances in the cell biology of RNA silencing have unraveled an intriguing association of post-transcriptionally regulated RNA with endolysosomal membranes in several circumstances of mRNA localization, microRNA activity and viral RNA transport and packaging.  	miRNA-corp.d117.s4.e1	Relation_Trigger	association 	2
miRNA-corp.d117.s4	Recent advances in the cell biology of RNA silencing have unraveled an intriguing association of post-transcriptionally regulated RNA with endolysosomal membranes in several circumstances of mRNA localization, microRNA activity and viral RNA transport and packaging.  	miRNA-corp.d117.s4.e2	Relation_Trigger	regulated 	3
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e0	Specific_miRNAs	miR-155 	1
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e1	Specific_miRNAs	miR-516a-3p 	2
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e2	Specific_miRNAs	miR-128a 	3
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e4	Non-Specific_miRNAs	miRs 	5
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e5	Non-Specific_miRNAs	miRs 	6
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e6	Genes/Proteins	Wee1 	7
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e7	Genes/Proteins	Wee1 	8
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e8	Relation_Trigger	overexpression 	9
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e9	Relation_Trigger	target 	10
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e10	Relation_Trigger	overexpressed 	11
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e11	Relation_Trigger	inhibited Wee1 protein expression 	12
miRNA-corp.d118.s0	A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.  	miRNA-corp.d118.s0.e12	Relation_Trigger	targeted the 3'-untranslated region 	13
miRNA-corp.d118.s1	RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR.  	miRNA-corp.d118.s1.e0	Genes/Proteins	Wee1 	1
miRNA-corp.d118.s1	RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR.  	miRNA-corp.d118.s1.e1	Relation_Trigger	change in mRNA expression 	2
miRNA-corp.d118.s1	RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR.  	miRNA-corp.d118.s1.e2	Relation_Trigger	protein expression was decreased 	3
miRNA-corp.d118.s1	RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR.  	miRNA-corp.d118.s1.e3	Genes/Proteins	prolactin 	4
miRNA-corp.d118.s1	RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR.  	miRNA-corp.d118.s1.e4	Diseases	tumors 	5
miRNA-corp.d118.s2	CONCLUSIONS: To our knowledge, this is the first report suggesting that regulation of Wee1 kinase by miRs may be linked to pituitary tumorigenesis.    	miRNA-corp.d118.s2.e0	Non-Specific_miRNAs	miRs 	1
miRNA-corp.d118.s2	CONCLUSIONS: To our knowledge, this is the first report suggesting that regulation of Wee1 kinase by miRs may be linked to pituitary tumorigenesis.    	miRNA-corp.d118.s2.e1	Relation_Trigger	regulation 	2
miRNA-corp.d118.s2	CONCLUSIONS: To our knowledge, this is the first report suggesting that regulation of Wee1 kinase by miRs may be linked to pituitary tumorigenesis.    	miRNA-corp.d118.s2.e2	Genes/Proteins	Wee1 	3
miRNA-corp.d118.s3	CONTEXT: The tumorigenic mechanisms involved in pituitary adenomas, especially of nonfunctional pituitary adenomas (NFAs), remains unclear.  	miRNA-corp.d118.s3.e0	Diseases	pituitary adenomas 	1
miRNA-corp.d118.s4	Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.   	miRNA-corp.d118.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d118.s4	Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.   	miRNA-corp.d118.s4.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d118.s4	Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.   	miRNA-corp.d118.s4.e2	Relation_Trigger	Down-regulation 	3
miRNA-corp.d118.s4	Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.   	miRNA-corp.d118.s4.e3	Genes/Proteins	Wee1 	4
miRNA-corp.d118.s4	Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.   	miRNA-corp.d118.s4.e4	Species	human 	5
miRNA-corp.d118.s5	OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.  	miRNA-corp.d118.s5.e0	Genes/Proteins	Wee1 	1
miRNA-corp.d118.s5	OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.  	miRNA-corp.d118.s5.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d118.s5	OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.  	miRNA-corp.d118.s5.e2	Non-Specific_miRNAs	miRs 	3
miRNA-corp.d118.s5	OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.  	miRNA-corp.d118.s5.e3	Diseases	pituitary tumors 	4
miRNA-corp.d118.s5	OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.  	miRNA-corp.d118.s5.e4	Relation_Trigger	regulate its expression 	5
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e0	Diseases	pituitary tumors 	1
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e1	Diseases	pituitary tumors 	2
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e2	Relation_Trigger	underexpressed 	3
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e3	Relation_Trigger	inhibitors 	4
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e4	Relation_Trigger	tumor suppressor 	5
miRNA-corp.d118.s6	Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.  	miRNA-corp.d118.s6.e5	Genes/Proteins	Wee1 	6
miRNA-corp.d118.s7	Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR.  	miRNA-corp.d118.s7.e0	Non-Specific_miRNAs	miRs 	1
miRNA-corp.d118.s7	Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR.  	miRNA-corp.d118.s7.e1	Non-Specific_miRNAs	miR 	2
miRNA-corp.d118.s7	Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR.  	miRNA-corp.d118.s7.e2	Non-Specific_miRNAs	miRs 	3
miRNA-corp.d118.s7	Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR.  	miRNA-corp.d118.s7.e3	Genes/Proteins	Wee1 	4
miRNA-corp.d118.s7	Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR.  	miRNA-corp.d118.s7.e4	Relation_Trigger	targeting the Wee1 3'-untranslated region 	5
miRNA-corp.d118.s8	DESIGN: Expression of Wee1 was examined by immunohistochemistry and quantitative real-time PCR (qRT-PCR).  	miRNA-corp.d118.s8.e0	Genes/Proteins	Wee1 	1
miRNA-corp.d118.s9	PATIENTS: A total of 57 pituitary tissue samples including 27 NFAs, 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands were analyzed.  	miRNA-corp.d118.s9.e0	Diseases	adenomas 	1
miRNA-corp.d118.s9	PATIENTS: A total of 57 pituitary tissue samples including 27 NFAs, 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands were analyzed.  	miRNA-corp.d118.s9.e1	Genes/Proteins	prolactin 	2
miRNA-corp.d118.s9	PATIENTS: A total of 57 pituitary tissue samples including 27 NFAs, 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands were analyzed.  	miRNA-corp.d118.s9.e2	Species	PATIENTS 	3
miRNA-corp.d118.s10	Dual-luciferase assay and transient transfection of miRs into Hela cells followed by immunoblot analysis of Wee1 protein and cell proliferation analysis were carried out.  	miRNA-corp.d118.s10.e0	Non-Specific_miRNAs	miRs 	1
miRNA-corp.d118.s10	Dual-luciferase assay and transient transfection of miRs into Hela cells followed by immunoblot analysis of Wee1 protein and cell proliferation analysis were carried out.  	miRNA-corp.d118.s10.e1	Genes/Proteins	Wee1 	2
miRNA-corp.d119.s0	Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about their roles in Alzheimer's disease (AD).  	miRNA-corp.d119.s0.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d119.s0	Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about their roles in Alzheimer's disease (AD).  	miRNA-corp.d119.s0.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d119.s0	Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about their roles in Alzheimer's disease (AD).  	miRNA-corp.d119.s0.e2	Diseases	AD 	3
miRNA-corp.d119.s0	Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about their roles in Alzheimer's disease (AD).  	miRNA-corp.d119.s0.e3	Diseases	cancer 	4
miRNA-corp.d119.s1	Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation.   	miRNA-corp.d119.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d119.s1	Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation.   	miRNA-corp.d119.s1.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d119.s1	Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation.   	miRNA-corp.d119.s1.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d119.s1	Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation.   	miRNA-corp.d119.s1.e3	Relation_Trigger	altered miRNA regulation 	4
miRNA-corp.d119.s2	These data provided the unique opportunity to study the relationship between miRNA and mRNA expression in normal and AD brains.  	miRNA-corp.d119.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d119.s2	These data provided the unique opportunity to study the relationship between miRNA and mRNA expression in normal and AD brains.  	miRNA-corp.d119.s2.e1	Diseases	AD 	2
miRNA-corp.d119.s3	In this study, we used microarrays for the first joint profiling and analysis of miRNAs and mRNAs expression in brain cortex from AD and age-matched control subjects.  	miRNA-corp.d119.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d119.s3	In this study, we used microarrays for the first joint profiling and analysis of miRNAs and mRNAs expression in brain cortex from AD and age-matched control subjects.  	miRNA-corp.d119.s3.e1	Diseases	AD 	2
miRNA-corp.d119.s4	Comparative analysis with independent cancer datasets showed that such miRNA-mRNA expression correlations are not static, but rather context-dependent.  	miRNA-corp.d119.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d119.s4	Comparative analysis with independent cancer datasets showed that such miRNA-mRNA expression correlations are not static, but rather context-dependent.  	miRNA-corp.d119.s4.e1	Relation_Trigger	expression correlations 	2
miRNA-corp.d119.s4	Comparative analysis with independent cancer datasets showed that such miRNA-mRNA expression correlations are not static, but rather context-dependent.  	miRNA-corp.d119.s4.e2	Diseases	cancer 	3
miRNA-corp.d119.s5	Using a non-parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those of their target mRNAs.  	miRNA-corp.d119.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d119.s5	Using a non-parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those of their target mRNAs.  	miRNA-corp.d119.s5.e1	Relation_Trigger	target 	2
miRNA-corp.d119.s5	Using a non-parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those of their target mRNAs.  	miRNA-corp.d119.s5.e2	Relation_Trigger	levels of many miRNAs can be either positively 	3
miRNA-corp.d119.s5	Using a non-parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those of their target mRNAs.  	miRNA-corp.d119.s5.e3	Relation_Trigger	negatively correlated 	4
miRNA-corp.d119.s6	Our results demonstrate a robust relationship between the levels of miRNAs and those of their targets in the brain.  	miRNA-corp.d119.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d119.s6	Our results demonstrate a robust relationship between the levels of miRNAs and those of their targets in the brain.  	miRNA-corp.d119.s6.e1	Relation_Trigger	targets 	2
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e1	Diseases	AD 	2
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e3	Relation_Trigger	associations 	4
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e4	Diseases	AD 	5
miRNA-corp.d119.s7	Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system.  	miRNA-corp.d119.s7.e5	Relation_Trigger	regulatory 	6
miRNA-corp.d119.s8	This has implications in the study of the molecular pathology of AD, as well as miRNA biology in general.    	miRNA-corp.d119.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d119.s8	This has implications in the study of the molecular pathology of AD, as well as miRNA biology in general.    	miRNA-corp.d119.s8.e1	Diseases	AD 	2
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e2	Diseases	AD 	3
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e3	Diseases	prion disease 	4
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e4	Diseases	fragile X syndrome 	5
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e5	Relation_Trigger	regulation 	6
miRNA-corp.d120.s0	In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.    	miRNA-corp.d120.s0.e6	Diseases	neurodegenerative diseases 	7
miRNA-corp.d120.s1	Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying diseases affecting major organs, such as the brain.  	miRNA-corp.d120.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d120.s1	Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying diseases affecting major organs, such as the brain.  	miRNA-corp.d120.s1.e1	Relation_Trigger	regulation of gene expression 	2
miRNA-corp.d120.s2	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.   	miRNA-corp.d120.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d120.s2	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.   	miRNA-corp.d120.s2.e1	Diseases	prion diseases 	2
miRNA-corp.d120.s2	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.   	miRNA-corp.d120.s2.e2	Diseases	Alzheimer's 	3
miRNA-corp.d120.s2	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.   	miRNA-corp.d120.s2.e3	Diseases	mental retardation 	4
miRNA-corp.d120.s3	MicroRNAs (miRNAs) are small, approximately 21- to 23-nucleotide (nt) non-coding RNA species that act as key regulators of gene expression along a central and well-defined cellular process known as RNA silencing, and involving the recognition and translational control of specific messenger RNA (mRNAs).  	miRNA-corp.d120.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d120.s3	MicroRNAs (miRNAs) are small, approximately 21- to 23-nucleotide (nt) non-coding RNA species that act as key regulators of gene expression along a central and well-defined cellular process known as RNA silencing, and involving the recognition and translational control of specific messenger RNA (mRNAs).  	miRNA-corp.d120.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d120.s3	MicroRNAs (miRNAs) are small, approximately 21- to 23-nucleotide (nt) non-coding RNA species that act as key regulators of gene expression along a central and well-defined cellular process known as RNA silencing, and involving the recognition and translational control of specific messenger RNA (mRNAs).  	miRNA-corp.d120.s3.e2	Relation_Trigger	regulators of gene expression 	3
miRNA-corp.d120.s4	Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region.  	miRNA-corp.d120.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d120.s4	Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region.  	miRNA-corp.d120.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d120.s4	Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region.  	miRNA-corp.d120.s4.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d120.s4	Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region.  	miRNA-corp.d120.s4.e3	Relation_Trigger	regulate mRNA translation 	4
miRNA-corp.d120.s4	Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region.  	miRNA-corp.d120.s4.e4	Relation_Trigger	binding sites 	5
miRNA-corp.d120.s5	Predicted to regulate up to 90% of the genes in humans, miRNAs may thus control cellular processes in all cells and tissues of the human body.  	miRNA-corp.d120.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d120.s5	Predicted to regulate up to 90% of the genes in humans, miRNAs may thus control cellular processes in all cells and tissues of the human body.  	miRNA-corp.d120.s5.e1	Relation_Trigger	regulate 	2
miRNA-corp.d120.s5	Predicted to regulate up to 90% of the genes in humans, miRNAs may thus control cellular processes in all cells and tissues of the human body.  	miRNA-corp.d120.s5.e2	Species	humans 	3
miRNA-corp.d120.s5	Predicted to regulate up to 90% of the genes in humans, miRNAs may thus control cellular processes in all cells and tissues of the human body.  	miRNA-corp.d120.s5.e3	Species	human 	4
miRNA-corp.d121.s0	Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.   	miRNA-corp.d121.s0.e0	Genes/Proteins	Phosphodiesterase-4D 	1
miRNA-corp.d121.s1	Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  	miRNA-corp.d121.s1.e0	Genes/Proteins	PDE4 	1
miRNA-corp.d121.s1	Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  	miRNA-corp.d121.s1.e1	Genes/Proteins	PDE4 	2
miRNA-corp.d121.s1	Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  	miRNA-corp.d121.s1.e2	Relation_Trigger	inhibition 	3
miRNA-corp.d121.s1	Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  	miRNA-corp.d121.s1.e3	Genes/Proteins	Phosphodiesterase-4 	4
miRNA-corp.d121.s2	However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  	miRNA-corp.d121.s2.e0	Relation_Trigger	inhibitors 	1
miRNA-corp.d121.s2	However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  	miRNA-corp.d121.s2.e1	Diseases	emesis 	2
miRNA-corp.d121.s3	PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  	miRNA-corp.d121.s3.e0	Genes/Proteins	PDE4 	1
miRNA-corp.d121.s3	PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  	miRNA-corp.d121.s3.e1	Genes/Proteins	PDE4A-D 	2
miRNA-corp.d121.s4	Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  	miRNA-corp.d121.s4.e0	Genes/Proteins	PDE4D 	1
miRNA-corp.d121.s4	Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  	miRNA-corp.d121.s4.e1	Species	Mice 	2
miRNA-corp.d121.s5	These effects were mimicked by repeated treatment with rolipram in wild-type mice.  	miRNA-corp.d121.s5.e0	Species	mice 	1
miRNA-corp.d121.s6	In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  	miRNA-corp.d121.s6.e0	Genes/Proteins	phosphorylated cAMP response element-binding protein 	1
miRNA-corp.d121.s6	In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  	miRNA-corp.d121.s6.e1	Genes/Proteins	pCREB 	2
miRNA-corp.d121.s6	In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  	miRNA-corp.d121.s6.e2	Genes/Proteins	PDE4D 	3
miRNA-corp.d121.s6	In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  	miRNA-corp.d121.s6.e3	Species	mice 	4
miRNA-corp.d121.s6	In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  	miRNA-corp.d121.s6.e4	Species	mice 	5
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e2	Genes/Proteins	PDE4D 	3
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e3	Genes/Proteins	PDE4D5 	4
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e4	Genes/Proteins	pCREB 	5
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e5	Relation_Trigger	targeting 	6
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e6	Relation_Trigger	downregulated 	7
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e7	Genes/Proteins	PDE4D4 	8
miRNA-corp.d121.s7	Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  	miRNA-corp.d121.s7.e8	Species	mouse 	9
miRNA-corp.d121.s8	Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  	miRNA-corp.d121.s8.e0	Genes/Proteins	PDE4D 	1
miRNA-corp.d121.s8	Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  	miRNA-corp.d121.s8.e1	Genes/Proteins	PDE4D 	2
miRNA-corp.d121.s8	Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  	miRNA-corp.d121.s8.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d121.s8	Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  	miRNA-corp.d121.s8.e3	Diseases	emesis 	4
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e0	Genes/Proteins	PDE4D 	1
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e1	Genes/Proteins	PDE4D 	2
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e2	Genes/Proteins	cAMP 	3
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e3	Genes/Proteins	CREB 	4
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e4	Genes/Proteins	PDE4D 	5
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e5	Genes/Proteins	PDE4D5 	6
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e6	Relation_Trigger	reduced expression 	7
miRNA-corp.d121.s9	The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  	miRNA-corp.d121.s9.e7	Diseases	emesis 	8
miRNA-corp.d121.s10	These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.    	miRNA-corp.d121.s10.e0	Genes/Proteins	PDE4 	1
miRNA-corp.d121.s10	These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.    	miRNA-corp.d121.s10.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d121.s10	These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.    	miRNA-corp.d121.s10.e2	Relation_Trigger	inhibitors 	3
miRNA-corp.d122.s0	High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P<0.0001).  	miRNA-corp.d122.s0.e0	Genes/Proteins	high-mobility group A2 	1
miRNA-corp.d122.s0	High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P<0.0001).  	miRNA-corp.d122.s0.e1	Relation_Trigger	High levels of high-mobility group A2 expression 	2
miRNA-corp.d122.s0	High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P<0.0001).  	miRNA-corp.d122.s0.e2	Relation_Trigger	correlated 	3
miRNA-corp.d122.s0	High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P<0.0001).  	miRNA-corp.d122.s0.e3	Genes/Proteins	proliferation marker Ki-67 	4
miRNA-corp.d122.s1	High levels of high-mobility group A2 expression were more frequently observed in macroadenomas than in microadenomas (P<0.05).  	miRNA-corp.d122.s1.e0	Genes/Proteins	high-mobility group A2 	1
miRNA-corp.d122.s1	High levels of high-mobility group A2 expression were more frequently observed in macroadenomas than in microadenomas (P<0.05).  	miRNA-corp.d122.s1.e1	Relation_Trigger	High levels of high-mobility group A2 expression 	2
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e0	Genes/Proteins	PRL 	1
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e1	Genes/Proteins	prolactin 	2
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e2	Genes/Proteins	PRL 	3
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e3	Diseases	pituitary adenomas 	4
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e4	Genes/Proteins	high-mobility group A2 	5
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e5	Genes/Proteins	adrenocorticotrophic hormone 	6
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e6	Genes/Proteins	follicle-stimulating hormone 	7
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e7	Genes/Proteins	luteinizing hormone 	8
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e8	Genes/Proteins	growth hormone 	9
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e9	Relation_Trigger	Overexpression 	10
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e10	Diseases	adenomas 	11
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e11	Diseases	adenomas 	12
miRNA-corp.d122.s2	Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.  	miRNA-corp.d122.s2.e12	Diseases	adenomas 	13
miRNA-corp.d122.s3	High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05).  	miRNA-corp.d122.s3.e0	Genes/Proteins	High-mobility group A2 	1
miRNA-corp.d122.s3	High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05).  	miRNA-corp.d122.s3.e1	Relation_Trigger	associated 	2
miRNA-corp.d122.s3	High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05).  	miRNA-corp.d122.s3.e2	Diseases	tumor 	3
miRNA-corp.d122.s3	High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05).  	miRNA-corp.d122.s3.e3	Diseases	adenomas 	4
miRNA-corp.d122.s4	However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.  	miRNA-corp.d122.s4.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s4	However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.  	miRNA-corp.d122.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d122.s4	However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.  	miRNA-corp.d122.s4.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d122.s4	However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.  	miRNA-corp.d122.s4.e3	Genes/Proteins	high-mobility group A2 	4
miRNA-corp.d122.s4	However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.  	miRNA-corp.d122.s4.e4	Species	human 	5
miRNA-corp.d122.s5	Using immunohistochemistry, we analyzed high-mobility group A2 expression with respect to various clinicopathologic factors in 98 pituitary adenomas.  	miRNA-corp.d122.s5.e0	Diseases	pituitary adenomas 	1
miRNA-corp.d122.s5	Using immunohistochemistry, we analyzed high-mobility group A2 expression with respect to various clinicopathologic factors in 98 pituitary adenomas.  	miRNA-corp.d122.s5.e1	Genes/Proteins	high-mobility group A2 	2
miRNA-corp.d122.s6	Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro.  	miRNA-corp.d122.s6.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s6	Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro.  	miRNA-corp.d122.s6.e1	Genes/Proteins	high-mobility group A2 	2
miRNA-corp.d122.s6	Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro.  	miRNA-corp.d122.s6.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d122.s6	Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro.  	miRNA-corp.d122.s6.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d122.s6	Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro.  	miRNA-corp.d122.s6.e4	Relation_Trigger	negatively regulated 	5
miRNA-corp.d122.s7	The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis.  	miRNA-corp.d122.s7.e0	Diseases	pituitary adenomas 	1
miRNA-corp.d122.s7	The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis.  	miRNA-corp.d122.s7.e1	Genes/Proteins	high-mobility group A2 	2
miRNA-corp.d122.s7	The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis.  	miRNA-corp.d122.s7.e2	Genes/Proteins	high-mobility group A2 	3
miRNA-corp.d122.s7	The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis.  	miRNA-corp.d122.s7.e3	Species	transgenic mice 	4
miRNA-corp.d122.s8	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.   	miRNA-corp.d122.s8.e0	Genes/Proteins	HMGA2 	1
miRNA-corp.d122.s8	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.   	miRNA-corp.d122.s8.e1	Specific_miRNAs	let-7 	2
miRNA-corp.d122.s8	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.   	miRNA-corp.d122.s8.e2	Diseases	pituitary adenomas 	3
miRNA-corp.d122.s8	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.   	miRNA-corp.d122.s8.e3	Relation_Trigger	Overexpression 	4
miRNA-corp.d122.s9	High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors.  	miRNA-corp.d122.s9.e0	Genes/Proteins	High-mobility group A2 	1
miRNA-corp.d122.s9	High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors.  	miRNA-corp.d122.s9.e1	Diseases	malignant tumors 	2
miRNA-corp.d122.s9	High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors.  	miRNA-corp.d122.s9.e2	Relation_Trigger	highly expressed 	3
miRNA-corp.d122.s10	Real-time quantitative RT-PCR analysis was carried out to evaluate the expression of let-7 in 55 pituitary adenomas.  	miRNA-corp.d122.s10.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s10	Real-time quantitative RT-PCR analysis was carried out to evaluate the expression of let-7 in 55 pituitary adenomas.  	miRNA-corp.d122.s10.e1	Diseases	pituitary adenomas 	2
miRNA-corp.d122.s11	Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).  	miRNA-corp.d122.s11.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s11	Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).  	miRNA-corp.d122.s11.e1	Relation_Trigger	decreased expression 	2
miRNA-corp.d122.s11	Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).  	miRNA-corp.d122.s11.e2	Diseases	high-grade tumors 	3
miRNA-corp.d122.s11	Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).  	miRNA-corp.d122.s11.e3	Relation_Trigger	correlated 	4
miRNA-corp.d122.s11	Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).  	miRNA-corp.d122.s11.e4	Diseases	adenomas 	5
miRNA-corp.d122.s12	An inverse correlation between let-7 and high-mobility group A2 expression was evident (R=-0.33, P<0.05).  	miRNA-corp.d122.s12.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s12	An inverse correlation between let-7 and high-mobility group A2 expression was evident (R=-0.33, P<0.05).  	miRNA-corp.d122.s12.e1	Genes/Proteins	high-mobility group A2 	2
miRNA-corp.d122.s12	An inverse correlation between let-7 and high-mobility group A2 expression was evident (R=-0.33, P<0.05).  	miRNA-corp.d122.s12.e2	Relation_Trigger	inverse correlation 	3
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e0	Specific_miRNAs	let-7 	1
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e1	Specific_miRNAs	let-7 	2
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e2	Genes/Proteins	high-mobility group A2 	3
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e3	Genes/Proteins	high-mobility group A2 	4
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e4	Relation_Trigger	loss of let-7 expression 	5
miRNA-corp.d122.s13	These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.    	miRNA-corp.d122.s13.e5	Relation_Trigger	upregulation 	6
miRNA-corp.d123.s0	MicroRNAs (miRNAs) are known to influence many important cellular processes, including proliferation, apoptosis, neurogenesis, angiogenesis, and morphogenesis, all processes that are involved in TBI pathophysiology.  	miRNA-corp.d123.s0.e0	Diseases	TBI 	1
miRNA-corp.d123.s0	MicroRNAs (miRNAs) are known to influence many important cellular processes, including proliferation, apoptosis, neurogenesis, angiogenesis, and morphogenesis, all processes that are involved in TBI pathophysiology.  	miRNA-corp.d123.s0.e1	Non-Specific_miRNAs	MicroRNAs 	2
miRNA-corp.d123.s0	MicroRNAs (miRNAs) are known to influence many important cellular processes, including proliferation, apoptosis, neurogenesis, angiogenesis, and morphogenesis, all processes that are involved in TBI pathophysiology.  	miRNA-corp.d123.s0.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d123.s1	Multiple cellular, molecular, and biochemical changes contribute to outcome after traumatic brain injury (TBI).  	miRNA-corp.d123.s1.e0	Diseases	traumatic brain injury 	1
miRNA-corp.d123.s1	Multiple cellular, molecular, and biochemical changes contribute to outcome after traumatic brain injury (TBI).  	miRNA-corp.d123.s1.e1	Diseases	TBI 	2
miRNA-corp.d123.s2	In the present study, we used a microarray platform to examine changes in the hippocampal expression levels of 444 verified rodent miRNAs at 3 and 24 hr after controlled cortical impact injury.  	miRNA-corp.d123.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d123.s2	In the present study, we used a microarray platform to examine changes in the hippocampal expression levels of 444 verified rodent miRNAs at 3 and 24 hr after controlled cortical impact injury.  	miRNA-corp.d123.s2.e1	Relation_Trigger	changes in the hippocampal expression 	2
miRNA-corp.d123.s2	In the present study, we used a microarray platform to examine changes in the hippocampal expression levels of 444 verified rodent miRNAs at 3 and 24 hr after controlled cortical impact injury.  	miRNA-corp.d123.s2.e2	Diseases	injury 	3
miRNA-corp.d123.s3	However, it has not yet been determined whether miRNA expression is altered after TBI.  	miRNA-corp.d123.s3.e0	Diseases	TBI 	1
miRNA-corp.d123.s3	However, it has not yet been determined whether miRNA expression is altered after TBI.  	miRNA-corp.d123.s3.e1	Relation_Trigger	expression is altered 	2
miRNA-corp.d123.s3	However, it has not yet been determined whether miRNA expression is altered after TBI.  	miRNA-corp.d123.s3.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d123.s4	We extended the microarray findings using quantitative polymerase chain reaction analysis for a subset of the miRNAs with altered expression levels (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711).  	miRNA-corp.d123.s4.e0	Relation_Trigger	altered expression levels 	1
miRNA-corp.d123.s4	We extended the microarray findings using quantitative polymerase chain reaction analysis for a subset of the miRNAs with altered expression levels (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711).  	miRNA-corp.d123.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d123.s4	We extended the microarray findings using quantitative polymerase chain reaction analysis for a subset of the miRNAs with altered expression levels (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711).  	miRNA-corp.d123.s4.e2	Specific_miRNAs	miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711 	3
miRNA-corp.d123.s5	Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury.  	miRNA-corp.d123.s5.e0	Relation_Trigger	decreased expression levels 	1
miRNA-corp.d123.s5	Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury.  	miRNA-corp.d123.s5.e1	Relation_Trigger	increased expression levels 	2
miRNA-corp.d123.s5	Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury.  	miRNA-corp.d123.s5.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d123.s5	Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury.  	miRNA-corp.d123.s5.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d123.s5	Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury.  	miRNA-corp.d123.s5.e4	Diseases	injury 	5
miRNA-corp.d123.s6	Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs.    	miRNA-corp.d123.s6.e0	Diseases	TBI 	1
miRNA-corp.d123.s6	Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs.    	miRNA-corp.d123.s6.e1	Relation_Trigger	regulated 	2
miRNA-corp.d123.s6	Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs.    	miRNA-corp.d123.s6.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d123.s6	Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs.    	miRNA-corp.d123.s6.e3	Relation_Trigger	targets 	4
miRNA-corp.d123.s7	Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation.  	miRNA-corp.d123.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d123.s7	Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation.  	miRNA-corp.d123.s7.e1	Relation_Trigger	transcriptional regulation 	2
miRNA-corp.d123.s7	Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation.  	miRNA-corp.d123.s7.e2	Relation_Trigger	predicted targets 	3
miRNA-corp.d123.s7	Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation.  	miRNA-corp.d123.s7.e3	Diseases	injury 	4
miRNA-corp.d123.s8	Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes.   	miRNA-corp.d123.s8.e0	Diseases	Traumatic brain injury 	1
miRNA-corp.d123.s8	Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes.   	miRNA-corp.d123.s8.e1	Relation_Trigger	alters expression 	2
miRNA-corp.d123.s8	Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes.   	miRNA-corp.d123.s8.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d123.s8	Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes.   	miRNA-corp.d123.s8.e3	Relation_Trigger	potential regulators 	4
miRNA-corp.d124.s0	Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.    	miRNA-corp.d124.s0.e0	Genes/Proteins	HTT 	1
miRNA-corp.d124.s0	Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.    	miRNA-corp.d124.s0.e1	Diseases	HD 	2
miRNA-corp.d124.s0	Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.    	miRNA-corp.d124.s0.e2	Relation_Trigger	inhibition 	3
miRNA-corp.d124.s1	Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells.  	miRNA-corp.d124.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d124.s1	Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells.  	miRNA-corp.d124.s1.e1	Relation_Trigger	inhibition of mutant HTT expression 	2
miRNA-corp.d124.s1	Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells.  	miRNA-corp.d124.s1.e2	Species	patient 	3
miRNA-corp.d124.s1	Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells.  	miRNA-corp.d124.s1.e3	Genes/Proteins	HTT 	4
miRNA-corp.d124.s2	We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles.  	miRNA-corp.d124.s2.e0	Genes/Proteins	HTT 	1
miRNA-corp.d124.s2	We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles.  	miRNA-corp.d124.s2.e1	Relation_Trigger	targeting 	2
miRNA-corp.d124.s2	We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles.  	miRNA-corp.d124.s2.e2	Relation_Trigger	block expression 	3
miRNA-corp.d124.s3	An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact.  	miRNA-corp.d124.s3.e0	Genes/Proteins	HTT 	1
miRNA-corp.d124.s3	An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact.  	miRNA-corp.d124.s3.e1	Relation_Trigger	block expression 	2
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e0	Genes/Proteins	HTT 	1
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e1	Genes/Proteins	huntingtin 	2
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e2	Diseases	Huntington's disease 	3
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e3	Diseases	HD 	4
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e4	Relation_Trigger	inhibition 	5
miRNA-corp.d124.s4	Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity.  	miRNA-corp.d124.s4.e5	Relation_Trigger	Inhibiting expression 	6
miRNA-corp.d124.s5	Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.   	miRNA-corp.d124.s5.e0	Genes/Proteins	huntingtin 	1
miRNA-corp.d124.s5	Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.   	miRNA-corp.d124.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d124.s5	Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.   	miRNA-corp.d124.s5.e2	Relation_Trigger	inhibition of huntingtin expression 	3
miRNA-corp.d125.s0	Thus we have identified a miRNA expression signature that can predict GBM patient survival.  	miRNA-corp.d125.s0.e0	Diseases	GBM 	1
miRNA-corp.d125.s0	Thus we have identified a miRNA expression signature that can predict GBM patient survival.  	miRNA-corp.d125.s0.e1	Species	patient 	2
miRNA-corp.d125.s0	Thus we have identified a miRNA expression signature that can predict GBM patient survival.  	miRNA-corp.d125.s0.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d125.s1	Cox multivariate analysis with patient age as a covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent predictor of patient survival (HR = 1.120; 95% CI = 1.04-1.20; p = 0.003).  	miRNA-corp.d125.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d125.s1	Cox multivariate analysis with patient age as a covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent predictor of patient survival (HR = 1.120; 95% CI = 1.04-1.20; p = 0.003).  	miRNA-corp.d125.s1.e1	Species	patient 	2
miRNA-corp.d125.s1	Cox multivariate analysis with patient age as a covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent predictor of patient survival (HR = 1.120; 95% CI = 1.04-1.20; p = 0.003).  	miRNA-corp.d125.s1.e2	Species	patient 	3
miRNA-corp.d125.s1	Cox multivariate analysis with patient age as a covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent predictor of patient survival (HR = 1.120; 95% CI = 1.04-1.20; p = 0.003).  	miRNA-corp.d125.s1.e3	Species	patient 	4
miRNA-corp.d125.s2	These findings may have implications in the understanding of gliomagenesis, development of targeted therapy and selection of high risk cancer patients for adjuvant therapy.    	miRNA-corp.d125.s2.e0	Relation_Trigger	targeted 	1
miRNA-corp.d125.s2	These findings may have implications in the understanding of gliomagenesis, development of targeted therapy and selection of high risk cancer patients for adjuvant therapy.    	miRNA-corp.d125.s2.e1	Diseases	cancer 	2
miRNA-corp.d125.s2	These findings may have implications in the understanding of gliomagenesis, development of targeted therapy and selection of high risk cancer patients for adjuvant therapy.    	miRNA-corp.d125.s2.e2	Species	patients 	3
miRNA-corp.d125.s3	GBM patients with high risk scores had overall poor survival compared to the patients with low risk scores.  	miRNA-corp.d125.s3.e0	Species	patients 	1
miRNA-corp.d125.s3	GBM patients with high risk scores had overall poor survival compared to the patients with low risk scores.  	miRNA-corp.d125.s3.e1	Diseases	GBM 	2
miRNA-corp.d125.s3	GBM patients with high risk scores had overall poor survival compared to the patients with low risk scores.  	miRNA-corp.d125.s3.e2	Species	patients 	3
miRNA-corp.d125.s4	Overall survival among the entire patient set was 35.0% at 2 years, 21.5% at 3 years, 18.5% at 4 years and 11.8% at 5 years in the low risk group, versus 11.0%, 5.5%, 0.0 and 0.0% respectively in the high risk group (HR = 2.0; 95% CI = 1.4-2.8; p<0.0001).  	miRNA-corp.d125.s4.e0	Species	patient 	1
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e3	Diseases	GBM 	4
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e4	Diseases	GBM 	5
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e5	Species	patient 	6
miRNA-corp.d125.s5	To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset.  	miRNA-corp.d125.s5.e6	Species	patients 	7
miRNA-corp.d125.s6	We divided the patients randomly into training and testing sets with equal number in each group.  	miRNA-corp.d125.s6.e0	Species	patients 	1
miRNA-corp.d125.s7	A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma.   	miRNA-corp.d125.s7.e0	Diseases	Glioblastoma 	1
miRNA-corp.d125.s7	A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma.   	miRNA-corp.d125.s7.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d125.s8	Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival.  	miRNA-corp.d125.s8.e0	Diseases	Glioblastoma 	1
miRNA-corp.d125.s8	Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival.  	miRNA-corp.d125.s8.e1	Diseases	GBM 	2
miRNA-corp.d125.s8	Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival.  	miRNA-corp.d125.s8.e2	Diseases	brain tumor 	3
miRNA-corp.d125.s8	Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival.  	miRNA-corp.d125.s8.e3	Species	patient 	4
miRNA-corp.d125.s9	Of these 10 miRNAs, 7 were found to be risky miRNAs and 3 were found to be protective.  	miRNA-corp.d125.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d125.s9	Of these 10 miRNAs, 7 were found to be risky miRNAs and 3 were found to be protective.  	miRNA-corp.d125.s9.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d125.s11	We identified 10 significant miRNAs using Cox regression analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated the patients into high and low risk groups with significantly different survival times (hazard ratio [HR] = 2.4; 95% CI = 1.4-3.8; p<0.0001).  	miRNA-corp.d125.s11.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d125.s11	We identified 10 significant miRNAs using Cox regression analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated the patients into high and low risk groups with significantly different survival times (hazard ratio [HR] = 2.4; 95% CI = 1.4-3.8; p<0.0001).  	miRNA-corp.d125.s11.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d125.s11	We identified 10 significant miRNAs using Cox regression analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated the patients into high and low risk groups with significantly different survival times (hazard ratio [HR] = 2.4; 95% CI = 1.4-3.8; p<0.0001).  	miRNA-corp.d125.s11.e2	Species	patients 	3
miRNA-corp.d126.s0	Microarray analysis showed differential expression of multiple miRNAs in HIVE compared to control brains.  	miRNA-corp.d126.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d126.s0	Microarray analysis showed differential expression of multiple miRNAs in HIVE compared to control brains.  	miRNA-corp.d126.s0.e1	Diseases	HIVE 	2
miRNA-corp.d126.s0	Microarray analysis showed differential expression of multiple miRNAs in HIVE compared to control brains.  	miRNA-corp.d126.s0.e2	Relation_Trigger	differential expression 	3
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e1	Genes/Proteins	caspase-6 	2
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e2	Relation_Trigger	differentially expressed 	3
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e3	Relation_Trigger	targeting 	4
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e4	Relation_Trigger	down-regulated 	5
miRNA-corp.d126.s1	Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs.  	miRNA-corp.d126.s1.e5	Relation_Trigger	Target 	6
miRNA-corp.d126.s2	Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients.  	miRNA-corp.d126.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d126.s2	Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients.  	miRNA-corp.d126.s2.e1	Diseases	HIVE 	2
miRNA-corp.d126.s2	Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients.  	miRNA-corp.d126.s2.e2	Genes/Proteins	caspase-6 	3
miRNA-corp.d126.s2	Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients.  	miRNA-corp.d126.s2.e3	Relation_Trigger	higher levels 	4
miRNA-corp.d126.s2	Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients.  	miRNA-corp.d126.s2.e4	Species	patients 	5
miRNA-corp.d126.s3	Immunohistochemical analysis showed localization of the cleaved form of caspase-6 in astrocytes in HIVE brain sections.  	miRNA-corp.d126.s3.e0	Genes/Proteins	caspase-6 	1
miRNA-corp.d126.s3	Immunohistochemical analysis showed localization of the cleaved form of caspase-6 in astrocytes in HIVE brain sections.  	miRNA-corp.d126.s3.e1	Diseases	HIVE 	2
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e0	Genes/Proteins	p53 	1
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e1	Genes/Proteins	caspase-6 	2
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e2	Relation_Trigger	up-regulation 	3
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e3	Relation_Trigger	activation 	4
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e4	Diseases	cell injury 	5
miRNA-corp.d126.s4	Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury.  	miRNA-corp.d126.s4.e5	Species	human 	6
miRNA-corp.d126.s5	Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities.  	miRNA-corp.d126.s5.e0	Genes/Proteins	caspase-6 	1
miRNA-corp.d126.s5	Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities.  	miRNA-corp.d126.s5.e1	Relation_Trigger	associated 	2
miRNA-corp.d126.s5	Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities.  	miRNA-corp.d126.s5.e2	Relation_Trigger	activation 	3
miRNA-corp.d126.s5	Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities.  	miRNA-corp.d126.s5.e3	Diseases	neurobehavioral abnormalities 	4
miRNA-corp.d126.s5	Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities.  	miRNA-corp.d126.s5.e4	Species	Transgenic mice 	5
miRNA-corp.d126.s6	Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.    	miRNA-corp.d126.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d126.s6	Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.    	miRNA-corp.d126.s6.e1	Diseases	HIV infection 	2
miRNA-corp.d126.s6	Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.    	miRNA-corp.d126.s6.e2	Relation_Trigger	alterations in miRNA profile 	3
miRNA-corp.d126.s6	Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.    	miRNA-corp.d126.s6.e3	Relation_Trigger	dysregulation 	4
miRNA-corp.d126.s7	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival.   	miRNA-corp.d126.s7.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d126.s7	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival.   	miRNA-corp.d126.s7.e1	Genes/Proteins	caspase-6 	2
miRNA-corp.d126.s7	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival.   	miRNA-corp.d126.s7.e2	Relation_Trigger	regulates 	3
miRNA-corp.d126.s8	MicroRNAs (miRNAs) are small noncoding RNA molecules, which are known to regulate gene expression in physiological and pathological conditions.  	miRNA-corp.d126.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d126.s8	MicroRNAs (miRNAs) are small noncoding RNA molecules, which are known to regulate gene expression in physiological and pathological conditions.  	miRNA-corp.d126.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d126.s8	MicroRNAs (miRNAs) are small noncoding RNA molecules, which are known to regulate gene expression in physiological and pathological conditions.  	miRNA-corp.d126.s8.e2	Relation_Trigger	regulate gene expression 	3
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e1	Diseases	HIV infection 	2
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e2	Diseases	HIV encephalitis 	3
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e3	Diseases	HIVE 	4
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e4	Diseases	neuroinflammatory/degenerative disorder 	5
miRNA-corp.d126.s9	miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain.  	miRNA-corp.d126.s9.e5	Species	patients 	6
miRNA-corp.d127.s1	Implantation of adult human mesenchymal stem cells (MSCs) to treat neural disorders shows promise.  	miRNA-corp.d127.s1.e0	Diseases	neural disorders 	1
miRNA-corp.d127.s1	Implantation of adult human mesenchymal stem cells (MSCs) to treat neural disorders shows promise.  	miRNA-corp.d127.s1.e1	Species	human 	2
miRNA-corp.d127.s2	Depending on their microenvironment, MSCs could potentially be used for the repair and/or replacement of neurons in traumatic brain injury or the treatment of Parkinson's disease.  	miRNA-corp.d127.s2.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d127.s2	Depending on their microenvironment, MSCs could potentially be used for the repair and/or replacement of neurons in traumatic brain injury or the treatment of Parkinson's disease.  	miRNA-corp.d127.s2.e1	Diseases	brain injury 	2
miRNA-corp.d127.s3	This cross-disciplinary review incorporates aspects of neuroscience, stem cell biology, cancer biology and immunology to discuss interactions between inflammatory mediators and MSCs.  	miRNA-corp.d127.s3.e0	Diseases	cancer 	1
miRNA-corp.d127.s4	We first discuss the role of microRNAs (miRNAs) in neurological development.  	miRNA-corp.d127.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d127.s4	We first discuss the role of microRNAs (miRNAs) in neurological development.  	miRNA-corp.d127.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d127.s5	Neurogenesis: role for microRNAs and mesenchymal stem cells in pathological states.   	miRNA-corp.d127.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d127.s6	Exploring the predisposition of MSCs to oncogenesis is critical for translational science since the implementation of safeguarding measures prior to therapy can lead to the successful delivery of stem cells to patients.  	miRNA-corp.d127.s6.e0	Species	patients 	1
miRNA-corp.d127.s8	Secondly, we discuss the ability of MSCs to transdifferentiate into functional neurons, which are regulated by miRNAs, and the implications of these cells for the therapy of neuropathological states.  	miRNA-corp.d127.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d127.s8	Secondly, we discuss the ability of MSCs to transdifferentiate into functional neurons, which are regulated by miRNAs, and the implications of these cells for the therapy of neuropathological states.  	miRNA-corp.d127.s8.e1	Relation_Trigger	regulated 	2
miRNA-corp.d127.s9	Immune mediators could be central to MSC responses within a region of tissue injury and are also discussed in detail.  	miRNA-corp.d127.s9.e0	Diseases	tissue injury 	1
miRNA-corp.d127.s10	Thus, we discuss a key gene, RE-1 silencing transcription factor (REST), based on its dual role in neurogenesis and cancer development.  	miRNA-corp.d127.s10.e0	Genes/Proteins	RE-1 silencing transcription factor 	1
miRNA-corp.d127.s10	Thus, we discuss a key gene, RE-1 silencing transcription factor (REST), based on its dual role in neurogenesis and cancer development.  	miRNA-corp.d127.s10.e1	Genes/Proteins	REST 	2
miRNA-corp.d127.s10	Thus, we discuss a key gene, RE-1 silencing transcription factor (REST), based on its dual role in neurogenesis and cancer development.  	miRNA-corp.d127.s10.e2	Diseases	cancer 	3
miRNA-corp.d128.s0	Language brain dominance in patients with refractory temporal lobe epilepsy: a comparative study between functional magnetic resonance imaging and dichotic listening test.   	miRNA-corp.d128.s0.e0	Diseases	refractory temporal lobe epilepsy 	1
miRNA-corp.d128.s0	Language brain dominance in patients with refractory temporal lobe epilepsy: a comparative study between functional magnetic resonance imaging and dichotic listening test.   	miRNA-corp.d128.s0.e1	Species	patients 	2
miRNA-corp.d128.s1	PURPOSE: To identify brain dominance for language functions with DLT and correlate these results with those obtained from fMRI in patients suffering from intractable temporal lobe epilepsy.  	miRNA-corp.d128.s1.e0	Diseases	intractable temporal lobe epilepsy 	1
miRNA-corp.d128.s1	PURPOSE: To identify brain dominance for language functions with DLT and correlate these results with those obtained from fMRI in patients suffering from intractable temporal lobe epilepsy.  	miRNA-corp.d128.s1.e1	Relation_Trigger	correlate 	2
miRNA-corp.d128.s1	PURPOSE: To identify brain dominance for language functions with DLT and correlate these results with those obtained from fMRI in patients suffering from intractable temporal lobe epilepsy.  	miRNA-corp.d128.s1.e2	Species	patients 	3
miRNA-corp.d128.s2	METHOD: This study reports on 13 patients who underwent pre-surgical epileptic evaluation between April and October 2004 at the Epilepsy Surgery Program, Hospital Sao Lucas, PUCRS.  	miRNA-corp.d128.s2.e0	Species	patients 	1
miRNA-corp.d128.s3	In DLT, dominance was assessed through a consonant-vowel task, whereas in fMRI patients performed a verb generation task.  	miRNA-corp.d128.s3.e0	Species	patients 	1
miRNA-corp.d128.s4	These findings indicate that DLT (a non-invasive procedure) could be a useful tool to evaluate language brain dominance in pre-surgical epileptic patients as it is cheaper to perform than fMRI.    	miRNA-corp.d128.s4.e0	Species	patients 	1
miRNA-corp.d128.s5	CONCLUSION: DLT was found to significantly correlate with fMRI.  	miRNA-corp.d128.s5.e0	Relation_Trigger	correlate 	1
miRNA-corp.d128.s6	RESULTS: Our results identified a correlation between the fMRI lateralization index and the DLT ear predominance index and reply difference index (r=0.6, p=0.02; Pearson Correlation Coefficient), showing positive correlation between results obtained from fMRI and DLT.  	miRNA-corp.d128.s6.e0	Relation_Trigger	positive correlation 	1
miRNA-corp.d128.s6	RESULTS: Our results identified a correlation between the fMRI lateralization index and the DLT ear predominance index and reply difference index (r=0.6, p=0.02; Pearson Correlation Coefficient), showing positive correlation between results obtained from fMRI and DLT.  	miRNA-corp.d128.s6.e1	Relation_Trigger	correlation 	2
miRNA-corp.d129.s0	Finally, a phylogenetic analysis shows that ADCK3 belongs to the family of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.    	miRNA-corp.d129.s0.e0	Relation_Trigger	regulatory 	1
miRNA-corp.d129.s0	Finally, a phylogenetic analysis shows that ADCK3 belongs to the family of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.    	miRNA-corp.d129.s0.e1	Genes/Proteins	ADCK3 belongs 	2
miRNA-corp.d129.s0	Finally, a phylogenetic analysis shows that ADCK3 belongs to the family of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.    	miRNA-corp.d129.s0.e2	Genes/Proteins	ADCK3 	3
miRNA-corp.d129.s0	Finally, a phylogenetic analysis shows that ADCK3 belongs to the family of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.    	miRNA-corp.d129.s0.e3	Relation_Trigger	regulates 	4
miRNA-corp.d129.s1	ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency.   	miRNA-corp.d129.s1.e0	Diseases	recessive ataxia 	1
miRNA-corp.d129.s1	ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency.   	miRNA-corp.d129.s1.e1	Genes/Proteins	ADCK3 	2
miRNA-corp.d129.s1	ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency.   	miRNA-corp.d129.s1.e2	Relation_Trigger	associated 	3
miRNA-corp.d129.s2	Muscle coenzyme Q(10) (CoQ(10) or ubiquinone) deficiency has been identified in more than 20 patients with presumed autosomal-recessive ataxia.  	miRNA-corp.d129.s2.e0	Diseases	autosomal-recessive ataxia 	1
miRNA-corp.d129.s2	Muscle coenzyme Q(10) (CoQ(10) or ubiquinone) deficiency has been identified in more than 20 patients with presumed autosomal-recessive ataxia.  	miRNA-corp.d129.s2.e1	Species	patients 	2
miRNA-corp.d129.s3	However, mutations in genes required for CoQ(10) biosynthetic pathway have been identified only in patients with infantile-onset multisystemic diseases or isolated nephropathy.  	miRNA-corp.d129.s3.e0	Diseases	isolated nephropathy 	1
miRNA-corp.d129.s3	However, mutations in genes required for CoQ(10) biosynthetic pathway have been identified only in patients with infantile-onset multisystemic diseases or isolated nephropathy.  	miRNA-corp.d129.s3.e1	Species	patients 	2
miRNA-corp.d129.s4	Our SNP-based genome-wide scan in a large consanguineous family revealed a locus for autosomal-recessive ataxia at chromosome 1q41.  	miRNA-corp.d129.s4.e0	Diseases	autosomal-recessive ataxia 	1
miRNA-corp.d129.s5	The causative mutation is a homozygous splice-site mutation in the aarF-domain-containing kinase 3 gene (ADCK3).  	miRNA-corp.d129.s5.e0	Genes/Proteins	aarF-domain-containing kinase 3 gene 	1
miRNA-corp.d129.s5	The causative mutation is a homozygous splice-site mutation in the aarF-domain-containing kinase 3 gene (ADCK3).  	miRNA-corp.d129.s5.e1	Genes/Proteins	ADCK3 	2
miRNA-corp.d129.s6	Five additional mutations in ADCK3 were found in three patients with sporadic ataxia, including one known to have CoQ(10) deficiency in muscle.  	miRNA-corp.d129.s6.e0	Diseases	sporadic ataxia 	1
miRNA-corp.d129.s6	Five additional mutations in ADCK3 were found in three patients with sporadic ataxia, including one known to have CoQ(10) deficiency in muscle.  	miRNA-corp.d129.s6.e1	Genes/Proteins	ADCK3 	2
miRNA-corp.d129.s6	Five additional mutations in ADCK3 were found in three patients with sporadic ataxia, including one known to have CoQ(10) deficiency in muscle.  	miRNA-corp.d129.s6.e2	Species	patients 	3
miRNA-corp.d129.s7	All of the patients have childhood-onset cerebellar ataxia with slow progression, and three of six have mildly elevated lactate levels.  	miRNA-corp.d129.s7.e0	Relation_Trigger	elevated lactate levels 	1
miRNA-corp.d129.s7	All of the patients have childhood-onset cerebellar ataxia with slow progression, and three of six have mildly elevated lactate levels.  	miRNA-corp.d129.s7.e1	Diseases	cerebellar ataxia 	2
miRNA-corp.d129.s7	All of the patients have childhood-onset cerebellar ataxia with slow progression, and three of six have mildly elevated lactate levels.  	miRNA-corp.d129.s7.e2	Species	patients 	3
miRNA-corp.d129.s8	ADCK3 is a mitochondrial protein homologous to the yeast COQ8 and the bacterial UbiB proteins, which are required for CoQ biosynthesis.  	miRNA-corp.d129.s8.e0	Genes/Proteins	ADCK3 	1
miRNA-corp.d129.s8	ADCK3 is a mitochondrial protein homologous to the yeast COQ8 and the bacterial UbiB proteins, which are required for CoQ biosynthesis.  	miRNA-corp.d129.s8.e1	Genes/Proteins	COQ8 	2
miRNA-corp.d129.s9	Three out of four patients tested showed a low endogenous pool of CoQ(10) in their fibroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is also involved in CoQ(10) biosynthesis.  	miRNA-corp.d129.s9.e0	Relation_Trigger	impaired 	1
miRNA-corp.d129.s9	Three out of four patients tested showed a low endogenous pool of CoQ(10) in their fibroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is also involved in CoQ(10) biosynthesis.  	miRNA-corp.d129.s9.e1	Genes/Proteins	ADCK3 	2
miRNA-corp.d129.s9	Three out of four patients tested showed a low endogenous pool of CoQ(10) in their fibroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is also involved in CoQ(10) biosynthesis.  	miRNA-corp.d129.s9.e2	Species	patients 	3
miRNA-corp.d129.s9	Three out of four patients tested showed a low endogenous pool of CoQ(10) in their fibroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is also involved in CoQ(10) biosynthesis.  	miRNA-corp.d129.s9.e3	Species	patients 	4
miRNA-corp.d129.s10	The deleterious nature of the three identified missense changes was confirmed by the introduction of them at the corresponding positions of the yeast COQ8 gene.  	miRNA-corp.d129.s10.e0	Genes/Proteins	COQ8 	1
miRNA-corp.d130.s0	Our method significantly decreased the duration of hospital admission for monitoring and minimal complications occurred only in 8% of patients.  	miRNA-corp.d130.s0.e0	Relation_Trigger	significantly decreased 	1
miRNA-corp.d130.s0	Our method significantly decreased the duration of hospital admission for monitoring and minimal complications occurred only in 8% of patients.  	miRNA-corp.d130.s0.e1	Species	patients 	2
miRNA-corp.d130.s2	These qualities, together with good surgery results validate our method for the investigation and treatment of refractory seizure cases.    	miRNA-corp.d130.s2.e0	Diseases	refractory seizure 	1
miRNA-corp.d130.s3	RESULTS: Our monitoring answered the study question in 88% of the patients.  	miRNA-corp.d130.s3.e0	Species	patients 	1
miRNA-corp.d130.s4	We prospectively assessed the yield and safety of the telemetry investigation as well as epilepsy surgery outcomes.  	miRNA-corp.d130.s4.e0	Diseases	epilepsy 	1
miRNA-corp.d130.s5	Our results changed the management in 74% of cases and potentially improved quality of life by decreasing the AEDs consumption and number of seizures per month.  	miRNA-corp.d130.s5.e0	Diseases	seizures 	1
miRNA-corp.d130.s7	Over all, 22% received epilepsy surgery and became either seizure free or their seizures became non-disabling.  	miRNA-corp.d130.s7.e0	Diseases	seizure 	1
miRNA-corp.d130.s7	Over all, 22% received epilepsy surgery and became either seizure free or their seizures became non-disabling.  	miRNA-corp.d130.s7.e1	Diseases	seizures 	2
miRNA-corp.d130.s7	Over all, 22% received epilepsy surgery and became either seizure free or their seizures became non-disabling.  	miRNA-corp.d130.s7.e2	Diseases	epilepsy 	3
miRNA-corp.d130.s12	Over a 2.5-year period, 50 patients that met the indications for VEEG monitoring were admitted by an epileptologist to neuro-observation units with continuous monitoring, nursing coverage and EEG technicians support during working hours and on-call thereafter.  	miRNA-corp.d130.s12.e0	Species	patients 	1
miRNA-corp.d131.s1	Gliomas are the most common form of primary brain tumors and are associated with a poor clinical outcome.  	miRNA-corp.d131.s1.e0	Diseases	Gliomas 	1
miRNA-corp.d131.s1	Gliomas are the most common form of primary brain tumors and are associated with a poor clinical outcome.  	miRNA-corp.d131.s1.e1	Diseases	brain tumors 	2
miRNA-corp.d131.s1	Gliomas are the most common form of primary brain tumors and are associated with a poor clinical outcome.  	miRNA-corp.d131.s1.e2	Relation_Trigger	associated 	3
miRNA-corp.d131.s2	microRNAs in gliomas: small regulators of a big problem.   	miRNA-corp.d131.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d131.s2	microRNAs in gliomas: small regulators of a big problem.   	miRNA-corp.d131.s2.e1	Diseases	gliomas 	2
miRNA-corp.d131.s2	microRNAs in gliomas: small regulators of a big problem.   	miRNA-corp.d131.s2.e2	Relation_Trigger	regulators 	3
miRNA-corp.d131.s3	This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.    	miRNA-corp.d131.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d131.s3	This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.    	miRNA-corp.d131.s3.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d131.s3	This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.    	miRNA-corp.d131.s3.e2	Diseases	glioma 	3
miRNA-corp.d131.s3	This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.    	miRNA-corp.d131.s3.e3	Diseases	glioma 	4
miRNA-corp.d131.s3	This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.    	miRNA-corp.d131.s3.e4	Species	patients 	5
miRNA-corp.d131.s4	Here we review the current state of knowledge related to the role of microRNAs in glial tumor development.  	miRNA-corp.d131.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d131.s4	Here we review the current state of knowledge related to the role of microRNAs in glial tumor development.  	miRNA-corp.d131.s4.e1	Diseases	glial tumor 	2
miRNA-corp.d131.s5	It is now evident that microRNAs regulate a wide variety of tumorigenic processes including cellular proliferation, differentiation, angiogenesis, invasion, and apoptosis.  	miRNA-corp.d131.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d131.s5	It is now evident that microRNAs regulate a wide variety of tumorigenic processes including cellular proliferation, differentiation, angiogenesis, invasion, and apoptosis.  	miRNA-corp.d131.s5.e1	Relation_Trigger	regulate 	2
miRNA-corp.d131.s6	This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years.  	miRNA-corp.d131.s6.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d131.s6	This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years.  	miRNA-corp.d131.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d131.s6	This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years.  	miRNA-corp.d131.s6.e2	Relation_Trigger	aberrant miRNA expression 	3
miRNA-corp.d131.s6	This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years.  	miRNA-corp.d131.s6.e3	Diseases	cancer 	4
miRNA-corp.d131.s6	This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years.  	miRNA-corp.d131.s6.e4	Species	human 	5
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e0	Specific_miRNAs	miR-93 	1
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e1	Genes/Proteins	MICA 	2
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e5	Relation_Trigger	decreased expression 	6
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e6	Relation_Trigger	target 	7
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e7	Specific_miRNAs	miR-17-5 	8
miRNA-corp.d132.s0	Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression.  	miRNA-corp.d132.s0.e8	Specific_miRNAs	miR-20a 	9
miRNA-corp.d132.s1	However, it was not sufficient for surface protein expression, which was controlled posttranscriptionally via a separate pathway involving the ataxia telangiectasia mutated/ataxia telangiectasia and Rad3 related kinases.  	miRNA-corp.d132.s1.e0	Genes/Proteins	ataxia telangiectasia mutated 	1
miRNA-corp.d132.s1	However, it was not sufficient for surface protein expression, which was controlled posttranscriptionally via a separate pathway involving the ataxia telangiectasia mutated/ataxia telangiectasia and Rad3 related kinases.  	miRNA-corp.d132.s1.e1	Genes/Proteins	ataxia telangiectasia and Rad3 related 	2
miRNA-corp.d132.s2	Thus, TLR stimulation allows expression of NKG2D ligands through multiple pathways, including downmodulation of specific miRNAs.    	miRNA-corp.d132.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d132.s2	Thus, TLR stimulation allows expression of NKG2D ligands through multiple pathways, including downmodulation of specific miRNAs.    	miRNA-corp.d132.s2.e1	Relation_Trigger	downmodulation 	2
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e0	Genes/Proteins	TLR-4 	1
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e1	Genes/Proteins	TLR-3 	2
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e2	Genes/Proteins	MICA 	3
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e3	Genes/Proteins	MICB 	4
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e4	Genes/Proteins	TLR-7/8 	5
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e5	Genes/Proteins	CL097 	6
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e6	Genes/Proteins	MICB 	7
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e7	Genes/Proteins	MICA 	8
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e8	Relation_Trigger	upregulated 	9
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e9	Relation_Trigger	upregulated 	10
miRNA-corp.d132.s3	In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither.  	miRNA-corp.d132.s3.e10	Relation_Trigger	upregulated 	11
miRNA-corp.d132.s4	However, NKG2D ligands can also be induced on human macrophages by TLR stimulation, which has been far less studied.  	miRNA-corp.d132.s4.e0	Species	human 	1
miRNA-corp.d132.s5	This finding suggests that increased levels of MICA mRNA following LPS stimulation resulted from increased transcription.  	miRNA-corp.d132.s5.e0	Genes/Proteins	MICA 	1
miRNA-corp.d132.s5	This finding suggests that increased levels of MICA mRNA following LPS stimulation resulted from increased transcription.  	miRNA-corp.d132.s5.e1	Relation_Trigger	increased levels 	2
miRNA-corp.d132.s6	To probe how LPS stimulation triggers MICA expression, we determined that the stability of MICA mRNA was much longer than that of MICB mRNA, but neither was changed by LPS stimulation.  	miRNA-corp.d132.s6.e0	Genes/Proteins	MICA 	1
miRNA-corp.d132.s6	To probe how LPS stimulation triggers MICA expression, we determined that the stability of MICA mRNA was much longer than that of MICB mRNA, but neither was changed by LPS stimulation.  	miRNA-corp.d132.s6.e1	Genes/Proteins	MICB 	2
miRNA-corp.d132.s6	To probe how LPS stimulation triggers MICA expression, we determined that the stability of MICA mRNA was much longer than that of MICB mRNA, but neither was changed by LPS stimulation.  	miRNA-corp.d132.s6.e2	Genes/Proteins	MICA 	3
miRNA-corp.d132.s7	Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk.   	miRNA-corp.d132.s7.e0	Genes/Proteins	TLR-4 	1
miRNA-corp.d132.s8	This establishes recognition of "induced self" as an important strategy for surveillance of infections or tumor transformation.  	miRNA-corp.d132.s8.e0	Diseases	infections 	1
miRNA-corp.d132.s8	This establishes recognition of "induced self" as an important strategy for surveillance of infections or tumor transformation.  	miRNA-corp.d132.s8.e1	Diseases	tumor 	2
miRNA-corp.d132.s9	The activating receptor NKG2D recognizes proteins that are not normally expressed at the surface of most cells but are expressed during a cellular "stress" response (e.g., upon induction of the DNA damage pathway).  	miRNA-corp.d132.s9.e0	Genes/Proteins	NKG2D 	1
miRNA-corp.d132.s9	The activating receptor NKG2D recognizes proteins that are not normally expressed at the surface of most cells but are expressed during a cellular "stress" response (e.g., upon induction of the DNA damage pathway).  	miRNA-corp.d132.s9.e1	Relation_Trigger	activating 	2
miRNA-corp.d132.s9	The activating receptor NKG2D recognizes proteins that are not normally expressed at the surface of most cells but are expressed during a cellular "stress" response (e.g., upon induction of the DNA damage pathway).  	miRNA-corp.d132.s9.e2	Diseases	DNA damage 	3
miRNA-corp.d133.s0	MicroRNA in Situ Hybridization in the Human Entorhinal and Transentorhinal Cortex.   	miRNA-corp.d133.s0.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d133.s0	MicroRNA in Situ Hybridization in the Human Entorhinal and Transentorhinal Cortex.   	miRNA-corp.d133.s0.e1	Species	Human 	2
miRNA-corp.d133.s1	MicroRNAs (miRNAs) play key roles in gene expression regulation in both healthy and disease brains.  	miRNA-corp.d133.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d133.s1	MicroRNAs (miRNAs) play key roles in gene expression regulation in both healthy and disease brains.  	miRNA-corp.d133.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d133.s1	MicroRNAs (miRNAs) play key roles in gene expression regulation in both healthy and disease brains.  	miRNA-corp.d133.s1.e2	Relation_Trigger	expression regulation 	3
miRNA-corp.d133.s2	To better understand those roles, it is necessary to characterize the miRNAs that are expressed in particular cell types under a range of conditions.  	miRNA-corp.d133.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d133.s3	In situ hybridization (ISH) can demonstrate cell- and lamina-specific patterns of miRNA expression that would be lost in tissue-level expression profiling.  	miRNA-corp.d133.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d133.s4	In the present study, ISH was performed with special focus on the human entorhinal cortex (EC) and transentorhinal cortex (TEC).  	miRNA-corp.d133.s4.e0	Species	human 	1
miRNA-corp.d133.s5	The TEC is the area of the cerebral cortex that first develops neurofibrillary tangles in Alzheimer's disease (AD).  	miRNA-corp.d133.s5.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d133.s5	The TEC is the area of the cerebral cortex that first develops neurofibrillary tangles in Alzheimer's disease (AD).  	miRNA-corp.d133.s5.e1	Diseases	AD 	2
miRNA-corp.d133.s6	However, the reason for TEC's special vulnerability to AD-type pathology is unknown.  	miRNA-corp.d133.s6.e0	Diseases	AD 	1
miRNA-corp.d133.s7	MiRNA ISH was performed on three human brains with well-characterized clinical and pathological parameters.  	miRNA-corp.d133.s7.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d133.s7	MiRNA ISH was performed on three human brains with well-characterized clinical and pathological parameters.  	miRNA-corp.d133.s7.e1	Species	human 	2
miRNA-corp.d133.s8	Locked nucleic acid ISH probes were used referent to miR-107, miR-124, miR-125b, and miR-320.  	miRNA-corp.d133.s8.e0	Specific_miRNAs	miR-107 	1
miRNA-corp.d133.s8	Locked nucleic acid ISH probes were used referent to miR-107, miR-124, miR-125b, and miR-320.  	miRNA-corp.d133.s8.e1	Specific_miRNAs	miR-124 	2
miRNA-corp.d133.s8	Locked nucleic acid ISH probes were used referent to miR-107, miR-124, miR-125b, and miR-320.  	miRNA-corp.d133.s8.e2	Specific_miRNAs	miR-125b 	3
miRNA-corp.d133.s8	Locked nucleic acid ISH probes were used referent to miR-107, miR-124, miR-125b, and miR-320.  	miRNA-corp.d133.s8.e3	Specific_miRNAs	miR-320 	4
miRNA-corp.d133.s9	In order to correlate the ISH data with AD pathology, the ISH staining was compared with near-adjacent slides processed using Thioflavine stains.  	miRNA-corp.d133.s9.e0	Diseases	AD 	1
miRNA-corp.d133.s9	In order to correlate the ISH data with AD pathology, the ISH staining was compared with near-adjacent slides processed using Thioflavine stains.  	miRNA-corp.d133.s9.e1	Relation_Trigger	correlate 	2
miRNA-corp.d133.s10	MiRNA ISH is among the first methods to show special staining characteristics of cells and laminae of the human TEC.    	miRNA-corp.d133.s10.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d133.s10	MiRNA ISH is among the first methods to show special staining characteristics of cells and laminae of the human TEC.    	miRNA-corp.d133.s10.e1	Species	human 	2
miRNA-corp.d133.s11	As with other areas of brain, the TEC and EC have characteristic miRNA expression patterns.  	miRNA-corp.d133.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d133.s12	Not all neurons or cortical lamina stain with equal intensity for individual miRNAs.  	miRNA-corp.d133.s12.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d134.s0	Our in vitro results suggested that Aβ42 oligomer-induced miR-106b leads to impairment in TGF-β signaling through TβR II, concomitant with retinoic acid-induced neurodegeneration in SH-SY5Y cells.  	miRNA-corp.d134.s0.e0	Genes/Proteins	TβR II 	1
miRNA-corp.d134.s0	Our in vitro results suggested that Aβ42 oligomer-induced miR-106b leads to impairment in TGF-β signaling through TβR II, concomitant with retinoic acid-induced neurodegeneration in SH-SY5Y cells.  	miRNA-corp.d134.s0.e1	Specific_miRNAs	miR-106b 	2
miRNA-corp.d134.s0	Our in vitro results suggested that Aβ42 oligomer-induced miR-106b leads to impairment in TGF-β signaling through TβR II, concomitant with retinoic acid-induced neurodegeneration in SH-SY5Y cells.  	miRNA-corp.d134.s0.e2	Relation_Trigger	impairment 	3
miRNA-corp.d134.s0	Our in vitro results suggested that Aβ42 oligomer-induced miR-106b leads to impairment in TGF-β signaling through TβR II, concomitant with retinoic acid-induced neurodegeneration in SH-SY5Y cells.  	miRNA-corp.d134.s0.e3	Genes/Proteins	TGF-β 	4
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e0	Genes/Proteins	TβR II 	1
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e1	Specific_miRNAs	miR-106b 	2
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e2	Specific_miRNAs	miR-106b 	3
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e3	Diseases	AD 	4
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e4	Relation_Trigger	functional target 	5
miRNA-corp.d134.s1	These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.    	miRNA-corp.d134.s1.e5	Genes/Proteins	TGF-β 	6
miRNA-corp.d134.s2	MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD).  	miRNA-corp.d134.s2.e0	Diseases	Alzheimer's diseases 	1
miRNA-corp.d134.s2	MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD).  	miRNA-corp.d134.s2.e1	Diseases	AD 	2
miRNA-corp.d134.s2	MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD).  	miRNA-corp.d134.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d134.s2	MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD).  	miRNA-corp.d134.s2.e3	Non-Specific_miRNAs	MicroRNAs 	4
miRNA-corp.d134.s2	MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD).  	miRNA-corp.d134.s2.e3	Relation_Trigger	abundantly expressed 	5
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e0	Specific_miRNAs	miR-106b 	1
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e2	Genes/Proteins	TGF-β type II receptor 	3
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e3	Relation_Trigger	aberrantly expressed 	4
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e4	Relation_Trigger	targets 	5
miRNA-corp.d134.s3	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.   	miRNA-corp.d134.s3.e5	Species	transgenic mouse 	6
miRNA-corp.d134.s4	However, it is unclear whether miRNAs involved in AD pathogenesis by regulating TGF-β signaling.  	miRNA-corp.d134.s4.e0	Diseases	AD 	1
miRNA-corp.d134.s4	However, it is unclear whether miRNAs involved in AD pathogenesis by regulating TGF-β signaling.  	miRNA-corp.d134.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d134.s4	However, it is unclear whether miRNAs involved in AD pathogenesis by regulating TGF-β signaling.  	miRNA-corp.d134.s4.e2	Relation_Trigger	regulating 	3
miRNA-corp.d134.s4	However, it is unclear whether miRNAs involved in AD pathogenesis by regulating TGF-β signaling.  	miRNA-corp.d134.s4.e3	Genes/Proteins	TGF-β 	4
miRNA-corp.d134.s5	Growing body of evidence suggests that the TGF-β signaling pathway plays a key role in the pathogenesis of AD.  	miRNA-corp.d134.s5.e0	Diseases	AD 	1
miRNA-corp.d134.s5	Growing body of evidence suggests that the TGF-β signaling pathway plays a key role in the pathogenesis of AD.  	miRNA-corp.d134.s5.e1	Genes/Proteins	TGF-β 	2
miRNA-corp.d134.s6	Sequence analysis revealed two putative binding sites for miR-106b in the 3' UTR of the TβR II mRNA.  	miRNA-corp.d134.s6.e0	Genes/Proteins	TβR II 	1
miRNA-corp.d134.s6	Sequence analysis revealed two putative binding sites for miR-106b in the 3' UTR of the TβR II mRNA.  	miRNA-corp.d134.s6.e1	Specific_miRNAs	miR-106b 	2
miRNA-corp.d134.s6	Sequence analysis revealed two putative binding sites for miR-106b in the 3' UTR of the TβR II mRNA.  	miRNA-corp.d134.s6.e2	Relation_Trigger	binding sites 	3
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e0	Genes/Proteins	TGF-β type II receptor 	1
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e1	Genes/Proteins	TβR II 	2
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e2	Specific_miRNAs	miR-106b 	3
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e3	Diseases	AD 	4
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e4	Relation_Trigger	aberrantly expressed 	5
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e5	Species	transgenic mouse 	6
miRNA-corp.d134.s7	Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD).  	miRNA-corp.d134.s7.e6	Species	mice 	7
miRNA-corp.d134.s8	After induced neurodifferentiation with all-trans retinoic acid, we observed significant neurodegeneration in SH-SY5Y cells stably transfected with miR-106b.  	miRNA-corp.d134.s8.e0	Specific_miRNAs	miR-106b 	1
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e0	Genes/Proteins	TβR II 	1
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e1	Genes/Proteins	TβR II 	2
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e2	Specific_miRNAs	miR-106b 	3
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e3	Specific_miRNAs	miR-106b 	4
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e4	Relation_Trigger	inversely correlated 	5
miRNA-corp.d134.s9	Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro.  	miRNA-corp.d134.s9.e5	Relation_Trigger	inhibit the TβR II translation 	6
miRNA-corp.d134.s10	Exposure of SH-SY5Y cells to Aβ42 oligomers led to the expression of miR-106b was first increased and then decreased and TβR II levels reduced.  	miRNA-corp.d134.s10.e0	Specific_miRNAs	miR-106b 	1
miRNA-corp.d134.s10	Exposure of SH-SY5Y cells to Aβ42 oligomers led to the expression of miR-106b was first increased and then decreased and TβR II levels reduced.  	miRNA-corp.d134.s10.e1	Genes/Proteins	TβR II 	2
miRNA-corp.d134.s10	Exposure of SH-SY5Y cells to Aβ42 oligomers led to the expression of miR-106b was first increased and then decreased and TβR II levels reduced.  	miRNA-corp.d134.s10.e2	Relation_Trigger	levels reduced 	3
miRNA-corp.d134.s10	Exposure of SH-SY5Y cells to Aβ42 oligomers led to the expression of miR-106b was first increased and then decreased and TβR II levels reduced.  	miRNA-corp.d134.s10.e3	Relation_Trigger	expression of miR-106b was first increased 	4
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e0	Genes/Proteins	phospho-Smad2/3 	1
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e1	Genes/Proteins	p-Smad2/3 	2
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e2	Genes/Proteins	Smad2/3 	3
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e3	Genes/Proteins	Smad6/7 	4
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e4	Specific_miRNAs	miR-106b 	5
miRNA-corp.d134.s11	Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.  	miRNA-corp.d134.s11.e5	Relation_Trigger	increased Smad6/7 protein levels 	6
miRNA-corp.d135.s0	Nuclear factor TDP-43 can affect selected microRNA levels.   	miRNA-corp.d135.s0.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s0	Nuclear factor TDP-43 can affect selected microRNA levels.   	miRNA-corp.d135.s0.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d135.s0	Nuclear factor TDP-43 can affect selected microRNA levels.   	miRNA-corp.d135.s0.e2	Relation_Trigger	affect selected microRNA levels 	3
miRNA-corp.d135.s1	TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis.  	miRNA-corp.d135.s1.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s1	TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis.  	miRNA-corp.d135.s1.e1	Diseases	amyotrophic lateral sclerosis 	2
miRNA-corp.d135.s1	TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis.  	miRNA-corp.d135.s1.e2	Diseases	frontotemporal lobar degeneration 	3
miRNA-corp.d135.s1	TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis.  	miRNA-corp.d135.s1.e3	Diseases	neurodegenerative diseases 	4
miRNA-corp.d135.s1	TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis.  	miRNA-corp.d135.s1.e4	Species	patients 	5
miRNA-corp.d135.s2	Apart from its involvement in transcription, splicing and mRNA stability, TDP-43 has also been described as a Drosha-associated protein.  	miRNA-corp.d135.s2.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s2	Apart from its involvement in transcription, splicing and mRNA stability, TDP-43 has also been described as a Drosha-associated protein.  	miRNA-corp.d135.s2.e1	Genes/Proteins	Drosha 	2
miRNA-corp.d135.s3	TDP-43 is a ubiquitous protein whose specific functions are probably crucial to establishing its pathogenic role.  	miRNA-corp.d135.s3.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s4	Here we report for the first time which changes occur in the total miRNA population following TDP-43 knockdown in culture cells.  	miRNA-corp.d135.s4.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s4	Here we report for the first time which changes occur in the total miRNA population following TDP-43 knockdown in culture cells.  	miRNA-corp.d135.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d135.s5	However, our knowledge of the role of TDP-43 in the microRNA (miRNA) synthesis pathway is limited to the association mentioned above.  	miRNA-corp.d135.s5.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s5	However, our knowledge of the role of TDP-43 in the microRNA (miRNA) synthesis pathway is limited to the association mentioned above.  	miRNA-corp.d135.s5.e1	Relation_Trigger	association 	2
miRNA-corp.d135.s5	However, our knowledge of the role of TDP-43 in the microRNA (miRNA) synthesis pathway is limited to the association mentioned above.  	miRNA-corp.d135.s5.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d135.s5	However, our knowledge of the role of TDP-43 in the microRNA (miRNA) synthesis pathway is limited to the association mentioned above.  	miRNA-corp.d135.s5.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e0	Specific_miRNAs	miR-663 	1
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e1	Genes/Proteins	TDP-43 	2
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e4	Specific_miRNAs	let-7b 	5
miRNA-corp.d135.s6	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).  	miRNA-corp.d135.s6.e5	Relation_Trigger	binding 	6
miRNA-corp.d135.s7	In particular, we have observed that let-7b and miR-663 expression levels are down- and upregulated, respectively.  	miRNA-corp.d135.s7.e0	Specific_miRNAs	let-7b 	1
miRNA-corp.d135.s7	In particular, we have observed that let-7b and miR-663 expression levels are down- and upregulated, respectively.  	miRNA-corp.d135.s7.e1	Specific_miRNAs	miR-663 	2
miRNA-corp.d135.s7	In particular, we have observed that let-7b and miR-663 expression levels are down- and upregulated, respectively.  	miRNA-corp.d135.s7.e2	Relation_Trigger	levels are down- and upregulated 	3
miRNA-corp.d135.s8	Using microarray data and real-time PCR we have also identified several candidate transcripts whose expression levels are selectively affected by these TDP-43-miRNA interactions.    	miRNA-corp.d135.s8.e0	Genes/Proteins	TDP-43 	1
miRNA-corp.d135.s8	Using microarray data and real-time PCR we have also identified several candidate transcripts whose expression levels are selectively affected by these TDP-43-miRNA interactions.    	miRNA-corp.d135.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d135.s8	Using microarray data and real-time PCR we have also identified several candidate transcripts whose expression levels are selectively affected by these TDP-43-miRNA interactions.    	miRNA-corp.d135.s8.e2	Relation_Trigger	expression levels are selectively affected 	3
miRNA-corp.d136.s0	Altered microRNA expression following traumatic spinal cord injury.   	miRNA-corp.d136.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d136.s0	Altered microRNA expression following traumatic spinal cord injury.   	miRNA-corp.d136.s0.e1	Diseases	traumatic spinal cord injury 	2
miRNA-corp.d136.s0	Altered microRNA expression following traumatic spinal cord injury.   	miRNA-corp.d136.s0.e2	Relation_Trigger	Altered microRNA expression 	3
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e1	Non-Specific_miRNAs	MicroRNAs 	2
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e2	Relation_Trigger	target 	3
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e3	Relation_Trigger	translational inhibition 	4
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e4	Relation_Trigger	regulate gene expression 	5
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e5	Relation_Trigger	binding 	6
miRNA-corp.d136.s1	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation.  	miRNA-corp.d136.s1.e6	Relation_Trigger	negatively regulate 	7
miRNA-corp.d136.s2	We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis.  	miRNA-corp.d136.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d136.s2	We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis.  	miRNA-corp.d136.s2.e1	Diseases	spinal cord injury 	2
miRNA-corp.d136.s2	We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis.  	miRNA-corp.d136.s2.e2	Diseases	SCI 	3
miRNA-corp.d136.s2	We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis.  	miRNA-corp.d136.s2.e3	Relation_Trigger	alteration in temporal expression 	4
miRNA-corp.d136.s2	We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis.  	miRNA-corp.d136.s2.e4	Species	rats 	5
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e1	Diseases	SCI 	2
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e2	Relation_Trigger	up-regulation 	3
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e3	Relation_Trigger	down-regulation 	4
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e4	Relation_Trigger	up-regulation 	5
miRNA-corp.d136.s3	These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI.  	miRNA-corp.d136.s3.e5	Relation_Trigger	down-regulation 	6
miRNA-corp.d136.s4	The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI.  	miRNA-corp.d136.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d136.s4	The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI.  	miRNA-corp.d136.s4.e1	Diseases	SCI 	2
miRNA-corp.d136.s4	The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI.  	miRNA-corp.d136.s4.e2	Diseases	SCI 	3
miRNA-corp.d136.s4	The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI.  	miRNA-corp.d136.s4.e3	Relation_Trigger	potential targets 	4
miRNA-corp.d136.s4	The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI.  	miRNA-corp.d136.s4.e4	Diseases	inflammation 	5
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e1	Diseases	SCI 	2
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e2	Diseases	SCI 	3
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e3	Relation_Trigger	abnormal expression 	4
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e4	Relation_Trigger	potential targets 	5
miRNA-corp.d136.s5	These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.    	miRNA-corp.d136.s5.e5	Relation_Trigger	targets for therapeutic 	6
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e0	Diseases	systemic autoimmune diseases 	1
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e1	Diseases	Behcet's disease 	2
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e2	Diseases	BD 	3
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e3	Diseases	Sjoegren's syndrome 	4
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e4	Diseases	SS 	5
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e5	Diseases	systemic sclerosis 	6
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e6	Diseases	SSc 	7
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e7	Relation_Trigger	impairment 	8
miRNA-corp.d137.s0	Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases.  	miRNA-corp.d137.s0.e8	Diseases	systemic lupus erythematosus 	9
miRNA-corp.d137.s1	An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem.  	miRNA-corp.d137.s1.e0	Diseases	nervous impairment 	1
miRNA-corp.d137.s1	An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem.  	miRNA-corp.d137.s1.e1	Diseases	MS 	2
miRNA-corp.d137.s1	An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem.  	miRNA-corp.d137.s1.e2	Relation_Trigger	impairment 	3
miRNA-corp.d137.s1	An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem.  	miRNA-corp.d137.s1.e3	Diseases	connective tissue disease 	4
miRNA-corp.d137.s1	An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem.  	miRNA-corp.d137.s1.e4	Diseases	neurological syndrome 	5
miRNA-corp.d137.s2	Although the white matter abnormalities seen by magnetic resonance imaging may be similar in non-MS autoimmune demyelination and MS, it is the most important diagnostic tool in the differential diagnosis of the mentioned conditions.  	miRNA-corp.d137.s2.e0	Diseases	MS 	1
miRNA-corp.d137.s3	Investigating the presence of various autoantibodies potentially involved in the pathogenesis of demyelinating lesions as well as cerebrospinal fluid (CSF) analysis can be helpful.    	miRNA-corp.d137.s3.e0	Diseases	demyelinating lesions 	1
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e0	Diseases	multiple sclerosis 	1
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e1	Diseases	MS 	2
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e2	Diseases	demyelination 	3
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e3	Diseases	Connective tissue diseases 	4
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e4	Diseases	optic neuritis 	5
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e5	Diseases	transverse myelitis 	6
miRNA-corp.d137.s5	Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis.  	miRNA-corp.d137.s5.e6	Species	patients 	7
miRNA-corp.d138.s0	Targeting miRNAs in Alzheimer's disease.      	miRNA-corp.d138.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d138.s0	Targeting miRNAs in Alzheimer's disease.      	miRNA-corp.d138.s0.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d138.s0	Targeting miRNAs in Alzheimer's disease.      	miRNA-corp.d138.s0.e2	Relation_Trigger	Targeting 	3
miRNA-corp.d139.s0	CONCLUSIONS: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.    	miRNA-corp.d139.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d139.s0	CONCLUSIONS: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.    	miRNA-corp.d139.s0.e1	Diseases	tissue injury 	2
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e0	Specific_miRNAs	miR-124 	1
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e1	Specific_miRNAs	miR-133a 	2
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e2	Specific_miRNAs	miR-122 	3
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e3	Diseases	brain injury 	4
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e4	Relation_Trigger	concentrations remained at baseline values 	5
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e5	Relation_Trigger	concentration increased 	6
miRNA-corp.d139.s1	The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values.  	miRNA-corp.d139.s1.e6	Species	rats 	7
miRNA-corp.d139.s2	Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathologic results.  	miRNA-corp.d139.s2.e0	Specific_miRNAs	miR-122 	1
miRNA-corp.d139.s2	Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathologic results.  	miRNA-corp.d139.s2.e1	Relation_Trigger	correlated 	2
miRNA-corp.d139.s3	Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.   	miRNA-corp.d139.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d139.s3	Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.   	miRNA-corp.d139.s3.e1	Diseases	tissue injury 	2
miRNA-corp.d139.s4	BACKGROUND: MicroRNAs (miRNAs) are endogenous, small noncoding RNAs.  	miRNA-corp.d139.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d139.s4	BACKGROUND: MicroRNAs (miRNAs) are endogenous, small noncoding RNAs.  	miRNA-corp.d139.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d139.s5	Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury.  	miRNA-corp.d139.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d139.s5	Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury.  	miRNA-corp.d139.s5.e1	Diseases	tissue injury 	2
miRNA-corp.d139.s6	METHODS: We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury.  	miRNA-corp.d139.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d139.s6	METHODS: We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury.  	miRNA-corp.d139.s6.e1	Diseases	tissue injury 	2
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e0	Specific_miRNAs	miR-122 	1
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e1	Specific_miRNAs	miR-133a 	2
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e2	Specific_miRNAs	miR-124 	3
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e3	Diseases	stroke 	4
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e5	Species	rats 	6
miRNA-corp.d139.s7	We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  	miRNA-corp.d139.s7.e6	Species	rat 	7
miRNA-corp.d139.s8	RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively.  	miRNA-corp.d139.s8.e0	Specific_miRNAs	miR-122 	1
miRNA-corp.d139.s8	RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively.  	miRNA-corp.d139.s8.e1	Specific_miRNAs	miR-133a 	2
miRNA-corp.d139.s8	RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively.  	miRNA-corp.d139.s8.e2	Specific_miRNAs	miR-124 	3
miRNA-corp.d139.s8	RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively.  	miRNA-corp.d139.s8.e3	Diseases	injuries in liver 	4
miRNA-corp.d139.s8	RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively.  	miRNA-corp.d139.s8.e4	Relation_Trigger	increases in plasma concentrations 	5
miRNA-corp.d139.s9	miR-122 and miR-133a illustrated specificity for liver and muscle toxicity, respectively, because they were not detectable in the plasma of animals with toxicity to the other organ.  	miRNA-corp.d139.s9.e0	Specific_miRNAs	miR-122 	1
miRNA-corp.d139.s9	miR-122 and miR-133a illustrated specificity for liver and muscle toxicity, respectively, because they were not detectable in the plasma of animals with toxicity to the other organ.  	miRNA-corp.d139.s9.e1	Specific_miRNAs	miR-133a 	2
miRNA-corp.d139.s10	This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity.  	miRNA-corp.d139.s10.e0	Genes/Proteins	alanine aminotransferase 	1
miRNA-corp.d139.s10	This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity.  	miRNA-corp.d139.s10.e1	Genes/Proteins	aspartate aminotransferase 	2
miRNA-corp.d140.s0	Atrial fibrillation (AF) is an emerging clinical problem with multifaceted issues: current and expected prevalence, significant morbidity, potentially fatal outcome (e.g., stroke) and gaps in therapeutic approaches.  	miRNA-corp.d140.s0.e0	Diseases	Atrial fibrillation 	1
miRNA-corp.d140.s0	Atrial fibrillation (AF) is an emerging clinical problem with multifaceted issues: current and expected prevalence, significant morbidity, potentially fatal outcome (e.g., stroke) and gaps in therapeutic approaches.  	miRNA-corp.d140.s0.e1	Diseases	AF 	2
miRNA-corp.d140.s0	Atrial fibrillation (AF) is an emerging clinical problem with multifaceted issues: current and expected prevalence, significant morbidity, potentially fatal outcome (e.g., stroke) and gaps in therapeutic approaches.  	miRNA-corp.d140.s0.e2	Diseases	stroke 	3
miRNA-corp.d140.s1	Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.   	miRNA-corp.d140.s1.e0	Relation_Trigger	Targeting 	1
miRNA-corp.d140.s1	Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.   	miRNA-corp.d140.s1.e1	Diseases	atrial fibrillation 	2
miRNA-corp.d140.s3	Current anti-arrhythmic strategies not only fail to guarantee effective rhythm control, but also cause "on target" (i.e., pro-arrhythmia, namely torsade de pointes) and "off target" (i.e., extra-cardiac toxicities) side effects.  	miRNA-corp.d140.s3.e0	Diseases	arrhythmia 	1
miRNA-corp.d140.s3	Current anti-arrhythmic strategies not only fail to guarantee effective rhythm control, but also cause "on target" (i.e., pro-arrhythmia, namely torsade de pointes) and "off target" (i.e., extra-cardiac toxicities) side effects.  	miRNA-corp.d140.s3.e1	Relation_Trigger	target 	2
miRNA-corp.d140.s3	Current anti-arrhythmic strategies not only fail to guarantee effective rhythm control, but also cause "on target" (i.e., pro-arrhythmia, namely torsade de pointes) and "off target" (i.e., extra-cardiac toxicities) side effects.  	miRNA-corp.d140.s3.e2	Relation_Trigger	target 	3
miRNA-corp.d140.s3	Current anti-arrhythmic strategies not only fail to guarantee effective rhythm control, but also cause "on target" (i.e., pro-arrhythmia, namely torsade de pointes) and "off target" (i.e., extra-cardiac toxicities) side effects.  	miRNA-corp.d140.s3.e3	Diseases	torsade de pointes 	4
miRNA-corp.d140.s4	Fascinating and innovative strategies have been proposed (e.g., miRNAs modulation), but the actual benefit is debated.  	miRNA-corp.d140.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d140.s4	Fascinating and innovative strategies have been proposed (e.g., miRNAs modulation), but the actual benefit is debated.  	miRNA-corp.d140.s4.e1	Relation_Trigger	modulation 	2
miRNA-corp.d140.s5	This review will provide mechanistic insights into structural remodeling and highlight emerging upstream strategies in AF management.    	miRNA-corp.d140.s5.e0	Diseases	AF 	1
miRNA-corp.d140.s6	A body of evidence has emerged supporting structural remodeling as the main arrhythmogenic substrate perpetuating AF. Fibrosis, inflammation and oxidative stress appear strongly interconnected in the pathogenesis of remodeling-induced abnormalities.  	miRNA-corp.d140.s6.e0	Diseases	AF 	1
miRNA-corp.d140.s6	A body of evidence has emerged supporting structural remodeling as the main arrhythmogenic substrate perpetuating AF. Fibrosis, inflammation and oxidative stress appear strongly interconnected in the pathogenesis of remodeling-induced abnormalities.  	miRNA-corp.d140.s6.e1	Diseases	Fibrosis 	2
miRNA-corp.d140.s6	A body of evidence has emerged supporting structural remodeling as the main arrhythmogenic substrate perpetuating AF. Fibrosis, inflammation and oxidative stress appear strongly interconnected in the pathogenesis of remodeling-induced abnormalities.  	miRNA-corp.d140.s6.e2	Diseases	inflammation 	3
miRNA-corp.d140.s8	Therefore, pharmacological modulation of non-ionic targets (the so called "upstream" therapy) has gained interest as a preventive strategy in AF.  	miRNA-corp.d140.s8.e0	Diseases	AF 	1
miRNA-corp.d140.s8	Therefore, pharmacological modulation of non-ionic targets (the so called "upstream" therapy) has gained interest as a preventive strategy in AF.  	miRNA-corp.d140.s8.e1	Relation_Trigger	modulation 	2
miRNA-corp.d140.s8	Therefore, pharmacological modulation of non-ionic targets (the so called "upstream" therapy) has gained interest as a preventive strategy in AF.  	miRNA-corp.d140.s8.e2	Relation_Trigger	targets 	3
miRNA-corp.d140.s9	At the present state of knowledge, renin-angiotensin-aldosterone system blockers and statins offer evidence for potential clinical exploitation, while several remodeling-targeted therapies have been tested only experimentally or failed when studied for human validation.  	miRNA-corp.d140.s9.e0	Genes/Proteins	angiotensin 	1
miRNA-corp.d140.s9	At the present state of knowledge, renin-angiotensin-aldosterone system blockers and statins offer evidence for potential clinical exploitation, while several remodeling-targeted therapies have been tested only experimentally or failed when studied for human validation.  	miRNA-corp.d140.s9.e1	Genes/Proteins	renin 	2
miRNA-corp.d140.s9	At the present state of knowledge, renin-angiotensin-aldosterone system blockers and statins offer evidence for potential clinical exploitation, while several remodeling-targeted therapies have been tested only experimentally or failed when studied for human validation.  	miRNA-corp.d140.s9.e2	Species	human 	3
miRNA-corp.d141.s0	Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence.  	miRNA-corp.d141.s0.e0	Relation_Trigger	alterations in gene expression 	1
miRNA-corp.d141.s0	Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence.  	miRNA-corp.d141.s0.e1	Relation_Trigger	expression without changes 	2
miRNA-corp.d141.s1	Epigenetic changes in gliomas.   	miRNA-corp.d141.s1.e0	Diseases	gliomas 	1
miRNA-corp.d141.s2	In this review, we will first describe briefly histone modifications, DNA methylation and miRNAs and the functions of these epigenetic marks during different cellular processes involving DNA metabolism.  	miRNA-corp.d141.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d141.s3	While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells.  	miRNA-corp.d141.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d141.s3	While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells.  	miRNA-corp.d141.s3.e1	Relation_Trigger	regulate gene expression 	2
miRNA-corp.d141.s3	While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells.  	miRNA-corp.d141.s3.e2	Diseases	cancer 	3
miRNA-corp.d141.s5	We will then highlight some epigenetic changes in glioblastomas, a malignant form of brain tumor, and potential application of epigenetic means for diagnosis, prognosis, and treatment of gliomas.  	miRNA-corp.d141.s5.e0	Diseases	gliomas 	1
miRNA-corp.d141.s5	We will then highlight some epigenetic changes in glioblastomas, a malignant form of brain tumor, and potential application of epigenetic means for diagnosis, prognosis, and treatment of gliomas.  	miRNA-corp.d141.s5.e1	Diseases	glioblastomas 	2
miRNA-corp.d141.s5	We will then highlight some epigenetic changes in glioblastomas, a malignant form of brain tumor, and potential application of epigenetic means for diagnosis, prognosis, and treatment of gliomas.  	miRNA-corp.d141.s5.e2	Diseases	brain tumor 	3
miRNA-corp.d142.s0	Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases.   	miRNA-corp.d142.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d142.s0	Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases.   	miRNA-corp.d142.s0.e1	Diseases	Alzheimer's 	2
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e2	Genes/Proteins	ribonuclease III Dicer 	3
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e3	Relation_Trigger	regulate up 	4
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e4	Species	humans 	5
miRNA-corp.d142.s1	Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body!  	miRNA-corp.d142.s1.e5	Species	human 	6
miRNA-corp.d142.s2	Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying age-related diseases affecting major organs, such as the brain.  	miRNA-corp.d142.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d142.s2	Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying age-related diseases affecting major organs, such as the brain.  	miRNA-corp.d142.s2.e1	Relation_Trigger	regulation of gene expression 	2
miRNA-corp.d142.s3	Here, we discuss some of the limitations associated to the interpretation and applicability of miRNA data, based on our recent study on the etiology of Alzheimer's disease (AD).  	miRNA-corp.d142.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d142.s3	Here, we discuss some of the limitations associated to the interpretation and applicability of miRNA data, based on our recent study on the etiology of Alzheimer's disease (AD).  	miRNA-corp.d142.s3.e1	Relation_Trigger	associated 	2
miRNA-corp.d142.s3	Here, we discuss some of the limitations associated to the interpretation and applicability of miRNA data, based on our recent study on the etiology of Alzheimer's disease (AD).  	miRNA-corp.d142.s3.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d142.s3	Here, we discuss some of the limitations associated to the interpretation and applicability of miRNA data, based on our recent study on the etiology of Alzheimer's disease (AD).  	miRNA-corp.d142.s3.e3	Diseases	AD 	4
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e0	Genes/Proteins	APP 	1
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e2	Genes/Proteins	beta-amyloid (Abeta) precursor protein (APP)-converting enzyme 	3
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e3	Relation_Trigger	deregulation 	4
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e4	Specific_miRNAs	miR-298 	5
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e5	Specific_miRNAs	miR-328 	6
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e6	Diseases	AD 	7
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e7	Diseases	AD 	8
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e8	Genes/Proteins	BACE 	9
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e9	Genes/Proteins	BACE 	10
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e10	Relation_Trigger	regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation 	11
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e11	Species	mouse 	12
miRNA-corp.d142.s4	Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD.  	miRNA-corp.d142.s4.e12	Species	murine 	13
miRNA-corp.d142.s5	However, whether miRNA data can be extrapolated and transposed to the human context of age-related diseases, such as AD, not only requires caution, but also warrants several considerations.    	miRNA-corp.d142.s5.e0	Diseases	AD 	1
miRNA-corp.d142.s5	However, whether miRNA data can be extrapolated and transposed to the human context of age-related diseases, such as AD, not only requires caution, but also warrants several considerations.    	miRNA-corp.d142.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d142.s5	However, whether miRNA data can be extrapolated and transposed to the human context of age-related diseases, such as AD, not only requires caution, but also warrants several considerations.    	miRNA-corp.d142.s5.e2	Species	human 	3
miRNA-corp.d143.s0	Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis.  	miRNA-corp.d143.s0.e0	Genes/Proteins	caveolin-1 	1
miRNA-corp.d143.s0	Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis.  	miRNA-corp.d143.s0.e1	Genes/Proteins	calmodulin 	2
miRNA-corp.d143.s0	Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis.  	miRNA-corp.d143.s0.e2	Genes/Proteins	eNOS 	3
miRNA-corp.d143.s0	Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis.  	miRNA-corp.d143.s0.e3	Genes/Proteins	endothelial NO synthase 	4
miRNA-corp.d143.s2	NO production and endothelium-dependent contraction in response to the NOS inhibitor NG-nitro-L-arginine (L-NNA; 100 microM) was enhanced by 50 to 100% in carotid arteries from rats treated with daidzein or 17beta-estradiol.  	miRNA-corp.d143.s2.e0	Relation_Trigger	inhibitor 	1
miRNA-corp.d143.s2	NO production and endothelium-dependent contraction in response to the NOS inhibitor NG-nitro-L-arginine (L-NNA; 100 microM) was enhanced by 50 to 100% in carotid arteries from rats treated with daidzein or 17beta-estradiol.  	miRNA-corp.d143.s2.e1	Species	rats 	2
miRNA-corp.d143.s3	Acetylcholine-induced relaxation was selectively enhanced in carotid arteries from rats treated with daidzein.  	miRNA-corp.d143.s3.e0	Species	rats 	1
miRNA-corp.d143.s4	The use of estrogen for protection against vascular dysfunction is limited due to its effects on the reproductive system, particularly in males.  	miRNA-corp.d143.s4.e0	Diseases	vascular dysfunction 	1
miRNA-corp.d143.s6	Male rats were administered vehicle, 17beta-estradiol (0.1 mg/kg s.c.), or daidzein (0.2 mg/kg s.c.) daily for 7 days.  	miRNA-corp.d143.s6.e0	Species	rats 	1
miRNA-corp.d143.s8	Similarly, constrictor responses of the basilar artery to L-NNA in vivo were selectively augmented by approximately 100% by 17beta-estradiol treatment and tended to be approximately 50% greater in daidzein-treated rats.  	miRNA-corp.d143.s8.e0	Species	rats 	1
miRNA-corp.d143.s9	Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol.   	miRNA-corp.d143.s9.e0	Species	rats 	1
miRNA-corp.d143.s10	These data suggest that short-term administration of daidzein or 17beta-estradiol modulates cerebral artery reactivity in males by enhancing synthesis and release of endothelium-derived NO. Isoflavone therapy may therefore be a feasible approach to protect against cerebrovascular disease and stroke.    	miRNA-corp.d143.s10.e0	Relation_Trigger	modulates 	1
miRNA-corp.d143.s10	These data suggest that short-term administration of daidzein or 17beta-estradiol modulates cerebral artery reactivity in males by enhancing synthesis and release of endothelium-derived NO. Isoflavone therapy may therefore be a feasible approach to protect against cerebrovascular disease and stroke.    	miRNA-corp.d143.s10.e1	Diseases	cerebrovascular disease 	2
miRNA-corp.d143.s10	These data suggest that short-term administration of daidzein or 17beta-estradiol modulates cerebral artery reactivity in males by enhancing synthesis and release of endothelium-derived NO. Isoflavone therapy may therefore be a feasible approach to protect against cerebrovascular disease and stroke.    	miRNA-corp.d143.s10.e2	Diseases	stroke 	3
miRNA-corp.d143.s11	Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats.  	miRNA-corp.d143.s11.e0	Genes/Proteins	caveolin-1 	1
miRNA-corp.d143.s11	Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats.  	miRNA-corp.d143.s11.e1	Genes/Proteins	calmodulin 	2
miRNA-corp.d143.s11	Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats.  	miRNA-corp.d143.s11.e2	Relation_Trigger	Expression of caveolin-1 was decreased 	3
miRNA-corp.d143.s11	Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats.  	miRNA-corp.d143.s11.e3	Species	rats 	4
miRNA-corp.d143.s12	eNOS expression was unaffected by the treatments.  	miRNA-corp.d143.s12.e0	Genes/Proteins	eNOS 	1
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e1	Diseases	AD 	2
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e2	Non-Specific_miRNAs	micro RNA 	3
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e5	Relation_Trigger	significantly altered 	6
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e6	Diseases	neurological disorders 	7
miRNA-corp.d144.s0	Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls.  	miRNA-corp.d144.s0.e7	Species	Human 	8
miRNA-corp.d144.s1	An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells.   	miRNA-corp.d144.s1.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d144.s1	An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells.   	miRNA-corp.d144.s1.e1	Specific_miRNAs	micro RNA-146a 	2
miRNA-corp.d144.s1	An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells.   	miRNA-corp.d144.s1.e2	Species	human 	3
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e1	Genes/Proteins	CFH 	2
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e2	Diseases	AD 	3
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e3	Genes/Proteins	interleukin-1beta 	4
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e4	Relation_Trigger	Up-regulation 	5
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e5	Relation_Trigger	down-regulation 	6
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e6	Genes/Proteins	Abeta42 	7
miRNA-corp.d144.s2	Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture.  	miRNA-corp.d144.s2.e7	Species	human 	8
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e1	Genes/Proteins	complement factor H  	2
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e2	Genes/Proteins	CFH 	3
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e3	Diseases	AD 	4
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e4	Relation_Trigger	up-regulation 	5
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e5	Relation_Trigger	highly complementary to the 3'-untranslated region 	6
miRNA-corp.d144.s3	Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain.  	miRNA-corp.d144.s3.e6	Relation_Trigger	repressor 	7
miRNA-corp.d144.s4	Treatment of stressed HN cells with the NF-kappaB inhibitor pyrollidine dithiocarbamate or the resveratrol analog CAY10512 abrogated this response.  	miRNA-corp.d144.s4.e0	Relation_Trigger	inhibitor 	1
miRNA-corp.d144.s5	Transfection of HN cells using an NF-kappaB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression.  	miRNA-corp.d144.s5.e0	Genes/Proteins	CFH 	1
miRNA-corp.d144.s5	Transfection of HN cells using an NF-kappaB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression.  	miRNA-corp.d144.s5.e1	Specific_miRNAs	miRNA-146a 	2
miRNA-corp.d144.s5	Transfection of HN cells using an NF-kappaB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression.  	miRNA-corp.d144.s5.e2	Relation_Trigger	decreases in CFH gene expression 	3
miRNA-corp.d144.s5	Transfection of HN cells using an NF-kappaB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression.  	miRNA-corp.d144.s5.e3	Relation_Trigger	up-regulation 	4
miRNA-corp.d144.s6	Incubation of an antisense oligonucleotide to miRNA-146a (anti-miRNA-146a; AM-146a) was found to restore CFH expression levels.  	miRNA-corp.d144.s6.e0	Genes/Proteins	CFH 	1
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e0	Genes/Proteins	CFH 	1
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e1	Diseases	AD 	2
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e2	Diseases	AD 	3
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e3	Specific_miRNAs	miRNA-146a 	4
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e4	Relation_Trigger	regulate 	5
miRNA-corp.d144.s7	These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.    	miRNA-corp.d144.s7.e5	Relation_Trigger	modulation of CFH gene expression 	6
miRNA-corp.d145.s0	Meanwhile, 3NP rats showed dynamic changes in the miRNA profiles during disease development and a few miRNAs with altered expression.  	miRNA-corp.d145.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d145.s0	Meanwhile, 3NP rats showed dynamic changes in the miRNA profiles during disease development and a few miRNAs with altered expression.  	miRNA-corp.d145.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d145.s0	Meanwhile, 3NP rats showed dynamic changes in the miRNA profiles during disease development and a few miRNAs with altered expression.  	miRNA-corp.d145.s0.e2	Relation_Trigger	altered expression 	3
miRNA-corp.d145.s0	Meanwhile, 3NP rats showed dynamic changes in the miRNA profiles during disease development and a few miRNAs with altered expression.  	miRNA-corp.d145.s0.e3	Species	rats 	4
miRNA-corp.d145.s1	In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly.  	miRNA-corp.d145.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d145.s1	In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly.  	miRNA-corp.d145.s1.e1	Genes/Proteins	Drosha 	2
miRNA-corp.d145.s1	In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly.  	miRNA-corp.d145.s1.e2	Relation_Trigger	downregulation 	3
miRNA-corp.d145.s1	In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly.  	miRNA-corp.d145.s1.e3	Relation_Trigger	level of Drosha decreased 	4
miRNA-corp.d145.s1	In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly.  	miRNA-corp.d145.s1.e4	Species	mice 	5
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e1	Specific_miRNAs	miR-22 	2
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e2	Specific_miRNAs	miR-29c 	3
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e3	Specific_miRNAs	miR-128 	4
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e4	Specific_miRNAs	miR-132 	5
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e5	Specific_miRNAs	miR-138 	6
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e6	Specific_miRNAs	miR-218 	7
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e7	Specific_miRNAs	miR-222 	8
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e8	Specific_miRNAs	miR-344 	9
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e9	Specific_miRNAs	miR-674 	10
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e10	Relation_Trigger	down-regulated 	11
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e11	Species	mice 	12
miRNA-corp.d145.s2	Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.  	miRNA-corp.d145.s2.e12	Species	mice 	13
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e0	Genes/Proteins	Exportin-5 	1
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e1	Genes/Proteins	Dicer 	2
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e2	Relation_Trigger	expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased 	3
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e3	Relation_Trigger	expression of Dicer was decreased 	4
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e4	Genes/Proteins	Drosha 	5
miRNA-corp.d145.s3	Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months.  	miRNA-corp.d145.s3.e5	Genes/Proteins	DGCR8 	6
miRNA-corp.d145.s4	YAC128 mice showed upregulation-dominant miRNA expressions at 5 months and downregulation-dominant expressions at 12 months.  	miRNA-corp.d145.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d145.s4	YAC128 mice showed upregulation-dominant miRNA expressions at 5 months and downregulation-dominant expressions at 12 months.  	miRNA-corp.d145.s4.e1	Species	mice 	2
miRNA-corp.d145.s5	After characterizing the phenotypes by behavioral tests and histological analyses, we profiled striatal miRNAs using a miRNA microarray and we measured the key molecules involved in miRNA biogenesis and function.  	miRNA-corp.d145.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d145.s5	After characterizing the phenotypes by behavioral tests and histological analyses, we profiled striatal miRNAs using a miRNA microarray and we measured the key molecules involved in miRNA biogenesis and function.  	miRNA-corp.d145.s5.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d145.s5	After characterizing the phenotypes by behavioral tests and histological analyses, we profiled striatal miRNAs using a miRNA microarray and we measured the key molecules involved in miRNA biogenesis and function.  	miRNA-corp.d145.s5.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e2	Diseases	HD 	3
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e3	Relation_Trigger	regulators 	4
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e4	Species	mice 	5
miRNA-corp.d145.s6	Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model.  	miRNA-corp.d145.s6.e5	Species	rat 	6
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e3	Diseases	HD 	4
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e4	Diseases	HD 	5
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e5	Relation_Trigger	regulating gene expression 	6
miRNA-corp.d145.s7	MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood.  	miRNA-corp.d145.s7.e6	Relation_Trigger	regulation 	7
miRNA-corp.d145.s8	Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion.  	miRNA-corp.d145.s8.e0	Diseases	Huntington's disease 	1
miRNA-corp.d145.s8	Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion.  	miRNA-corp.d145.s8.e1	Diseases	HD 	2
miRNA-corp.d145.s8	Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion.  	miRNA-corp.d145.s8.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d145.s9	Altered microRNA regulation in Huntington's disease models.   	miRNA-corp.d145.s9.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d145.s9	Altered microRNA regulation in Huntington's disease models.   	miRNA-corp.d145.s9.e1	Diseases	Huntington's disease 	2
miRNA-corp.d145.s9	Altered microRNA regulation in Huntington's disease models.   	miRNA-corp.d145.s9.e2	Relation_Trigger	Altered microRNA regulation 	3
miRNA-corp.d145.s10	This information should aid in future studies on therapeutic application of miRNAs in HD.    	miRNA-corp.d145.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d145.s10	This information should aid in future studies on therapeutic application of miRNAs in HD.    	miRNA-corp.d145.s10.e1	Diseases	HD 	2
miRNA-corp.d145.s11	Our results show that transgenic HD mice have abnormal miRNA biogenesis.  	miRNA-corp.d145.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d145.s11	Our results show that transgenic HD mice have abnormal miRNA biogenesis.  	miRNA-corp.d145.s11.e1	Diseases	HD 	2
miRNA-corp.d145.s11	Our results show that transgenic HD mice have abnormal miRNA biogenesis.  	miRNA-corp.d145.s11.e2	Species	mice 	3
miRNA-corp.d146.s0	The prevalence of neurodegenerative disorders is rising steadily as human life expectancy increases.  	miRNA-corp.d146.s0.e0	Diseases	neurodegenerative disorders 	1
miRNA-corp.d146.s0	The prevalence of neurodegenerative disorders is rising steadily as human life expectancy increases.  	miRNA-corp.d146.s0.e1	Species	human 	2
miRNA-corp.d146.s1	However, limited knowledge of the molecular basis of disease pathogenesis is a major hurdle in the identification of drug targets and development of therapeutic strategies for these largely incurable disorders.  	miRNA-corp.d146.s1.e0	Relation_Trigger	targets 	1
miRNA-corp.d146.s2	MicroRNAs: novel therapeutic targets in neurodegenerative diseases.   	miRNA-corp.d146.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d146.s2	MicroRNAs: novel therapeutic targets in neurodegenerative diseases.   	miRNA-corp.d146.s2.e1	Relation_Trigger	therapeutic targets 	2
miRNA-corp.d146.s2	MicroRNAs: novel therapeutic targets in neurodegenerative diseases.   	miRNA-corp.d146.s2.e2	Diseases	neurodegenerative diseases 	3
miRNA-corp.d146.s3	Our bioinformatic analysis suggests novel miRNA-target interactions that could potentially influence neurodegeneration.  	miRNA-corp.d146.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d146.s4	The recent development of molecules that alter miRNA expression promises valuable tools that will enhance the therapeutic potential of miRNAs.    	miRNA-corp.d146.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d146.s4	The recent development of molecules that alter miRNA expression promises valuable tools that will enhance the therapeutic potential of miRNAs.    	miRNA-corp.d146.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d146.s4	The recent development of molecules that alter miRNA expression promises valuable tools that will enhance the therapeutic potential of miRNAs.    	miRNA-corp.d146.s4.e2	Relation_Trigger	alter miRNA expression 	3
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e3	Diseases	Parkinson's disease 	4
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e4	Relation_Trigger	regulatory 	5
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e5	Relation_Trigger	regulatory 	6
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e6	Relation_Trigger	differential expression 	7
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e7	Diseases	ataxia 	8
miRNA-corp.d146.s5	Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration.  	miRNA-corp.d146.s5.e8	Species	patients 	9
miRNA-corp.d146.s6	miRNAs that can target known mediators of neurodegeneration offer potential therapeutic targets.  	miRNA-corp.d146.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d146.s6	miRNAs that can target known mediators of neurodegeneration offer potential therapeutic targets.  	miRNA-corp.d146.s6.e1	Relation_Trigger	target 	2
miRNA-corp.d146.s6	miRNAs that can target known mediators of neurodegeneration offer potential therapeutic targets.  	miRNA-corp.d146.s6.e2	Relation_Trigger	therapeutic targets 	3
miRNA-corp.d147.s0	To our knowledge, this is the first report of miRNA profiles in A. cantonensis, which may represent a new platform for studying regulation of genes and their networks in A. cantonensis.    	miRNA-corp.d147.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d147.s0	To our knowledge, this is the first report of miRNA profiles in A. cantonensis, which may represent a new platform for studying regulation of genes and their networks in A. cantonensis.    	miRNA-corp.d147.s0.e1	Relation_Trigger	regulation 	2
miRNA-corp.d147.s1	Nucleotide bias analysis showed that uracil was the prominent nucleotide, particularly at positions of 1, 10, 14, 17 and 22, approximately at the beginning, middle and the end of the conserved miRNAs.  	miRNA-corp.d147.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d147.s2	No new miRNA sequence was found.  	miRNA-corp.d147.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d147.s3	A total of 8861,260 and 10,957,957 high quality reads with 20 and 23 conserved miRNAs were obtained in females and males, respectively.  	miRNA-corp.d147.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d147.s4	The objective of this study was to determine and characterize miRNAs of female and male adults of A. cantonensis by Solexa deep sequencing.  	miRNA-corp.d147.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d147.s6	microRNAs (miRNAs) are endogenous small non-coding RNAs that play crucial roles in gene expression regulation, cellular function and defense, homeostasis and pathogenesis.  	miRNA-corp.d147.s6.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d147.s6	microRNAs (miRNAs) are endogenous small non-coding RNAs that play crucial roles in gene expression regulation, cellular function and defense, homeostasis and pathogenesis.  	miRNA-corp.d147.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d147.s6	microRNAs (miRNAs) are endogenous small non-coding RNAs that play crucial roles in gene expression regulation, cellular function and defense, homeostasis and pathogenesis.  	miRNA-corp.d147.s6.e2	Relation_Trigger	expression regulation 	3
miRNA-corp.d147.s7	Angiostrongylus cantonensis causes eosinophilic meningitis and eosinophilic pleocytosis in humans and is of significant socio-economic importance globally.  	miRNA-corp.d147.s7.e0	Diseases	eosinophilic meningitis 	1
miRNA-corp.d147.s7	Angiostrongylus cantonensis causes eosinophilic meningitis and eosinophilic pleocytosis in humans and is of significant socio-economic importance globally.  	miRNA-corp.d147.s7.e1	Diseases	eosinophilic pleocytosis 	2
miRNA-corp.d147.s7	Angiostrongylus cantonensis causes eosinophilic meningitis and eosinophilic pleocytosis in humans and is of significant socio-economic importance globally.  	miRNA-corp.d147.s7.e2	Species	humans 	3
miRNA-corp.d147.s8	Angiostrongylus cantonensis: Identification and characterization of microRNAs in male and female adults.   	miRNA-corp.d147.s8.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d148.s0	The miR-146a expression was confirmed to be present in reactive astrocytes.  	miRNA-corp.d148.s0.e0	Specific_miRNAs	miR-146a 	1
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e0	Relation_Trigger	increased astroglial expression 	1
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e1	Diseases	TLE 	2
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e3	Diseases	hippocampal sclerosis 	4
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e4	Diseases	gliosis 	5
miRNA-corp.d148.s1	In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred.  	miRNA-corp.d148.s1.e5	Species	human 	6
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e1	Relation_Trigger	increased and persistent expression 	2
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e2	Relation_Trigger	modulation 	3
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e3	Diseases	TLE 	4
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e4	Specific_miRNAs	miR-146a 	5
miRNA-corp.d148.s2	The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.    	miRNA-corp.d148.s2.e5	Relation_Trigger	target 	6
miRNA-corp.d148.s3	Increasing evidence supports the involvement of inflammatory and immune processes in temporal lobe epilepsy (TLE).  	miRNA-corp.d148.s3.e0	Diseases	temporal lobe epilepsy 	1
miRNA-corp.d148.s3	Increasing evidence supports the involvement of inflammatory and immune processes in temporal lobe epilepsy (TLE).  	miRNA-corp.d148.s3.e1	Diseases	TLE 	2
miRNA-corp.d148.s4	Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.   	miRNA-corp.d148.s4.e0	Diseases	temporal lobe epilepsy 	1
miRNA-corp.d148.s4	Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.   	miRNA-corp.d148.s4.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d148.s4	Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.   	miRNA-corp.d148.s4.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d148.s4	Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.   	miRNA-corp.d148.s4.e3	Diseases	inflammation 	4
miRNA-corp.d148.s4	Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.   	miRNA-corp.d148.s4.e4	Species	human 	5
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e0	Diseases	TLE 	1
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e1	Specific_miRNAs	miRNA-146a 	2
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e3	Diseases	TLE 	4
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e4	Species	rat 	5
miRNA-corp.d148.s5	We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE.  	miRNA-corp.d148.s5.e5	Species	human 	6
miRNA-corp.d148.s6	MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function.  	miRNA-corp.d148.s6.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d148.s6	MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function.  	miRNA-corp.d148.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d148.s6	MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function.  	miRNA-corp.d148.s6.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d148.s6	MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function.  	miRNA-corp.d148.s6.e3	Relation_Trigger	negative regulators 	4
miRNA-corp.d148.s6	MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function.  	miRNA-corp.d148.s6.e4	Relation_Trigger	regulators of gene expression 	5
miRNA-corp.d148.s7	Prominent upregulation of miR-146a activation was evident at 1 week after SE and persisted in the chronic phase.  	miRNA-corp.d148.s7.e0	Diseases	SE 	1
miRNA-corp.d148.s7	Prominent upregulation of miR-146a activation was evident at 1 week after SE and persisted in the chronic phase.  	miRNA-corp.d148.s7.e1	Relation_Trigger	upregulation 	2
miRNA-corp.d148.s7	Prominent upregulation of miR-146a activation was evident at 1 week after SE and persisted in the chronic phase.  	miRNA-corp.d148.s7.e2	Relation_Trigger	activation 	3
miRNA-corp.d148.s7	Prominent upregulation of miR-146a activation was evident at 1 week after SE and persisted in the chronic phase.  	miRNA-corp.d148.s7.e3	Specific_miRNAs	miR-146a 	4
miRNA-corp.d148.s8	miR-146a analysis in rat hippocampus was performed by polymerase chain reaction and immunocytochemistry at 1 week and 3-4 months after induction of status epilepticus (SE).  	miRNA-corp.d148.s8.e0	Diseases	status epilepticus 	1
miRNA-corp.d148.s8	miR-146a analysis in rat hippocampus was performed by polymerase chain reaction and immunocytochemistry at 1 week and 3-4 months after induction of status epilepticus (SE).  	miRNA-corp.d148.s8.e1	Diseases	SE 	2
miRNA-corp.d148.s8	miR-146a analysis in rat hippocampus was performed by polymerase chain reaction and immunocytochemistry at 1 week and 3-4 months after induction of status epilepticus (SE).  	miRNA-corp.d148.s8.e2	Specific_miRNAs	miR-146a 	3
miRNA-corp.d148.s8	miR-146a analysis in rat hippocampus was performed by polymerase chain reaction and immunocytochemistry at 1 week and 3-4 months after induction of status epilepticus (SE).  	miRNA-corp.d148.s8.e3	Species	rat 	4
miRNA-corp.d149.s0	However, none of these individuals reported here have epilepsy, although two have an abnormal EEG.  	miRNA-corp.d149.s0.e0	Diseases	epilepsy 	1
miRNA-corp.d149.s1	CONCLUSIONS: The phenotype of chromosome 15q13.2q13.3 BP4-BP5 microdeletion/duplication syndrome may include features of autism spectrum disorder, a variety of neuropsychiatric disorders, and cognitive impairment.  	miRNA-corp.d149.s1.e0	Diseases	autism spectrum disorder 	1
miRNA-corp.d149.s1	CONCLUSIONS: The phenotype of chromosome 15q13.2q13.3 BP4-BP5 microdeletion/duplication syndrome may include features of autism spectrum disorder, a variety of neuropsychiatric disorders, and cognitive impairment.  	miRNA-corp.d149.s1.e1	Diseases	neuropsychiatric disorders 	2
miRNA-corp.d149.s1	CONCLUSIONS: The phenotype of chromosome 15q13.2q13.3 BP4-BP5 microdeletion/duplication syndrome may include features of autism spectrum disorder, a variety of neuropsychiatric disorders, and cognitive impairment.  	miRNA-corp.d149.s1.e2	Diseases	cognitive impairment 	3
miRNA-corp.d149.s3	PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository.  	miRNA-corp.d149.s3.e0	Diseases	autism 	1
miRNA-corp.d149.s3	PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository.  	miRNA-corp.d149.s3.e1	Species	PATIENTS 	2
miRNA-corp.d149.s3	PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository.  	miRNA-corp.d149.s3.e2	Diseases	Autism 	3
miRNA-corp.d149.s3	PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository.  	miRNA-corp.d149.s3.e3	Species	patients 	4
miRNA-corp.d149.s3	PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository.  	miRNA-corp.d149.s3.e4	Species	Children's 	5
miRNA-corp.d149.s4	RESULTS: We report the clinical features of five patients with a BP4-BP5 deletion, three with a BP4-BP5 duplication, and two with an overlapping but smaller duplication identified by whole genome high resolution oligonucleotide array CGH.  	miRNA-corp.d149.s4.e0	Species	patients 	1
miRNA-corp.d149.s5	Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders.   	miRNA-corp.d149.s5.e0	Diseases	autism 	1
miRNA-corp.d149.s5	Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders.   	miRNA-corp.d149.s5.e1	Diseases	neuropsychiatric disorders 	2
miRNA-corp.d149.s6	BACKGROUND: Segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2q13.3 mediate a recurrent genomic imbalance syndrome associated with mental retardation, epilepsy, and/or electroencephalogram (EEG) abnormalities.  	miRNA-corp.d149.s6.e0	Diseases	epilepsy 	1
miRNA-corp.d149.s6	BACKGROUND: Segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2q13.3 mediate a recurrent genomic imbalance syndrome associated with mental retardation, epilepsy, and/or electroencephalogram (EEG) abnormalities.  	miRNA-corp.d149.s6.e1	Relation_Trigger	associated 	2
miRNA-corp.d149.s6	BACKGROUND: Segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2q13.3 mediate a recurrent genomic imbalance syndrome associated with mental retardation, epilepsy, and/or electroencephalogram (EEG) abnormalities.  	miRNA-corp.d149.s6.e2	Diseases	mental retardation 	3
miRNA-corp.d149.s6	BACKGROUND: Segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2q13.3 mediate a recurrent genomic imbalance syndrome associated with mental retardation, epilepsy, and/or electroencephalogram (EEG) abnormalities.  	miRNA-corp.d149.s6.e3	Diseases	electroencephalogram (EEG) abnormalities 	4
miRNA-corp.d149.s7	BP4-BP5 covers approximately 1.5 Mb (chr15:28.719-30.298 Mb) and includes six reference genes and 1 miRNA gene, while the smaller duplications cover approximately 500 kb (chr15:28.902-29.404 Mb) and contain three reference genes and one miRNA gene.  	miRNA-corp.d149.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d149.s7	BP4-BP5 covers approximately 1.5 Mb (chr15:28.719-30.298 Mb) and includes six reference genes and 1 miRNA gene, while the smaller duplications cover approximately 500 kb (chr15:28.902-29.404 Mb) and contain three reference genes and one miRNA gene.  	miRNA-corp.d149.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d149.s8	Cognitive impairment varied from moderate mental retardation to normal IQ with learning disability.  	miRNA-corp.d149.s8.e0	Diseases	mental retardation 	1
miRNA-corp.d149.s8	Cognitive impairment varied from moderate mental retardation to normal IQ with learning disability.  	miRNA-corp.d149.s8.e1	Diseases	Cognitive impairment 	2
miRNA-corp.d149.s8	Cognitive impairment varied from moderate mental retardation to normal IQ with learning disability.  	miRNA-corp.d149.s8.e2	Diseases	learning disability 	3
miRNA-corp.d149.s9	These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder.  	miRNA-corp.d149.s9.e0	Diseases	autism spectrum disorder 	1
miRNA-corp.d149.s9	These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder.  	miRNA-corp.d149.s9.e1	Diseases	attention deficit hyperactivity disorder 	2
miRNA-corp.d149.s9	These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder.  	miRNA-corp.d149.s9.e2	Diseases	anxiety disorder 	3
miRNA-corp.d149.s9	These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder.  	miRNA-corp.d149.s9.e3	Diseases	mood disorder 	4
miRNA-corp.d149.s9	These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder.  	miRNA-corp.d149.s9.e4	Diseases	neuropsychiatric impairments 	5
miRNA-corp.d149.s10	The BP4-BP5 deletion and duplication events span CHRNA7, a candidate gene for seizures.  	miRNA-corp.d149.s10.e0	Diseases	seizures 	1
miRNA-corp.d150.s0	The KIAA0226 gene encodes a protein that we named rundataxin, with two conserved domains: an N-terminal RUN domain and a C-terminal domain containing a diacylglycerol binding-like motif.  	miRNA-corp.d150.s0.e0	Genes/Proteins	rundataxin 	1
miRNA-corp.d150.s0	The KIAA0226 gene encodes a protein that we named rundataxin, with two conserved domains: an N-terminal RUN domain and a C-terminal domain containing a diacylglycerol binding-like motif.  	miRNA-corp.d150.s0.e1	Genes/Proteins	KIAA0226 	2
miRNA-corp.d150.s1	Mutation screening of all coding sequences revealed a single nucleotide deletion, 2927delC, in exon 19 of the KIAA0226 gene, which results in a frame shift of the C-terminal domain (p.Ala943ValfsX146).  	miRNA-corp.d150.s1.e0	Genes/Proteins	KIAA0226 	1
miRNA-corp.d150.s2	The rundataxin pathway appears therefore distinct from the ataxia pathways involving deficiency in mitochondrial or nuclear proteins and broadens the range of mechanisms leading to recessive ataxias.    	miRNA-corp.d150.s2.e0	Diseases	ataxia 	1
miRNA-corp.d150.s2	The rundataxin pathway appears therefore distinct from the ataxia pathways involving deficiency in mitochondrial or nuclear proteins and broadens the range of mechanisms leading to recessive ataxias.    	miRNA-corp.d150.s2.e1	Diseases	ataxias 	2
miRNA-corp.d150.s3	The closest paralogue of rundataxin, the plekstrin homology domain family member M1, has been shown to colocalize with Rab7, a small GTPase associated with late endosomes/lysosomes, suggesting that rundataxin may also be associated with vesicular trafficking and signalling pathways through its RUN and diacylglycerol binding-like domains.  	miRNA-corp.d150.s3.e0	Relation_Trigger	associated 	1
miRNA-corp.d150.s3	The closest paralogue of rundataxin, the plekstrin homology domain family member M1, has been shown to colocalize with Rab7, a small GTPase associated with late endosomes/lysosomes, suggesting that rundataxin may also be associated with vesicular trafficking and signalling pathways through its RUN and diacylglycerol binding-like domains.  	miRNA-corp.d150.s3.e1	Relation_Trigger	associated 	2
miRNA-corp.d150.s3	The closest paralogue of rundataxin, the plekstrin homology domain family member M1, has been shown to colocalize with Rab7, a small GTPase associated with late endosomes/lysosomes, suggesting that rundataxin may also be associated with vesicular trafficking and signalling pathways through its RUN and diacylglycerol binding-like domains.  	miRNA-corp.d150.s3.e2	Genes/Proteins	rundataxin 	3
miRNA-corp.d150.s3	The closest paralogue of rundataxin, the plekstrin homology domain family member M1, has been shown to colocalize with Rab7, a small GTPase associated with late endosomes/lysosomes, suggesting that rundataxin may also be associated with vesicular trafficking and signalling pathways through its RUN and diacylglycerol binding-like domains.  	miRNA-corp.d150.s3.e3	Genes/Proteins	rundataxin 	4
miRNA-corp.d150.s4	The three patients presented with childhood onset gait and limb ataxia, dysarthria and had limited walking without aid into their teenage years.  	miRNA-corp.d150.s4.e0	Diseases	ataxia 	1
miRNA-corp.d150.s4	The three patients presented with childhood onset gait and limb ataxia, dysarthria and had limited walking without aid into their teenage years.  	miRNA-corp.d150.s4.e1	Diseases	dysarthria 	2
miRNA-corp.d150.s4	The three patients presented with childhood onset gait and limb ataxia, dysarthria and had limited walking without aid into their teenage years.  	miRNA-corp.d150.s4.e2	Species	patients 	3
miRNA-corp.d150.s5	We have identified a novel form of recessive ataxia that segregates in three children of a large consanguineous Saudi Arabian family.  	miRNA-corp.d150.s5.e0	Diseases	ataxia 	1
miRNA-corp.d150.s5	We have identified a novel form of recessive ataxia that segregates in three children of a large consanguineous Saudi Arabian family.  	miRNA-corp.d150.s5.e1	Species	children 	2
miRNA-corp.d150.s7	Two patients developed epilepsy at 7 months without relapse after treatment, and mental retardation.  	miRNA-corp.d150.s7.e0	Diseases	mental retardation 	1
miRNA-corp.d150.s7	Two patients developed epilepsy at 7 months without relapse after treatment, and mental retardation.  	miRNA-corp.d150.s7.e1	Diseases	epilepsy 	2
miRNA-corp.d150.s7	Two patients developed epilepsy at 7 months without relapse after treatment, and mental retardation.  	miRNA-corp.d150.s7.e2	Species	patients developed 	3
miRNA-corp.d150.s8	Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia.   	miRNA-corp.d150.s8.e0	Relation_Trigger	binding 	1
miRNA-corp.d150.s8	Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia.   	miRNA-corp.d150.s8.e1	Genes/Proteins	Rundataxin 	2
miRNA-corp.d150.s8	Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia.   	miRNA-corp.d150.s8.e2	Diseases	ataxia 	3
miRNA-corp.d151.s0	These tumors arise in the cerebellum and may attribute their origins to deregulated proliferation of neural progenitor cells during development.  	miRNA-corp.d151.s0.e0	Diseases	tumors 	1
miRNA-corp.d151.s0	These tumors arise in the cerebellum and may attribute their origins to deregulated proliferation of neural progenitor cells during development.  	miRNA-corp.d151.s0.e1	Relation_Trigger	deregulated 	2
miRNA-corp.d151.s1	However, only a few studies to date have focused on the role of miRNAs in medulloblastoma, the most common malignant pediatric brain tumor.  	miRNA-corp.d151.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d151.s1	However, only a few studies to date have focused on the role of miRNAs in medulloblastoma, the most common malignant pediatric brain tumor.  	miRNA-corp.d151.s1.e1	Diseases	medulloblastoma 	2
miRNA-corp.d151.s1	However, only a few studies to date have focused on the role of miRNAs in medulloblastoma, the most common malignant pediatric brain tumor.  	miRNA-corp.d151.s1.e2	Diseases	brain tumor 	3
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e0	Non-Specific_miRNAs	MiRNA 	1
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e1	Diseases	medulloblastoma 	2
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e2	Relation_Trigger	novel targets 	3
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e3	Diseases	medulloblastomas 	4
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e4	Relation_Trigger	targets of potential 	5
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e5	Relation_Trigger	correlating 	6
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e6	Diseases	tumor 	7
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e7	Species	mouse 	8
miRNA-corp.d151.s2	MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance.  	miRNA-corp.d151.s2.e8	Species	human 	9
miRNA-corp.d151.s3	Understanding the interplay between normal brain development and medulloblastoma pathogenesis is necessary in order for more efficient, less toxic targeted therapies to be developed and implemented.  	miRNA-corp.d151.s3.e0	Diseases	medulloblastoma 	1
miRNA-corp.d151.s3	Understanding the interplay between normal brain development and medulloblastoma pathogenesis is necessary in order for more efficient, less toxic targeted therapies to be developed and implemented.  	miRNA-corp.d151.s3.e1	Relation_Trigger	targeted 	2
miRNA-corp.d151.s4	Normal and oncogenic roles for microRNAs in the developing brain.   	miRNA-corp.d151.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d151.s5	Emerging evidence indicates that miRNAs are key players in mammalian development that, when altered, contribute to tumorigenesis.  	miRNA-corp.d151.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d151.s6	MicroRNAS (miRNAs) are small endogenous non-coding RNAs that play important roles in many different biological processes including proliferation, differentiation and apoptosis through silencing of target genes.  	miRNA-corp.d151.s6.e0	Non-Specific_miRNAs	MicroRNAS 	1
miRNA-corp.d151.s6	MicroRNAS (miRNAs) are small endogenous non-coding RNAs that play important roles in many different biological processes including proliferation, differentiation and apoptosis through silencing of target genes.  	miRNA-corp.d151.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d151.s6	MicroRNAS (miRNAs) are small endogenous non-coding RNAs that play important roles in many different biological processes including proliferation, differentiation and apoptosis through silencing of target genes.  	miRNA-corp.d151.s6.e2	Relation_Trigger	target 	3
miRNA-corp.d151.s7	This review summarizes the recent miRNA literature in both medulloblastoma and normal brain development.    	miRNA-corp.d151.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d151.s7	This review summarizes the recent miRNA literature in both medulloblastoma and normal brain development.    	miRNA-corp.d151.s7.e1	Diseases	medulloblastoma 	2
miRNA-corp.d152.s0	A miRNA signature of prion induced neurodegeneration.   	miRNA-corp.d152.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d152.s0	A miRNA signature of prion induced neurodegeneration.   	miRNA-corp.d152.s0.e1	Genes/Proteins	prion 	2
miRNA-corp.d152.s1	Compelling evidence links miRNAs to the control of neuronal development and differentiation, however, little is known about their role in neurodegeneration.  	miRNA-corp.d152.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d152.s2	MicroRNAs (miRNAs) are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular processes.  	miRNA-corp.d152.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d152.s2	MicroRNAs (miRNAs) are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular processes.  	miRNA-corp.d152.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d152.s2	MicroRNAs (miRNAs) are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular processes.  	miRNA-corp.d152.s2.e2	Relation_Trigger	regulators 	3
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e0	Specific_miRNAs	miR-342-3p 	1
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e1	Specific_miRNAs	miR-320 	2
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e2	Specific_miRNAs	let-7b 	3
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e3	Specific_miRNAs	miR-328 	4
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e4	Specific_miRNAs	miR-128 	5
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e5	Specific_miRNAs	miR-139-5p 	6
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e6	Specific_miRNAs	miR-146a 	7
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e7	Specific_miRNAs	miR-338-3p 	8
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e8	Specific_miRNAs	miR-337-3p 	9
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e9	Relation_Trigger	de-regulated 	10
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e10	Relation_Trigger	up-regulated 	11
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e11	Relation_Trigger	down-regulated 	12
miRNA-corp.d152.s3	We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated.  	miRNA-corp.d152.s3.e12	Non-Specific_miRNAs	miRNAs 	13
miRNA-corp.d152.s4	We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie.  	miRNA-corp.d152.s4.e0	Diseases	scrapie 	1
miRNA-corp.d152.s4	We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie.  	miRNA-corp.d152.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d152.s4	We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie.  	miRNA-corp.d152.s4.e2	Relation_Trigger	expression changes 	3
miRNA-corp.d152.s4	We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie.  	miRNA-corp.d152.s4.e3	Species	mouse 	4
miRNA-corp.d152.s4	We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie.  	miRNA-corp.d152.s4.e4	Species	mice 	5
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e0	Relation_Trigger	De-regulation 	1
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e4	Genes/Proteins	prion 	5
miRNA-corp.d152.s5	De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration.  	miRNA-corp.d152.s5.e5	Relation_Trigger	associated 	6
miRNA-corp.d152.s6	Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease.  	miRNA-corp.d152.s6.e0	Specific_miRNAs	miR-128 	1
miRNA-corp.d152.s6	Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease.  	miRNA-corp.d152.s6.e1	Relation_Trigger	de-regulated 	2
miRNA-corp.d152.s6	Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease.  	miRNA-corp.d152.s6.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d152.s6	Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease.  	miRNA-corp.d152.s6.e3	Diseases	neurodegenerative disease 	4
miRNA-corp.d152.s7	Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie.  	miRNA-corp.d152.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d152.s7	Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie.  	miRNA-corp.d152.s7.e1	Relation_Trigger	targets 	2
miRNA-corp.d152.s7	Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie.  	miRNA-corp.d152.s7.e2	Diseases	scrapie 	3
miRNA-corp.d152.s7	Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie.  	miRNA-corp.d152.s7.e3	Relation_Trigger	de-regulated 	4
miRNA-corp.d152.s7	Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie.  	miRNA-corp.d152.s7.e4	Species	mouse 	5
miRNA-corp.d152.s8	We used a co-ordinated approach to integrate miRNA and mRNA profiling, bioinformatic predictions and biochemical validation to determine miRNA regulated processes and genes potentially involved in disease progression.  	miRNA-corp.d152.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d152.s8	We used a co-ordinated approach to integrate miRNA and mRNA profiling, bioinformatic predictions and biochemical validation to determine miRNA regulated processes and genes potentially involved in disease progression.  	miRNA-corp.d152.s8.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d152.s8	We used a co-ordinated approach to integrate miRNA and mRNA profiling, bioinformatic predictions and biochemical validation to determine miRNA regulated processes and genes potentially involved in disease progression.  	miRNA-corp.d152.s8.e2	Relation_Trigger	regulated 	3
miRNA-corp.d152.s9	In particular, a correlation between miRNA expression and putative gene targets involved in intracellular protein-degradation pathways and signaling pathways related to cell death, synapse function and neurogenesis was identified.    	miRNA-corp.d152.s9.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d152.s9	In particular, a correlation between miRNA expression and putative gene targets involved in intracellular protein-degradation pathways and signaling pathways related to cell death, synapse function and neurogenesis was identified.    	miRNA-corp.d152.s9.e1	Relation_Trigger	correlation between miRNA expression 	2
miRNA-corp.d152.s9	In particular, a correlation between miRNA expression and putative gene targets involved in intracellular protein-degradation pathways and signaling pathways related to cell death, synapse function and neurogenesis was identified.    	miRNA-corp.d152.s9.e2	Relation_Trigger	targets 	3
miRNA-corp.d153.s0	Type III RNase Dicer is responsible for the maturation and function of microRNA (miRNA) molecules in the cell.  	miRNA-corp.d153.s0.e0	Genes/Proteins	Type III RNase Dicer 	1
miRNA-corp.d153.s0	Type III RNase Dicer is responsible for the maturation and function of microRNA (miRNA) molecules in the cell.  	miRNA-corp.d153.s0.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d153.s0	Type III RNase Dicer is responsible for the maturation and function of microRNA (miRNA) molecules in the cell.  	miRNA-corp.d153.s0.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d153.s1	Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration.   	miRNA-corp.d153.s1.e0	Genes/Proteins	Dicer 	1
miRNA-corp.d153.s3	Here we show that the absence of Dicer in the adult forebrain is accompanied by a mixed neurodegenerative phenotype.  	miRNA-corp.d153.s3.e0	Genes/Proteins	Dicer 	1
miRNA-corp.d153.s5	It is now well-documented that Dicer and the fine-tuning of the miRNA gene network are important for neuronal integrity.  	miRNA-corp.d153.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d153.s5	It is now well-documented that Dicer and the fine-tuning of the miRNA gene network are important for neuronal integrity.  	miRNA-corp.d153.s5.e1	Genes/Proteins	Dicer 	2
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e0	Genes/Proteins	ERK1/2 	1
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e1	Genes/Proteins	ERK1 	2
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e2	Specific_miRNAs	miR-15 	3
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e4	Relation_Trigger	potent regulators 	5
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e5	Relation_Trigger	co-expressed 	6
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e6	Relation_Trigger	regulators of ERK1 expression 	7
miRNA-corp.d153.s6	We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo.  	miRNA-corp.d153.s6.e7	Species	mouse 	8
miRNA-corp.d153.s7	Finally, we show that miR-15a is specifically downregulated in Alzheimer's disease brain.  	miRNA-corp.d153.s7.e0	Specific_miRNAs	miR-15a 	1
miRNA-corp.d153.s7	Finally, we show that miR-15a is specifically downregulated in Alzheimer's disease brain.  	miRNA-corp.d153.s7.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d153.s7	Finally, we show that miR-15a is specifically downregulated in Alzheimer's disease brain.  	miRNA-corp.d153.s7.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d153.s8	Interestingly, neuronal degeneration coincides with the hyperphosphorylation of endogenous tau at several epitopes previously associated with neurofibrillary pathology.  	miRNA-corp.d153.s8.e0	Relation_Trigger	associated 	1
miRNA-corp.d153.s8	Interestingly, neuronal degeneration coincides with the hyperphosphorylation of endogenous tau at several epitopes previously associated with neurofibrillary pathology.  	miRNA-corp.d153.s8.e1	Diseases	neuronal degeneration 	2
miRNA-corp.d153.s9	Transcriptome analysis of enzymes involved in tau phosphorylation identified ERK1 as one of the candidate kinases responsible for this event in vivo.  	miRNA-corp.d153.s9.e0	Genes/Proteins	ERK1 	1
miRNA-corp.d153.s10	In summary, these results support the hypothesis that changes in the miRNA network may contribute to a neurodegenerative phenotype by affecting tau phosphorylation.    	miRNA-corp.d153.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d154.s0	MiR-21 can be induced in neurons by prolonged N-methyl-D-aspartic acid receptor stimulation, an excitotoxic process active in HIV and other neurodegenerative diseases.  	miRNA-corp.d154.s0.e0	Specific_miRNAs	MiR-21 	1
miRNA-corp.d154.s0	MiR-21 can be induced in neurons by prolonged N-methyl-D-aspartic acid receptor stimulation, an excitotoxic process active in HIV and other neurodegenerative diseases.  	miRNA-corp.d154.s0.e1	Diseases	neurodegenerative diseases 	2
miRNA-corp.d154.s1	Introduction of miR-21 into human neurons leads to pathological functional defects.  	miRNA-corp.d154.s1.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d154.s1	Introduction of miR-21 into human neurons leads to pathological functional defects.  	miRNA-corp.d154.s1.e1	Species	human 	2
miRNA-corp.d154.s2	Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression.  	miRNA-corp.d154.s2.e0	Relation_Trigger	specifically targets 	1
miRNA-corp.d154.s2	Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression.  	miRNA-corp.d154.s2.e1	Relation_Trigger	reduces its expression 	2
miRNA-corp.d154.s2	Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression.  	miRNA-corp.d154.s2.e2	Genes/Proteins	myocyte enhancer factor 2C 	3
miRNA-corp.d154.s2	Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression.  	miRNA-corp.d154.s2.e3	Genes/Proteins	MEF2C 	4
miRNA-corp.d154.s2	Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression.  	miRNA-corp.d154.s2.e4	Specific_miRNAs	miR-21 	5
miRNA-corp.d154.s3	MEF2C is dramatically downregulated in neurons of HIV-associated dementia patients as well as monkeys with SIVE.  	miRNA-corp.d154.s3.e0	Diseases	dementia 	1
miRNA-corp.d154.s3	MEF2C is dramatically downregulated in neurons of HIV-associated dementia patients as well as monkeys with SIVE.  	miRNA-corp.d154.s3.e1	Relation_Trigger	downregulated 	2
miRNA-corp.d154.s3	MEF2C is dramatically downregulated in neurons of HIV-associated dementia patients as well as monkeys with SIVE.  	miRNA-corp.d154.s3.e2	Genes/Proteins	MEF2C 	3
miRNA-corp.d154.s3	MEF2C is dramatically downregulated in neurons of HIV-associated dementia patients as well as monkeys with SIVE.  	miRNA-corp.d154.s3.e3	Species	patients 	4
miRNA-corp.d154.s4	Together, this study elucidates a novel role for miR-21 in the brain, not only as a potential signature of neurological disease but also as a crucial effector of HIV induced neuronal dysfunction and neurodegeneration.    	miRNA-corp.d154.s4.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d154.s4	Together, this study elucidates a novel role for miR-21 in the brain, not only as a potential signature of neurological disease but also as a crucial effector of HIV induced neuronal dysfunction and neurodegeneration.    	miRNA-corp.d154.s4.e1	Diseases	neurological disease 	2
miRNA-corp.d154.s4	Together, this study elucidates a novel role for miR-21 in the brain, not only as a potential signature of neurological disease but also as a crucial effector of HIV induced neuronal dysfunction and neurodegeneration.    	miRNA-corp.d154.s4.e2	Diseases	HIV induced neuronal dysfunction 	3
miRNA-corp.d154.s5	MicroRNAs (miRNAs) play important roles in regulating a plethora of physiological and pathophysiogical processes including neurodegeneration.  	miRNA-corp.d154.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d154.s5	MicroRNAs (miRNAs) play important roles in regulating a plethora of physiological and pathophysiogical processes including neurodegeneration.  	miRNA-corp.d154.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d154.s5	MicroRNAs (miRNAs) play important roles in regulating a plethora of physiological and pathophysiogical processes including neurodegeneration.  	miRNA-corp.d154.s5.e2	Relation_Trigger	regulating 	3
miRNA-corp.d154.s6	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.   	miRNA-corp.d154.s6.e0	Relation_Trigger	dysregulates the expression 	1
miRNA-corp.d154.s6	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.   	miRNA-corp.d154.s6.e1	Specific_miRNAs	MicroRNA-21 	2
miRNA-corp.d154.s6	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.   	miRNA-corp.d154.s6.e2	Genes/Proteins	MEF2C 	3
miRNA-corp.d154.s6	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.   	miRNA-corp.d154.s6.e3	Diseases	SIV/HIV neurological disease 	4
miRNA-corp.d154.s6	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.   	miRNA-corp.d154.s6.e4	Species	human 	5
miRNA-corp.d154.s7	In situ hybridization of the diseased brain sections revealed induction of miR-21 in neurons.  	miRNA-corp.d154.s7.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e1	Diseases	dementia 	2
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e2	Diseases	encephalitis 	3
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e3	Specific_miRNAs	miR-21 	4
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e4	Relation_Trigger	upregulated 	5
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e5	Relation_Trigger	associated 	6
miRNA-corp.d154.s8	In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain.  	miRNA-corp.d154.s8.e6	Species	humans 	7
miRNA-corp.d155.s0	However, by examining pairs in which the significance of the correlation coefficients is modestly relaxed, negative correlations do tend to predict targets and positive correlations tend to predict physically proximate pairs.  	miRNA-corp.d155.s0.e0	Relation_Trigger	targets 	1
miRNA-corp.d155.s0	However, by examining pairs in which the significance of the correlation coefficients is modestly relaxed, negative correlations do tend to predict targets and positive correlations tend to predict physically proximate pairs.  	miRNA-corp.d155.s0.e1	Relation_Trigger	correlation 	2
miRNA-corp.d155.s0	However, by examining pairs in which the significance of the correlation coefficients is modestly relaxed, negative correlations do tend to predict targets and positive correlations tend to predict physically proximate pairs.  	miRNA-corp.d155.s0.e2	Relation_Trigger	negative correlations 	3
miRNA-corp.d155.s0	However, by examining pairs in which the significance of the correlation coefficients is modestly relaxed, negative correlations do tend to predict targets and positive correlations tend to predict physically proximate pairs.  	miRNA-corp.d155.s0.e3	Relation_Trigger	positive correlations 	4
miRNA-corp.d155.s1	A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs.  	miRNA-corp.d155.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d155.s1	A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs.  	miRNA-corp.d155.s1.e1	Relation_Trigger	high correlation 	2
miRNA-corp.d155.s1	A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs.  	miRNA-corp.d155.s1.e2	Relation_Trigger	over-expressing 	3
miRNA-corp.d155.s1	A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs.  	miRNA-corp.d155.s1.e3	Relation_Trigger	suppressing 	4
miRNA-corp.d155.s1	A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs.  	miRNA-corp.d155.s1.e4	Relation_Trigger	correlated 	5
miRNA-corp.d155.s2	Most of these highest correlation pairs do not contain sufficiently complementary sequences to predict a target relationship; nor do they lie in physical proximity to each other.  	miRNA-corp.d155.s2.e0	Relation_Trigger	highest correlation 	1
miRNA-corp.d155.s2	Most of these highest correlation pairs do not contain sufficiently complementary sequences to predict a target relationship; nor do they lie in physical proximity to each other.  	miRNA-corp.d155.s2.e1	Relation_Trigger	target 	2
miRNA-corp.d155.s3	From these data sets, we inferred and validated a tumor suppression pathway linked to miR-181c.    	miRNA-corp.d155.s3.e0	Specific_miRNAs	miR-181c 	1
miRNA-corp.d155.s3	From these data sets, we inferred and validated a tumor suppression pathway linked to miR-181c.    	miRNA-corp.d155.s3.e1	Relation_Trigger	suppression 	2
miRNA-corp.d155.s3	From these data sets, we inferred and validated a tumor suppression pathway linked to miR-181c.    	miRNA-corp.d155.s3.e2	Diseases	tumor 	3
miRNA-corp.d155.s4	CONCLUSIONS/SIGNIFICANCE: Sufficient information exists within a set of tumor samples to detect endogenous correlations between miRNA and mRNA levels.  	miRNA-corp.d155.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d155.s4	CONCLUSIONS/SIGNIFICANCE: Sufficient information exists within a set of tumor samples to detect endogenous correlations between miRNA and mRNA levels.  	miRNA-corp.d155.s4.e1	Relation_Trigger	correlations 	2
miRNA-corp.d155.s4	CONCLUSIONS/SIGNIFICANCE: Sufficient information exists within a set of tumor samples to detect endogenous correlations between miRNA and mRNA levels.  	miRNA-corp.d155.s4.e2	Diseases	tumor 	3
miRNA-corp.d155.s5	Based on the validations the causal arrow for these correlations is likely to be directed from the miRNAs to the mRNAs.  	miRNA-corp.d155.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d155.s5	Based on the validations the causal arrow for these correlations is likely to be directed from the miRNAs to the mRNAs.  	miRNA-corp.d155.s5.e1	Relation_Trigger	correlations 	2
miRNA-corp.d155.s6	METHODOLOGY/PRINCIPAL FINDINGS: RNA was extracted from 12 human primary brain tumor biopsies.  	miRNA-corp.d155.s6.e0	Diseases	primary brain tumor 	1
miRNA-corp.d155.s6	METHODOLOGY/PRINCIPAL FINDINGS: RNA was extracted from 12 human primary brain tumor biopsies.  	miRNA-corp.d155.s6.e1	Species	human 	2
miRNA-corp.d155.s7	These samples were used to determine genome-wide mRNA expression levels by microarray analysis and a miRNA profile by real-time reverse transcription PCR.  	miRNA-corp.d155.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d155.s8	Correlation coefficients were determined for all possible mRNA-miRNA pairs and the distribution of these correlations compared to the random distribution.  	miRNA-corp.d155.s8.e0	Relation_Trigger	Correlation 	1
miRNA-corp.d155.s8	Correlation coefficients were determined for all possible mRNA-miRNA pairs and the distribution of these correlations compared to the random distribution.  	miRNA-corp.d155.s8.e1	Relation_Trigger	correlations 	2
miRNA-corp.d155.s8	Correlation coefficients were determined for all possible mRNA-miRNA pairs and the distribution of these correlations compared to the random distribution.  	miRNA-corp.d155.s8.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d155.s9	An excess of high positive and negative correlation pairs were observed at the tails of these distributions.  	miRNA-corp.d155.s9.e0	Relation_Trigger	negative correlation 	1
miRNA-corp.d155.s10	BACKGROUND: microRNAs (miRNAs) are approximately 21 nucleotide non-coding transcripts capable of regulating gene expression.  	miRNA-corp.d155.s10.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d155.s10	BACKGROUND: microRNAs (miRNAs) are approximately 21 nucleotide non-coding transcripts capable of regulating gene expression.  	miRNA-corp.d155.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d155.s10	BACKGROUND: microRNAs (miRNAs) are approximately 21 nucleotide non-coding transcripts capable of regulating gene expression.  	miRNA-corp.d155.s10.e2	Relation_Trigger	regulating gene expression 	3
miRNA-corp.d155.s11	Detection of a microRNA signal in an in vivo expression set of mRNAs.   	miRNA-corp.d155.s11.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d155.s12	As a result, translation of the target mRNA is inhibited and the mRNA may be destabilized.  	miRNA-corp.d155.s12.e0	Relation_Trigger	target 	1
miRNA-corp.d155.s12	As a result, translation of the target mRNA is inhibited and the mRNA may be destabilized.  	miRNA-corp.d155.s12.e1	Relation_Trigger	inhibited 	2
miRNA-corp.d155.s13	The most widely studied mechanism of regulation involves binding of a miRNA to the target mRNA.  	miRNA-corp.d155.s13.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d155.s13	The most widely studied mechanism of regulation involves binding of a miRNA to the target mRNA.  	miRNA-corp.d155.s13.e1	Relation_Trigger	target 	2
miRNA-corp.d155.s13	The most widely studied mechanism of regulation involves binding of a miRNA to the target mRNA.  	miRNA-corp.d155.s13.e2	Relation_Trigger	regulation 	3
miRNA-corp.d155.s13	The most widely studied mechanism of regulation involves binding of a miRNA to the target mRNA.  	miRNA-corp.d155.s13.e3	Relation_Trigger	binding 	4
miRNA-corp.d155.s14	We asked whether endogenous fluctuations in a set of mRNA and miRNA profiles contain correlated changes that are statistically distinguishable from the many other fluctuations in the data set.  	miRNA-corp.d155.s14.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d155.s14	We asked whether endogenous fluctuations in a set of mRNA and miRNA profiles contain correlated changes that are statistically distinguishable from the many other fluctuations in the data set.  	miRNA-corp.d155.s14.e1	Relation_Trigger	correlated 	2
miRNA-corp.d155.s15	The inhibitory effects of miRNAs have been linked to diverse cellular processes including malignant proliferation, apoptosis, development, differentiation, and metabolic processes.  	miRNA-corp.d155.s15.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d155.s15	The inhibitory effects of miRNAs have been linked to diverse cellular processes including malignant proliferation, apoptosis, development, differentiation, and metabolic processes.  	miRNA-corp.d155.s15.e1	Relation_Trigger	inhibitory effects 	2
miRNA-corp.d156.s0	A novel microRNA and transcription factor mediated regulatory network in schizophrenia.   	miRNA-corp.d156.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d156.s0	A novel microRNA and transcription factor mediated regulatory network in schizophrenia.   	miRNA-corp.d156.s0.e1	Diseases	schizophrenia 	2
miRNA-corp.d156.s0	A novel microRNA and transcription factor mediated regulatory network in schizophrenia.   	miRNA-corp.d156.s0.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d156.s1	Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression.  	miRNA-corp.d156.s1.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d156.s1	Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression.  	miRNA-corp.d156.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d156.s1	Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression.  	miRNA-corp.d156.s1.e2	Diseases	schizophrenia 	3
miRNA-corp.d156.s1	Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression.  	miRNA-corp.d156.s1.e3	Relation_Trigger	regulators of this gene expression 	4
miRNA-corp.d156.s1	Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression.  	miRNA-corp.d156.s1.e4	Relation_Trigger	changes in gene expression 	5
miRNA-corp.d156.s2	BACKGROUND: Schizophrenia is a complex brain disorder with molecular mechanisms that have yet to be elucidated.  	miRNA-corp.d156.s2.e0	Diseases	Schizophrenia 	1
miRNA-corp.d156.s2	BACKGROUND: Schizophrenia is a complex brain disorder with molecular mechanisms that have yet to be elucidated.  	miRNA-corp.d156.s2.e1	Diseases	brain disorder 	2
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e1	Diseases	schizophrenia 	2
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e2	Diseases	schizophrenia 	3
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e4	Relation_Trigger	regulatory 	5
miRNA-corp.d156.s3	We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia.  	miRNA-corp.d156.s3.e5	Non-Specific_miRNAs	miRNA 	6
miRNA-corp.d156.s4	So far, several miRNA-TF mediated regulatory modules have been verified.  	miRNA-corp.d156.s4.e0	Relation_Trigger	regulatory 	1
miRNA-corp.d156.s4	So far, several miRNA-TF mediated regulatory modules have been verified.  	miRNA-corp.d156.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d156.s5	Our evaluation revealed that these observed FFLs were significantly enriched in schizophrenia genes.  	miRNA-corp.d156.s5.e0	Diseases	schizophrenia 	1
miRNA-corp.d156.s6	RESULTS: We identified 32 feed-forward loops (FFLs) among our compiled schizophrenia-related miRNAs, TFs and genes.  	miRNA-corp.d156.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d156.s6	RESULTS: We identified 32 feed-forward loops (FFLs) among our compiled schizophrenia-related miRNAs, TFs and genes.  	miRNA-corp.d156.s6.e1	Diseases	schizophrenia 	2
miRNA-corp.d156.s7	By converging the FFLs and mutual feedback loops, we constructed a novel miRNA-TF regulatory network for schizophrenia.  	miRNA-corp.d156.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d156.s7	By converging the FFLs and mutual feedback loops, we constructed a novel miRNA-TF regulatory network for schizophrenia.  	miRNA-corp.d156.s7.e1	Diseases	schizophrenia 	2
miRNA-corp.d156.s7	By converging the FFLs and mutual feedback loops, we constructed a novel miRNA-TF regulatory network for schizophrenia.  	miRNA-corp.d156.s7.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d156.s8	Our analysis revealed EGR3 and hsa-miR-195 were core regulators in this regulatory network.  	miRNA-corp.d156.s8.e0	Specific_miRNAs	hsa-miR-195 	1
miRNA-corp.d156.s8	Our analysis revealed EGR3 and hsa-miR-195 were core regulators in this regulatory network.  	miRNA-corp.d156.s8.e1	Genes/Proteins	EGR3 	2
miRNA-corp.d156.s8	Our analysis revealed EGR3 and hsa-miR-195 were core regulators in this regulatory network.  	miRNA-corp.d156.s8.e2	Relation_Trigger	core regulators 	3
miRNA-corp.d156.s8	Our analysis revealed EGR3 and hsa-miR-195 were core regulators in this regulatory network.  	miRNA-corp.d156.s8.e3	Relation_Trigger	regulatory 	4
miRNA-corp.d156.s9	We next proposed a model highlighting EGR3 and miRNAs involved in signaling pathways and regulatory networks in the nervous system.  	miRNA-corp.d156.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d156.s9	We next proposed a model highlighting EGR3 and miRNAs involved in signaling pathways and regulatory networks in the nervous system.  	miRNA-corp.d156.s9.e1	Genes/Proteins	EGR3 	2
miRNA-corp.d156.s9	We next proposed a model highlighting EGR3 and miRNAs involved in signaling pathways and regulatory networks in the nervous system.  	miRNA-corp.d156.s9.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d156.s10	It represents the first investigation of a miRNA-TF regulatory network for a complex disease, as demonstrated in schizophrenia.    	miRNA-corp.d156.s10.e0	Diseases	schizophrenia 	1
miRNA-corp.d156.s10	It represents the first investigation of a miRNA-TF regulatory network for a complex disease, as demonstrated in schizophrenia.    	miRNA-corp.d156.s10.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d156.s10	It represents the first investigation of a miRNA-TF regulatory network for a complex disease, as demonstrated in schizophrenia.    	miRNA-corp.d156.s10.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d156.s11	CONCLUSIONS: This study provides many insights on the regulatory mechanisms of genes involved in schizophrenia.  	miRNA-corp.d156.s11.e0	Diseases	schizophrenia 	1
miRNA-corp.d156.s11	CONCLUSIONS: This study provides many insights on the regulatory mechanisms of genes involved in schizophrenia.  	miRNA-corp.d156.s11.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d156.s12	Finally, we suggested several single nucleotide polymorphisms (SNPs) located on miRNAs, their target sites, and TFBSs, which may have an effect in schizophrenia gene regulation.  	miRNA-corp.d156.s12.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d156.s12	Finally, we suggested several single nucleotide polymorphisms (SNPs) located on miRNAs, their target sites, and TFBSs, which may have an effect in schizophrenia gene regulation.  	miRNA-corp.d156.s12.e1	Diseases	schizophrenia 	2
miRNA-corp.d156.s12	Finally, we suggested several single nucleotide polymorphisms (SNPs) located on miRNAs, their target sites, and TFBSs, which may have an effect in schizophrenia gene regulation.  	miRNA-corp.d156.s12.e2	Relation_Trigger	regulation 	3
miRNA-corp.d156.s12	Finally, we suggested several single nucleotide polymorphisms (SNPs) located on miRNAs, their target sites, and TFBSs, which may have an effect in schizophrenia gene regulation.  	miRNA-corp.d156.s12.e3	Relation_Trigger	target 	4
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e0	Genes/Proteins	HES1 	1
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e1	Specific_miRNAs	miR-199b-5p 	2
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e2	Genes/Proteins	HES1 	3
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e3	Specific_miRNAs	miR-199b-5p 	4
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e4	Diseases	MB 	5
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e5	Relation_Trigger	targeting 	6
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e6	Relation_Trigger	negatively regulates 	7
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e7	Non-Specific_miRNAs	miRNA 	8
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e8	Relation_Trigger	regulator 	9
miRNA-corp.d157.s0	METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells.  	miRNA-corp.d157.s0.e9	Relation_Trigger	Down-regulation of HES1 expression 	10
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e0	Specific_miRNAs	MiR-199b-5p 	1
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e1	Relation_Trigger	blocks expression 	2
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e2	Diseases	MB 	3
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e3	Relation_Trigger	over-expression 	4
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e4	Relation_Trigger	impairs 	5
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e5	Diseases	MB 	6
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e6	Diseases	cancer 	7
miRNA-corp.d157.s1	MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells.  	miRNA-corp.d157.s1.e7	Species	nude mice 	8
miRNA-corp.d157.s2	In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001).  	miRNA-corp.d157.s2.e0	Diseases	MB 	1
miRNA-corp.d157.s2	In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001).  	miRNA-corp.d157.s2.e1	Specific_miRNAs	miR-199b-5p 	2
miRNA-corp.d157.s2	In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001).  	miRNA-corp.d157.s2.e2	Relation_Trigger	expression of miR-199b-5p in the non-metastatic cases was significantly higher 	3
miRNA-corp.d157.s2	In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001).  	miRNA-corp.d157.s2.e3	Species	patients 	4
miRNA-corp.d157.s3	Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients.  	miRNA-corp.d157.s3.e0	Specific_miRNAs	miR-199b 	1
miRNA-corp.d157.s3	Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients.  	miRNA-corp.d157.s3.e1	Relation_Trigger	Correlation 	2
miRNA-corp.d157.s3	Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients.  	miRNA-corp.d157.s3.e2	Relation_Trigger	high levels of miR-199b expression 	3
miRNA-corp.d157.s3	Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients.  	miRNA-corp.d157.s3.e3	Species	patients 	4
miRNA-corp.d157.s3	Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients.  	miRNA-corp.d157.s3.e4	Species	patients 	5
miRNA-corp.d157.s4	Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages.  	miRNA-corp.d157.s4.e0	Diseases	medulloblastoma tumors 	1
miRNA-corp.d157.s4	Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages.  	miRNA-corp.d157.s4.e1	Diseases	MBs 	2
miRNA-corp.d157.s4	Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages.  	miRNA-corp.d157.s4.e2	Relation_Trigger	impairment 	3
miRNA-corp.d157.s4	Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages.  	miRNA-corp.d157.s4.e3	Diseases	tumors 	4
miRNA-corp.d157.s5	MBs occur bimodally, with the peak incidence seen between 3-4 years and 8-9 years of age, although it can also occur in adults.  	miRNA-corp.d157.s5.e0	Diseases	MBs 	1
miRNA-corp.d157.s6	Notch regulates a subset of the MB cells that have stem-cell-like properties and can promote tumor growth.  	miRNA-corp.d157.s6.e0	Diseases	MB 	1
miRNA-corp.d157.s6	Notch regulates a subset of the MB cells that have stem-cell-like properties and can promote tumor growth.  	miRNA-corp.d157.s6.e1	Relation_Trigger	regulates 	2
miRNA-corp.d157.s6	Notch regulates a subset of the MB cells that have stem-cell-like properties and can promote tumor growth.  	miRNA-corp.d157.s6.e2	Diseases	tumor 	3
miRNA-corp.d157.s7	On the basis of this evidence, we hypothesized that miRNAs targeting the Notch pathway can regulated these phenomena, and can be used in anti-cancer therapies.  	miRNA-corp.d157.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d157.s7	On the basis of this evidence, we hypothesized that miRNAs targeting the Notch pathway can regulated these phenomena, and can be used in anti-cancer therapies.  	miRNA-corp.d157.s7.e1	Relation_Trigger	targeting 	2
miRNA-corp.d157.s7	On the basis of this evidence, we hypothesized that miRNAs targeting the Notch pathway can regulated these phenomena, and can be used in anti-cancer therapies.  	miRNA-corp.d157.s7.e2	Relation_Trigger	regulated 	3
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e2	Relation_Trigger	regulation of gene expression 	3
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e3	Relation_Trigger	negative regulation 	4
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e4	Relation_Trigger	oncosuppressors 	5
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e5	Relation_Trigger	altered expression 	6
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e6	Diseases	cancers 	7
miRNA-corp.d157.s8	BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types.  	miRNA-corp.d157.s8.e7	Diseases	tumor 	8
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e0	Specific_miRNAs	MicroRNA-199b-5p 	1
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e1	Genes/Proteins	HES1 	2
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e2	Diseases	medulloblastoma 	3
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e3	Relation_Trigger	impairs 	4
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e4	Relation_Trigger	negative regulation 	5
miRNA-corp.d157.s9	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.   	miRNA-corp.d157.s9.e5	Diseases	cancer 	6
miRNA-corp.d157.s10	To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.    	miRNA-corp.d157.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d157.s10	To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.    	miRNA-corp.d157.s10.e1	Diseases	brain tumors 	2
miRNA-corp.d157.s10	To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.    	miRNA-corp.d157.s10.e2	Diseases	tumor 	3
miRNA-corp.d157.s10	To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.    	miRNA-corp.d157.s10.e3	Relation_Trigger	targeting 	4
miRNA-corp.d157.s11	CONCLUSIONS/SIGNIFICANCE: Despite advances in our understanding of the pathogenesis of MB, one-third of these patients remain incurable and current treatments can significantly damage long-term survivors.  	miRNA-corp.d157.s11.e0	Diseases	MB 	1
miRNA-corp.d157.s11	CONCLUSIONS/SIGNIFICANCE: Despite advances in our understanding of the pathogenesis of MB, one-third of these patients remain incurable and current treatments can significantly damage long-term survivors.  	miRNA-corp.d157.s11.e1	Species	patients 	2
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e0	Specific_miRNAs	miR-199b-5p 	1
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e1	Specific_miRNAs	miR-199b-5p 	2
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e2	Diseases	MB 	3
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e3	Diseases	Infection 	4
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e4	Diseases	MB 	5
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e5	Diseases	tumor 	6
miRNA-corp.d157.s12	Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept.  	miRNA-corp.d157.s12.e6	Species	mouse 	7
miRNA-corp.d157.s13	We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life.  	miRNA-corp.d157.s13.e0	Specific_miRNAs	miR199b-5p 	1
miRNA-corp.d157.s13	We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life.  	miRNA-corp.d157.s13.e1	Diseases	MB 	2
miRNA-corp.d157.s13	We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life.  	miRNA-corp.d157.s13.e2	Diseases	MB tumor 	3
miRNA-corp.d157.s13	We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life.  	miRNA-corp.d157.s13.e3	Diseases	tumor 	4
miRNA-corp.d157.s13	We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life.  	miRNA-corp.d157.s13.e4	Species	patient 	5
miRNA-corp.d157.s14	Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB.  	miRNA-corp.d157.s14.e0	Specific_miRNAs	miR-199b-5p 	1
miRNA-corp.d157.s14	Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB.  	miRNA-corp.d157.s14.e1	Diseases	MB 	2
miRNA-corp.d157.s14	Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB.  	miRNA-corp.d157.s14.e2	Relation_Trigger	expression correlates 	3
miRNA-corp.d157.s14	Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB.  	miRNA-corp.d157.s14.e3	Species	patients 	4
miRNA-corp.d157.s15	These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations.  	miRNA-corp.d157.s15.e0	Specific_miRNAs	miR-199b-5p 	1
miRNA-corp.d157.s15	These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations.  	miRNA-corp.d157.s15.e1	Diseases	MBs 	2
miRNA-corp.d157.s15	These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations.  	miRNA-corp.d157.s15.e2	Relation_Trigger	down-regulation 	3
miRNA-corp.d157.s16	Furthermore, two cell lines (Med8a and UW228) showed significant up-regulation of miR-199b-5p upon treatment.  	miRNA-corp.d157.s16.e0	Specific_miRNAs	miR-199b-5p 	1
miRNA-corp.d157.s16	Furthermore, two cell lines (Med8a and UW228) showed significant up-regulation of miR-199b-5p upon treatment.  	miRNA-corp.d157.s16.e1	Relation_Trigger	up-regulation 	2
miRNA-corp.d157.s17	Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation.  	miRNA-corp.d157.s17.e0	Specific_miRNAs	miR-199b-5p 	1
miRNA-corp.d157.s17	Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation.  	miRNA-corp.d157.s17.e1	Relation_Trigger	lower miR-199b-5p expression 	2
miRNA-corp.d157.s17	Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation.  	miRNA-corp.d157.s17.e2	Relation_Trigger	regulation 	3
miRNA-corp.d158.s0	Many tools have been developed to help describe the repertoire of miRNAs present at the tissue level in a given sample.  	miRNA-corp.d158.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d158.s1	To understand how miRNAs contribute to normal biologic functions and disease states, it is critical to understand the miRNAs that are expressed in particular cell types under a range of conditions.  	miRNA-corp.d158.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d158.s1	To understand how miRNAs contribute to normal biologic functions and disease states, it is critical to understand the miRNAs that are expressed in particular cell types under a range of conditions.  	miRNA-corp.d158.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d158.s3	However, tissue level miRNA profiling is inadequate to pinpoint the cellular and sub-cellular distribution of individual miRNAs.  	miRNA-corp.d158.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d158.s3	However, tissue level miRNA profiling is inadequate to pinpoint the cellular and sub-cellular distribution of individual miRNAs.  	miRNA-corp.d158.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d158.s4	In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain.   	miRNA-corp.d158.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d158.s4	In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain.   	miRNA-corp.d158.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d158.s4	In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain.   	miRNA-corp.d158.s4.e2	Species	human 	3
miRNA-corp.d158.s6	MicroRNAs (miRNAs) play fundamental roles in human brain neurochemistry.  	miRNA-corp.d158.s6.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d158.s6	MicroRNAs (miRNAs) play fundamental roles in human brain neurochemistry.  	miRNA-corp.d158.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d158.s6	MicroRNAs (miRNAs) play fundamental roles in human brain neurochemistry.  	miRNA-corp.d158.s6.e2	Species	human 	3
miRNA-corp.d158.s7	Thus, in situ hybridization is an important experimental complement to tissue level miRNA expression profiling.  	miRNA-corp.d158.s7.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d158.s8	We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease.  	miRNA-corp.d158.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d158.s8	We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease.  	miRNA-corp.d158.s8.e1	Relation_Trigger	expression that would be lost 	2
miRNA-corp.d158.s8	We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease.  	miRNA-corp.d158.s8.e2	Relation_Trigger	lost on most tissue level expression 	3
miRNA-corp.d158.s8	We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease.  	miRNA-corp.d158.s8.e3	Diseases	human brain disease 	4
miRNA-corp.d158.s8	We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease.  	miRNA-corp.d158.s8.e4	Species	human 	5
miRNA-corp.d158.s9	Technical and theoretical aspects of this important technique are described, especially those pertinent to studying the human brain.    	miRNA-corp.d158.s9.e0	Species	human 	1
miRNA-corp.d159.s0	However, we report the experience of a patient who inadvertently received live polio vaccine whilst receiving anti-TNF therapy.  	miRNA-corp.d159.s0.e0	Diseases	polio 	1
miRNA-corp.d159.s0	However, we report the experience of a patient who inadvertently received live polio vaccine whilst receiving anti-TNF therapy.  	miRNA-corp.d159.s0.e1	Species	patient 	2
miRNA-corp.d159.s1	International guidelines state that live vaccines are contraindicated in patients on anti-TNF therapy.  	miRNA-corp.d159.s1.e0	Species	patients 	1
miRNA-corp.d159.s2	Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis.   	miRNA-corp.d159.s2.e0	Diseases	polio 	1
miRNA-corp.d159.s2	Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis.   	miRNA-corp.d159.s2.e1	Diseases	arthritis 	2
miRNA-corp.d159.s3	Patients should be counseled regarding the risks of live vaccines prior to treatment with anti-TNF therapy.    	miRNA-corp.d159.s3.e0	Species	Patients 	1
miRNA-corp.d159.s4	However, if we consider adult patients with rheumatic diseases to have altered immunocompetence, it is recommended that they receive the usual inactivated vaccines according to standard schedules, and live vaccines should be avoided in those who are treated with more potent forms of immune suppression.  	miRNA-corp.d159.s4.e0	Relation_Trigger	suppression 	1
miRNA-corp.d159.s4	However, if we consider adult patients with rheumatic diseases to have altered immunocompetence, it is recommended that they receive the usual inactivated vaccines according to standard schedules, and live vaccines should be avoided in those who are treated with more potent forms of immune suppression.  	miRNA-corp.d159.s4.e1	Diseases	rheumatic diseases 	2
miRNA-corp.d159.s4	However, if we consider adult patients with rheumatic diseases to have altered immunocompetence, it is recommended that they receive the usual inactivated vaccines according to standard schedules, and live vaccines should be avoided in those who are treated with more potent forms of immune suppression.  	miRNA-corp.d159.s4.e2	Species	patients 	3
miRNA-corp.d159.s5	No clear guidelines are available for all vaccines in patients with specific rheumatic diseases.  	miRNA-corp.d159.s5.e0	Diseases	rheumatic diseases 	1
miRNA-corp.d159.s5	No clear guidelines are available for all vaccines in patients with specific rheumatic diseases.  	miRNA-corp.d159.s5.e1	Species	patients 	2
miRNA-corp.d159.s6	Patient did not suffer from any infectious sequel as a result.  	miRNA-corp.d159.s6.e0	Species	Patient 	1
miRNA-corp.d160.s0	Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.    	miRNA-corp.d160.s0.e0	Diseases	astrocytoma 	1
miRNA-corp.d160.s0	Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.    	miRNA-corp.d160.s0.e1	Diseases	glioblastoma 	2
miRNA-corp.d160.s0	Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.    	miRNA-corp.d160.s0.e2	Diseases	astrocytoma 	3
miRNA-corp.d160.s0	Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.    	miRNA-corp.d160.s0.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d160.s0	Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.    	miRNA-corp.d160.s0.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e1	Specific_miRNAs	miR-23a 	2
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e2	Specific_miRNAs	miR-219-5p 	3
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e3	Specific_miRNAs	miR-218 	4
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e5	Non-Specific_miRNAs	miRNAs 	6
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e6	Diseases	glioblastoma 	7
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e7	Diseases	glioblastoma 	8
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e8	Relation_Trigger	overexpression 	9
miRNA-corp.d160.s1	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.  	miRNA-corp.d160.s1.e9	Relation_Trigger	Inhibition 	10
miRNA-corp.d160.s2	Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.  	miRNA-corp.d160.s2.e0	Diseases	glioblastoma 	1
miRNA-corp.d160.s2	Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.  	miRNA-corp.d160.s2.e1	Diseases	brain tumor 	2
miRNA-corp.d160.s3	Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).  	miRNA-corp.d160.s3.e0	Diseases	anaplastic astrocytoma 	1
miRNA-corp.d160.s3	Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).  	miRNA-corp.d160.s3.e1	Diseases	glioblastoma 	2
miRNA-corp.d160.s3	Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).  	miRNA-corp.d160.s3.e2	Diseases	astrocytoma 	3
miRNA-corp.d160.s4	Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.   	miRNA-corp.d160.s4.e0	Diseases	astrocytoma 	1
miRNA-corp.d160.s4	Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.   	miRNA-corp.d160.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d160.s4	Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.   	miRNA-corp.d160.s4.e2	Relation_Trigger	deregulated 	3
miRNA-corp.d160.s5	The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).  	miRNA-corp.d160.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d160.s5	The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).  	miRNA-corp.d160.s5.e1	Diseases	astrocytomas 	2
miRNA-corp.d160.s5	The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).  	miRNA-corp.d160.s5.e2	Relation_Trigger	differential expression 	3
miRNA-corp.d160.s6	More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.  	miRNA-corp.d160.s6.e0	Diseases	glioblastoma 	1
miRNA-corp.d160.s6	More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.  	miRNA-corp.d160.s6.e1	Diseases	astrocytoma 	2
miRNA-corp.d160.s6	More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.  	miRNA-corp.d160.s6.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d160.s7	We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.  	miRNA-corp.d160.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d160.s7	We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.  	miRNA-corp.d160.s7.e1	Relation_Trigger	differentially regulated 	2
miRNA-corp.d160.s7	We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.  	miRNA-corp.d160.s7.e2	Diseases	glioma 	3
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e0	Diseases	glioblastoma 	1
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e1	Diseases	anaplastic astrocytoma 	2
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e2	Diseases	astrocytoma 	3
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e5	Non-Specific_miRNAs	miRNA 	6
miRNA-corp.d160.s8	We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.  	miRNA-corp.d160.s8.e6	Relation_Trigger	deregulated 	7
miRNA-corp.d161.s0	Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.    	miRNA-corp.d161.s0.e0	Specific_miRNAs	miR-17 	1
miRNA-corp.d161.s0	Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.    	miRNA-corp.d161.s0.e1	Diseases	MBs 	2
miRNA-corp.d161.s0	Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.    	miRNA-corp.d161.s0.e2	Species	mouse 	3
miRNA-corp.d161.s0	Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.    	miRNA-corp.d161.s0.e3	Species	man 	4
miRNA-corp.d161.s0	Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.    	miRNA-corp.d161.s0.e4	Genes/Proteins	SHH 	5
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e0	Specific_miRNAs	miR-17 	1
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e1	Specific_miRNAs	miR-92 	2
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e2	Specific_miRNAs	miR-19a 	3
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e3	Specific_miRNAs	miR-20 	4
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e4	Diseases	MBs 	5
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e5	Relation_Trigger	overexpressed 	6
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e6	Relation_Trigger	activated 	7
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e7	Diseases	human MBs 	8
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e8	Non-Specific_miRNAs	miRNAs 	9
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e9	Genes/Proteins	Sonic Hedgehog 	10
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e10	Genes/Proteins	SHH 	11
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e11	Species	human 	12
miRNA-corp.d161.s1	Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease.  	miRNA-corp.d161.s1.e12	Species	human 	13
miRNA-corp.d161.s2	To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice.  	miRNA-corp.d161.s2.e0	Specific_miRNAs	miR-17 	1
miRNA-corp.d161.s2	To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice.  	miRNA-corp.d161.s2.e1	Diseases	MB 	2
miRNA-corp.d161.s2	To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice.  	miRNA-corp.d161.s2.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d161.s2	To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice.  	miRNA-corp.d161.s2.e3	Species	mice 	4
miRNA-corp.d161.s2	To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice.  	miRNA-corp.d161.s2.e4	Genes/Proteins	Ink4c 	5
miRNA-corp.d161.s3	These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance.  	miRNA-corp.d161.s3.e0	Diseases	MBs 	1
miRNA-corp.d161.s3	These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance.  	miRNA-corp.d161.s3.e1	Genes/Proteins	p53 	2
miRNA-corp.d161.s3	These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance.  	miRNA-corp.d161.s3.e2	Genes/Proteins	Ink4c 	3
miRNA-corp.d161.s3	These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance.  	miRNA-corp.d161.s3.e3	Species	mice 	4
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e0	Specific_miRNAs	miR-17 	1
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e1	Genes/Proteins	Ptch1 	2
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e2	Relation_Trigger	ectopically expressing 	3
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e3	Relation_Trigger	lost expression 	4
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e4	Species	mouse 	5
miRNA-corp.d161.s4	Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele.  	miRNA-corp.d161.s4.e5	Diseases	tumors 	6
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e0	Diseases	MB 	1
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e1	Diseases	MB 	2
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e4	Genes/Proteins	Ink4c 	5
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e5	Genes/Proteins	p53 	6
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e6	Genes/Proteins	Ink4c 	7
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e7	Relation_Trigger	regulate 	8
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e8	Relation_Trigger	alterations in miRNA expression 	9
miRNA-corp.d161.s6	Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-.  	miRNA-corp.d161.s6.e9	Species	mouse 	10
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e2	Diseases	MBs 	3
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e3	Relation_Trigger	increased expression 	4
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e4	Relation_Trigger	decreased expression 	5
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e5	Species	mouse 	6
miRNA-corp.d161.s7	We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype.  	miRNA-corp.d161.s7.e6	Species	mouse 	7
miRNA-corp.d161.s8	Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types.  	miRNA-corp.d161.s8.e0	Specific_miRNAs	miR-17 	1
miRNA-corp.d161.s8	Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types.  	miRNA-corp.d161.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d161.s8	Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types.  	miRNA-corp.d161.s8.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d161.s8	Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types.  	miRNA-corp.d161.s8.e3	Relation_Trigger	overexpressed 	4
miRNA-corp.d161.s8	Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types.  	miRNA-corp.d161.s8.e4	Diseases	tumor 	5
miRNA-corp.d161.s9	The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.   	miRNA-corp.d161.s9.e0	Specific_miRNAs	miR-17~92 	1
miRNA-corp.d161.s9	The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.   	miRNA-corp.d161.s9.e1	Diseases	medulloblastoma 	2
miRNA-corp.d161.s9	The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.   	miRNA-corp.d161.s9.e2	Genes/Proteins	Sonic Hedgehog 	3
miRNA-corp.d161.s10	Medulloblastomas (MBs) are the most common brain tumors in children.  	miRNA-corp.d161.s10.e0	Diseases	brain tumors 	1
miRNA-corp.d161.s10	Medulloblastomas (MBs) are the most common brain tumors in children.  	miRNA-corp.d161.s10.e1	Diseases	Medulloblastomas 	2
miRNA-corp.d161.s10	Medulloblastomas (MBs) are the most common brain tumors in children.  	miRNA-corp.d161.s10.e2	Diseases	MBs 	3
miRNA-corp.d161.s10	Medulloblastomas (MBs) are the most common brain tumors in children.  	miRNA-corp.d161.s10.e3	Diseases	tumors 	4
miRNA-corp.d161.s10	Medulloblastomas (MBs) are the most common brain tumors in children.  	miRNA-corp.d161.s10.e4	Species	children 	5
miRNA-corp.d162.s0	Autosomal-recessive cerebellar ataxias comprise a clinically and genetically heterogeneous group of neurodegenerative disorders.  	miRNA-corp.d162.s0.e0	Diseases	Autosomal-recessive cerebellar ataxias 	1
miRNA-corp.d162.s0	Autosomal-recessive cerebellar ataxias comprise a clinically and genetically heterogeneous group of neurodegenerative disorders.  	miRNA-corp.d162.s0.e1	Diseases	neurodegenerative disorders 	2
miRNA-corp.d162.s1	In contrast to their dominant counterparts, unraveling the molecular background of these ataxias has proven to be more complicated and the currently known mutations provide incomplete coverage for genotyping of patients.  	miRNA-corp.d162.s1.e0	Diseases	ataxias 	1
miRNA-corp.d162.s1	In contrast to their dominant counterparts, unraveling the molecular background of these ataxias has proven to be more complicated and the currently known mutations provide incomplete coverage for genotyping of patients.  	miRNA-corp.d162.s1.e1	Species	patients 	2
miRNA-corp.d162.s2	By combining SNP array-based linkage analysis and targeted resequencing of relevant sequences in the linkage interval with the use of next-generation sequencing technology, we identified a mutation in a gene and have shown its association with autosomal-recessive cerebellar ataxia.  	miRNA-corp.d162.s2.e0	Relation_Trigger	targeted 	1
miRNA-corp.d162.s2	By combining SNP array-based linkage analysis and targeted resequencing of relevant sequences in the linkage interval with the use of next-generation sequencing technology, we identified a mutation in a gene and have shown its association with autosomal-recessive cerebellar ataxia.  	miRNA-corp.d162.s2.e1	Relation_Trigger	association 	2
miRNA-corp.d162.s2	By combining SNP array-based linkage analysis and targeted resequencing of relevant sequences in the linkage interval with the use of next-generation sequencing technology, we identified a mutation in a gene and have shown its association with autosomal-recessive cerebellar ataxia.  	miRNA-corp.d162.s2.e2	Diseases	autosomal-recessive cerebellar ataxia 	3
miRNA-corp.d162.s3	In a Dutch consanguineous family with three affected siblings a homozygous 12.5 Mb region on chromosome 3 was targeted by array-based sequence capture.  	miRNA-corp.d162.s3.e0	Relation_Trigger	targeted 	1
miRNA-corp.d162.s4	Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia.   	miRNA-corp.d162.s4.e0	Relation_Trigger	Targeted 	1
miRNA-corp.d162.s4	Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia.   	miRNA-corp.d162.s4.e1	Diseases	autosomal-recessive cerebellar ataxia 	2
miRNA-corp.d162.s4	Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia.   	miRNA-corp.d162.s4.e2	Genes/Proteins	ANO10 	3
miRNA-corp.d162.s4	Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia.   	miRNA-corp.d162.s4.e3	Species	patients 	4
miRNA-corp.d162.s5	The analysis of ANO10 by Sanger sequencing revealed three additional mutations: a homozygous mutation (c.1150_1151del [p.Leu384fs]) in a Serbian family and a compound-heterozygous splice-site mutation (c.1476+1G>T) and a frameshift mutation (c.1604del [p.Leu535X]) in a French family.  	miRNA-corp.d162.s5.e0	Genes/Proteins	ANO10 	1
miRNA-corp.d162.s8	This variant was a leucine-to-arginine substitution in the DUF 590 domain of a 16K transmembrane protein, a putative calcium-activated chloride channel encoded by anoctamin 10 (ANO10).  	miRNA-corp.d162.s8.e0	Genes/Proteins	ANO10 	1
miRNA-corp.d162.s8	This variant was a leucine-to-arginine substitution in the DUF 590 domain of a 16K transmembrane protein, a putative calcium-activated chloride channel encoded by anoctamin 10 (ANO10).  	miRNA-corp.d162.s8.e1	Genes/Proteins	anoctamin 10 	2
miRNA-corp.d162.s9	Moreover, identifying a putative calcium-dependent chloride channel involved in cerebellar ataxia adds another pathway to the list of pathophysiological mechanisms that may cause cerebellar ataxia.    	miRNA-corp.d162.s9.e0	Diseases	cerebellar ataxia 	1
miRNA-corp.d162.s9	Moreover, identifying a putative calcium-dependent chloride channel involved in cerebellar ataxia adds another pathway to the list of pathophysiological mechanisms that may cause cerebellar ataxia.    	miRNA-corp.d162.s9.e1	Diseases	cerebellar ataxia 	2
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e0	Genes/Proteins	SNCA 	1
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e1	Genes/Proteins	SNCA 	2
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e2	Diseases	PD 	3
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e3	Relation_Trigger	over-expression 	4
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e4	Relation_Trigger	reduce levels 	5
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e5	Species	human 	6
miRNA-corp.d163.s0	Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.  	miRNA-corp.d163.s0.e6	Species	human 	7
miRNA-corp.d163.s1	Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD).  	miRNA-corp.d163.s1.e0	Genes/Proteins	Alpha-synuclein 	1
miRNA-corp.d163.s1	Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD).  	miRNA-corp.d163.s1.e1	Genes/Proteins	SNCA 	2
miRNA-corp.d163.s1	Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD).  	miRNA-corp.d163.s1.e2	Diseases	Parkinson's disease 	3
miRNA-corp.d163.s1	Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD).  	miRNA-corp.d163.s1.e3	Diseases	PD 	4
miRNA-corp.d163.s1	Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD).  	miRNA-corp.d163.s1.e4	Relation_Trigger	abundantly expressed 	5
miRNA-corp.d163.s2	A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons.   	miRNA-corp.d163.s2.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d163.s2	A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons.   	miRNA-corp.d163.s2.e1	Genes/Proteins	alpha-synuclein 	2
miRNA-corp.d163.s2	A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons.   	miRNA-corp.d163.s2.e2	Genes/Proteins	AAV 	3
miRNA-corp.d163.s3	Our in vitro data suggest that this miRNA-embedded silencing vector may be ideal for chronic in vivo SNCA gene silencing in DA neurons.    	miRNA-corp.d163.s3.e0	Genes/Proteins	SNCA 	1
miRNA-corp.d163.s3	Our in vitro data suggest that this miRNA-embedded silencing vector may be ideal for chronic in vivo SNCA gene silencing in DA neurons.    	miRNA-corp.d163.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d163.s4	However, the mir30 embedded vector was significantly less toxic to both PC12 and SH-SY5Y cells.  	miRNA-corp.d163.s4.e0	Specific_miRNAs	mir30 	1
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e0	Genes/Proteins	SNCA 	1
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e1	Genes/Proteins	tyrosine hydroxylase 	2
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e2	Relation_Trigger	decreased expression 	3
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e3	Genes/Proteins	vesicular monoamine transporter 	4
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e4	Genes/Proteins	dopamine transporter 	5
miRNA-corp.d163.s5	In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).  	miRNA-corp.d163.s5.e5	Species	rat 	6
miRNA-corp.d163.s7	The same hSNCA silencing sequence (shRNA) was used in both vectors, but in one vector, the shRNA was embedded in a microRNA backbone and driven by a pol II promoter, and in the other the shRNA was not embedded in a microRNA and was driven by a pol III promoter.  	miRNA-corp.d163.s7.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d163.s7	The same hSNCA silencing sequence (shRNA) was used in both vectors, but in one vector, the shRNA was embedded in a microRNA backbone and driven by a pol II promoter, and in the other the shRNA was not embedded in a microRNA and was driven by a pol III promoter.  	miRNA-corp.d163.s7.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d163.s8	To begin to develop a gene therapy for PD based on hSNCA gene silencing, two AAV gene silencing vectors were designed, and tested for efficiency and specificity of silencing, as well as toxicity in vitro.  	miRNA-corp.d163.s8.e0	Diseases	PD 	1
miRNA-corp.d163.s8	To begin to develop a gene therapy for PD based on hSNCA gene silencing, two AAV gene silencing vectors were designed, and tested for efficiency and specificity of silencing, as well as toxicity in vitro.  	miRNA-corp.d163.s8.e1	Genes/Proteins	AAV 	2
miRNA-corp.d164.s0	Taken together, induction of microRNA expression in BMC may contribute to the aberrant systemic decline in mRNA levels in sporadic AD.    	miRNA-corp.d164.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d164.s0	Taken together, induction of microRNA expression in BMC may contribute to the aberrant systemic decline in mRNA levels in sporadic AD.    	miRNA-corp.d164.s0.e1	Diseases	sporadic AD 	2
miRNA-corp.d164.s1	MicroRNA expression in Alzheimer blood mononuclear cells.   	miRNA-corp.d164.s1.e0	Diseases	Alzheimer 	1
miRNA-corp.d164.s1	MicroRNA expression in Alzheimer blood mononuclear cells.   	miRNA-corp.d164.s1.e1	Non-Specific_miRNAs	MicroRNA 	2
miRNA-corp.d164.s2	Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD).  	miRNA-corp.d164.s2.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d164.s2	Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD).  	miRNA-corp.d164.s2.e1	Diseases	AD 	2
miRNA-corp.d164.s2	Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD).  	miRNA-corp.d164.s2.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d164.s2	Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD).  	miRNA-corp.d164.s2.e3	Species	patients 	4
miRNA-corp.d164.s3	Noncoding microRNAs (miRNA) regulate gene expression by degrading messages or inhibiting translation.  	miRNA-corp.d164.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d164.s3	Noncoding microRNAs (miRNA) regulate gene expression by degrading messages or inhibiting translation.  	miRNA-corp.d164.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d164.s3	Noncoding microRNAs (miRNA) regulate gene expression by degrading messages or inhibiting translation.  	miRNA-corp.d164.s3.e2	Relation_Trigger	inhibiting translation 	3
miRNA-corp.d164.s3	Noncoding microRNAs (miRNA) regulate gene expression by degrading messages or inhibiting translation.  	miRNA-corp.d164.s3.e3	Relation_Trigger	regulate gene expression 	4
miRNA-corp.d164.s4	Using BMC as a paradigm for the study of systemic alterations in AD, we investigated whether peripheral miRNA expression is altered in this condition.  	miRNA-corp.d164.s4.e0	Diseases	AD 	1
miRNA-corp.d164.s4	Using BMC as a paradigm for the study of systemic alterations in AD, we investigated whether peripheral miRNA expression is altered in this condition.  	miRNA-corp.d164.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d164.s4	Using BMC as a paradigm for the study of systemic alterations in AD, we investigated whether peripheral miRNA expression is altered in this condition.  	miRNA-corp.d164.s4.e2	Relation_Trigger	expression is altered 	3
miRNA-corp.d164.s5	MicroRNA levels were assessed using the microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR.  	miRNA-corp.d164.s5.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d164.s5	MicroRNA levels were assessed using the microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR.  	miRNA-corp.d164.s5.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d164.s5	MicroRNA levels were assessed using the microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR.  	miRNA-corp.d164.s5.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d164.s5	MicroRNA levels were assessed using the microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR.  	miRNA-corp.d164.s5.e3	Species	human 	4
miRNA-corp.d164.s6	Sixteen AD patients and sixteen normal elderly controls (NEC) were matched for ethnicity, age, gender and education.  	miRNA-corp.d164.s6.e0	Diseases	AD 	1
miRNA-corp.d164.s6	Sixteen AD patients and sixteen normal elderly controls (NEC) were matched for ethnicity, age, gender and education.  	miRNA-corp.d164.s6.e1	Species	patients 	2
miRNA-corp.d164.s7	The expression of several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one or two APOE4 alleles.  	miRNA-corp.d164.s7.e0	Diseases	AD 	1
miRNA-corp.d164.s7	The expression of several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one or two APOE4 alleles.  	miRNA-corp.d164.s7.e1	Diseases	AD 	2
miRNA-corp.d164.s7	The expression of several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one or two APOE4 alleles.  	miRNA-corp.d164.s7.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d164.s7	The expression of several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one or two APOE4 alleles.  	miRNA-corp.d164.s7.e3	Relation_Trigger	expression of several BMC miRNAs was found to increase 	4
miRNA-corp.d164.s8	As compared to NEC, miRNAs significantly upregulated in AD subjects and confirmed by qPCR were miR-34a and 181b.  	miRNA-corp.d164.s8.e0	Specific_miRNAs	miR-34a and 181b 	1
miRNA-corp.d164.s8	As compared to NEC, miRNAs significantly upregulated in AD subjects and confirmed by qPCR were miR-34a and 181b.  	miRNA-corp.d164.s8.e1	Diseases	AD 	2
miRNA-corp.d164.s8	As compared to NEC, miRNAs significantly upregulated in AD subjects and confirmed by qPCR were miR-34a and 181b.  	miRNA-corp.d164.s8.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d164.s8	As compared to NEC, miRNAs significantly upregulated in AD subjects and confirmed by qPCR were miR-34a and 181b.  	miRNA-corp.d164.s8.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e0	Diseases	Alzheimer 	1
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e3	Relation_Trigger	correlated 	4
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e4	Relation_Trigger	upregulated 	5
miRNA-corp.d164.s9	Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity.  	miRNA-corp.d164.s9.e5	Relation_Trigger	Predicted target 	6
miRNA-corp.d164.s10	Several miRNAs targeting the same genes were within the functional category of Injury response/Redox homeostasis.  	miRNA-corp.d164.s10.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d164.s10	Several miRNAs targeting the same genes were within the functional category of Injury response/Redox homeostasis.  	miRNA-corp.d164.s10.e1	Relation_Trigger	targeting 	2
miRNA-corp.d164.s10	Several miRNAs targeting the same genes were within the functional category of Injury response/Redox homeostasis.  	miRNA-corp.d164.s10.e2	Diseases	Injury 	3
miRNA-corp.d165.s0	Despite the small sample available, we can show that this approach permits identification of meaningful structures, in particular two polycistronic miRNA genes related to transcriptional activity and likely to be relevant in the discrimination between gliosarcomas and other brain tumors.  	miRNA-corp.d165.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d165.s0	Despite the small sample available, we can show that this approach permits identification of meaningful structures, in particular two polycistronic miRNA genes related to transcriptional activity and likely to be relevant in the discrimination between gliosarcomas and other brain tumors.  	miRNA-corp.d165.s0.e1	Diseases	gliosarcomas 	2
miRNA-corp.d165.s0	Despite the small sample available, we can show that this approach permits identification of meaningful structures, in particular two polycistronic miRNA genes related to transcriptional activity and likely to be relevant in the discrimination between gliosarcomas and other brain tumors.  	miRNA-corp.d165.s0.e2	Diseases	brain tumors 	3
miRNA-corp.d165.s1	Our intention is to identify structures that contain information from both mRNAs and miRNAs, and that can explain the complexity of the data.  	miRNA-corp.d165.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d165.s7	Joint analysis of transcriptional and post- transcriptional brain tumor data: searching for emergent properties of cellular systems.   	miRNA-corp.d165.s7.e0	Diseases	brain tumor 	1
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e3	Diseases	PD 	4
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e4	Relation_Trigger	regulation 	5
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e5	Relation_Trigger	target 	6
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e6	Relation_Trigger	target 	7
miRNA-corp.d166.s0	To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1).  	miRNA-corp.d166.s0.e7	Species	human 	8
miRNA-corp.d166.s1	Data extracted by miRanda elucidates the mode of microRNA action based on the location of target sites in the Parkinson genes.  	miRNA-corp.d166.s1.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d166.s1	Data extracted by miRanda elucidates the mode of microRNA action based on the location of target sites in the Parkinson genes.  	miRNA-corp.d166.s1.e1	Relation_Trigger	target 	2
miRNA-corp.d166.s2	Sites prone to action of multiple miRNAs were identified as "hot spots."  	miRNA-corp.d166.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d166.s3	Important properties of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and their targets.  	miRNA-corp.d166.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d166.s3	Important properties of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and their targets.  	miRNA-corp.d166.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d166.s3	Important properties of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and their targets.  	miRNA-corp.d166.s3.e2	Relation_Trigger	targets 	3
miRNA-corp.d166.s4	Two sets of predicted results were explored for the occurrence of target sites of 112 miRNAs expressed in midbrain.  	miRNA-corp.d166.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d166.s4	Two sets of predicted results were explored for the occurrence of target sites of 112 miRNAs expressed in midbrain.  	miRNA-corp.d166.s4.e1	Relation_Trigger	target 	2
miRNA-corp.d166.s5	Overall, convergence of results predicted by two algorithms revealed that 48 target sites for midbrain-specific miRNA occur in close proximity in 9 genes.  	miRNA-corp.d166.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d166.s5	Overall, convergence of results predicted by two algorithms revealed that 48 target sites for midbrain-specific miRNA occur in close proximity in 9 genes.  	miRNA-corp.d166.s5.e1	Relation_Trigger	target 	2
miRNA-corp.d166.s6	This study will pave a way for selection of potential miRNA candidates for Parkinson's disease-related genes for quick therapeutic applications and diagnosis.    	miRNA-corp.d166.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d166.s6	This study will pave a way for selection of potential miRNA candidates for Parkinson's disease-related genes for quick therapeutic applications and diagnosis.    	miRNA-corp.d166.s6.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d166.s7	Parkinson's disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons.  	miRNA-corp.d166.s7.e0	Diseases	Parkinson's disease 	1
miRNA-corp.d166.s7	Parkinson's disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons.  	miRNA-corp.d166.s7.e1	Diseases	PD 	2
miRNA-corp.d166.s7	Parkinson's disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons.  	miRNA-corp.d166.s7.e2	Diseases	neurodisorder 	3
miRNA-corp.d166.s8	Interaction map and selection of microRNA targets in Parkinson's disease-related genes.   	miRNA-corp.d166.s8.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d166.s8	Interaction map and selection of microRNA targets in Parkinson's disease-related genes.   	miRNA-corp.d166.s8.e1	Relation_Trigger	targets 	2
miRNA-corp.d166.s8	Interaction map and selection of microRNA targets in Parkinson's disease-related genes.   	miRNA-corp.d166.s8.e2	Diseases	Parkinson's disease 	3
miRNA-corp.d167.s0	These studies suggest that miRNAs may be important for neuronal survival in the context of human neurodegenerative disease.  	miRNA-corp.d167.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d167.s0	These studies suggest that miRNAs may be important for neuronal survival in the context of human neurodegenerative disease.  	miRNA-corp.d167.s0.e1	Diseases	neurodegenerative disease 	2
miRNA-corp.d167.s0	These studies suggest that miRNAs may be important for neuronal survival in the context of human neurodegenerative disease.  	miRNA-corp.d167.s0.e2	Species	human 	3
miRNA-corp.d167.s1	These studies provide the foundation to define the miRNAs involved in neurodegenerative disease, and the biological pathways affected.    	miRNA-corp.d167.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d167.s1	These studies provide the foundation to define the miRNAs involved in neurodegenerative disease, and the biological pathways affected.    	miRNA-corp.d167.s1.e1	Diseases	neurodegenerative disease 	2
miRNA-corp.d167.s2	These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3).  	miRNA-corp.d167.s2.e0	Genes/Proteins	Ataxin-3 	1
miRNA-corp.d167.s2	These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3).  	miRNA-corp.d167.s2.e1	Relation_Trigger	upregulation 	2
miRNA-corp.d167.s2	These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3).  	miRNA-corp.d167.s2.e2	Diseases	disease spinocerebellar ataxia type 3 	3
miRNA-corp.d167.s2	These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3).  	miRNA-corp.d167.s2.e3	Diseases	SCA3 	4
miRNA-corp.d167.s2	These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3).  	miRNA-corp.d167.s2.e4	Species	human 	5
miRNA-corp.d167.s3	To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells.  	miRNA-corp.d167.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d167.s3	To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells.  	miRNA-corp.d167.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d167.s3	To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells.  	miRNA-corp.d167.s3.e2	Genes/Proteins	dicer 	3
miRNA-corp.d167.s3	To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells.  	miRNA-corp.d167.s3.e3	Relation_Trigger	loss of all miRNAs 	4
miRNA-corp.d167.s3	To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells.  	miRNA-corp.d167.s3.e4	Species	human 	5
miRNA-corp.d167.s4	A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins.   	miRNA-corp.d167.s4.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d167.s4	A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins.   	miRNA-corp.d167.s4.e1	Relation_Trigger	modulation 	2
miRNA-corp.d167.s4	A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins.   	miRNA-corp.d167.s4.e2	Species	human 	3
miRNA-corp.d167.s5	MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of target transcript mRNAs.  	miRNA-corp.d167.s5.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d167.s5	MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of target transcript mRNAs.  	miRNA-corp.d167.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d167.s5	MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of target transcript mRNAs.  	miRNA-corp.d167.s5.e2	Relation_Trigger	target 	3
miRNA-corp.d167.s5	MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of target transcript mRNAs.  	miRNA-corp.d167.s5.e3	Relation_Trigger	regulate the expression 	4
miRNA-corp.d167.s6	Many miRNAs have been defined, however their roles and the processes influenced by miRNA pathways are still being elucidated.  	miRNA-corp.d167.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d167.s6	Many miRNAs have been defined, however their roles and the processes influenced by miRNA pathways are still being elucidated.  	miRNA-corp.d167.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d167.s7	A role for miRNAs in development and cancer has been described.  	miRNA-corp.d167.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d167.s7	A role for miRNAs in development and cancer has been described.  	miRNA-corp.d167.s7.e1	Diseases	cancer 	2
miRNA-corp.d167.s8	We recently isolated the miRNA bantam (ban) in a genetic screen for modulators of pathogenicity of a human neurodegenerative disease model in Drosophila.  	miRNA-corp.d167.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d167.s8	We recently isolated the miRNA bantam (ban) in a genetic screen for modulators of pathogenicity of a human neurodegenerative disease model in Drosophila.  	miRNA-corp.d167.s8.e1	Relation_Trigger	modulators 	2
miRNA-corp.d167.s8	We recently isolated the miRNA bantam (ban) in a genetic screen for modulators of pathogenicity of a human neurodegenerative disease model in Drosophila.  	miRNA-corp.d167.s8.e2	Diseases	neurodegenerative disease 	3
miRNA-corp.d167.s8	We recently isolated the miRNA bantam (ban) in a genetic screen for modulators of pathogenicity of a human neurodegenerative disease model in Drosophila.  	miRNA-corp.d167.s8.e3	Species	human 	4
miRNA-corp.d168.s0	CONCLUSIONS/SIGNIFICANCE: We provide a list of ten miRNA loci potentially involved in the development of blood cancer or brain tumors.  	miRNA-corp.d168.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s0	CONCLUSIONS/SIGNIFICANCE: We provide a list of ten miRNA loci potentially involved in the development of blood cancer or brain tumors.  	miRNA-corp.d168.s0.e1	Diseases	brain tumors 	2
miRNA-corp.d168.s0	CONCLUSIONS/SIGNIFICANCE: We provide a list of ten miRNA loci potentially involved in the development of blood cancer or brain tumors.  	miRNA-corp.d168.s0.e2	Diseases	cancer 	3
miRNA-corp.d168.s1	There is independent experimental support from other studies for the involvement of miRNAs from at least three CIS-associated miRNA loci in cancer development.    	miRNA-corp.d168.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s1	There is independent experimental support from other studies for the involvement of miRNAs from at least three CIS-associated miRNA loci in cancer development.    	miRNA-corp.d168.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d168.s1	There is independent experimental support from other studies for the involvement of miRNAs from at least three CIS-associated miRNA loci in cancer development.    	miRNA-corp.d168.s1.e2	Diseases	cancer 	3
miRNA-corp.d168.s2	CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer.  	miRNA-corp.d168.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d168.s2	CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer.  	miRNA-corp.d168.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d168.s2	CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer.  	miRNA-corp.d168.s2.e2	Relation_Trigger	associated 	3
miRNA-corp.d168.s2	CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer.  	miRNA-corp.d168.s2.e3	Diseases	cancer 	4
miRNA-corp.d168.s2	CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer.  	miRNA-corp.d168.s2.e4	Species	human 	5
miRNA-corp.d168.s3	In addition we show that miRNA genes are enriched around promoter and/or terminator regions of RefSeq genes in both mouse and human.  	miRNA-corp.d168.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s3	In addition we show that miRNA genes are enriched around promoter and/or terminator regions of RefSeq genes in both mouse and human.  	miRNA-corp.d168.s3.e1	Species	mouse 	2
miRNA-corp.d168.s3	In addition we show that miRNA genes are enriched around promoter and/or terminator regions of RefSeq genes in both mouse and human.  	miRNA-corp.d168.s3.e2	Species	human 	3
miRNA-corp.d168.s4	Ten CIS-associated miRNA loci containing 22 miRNAs are located within 10 kb of known CIS insertions.  	miRNA-corp.d168.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s4	Ten CIS-associated miRNA loci containing 22 miRNAs are located within 10 kb of known CIS insertions.  	miRNA-corp.d168.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d168.s5	Only one CIS-associated miRNA locus overlaps a RefSeq protein-coding gene and six loci are located more than 10 kb from any RefSeq gene.  	miRNA-corp.d168.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s6	METHODOLOGY/PRINCIPAL FINDINGS: Using a public database of mapped retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched in close proximity to mouse miRNA loci.  	miRNA-corp.d168.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d168.s6	METHODOLOGY/PRINCIPAL FINDINGS: Using a public database of mapped retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched in close proximity to mouse miRNA loci.  	miRNA-corp.d168.s6.e1	Diseases	cancer 	2
miRNA-corp.d168.s6	METHODOLOGY/PRINCIPAL FINDINGS: Using a public database of mapped retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched in close proximity to mouse miRNA loci.  	miRNA-corp.d168.s6.e2	Species	mouse 	3
miRNA-corp.d168.s6	METHODOLOGY/PRINCIPAL FINDINGS: Using a public database of mapped retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched in close proximity to mouse miRNA loci.  	miRNA-corp.d168.s6.e3	Species	mouse 	4
miRNA-corp.d168.s7	Clustered inserts from cancer-associated regions (Common Integration Sites, CIS) have a higher association with miRNAs than non-clustered inserts.  	miRNA-corp.d168.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d168.s7	Clustered inserts from cancer-associated regions (Common Integration Sites, CIS) have a higher association with miRNAs than non-clustered inserts.  	miRNA-corp.d168.s7.e1	Relation_Trigger	higher association 	2
miRNA-corp.d168.s7	Clustered inserts from cancer-associated regions (Common Integration Sites, CIS) have a higher association with miRNAs than non-clustered inserts.  	miRNA-corp.d168.s7.e2	Diseases	cancer 	3
miRNA-corp.d168.s8	BACKGROUND: MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many organisms and play an important role in cancer.  	miRNA-corp.d168.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d168.s8	BACKGROUND: MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many organisms and play an important role in cancer.  	miRNA-corp.d168.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d168.s8	BACKGROUND: MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many organisms and play an important role in cancer.  	miRNA-corp.d168.s8.e2	Relation_Trigger	regulate 	3
miRNA-corp.d168.s8	BACKGROUND: MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many organisms and play an important role in cancer.  	miRNA-corp.d168.s8.e3	Diseases	cancer 	4
miRNA-corp.d168.s9	Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.   	miRNA-corp.d168.s9.e0	Non-Specific_miRNAs	microRNA 	1
miRNA-corp.d168.s9	Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.   	miRNA-corp.d168.s9.e1	Diseases	cancer 	2
miRNA-corp.d168.s9	Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.   	miRNA-corp.d168.s9.e2	Species	human 	3
miRNA-corp.d168.s9	Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.   	miRNA-corp.d168.s9.e3	Species	mouse 	4
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e1	Diseases	pituitary tumors 	2
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e2	Diseases	pituitary carcinomas 	3
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e3	Specific_miRNAs	microRNA-122 and -493 	4
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e4	Relation_Trigger	up-regulation 	5
miRNA-corp.d169.s0	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.   	miRNA-corp.d169.s0.e5	Genes/Proteins	ACTH 	6
miRNA-corp.d169.s1	Real-time RT-PCR and in situ hybridization were used to confirm and independently validate miRNAs that were significantly up-regulated or down-regulated between the pituitary tissues.  	miRNA-corp.d169.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d169.s1	Real-time RT-PCR and in situ hybridization were used to confirm and independently validate miRNAs that were significantly up-regulated or down-regulated between the pituitary tissues.  	miRNA-corp.d169.s1.e1	Relation_Trigger	down-regulated 	2
miRNA-corp.d169.s1	Real-time RT-PCR and in situ hybridization were used to confirm and independently validate miRNAs that were significantly up-regulated or down-regulated between the pituitary tissues.  	miRNA-corp.d169.s1.e2	Relation_Trigger	up-regulated 	3
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e2	Diseases	pituitary carcinomas 	3
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e3	Diseases	adenomas 	4
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e4	Genes/Proteins	ACTH 	5
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e5	Genes/Proteins	adrenocorticotropin 	6
miRNA-corp.d169.s2	We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).  	miRNA-corp.d169.s2.e6	Genes/Proteins	ACTH 	7
miRNA-corp.d169.s3	The expression of miRNAs in pituitary carcinomas has not been previously examined.  	miRNA-corp.d169.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d169.s3	The expression of miRNAs in pituitary carcinomas has not been previously examined.  	miRNA-corp.d169.s3.e1	Diseases	pituitary carcinomas 	2
miRNA-corp.d169.s4	MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and can function as tumor suppressor genes or oncogenes.  	miRNA-corp.d169.s4.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d169.s4	MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and can function as tumor suppressor genes or oncogenes.  	miRNA-corp.d169.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d169.s4	MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and can function as tumor suppressor genes or oncogenes.  	miRNA-corp.d169.s4.e2	Relation_Trigger	tumor suppressor 	3
miRNA-corp.d169.s5	MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.  	miRNA-corp.d169.s5.e0	Relation_Trigger	up-regulated 	1
miRNA-corp.d169.s5	MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.  	miRNA-corp.d169.s5.e1	Specific_miRNAs	MiRNA-493 	2
miRNA-corp.d169.s5	MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.  	miRNA-corp.d169.s5.e2	Genes/Proteins	ACTH 	3
miRNA-corp.d169.s5	MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.  	miRNA-corp.d169.s5.e3	Diseases	adenomas 	4
miRNA-corp.d169.s5	MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.  	miRNA-corp.d169.s5.e4	Diseases	carcinomas 	5
miRNA-corp.d169.s6	Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth.  	miRNA-corp.d169.s6.e0	Diseases	pituitary tumor 	1
miRNA-corp.d169.s6	Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth.  	miRNA-corp.d169.s6.e1	Specific_miRNAs	miRNA-493 	2
miRNA-corp.d169.s6	Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth.  	miRNA-corp.d169.s6.e2	Genes/Proteins	LGALS3 	3
miRNA-corp.d169.s6	Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth.  	miRNA-corp.d169.s6.e3	Genes/Proteins	RUNX2 	4
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e1	Relation_Trigger	down-regulated 	2
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e2	Relation_Trigger	down-regulated 	3
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e3	Relation_Trigger	down-regulated 	4
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e4	Diseases	adenomas 	5
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e5	Diseases	adenomas 	6
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e6	Diseases	carcinomas 	7
miRNA-corp.d169.s7	There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated).  	miRNA-corp.d169.s7.e7	Diseases	carcinomas 	8
miRNA-corp.d169.s8	Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas.  	miRNA-corp.d169.s8.e0	Diseases	pituitary carcinomas 	1
miRNA-corp.d169.s8	Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas.  	miRNA-corp.d169.s8.e1	Relation_Trigger	up-regulation 	2
miRNA-corp.d169.s8	Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas.  	miRNA-corp.d169.s8.e2	Specific_miRNAs	miRNA-122 	3
miRNA-corp.d169.s8	Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas.  	miRNA-corp.d169.s8.e3	Diseases	adenomas 	4
miRNA-corp.d169.s9	These results provide information about marker miRNAs that may lead to further insights into the regulation of pituitary tumor growth and development.    	miRNA-corp.d169.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d169.s9	These results provide information about marker miRNAs that may lead to further insights into the regulation of pituitary tumor growth and development.    	miRNA-corp.d169.s9.e1	Diseases	pituitary tumor 	2
miRNA-corp.d169.s9	These results provide information about marker miRNAs that may lead to further insights into the regulation of pituitary tumor growth and development.    	miRNA-corp.d169.s9.e2	Relation_Trigger	regulation 	3
miRNA-corp.d170.s0	METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme.  	miRNA-corp.d170.s0.e0	Diseases	MTLE 	1
miRNA-corp.d170.s0	METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme.  	miRNA-corp.d170.s0.e1	Diseases	HS 	2
miRNA-corp.d170.s0	METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme.  	miRNA-corp.d170.s0.e2	Diseases	Seizure 	3
miRNA-corp.d170.s0	METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme.  	miRNA-corp.d170.s0.e3	Species	patients 	4
miRNA-corp.d170.s0	METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme.  	miRNA-corp.d170.s0.e4	Species	patients 	5
miRNA-corp.d170.s1	Postoperative memory testing was performed in 86 patients (53%).  	miRNA-corp.d170.s1.e0	Species	patients 	1
miRNA-corp.d170.s2	At the last follow up, 72% of the patients who had undergone an ATL (mean follow up 6.7 years) and 71% of those who had undergone an SA (mean follow up 4.5 years) were seizure free (Engle Class IA).  	miRNA-corp.d170.s2.e0	Diseases	seizure 	1
miRNA-corp.d170.s2	At the last follow up, 72% of the patients who had undergone an ATL (mean follow up 6.7 years) and 71% of those who had undergone an SA (mean follow up 4.5 years) were seizure free (Engle Class IA).  	miRNA-corp.d170.s2.e1	Species	patients 	2
miRNA-corp.d170.s3	Estimated survival in patients in Engel Classes I, IA, and I and II combined did not differ between the two surgical techniques.  	miRNA-corp.d170.s3.e0	Species	patients 	1
miRNA-corp.d170.s4	Preoperatively, 58% of the patients had verbal memory scores one standard deviation (SD) below the normal mean.  	miRNA-corp.d170.s4.e0	Species	patients 	1
miRNA-corp.d170.s5	One third of the patients with preoperative scores in the normal range worsened after surgery, although this outcome was not related to the surgical technique.  	miRNA-corp.d170.s5.e0	Species	patients 	1
miRNA-corp.d170.s7	Nine (18%) of the 50 patients whose left side had been surgically treated improved their verbal memory scores by more than one SD. Seven (78%) of these nine underwent an SA (p = 0.05).  	miRNA-corp.d170.s7.e0	Species	patients 	1
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e0	Diseases	seizure 	1
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e1	Diseases	mesial temporal lobe epilepsy 	2
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e2	Diseases	hippocampal sclerosis 	3
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e3	Diseases	MTLE 	4
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e4	Diseases	HS 	5
miRNA-corp.d170.s8	OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).  	miRNA-corp.d170.s8.e5	Species	patients 	6
miRNA-corp.d170.s9	Seizure and memory outcome following temporal lobe surgery: selective compared with nonselective approaches for hippocampal sclerosis.   	miRNA-corp.d170.s9.e0	Diseases	Seizure 	1
miRNA-corp.d170.s9	Seizure and memory outcome following temporal lobe surgery: selective compared with nonselective approaches for hippocampal sclerosis.   	miRNA-corp.d170.s9.e1	Diseases	hippocampal sclerosis 	2
miRNA-corp.d170.s10	Preliminary data suggest that postoperative verbal memory scores may improve in patients who undergo selective resection of a sclerotic hippocampus in the dominant temporal lobe.    	miRNA-corp.d170.s10.e0	Species	patients 	1
miRNA-corp.d170.s11	CONCLUSIONS: Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS.  	miRNA-corp.d170.s11.e0	Diseases	seizure 	1
miRNA-corp.d170.s11	CONCLUSIONS: Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS.  	miRNA-corp.d170.s11.e1	Diseases	MTLE 	2
miRNA-corp.d170.s11	CONCLUSIONS: Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS.  	miRNA-corp.d170.s11.e2	Diseases	HS 	3
miRNA-corp.d170.s11	CONCLUSIONS: Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS.  	miRNA-corp.d170.s11.e3	Species	patients 	4
miRNA-corp.d171.s2	METHOD: A consecutive series of 40 patients who underwent microsurgical clipping for UIA were studied.  	miRNA-corp.d171.s2.e0	Species	patients 	1
miRNA-corp.d171.s6	Microsurgical clipping in forty patients with unruptured anterior cerebral circulation aneurysms: an investigation into cognitive outcome.   	miRNA-corp.d171.s6.e0	Diseases	aneurysms 	1
miRNA-corp.d171.s6	Microsurgical clipping in forty patients with unruptured anterior cerebral circulation aneurysms: an investigation into cognitive outcome.   	miRNA-corp.d171.s6.e1	Species	patients 	2
miRNA-corp.d171.s7	OBJECTIVE: It is a consensus that most unruptured intracranial aneurysms (UIA) can be treated with acceptably low morbidity.  	miRNA-corp.d171.s7.e0	Diseases	intracranial aneurysms 	1
miRNA-corp.d171.s8	However, some studies recently reported postoperative cognitive impairment, suggesting that it could be attributable to surgical damage.  	miRNA-corp.d171.s8.e0	Diseases	cognitive impairment 	1
miRNA-corp.d171.s9	Our goal is to evaluate cognitive function before and after microsurgical clipping in patients with UIA.  	miRNA-corp.d171.s9.e0	Species	patients 	1
miRNA-corp.d171.s10	ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size.  	miRNA-corp.d171.s10.e0	Relation_Trigger	associations 	1
miRNA-corp.d171.s10	ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size.  	miRNA-corp.d171.s10.e1	Diseases	aneurysm 	2
miRNA-corp.d171.s10	ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size.  	miRNA-corp.d171.s10.e2	Diseases	dyslipidemia 	3
miRNA-corp.d171.s10	ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size.  	miRNA-corp.d171.s10.e3	Diseases	hypertension 	4
miRNA-corp.d171.s10	ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size.  	miRNA-corp.d171.s10.e4	Diseases	hypertension 	5
miRNA-corp.d171.s11	CONCLUSION: The present study suggests that microsurgical clipping for UIA does not result in major cognitive dysfunction as determined by the MMSE.    	miRNA-corp.d171.s11.e0	Diseases	cognitive dysfunction 	1
miRNA-corp.d172.s0	MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish.   	miRNA-corp.d172.s0.e0	Diseases	spinal cord injury 	1
miRNA-corp.d172.s0	MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish.   	miRNA-corp.d172.s0.e1	Non-Specific_miRNAs	MicroRNA 	2
miRNA-corp.d172.s0	MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish.   	miRNA-corp.d172.s0.e2	Specific_miRNAs	miR-133b 	3
miRNA-corp.d172.s0	MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish.   	miRNA-corp.d172.s0.e3	Species	zebrafish 	4
miRNA-corp.d172.s1	MicroRNAs (miRNAs) play important roles during development and also in adult organisms by regulating the expression of multiple target genes.  	miRNA-corp.d172.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d172.s1	MicroRNAs (miRNAs) play important roles during development and also in adult organisms by regulating the expression of multiple target genes.  	miRNA-corp.d172.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d172.s1	MicroRNAs (miRNAs) play important roles during development and also in adult organisms by regulating the expression of multiple target genes.  	miRNA-corp.d172.s1.e2	Relation_Trigger	regulating the expression 	3
miRNA-corp.d172.s1	MicroRNAs (miRNAs) play important roles during development and also in adult organisms by regulating the expression of multiple target genes.  	miRNA-corp.d172.s1.e3	Relation_Trigger	target 	4
miRNA-corp.d172.s2	Here, we studied the function of miR-133b during zebrafish spinal cord regeneration and show upregulation of miR-133b expression in regenerating neurons of the brainstem after transection of the spinal cord.  	miRNA-corp.d172.s2.e0	Relation_Trigger	upregulation of miR-133b expression 	1
miRNA-corp.d172.s2	Here, we studied the function of miR-133b during zebrafish spinal cord regeneration and show upregulation of miR-133b expression in regenerating neurons of the brainstem after transection of the spinal cord.  	miRNA-corp.d172.s2.e1	Specific_miRNAs	miR-133b 	2
miRNA-corp.d172.s2	Here, we studied the function of miR-133b during zebrafish spinal cord regeneration and show upregulation of miR-133b expression in regenerating neurons of the brainstem after transection of the spinal cord.  	miRNA-corp.d172.s2.e2	Specific_miRNAs	miR-133b 	3
miRNA-corp.d172.s2	Here, we studied the function of miR-133b during zebrafish spinal cord regeneration and show upregulation of miR-133b expression in regenerating neurons of the brainstem after transection of the spinal cord.  	miRNA-corp.d172.s2.e3	Species	zebrafish 	4
miRNA-corp.d172.s3	miR-133b has been shown to promote tissue regeneration in other tissue, but its ability to do so in the nervous system has yet to be tested.  	miRNA-corp.d172.s3.e0	Specific_miRNAs	miR-133b 	1
miRNA-corp.d172.s4	Inhibition of miR-133b expression by antisense morpholino (MO) application resulted in impaired locomotor recovery and reduced regeneration of axons from neurons in the nucleus of the medial longitudinal fascicle, superior reticular formation and intermediate reticular formation.  	miRNA-corp.d172.s4.e0	Relation_Trigger	Inhibition of miR-133b expression 	1
miRNA-corp.d172.s4	Inhibition of miR-133b expression by antisense morpholino (MO) application resulted in impaired locomotor recovery and reduced regeneration of axons from neurons in the nucleus of the medial longitudinal fascicle, superior reticular formation and intermediate reticular formation.  	miRNA-corp.d172.s4.e1	Specific_miRNAs	miR-133b 	2
miRNA-corp.d172.s5	miR-133b targets the small GTPase RhoA, which is an inhibitor of axonal growth, as well as other neurite outgrowth-related molecules.  	miRNA-corp.d172.s5.e0	Genes/Proteins	RhoA 	1
miRNA-corp.d172.s5	miR-133b targets the small GTPase RhoA, which is an inhibitor of axonal growth, as well as other neurite outgrowth-related molecules.  	miRNA-corp.d172.s5.e1	Relation_Trigger	targets 	2
miRNA-corp.d172.s5	miR-133b targets the small GTPase RhoA, which is an inhibitor of axonal growth, as well as other neurite outgrowth-related molecules.  	miRNA-corp.d172.s5.e2	Specific_miRNAs	miR-133b 	3
miRNA-corp.d172.s5	miR-133b targets the small GTPase RhoA, which is an inhibitor of axonal growth, as well as other neurite outgrowth-related molecules.  	miRNA-corp.d172.s5.e3	Relation_Trigger	inhibitor 	4
miRNA-corp.d172.s6	Our results indicate that miR-133b is an important determinant in spinal cord regeneration of adult zebrafish through reduction in RhoA protein levels by direct interaction with its mRNA.  	miRNA-corp.d172.s6.e0	Genes/Proteins	RhoA 	1
miRNA-corp.d172.s6	Our results indicate that miR-133b is an important determinant in spinal cord regeneration of adult zebrafish through reduction in RhoA protein levels by direct interaction with its mRNA.  	miRNA-corp.d172.s6.e1	Relation_Trigger	reduction in RhoA protein levels 	2
miRNA-corp.d172.s6	Our results indicate that miR-133b is an important determinant in spinal cord regeneration of adult zebrafish through reduction in RhoA protein levels by direct interaction with its mRNA.  	miRNA-corp.d172.s6.e2	Specific_miRNAs	miR-133b 	3
miRNA-corp.d172.s6	Our results indicate that miR-133b is an important determinant in spinal cord regeneration of adult zebrafish through reduction in RhoA protein levels by direct interaction with its mRNA.  	miRNA-corp.d172.s6.e3	Species	zebrafish 	4
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e0	Diseases	spinal cord injury 	1
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e1	Genes/Proteins	RhoA 	2
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e2	Genes/Proteins	RhoA 	3
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e4	Relation_Trigger	therapeutic target 	5
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e5	Relation_Trigger	regulation 	6
miRNA-corp.d172.s7	While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish.  	miRNA-corp.d172.s7.e6	Species	zebrafish 	7
miRNA-corp.d172.s8	The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.    	miRNA-corp.d172.s8.e0	Diseases	spinal cord injury 	1
miRNA-corp.d172.s8	The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.    	miRNA-corp.d172.s8.e1	Specific_miRNAs	miR-133b 	2
miRNA-corp.d172.s8	The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.    	miRNA-corp.d172.s8.e2	Relation_Trigger	inhibit 	3
miRNA-corp.d172.s8	The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.    	miRNA-corp.d172.s8.e3	Relation_Trigger	suppress 	4
miRNA-corp.d172.s8	The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.    	miRNA-corp.d172.s8.e4	Species	zebrafish 	5
miRNA-corp.d173.s0	These findings further support the idea that iron- and aluminum-sulfates induce genotoxicity via a ROS-mediated up-regulation of specific regulatory elements and pathogenic genes that redirect brain cell fate towards progressive dysfunction and apoptotic cell death.    	miRNA-corp.d173.s0.e0	Relation_Trigger	dysfunction 	1
miRNA-corp.d173.s0	These findings further support the idea that iron- and aluminum-sulfates induce genotoxicity via a ROS-mediated up-regulation of specific regulatory elements and pathogenic genes that redirect brain cell fate towards progressive dysfunction and apoptotic cell death.    	miRNA-corp.d173.s0.e1	Relation_Trigger	regulatory 	2
miRNA-corp.d173.s0	These findings further support the idea that iron- and aluminum-sulfates induce genotoxicity via a ROS-mediated up-regulation of specific regulatory elements and pathogenic genes that redirect brain cell fate towards progressive dysfunction and apoptotic cell death.    	miRNA-corp.d173.s0.e2	Relation_Trigger	up-regulation 	3
miRNA-corp.d173.s1	Notably, these same miRNAs are up-regulated in AD brain.  	miRNA-corp.d173.s1.e0	Diseases	AD 	1
miRNA-corp.d173.s1	Notably, these same miRNAs are up-regulated in AD brain.  	miRNA-corp.d173.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d173.s1	Notably, these same miRNAs are up-regulated in AD brain.  	miRNA-corp.d173.s1.e2	Relation_Trigger	up-regulated 	3
miRNA-corp.d173.s2	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128.  	miRNA-corp.d173.s2.e0	Specific_miRNAs	miR-9 	1
miRNA-corp.d173.s2	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128.  	miRNA-corp.d173.s2.e1	Specific_miRNAs	miR-125b 	2
miRNA-corp.d173.s2	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128.  	miRNA-corp.d173.s2.e2	Specific_miRNAs	miR-128 	3
miRNA-corp.d173.s2	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128.  	miRNA-corp.d173.s2.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d173.s2	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128.  	miRNA-corp.d173.s2.e4	Relation_Trigger	up-regulate 	5
miRNA-corp.d173.s3	In this study we have extended our investigations to analyze the expression of micro RNA (miRNA) populations in iron- and aluminum-sulfate treated human neural cells in primary culture.  	miRNA-corp.d173.s3.e0	Non-Specific_miRNAs	micro RNA 	1
miRNA-corp.d173.s3	In this study we have extended our investigations to analyze the expression of micro RNA (miRNA) populations in iron- and aluminum-sulfate treated human neural cells in primary culture.  	miRNA-corp.d173.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d173.s3	In this study we have extended our investigations to analyze the expression of micro RNA (miRNA) populations in iron- and aluminum-sulfate treated human neural cells in primary culture.  	miRNA-corp.d173.s3.e2	Species	human 	3
miRNA-corp.d173.s4	Notably, iron- and aluminum-sulfate induce genes in cultured human brain cells that exhibit expression patterns similar to those observed to be up-regulated in moderate- to late-stage Alzheimer's disease (AD).  	miRNA-corp.d173.s4.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d173.s4	Notably, iron- and aluminum-sulfate induce genes in cultured human brain cells that exhibit expression patterns similar to those observed to be up-regulated in moderate- to late-stage Alzheimer's disease (AD).  	miRNA-corp.d173.s4.e1	Diseases	AD 	2
miRNA-corp.d173.s4	Notably, iron- and aluminum-sulfate induce genes in cultured human brain cells that exhibit expression patterns similar to those observed to be up-regulated in moderate- to late-stage Alzheimer's disease (AD).  	miRNA-corp.d173.s4.e2	Relation_Trigger	up-regulated 	3
miRNA-corp.d173.s4	Notably, iron- and aluminum-sulfate induce genes in cultured human brain cells that exhibit expression patterns similar to those observed to be up-regulated in moderate- to late-stage Alzheimer's disease (AD).  	miRNA-corp.d173.s4.e3	Species	human 	4
miRNA-corp.d173.s5	Previous studies have shown that following ROS induction, a family of pathogenic brain genes that promote inflammatory signalling, cellular apoptosis and brain cell death is significantly over-expressed.  	miRNA-corp.d173.s5.e0	Relation_Trigger	over-expressed 	1
miRNA-corp.d173.s6	Iron- and aluminum-sulfate together, at nanomolar concentrations, trigger the production of reactive oxygen species (ROS) in cultures of human brain cells.  	miRNA-corp.d173.s6.e0	Species	human 	1
miRNA-corp.d173.s7	Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells.   	miRNA-corp.d173.s7.e0	Non-Specific_miRNAs	micro RNA 	1
miRNA-corp.d173.s7	Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells.   	miRNA-corp.d173.s7.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d173.s7	Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells.   	miRNA-corp.d173.s7.e2	Species	human 	3
miRNA-corp.d174.s0	As a genetically complex disease, dysregulation of miRNA expression might be a feature of autism spectrum disorders (ASDs).  	miRNA-corp.d174.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d174.s0	As a genetically complex disease, dysregulation of miRNA expression might be a feature of autism spectrum disorders (ASDs).  	miRNA-corp.d174.s0.e1	Diseases	autism spectrum disorders 	2
miRNA-corp.d174.s0	As a genetically complex disease, dysregulation of miRNA expression might be a feature of autism spectrum disorders (ASDs).  	miRNA-corp.d174.s0.e2	Diseases	ASDs 	3
miRNA-corp.d174.s0	As a genetically complex disease, dysregulation of miRNA expression might be a feature of autism spectrum disorders (ASDs).  	miRNA-corp.d174.s0.e3	Relation_Trigger	dysregulation of miRNA expression 	4
miRNA-corp.d174.s1	Using multiplex quantitative polymerase chain reaction (PCR), we compared the expression of 466 human miRNAs from postmortem cerebellar cortex tissue of individuals with ASD (n = 13) and a control set of non-autistic cerebellar samples (n = 13).  	miRNA-corp.d174.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d174.s1	Using multiplex quantitative polymerase chain reaction (PCR), we compared the expression of 466 human miRNAs from postmortem cerebellar cortex tissue of individuals with ASD (n = 13) and a control set of non-autistic cerebellar samples (n = 13).  	miRNA-corp.d174.s1.e1	Diseases	ASD 	2
miRNA-corp.d174.s1	Using multiplex quantitative polymerase chain reaction (PCR), we compared the expression of 466 human miRNAs from postmortem cerebellar cortex tissue of individuals with ASD (n = 13) and a control set of non-autistic cerebellar samples (n = 13).  	miRNA-corp.d174.s1.e2	Species	human 	3
miRNA-corp.d174.s2	microRNAs (miRNAs) are approximately 21 nt transcripts capable of regulating the expression of many mRNAs and are abundant in the brain.  	miRNA-corp.d174.s2.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d174.s2	microRNAs (miRNAs) are approximately 21 nt transcripts capable of regulating the expression of many mRNAs and are abundant in the brain.  	miRNA-corp.d174.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d174.s2	microRNAs (miRNAs) are approximately 21 nt transcripts capable of regulating the expression of many mRNAs and are abundant in the brain.  	miRNA-corp.d174.s2.e2	Relation_Trigger	regulating the expression 	3
miRNA-corp.d174.s3	miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome.  	miRNA-corp.d174.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d174.s3	miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome.  	miRNA-corp.d174.s3.e1	Diseases	Tourette's syndrome 	2
miRNA-corp.d174.s3	miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome.  	miRNA-corp.d174.s3.e2	Diseases	Fragile x syndrome 	3
miRNA-corp.d174.s3	miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome.  	miRNA-corp.d174.s3.e3	Diseases	cancer 	4
miRNA-corp.d174.s3	miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome.  	miRNA-corp.d174.s3.e4	Diseases	neurological diseases 	5
miRNA-corp.d174.s4	To validate the finding, we reversed the analysis and compared each non-autism control to a single mean value for each miRNA across all autism cases.  	miRNA-corp.d174.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d174.s4	To validate the finding, we reversed the analysis and compared each non-autism control to a single mean value for each miRNA across all autism cases.  	miRNA-corp.d174.s4.e1	Diseases	autism 	2
miRNA-corp.d174.s5	In this analysis, the number of dysregulated miRNAs fell from 28 to 9 miRNAs.  	miRNA-corp.d174.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d174.s5	In this analysis, the number of dysregulated miRNAs fell from 28 to 9 miRNAs.  	miRNA-corp.d174.s5.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d174.s5	In this analysis, the number of dysregulated miRNAs fell from 28 to 9 miRNAs.  	miRNA-corp.d174.s5.e2	Relation_Trigger	dysregulated 	3
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e3	Diseases	autism 	4
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e4	Relation_Trigger	levels showed little variation 	5
miRNA-corp.d174.s6	While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value.  	miRNA-corp.d174.s6.e5	Relation_Trigger	dysfunction of miRNA expression 	6
miRNA-corp.d174.s7	Twenty-eight miRNAs were expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.  	miRNA-corp.d174.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d174.s7	Twenty-eight miRNAs were expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples.  	miRNA-corp.d174.s7.e1	Diseases	autism 	2
miRNA-corp.d174.s8	Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3.  	miRNA-corp.d174.s8.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d174.s8	Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3.  	miRNA-corp.d174.s8.e1	Genes/Proteins	SHANK3 	2
miRNA-corp.d174.s8	Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3.  	miRNA-corp.d174.s8.e2	Relation_Trigger	dysregulated 	3
miRNA-corp.d174.s8	Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3.  	miRNA-corp.d174.s8.e3	Relation_Trigger	predicted targets 	4
miRNA-corp.d174.s8	Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3.  	miRNA-corp.d174.s8.e4	Diseases	autism 	5
miRNA-corp.d174.s9	Heterogeneous dysregulation of microRNAs across the autism spectrum.   	miRNA-corp.d174.s9.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d174.s9	Heterogeneous dysregulation of microRNAs across the autism spectrum.   	miRNA-corp.d174.s9.e1	Diseases	autism 	2
miRNA-corp.d174.s9	Heterogeneous dysregulation of microRNAs across the autism spectrum.   	miRNA-corp.d174.s9.e2	Relation_Trigger	dysregulation 	3
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e2	Diseases	autism 	3
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e3	Diseases	autism 	4
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e4	Relation_Trigger	dysregulation 	5
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e5	Relation_Trigger	altered miRNA expression levels 	6
miRNA-corp.d174.s10	This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.    	miRNA-corp.d174.s10.e6	Species	patients 	7
miRNA-corp.d175.s0	A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons.  	miRNA-corp.d175.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d175.s0	A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons.  	miRNA-corp.d175.s0.e1	Genes/Proteins	APP 	2
miRNA-corp.d175.s0	A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons.  	miRNA-corp.d175.s0.e2	Relation_Trigger	correlation 	3
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e1	Genes/Proteins	APP 	2
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e2	Genes/Proteins	APP 	3
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e4	Relation_Trigger	regulators of APP expression 	5
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e5	Relation_Trigger	variations in miRNA expression 	6
miRNA-corp.d175.s1	We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease.  	miRNA-corp.d175.s1.e6	Relation_Trigger	changes in APP expression 	7
miRNA-corp.d175.s2	This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.    	miRNA-corp.d175.s2.e0	Specific_miRNAs	miR-106b 	1
miRNA-corp.d175.s2	This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.    	miRNA-corp.d175.s2.e1	Diseases	sporadic AD 	2
miRNA-corp.d175.s2	This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.    	miRNA-corp.d175.s2.e2	Relation_Trigger	significant decrease in miR-106b expression 	3
miRNA-corp.d175.s2	This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.    	miRNA-corp.d175.s2.e3	Species	patients 	4
miRNA-corp.d175.s3	MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.   	miRNA-corp.d175.s3.e0	Genes/Proteins	Amyloid precursor protein 	1
miRNA-corp.d175.s3	MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.   	miRNA-corp.d175.s3.e1	Diseases	Alzheimer's 	2
miRNA-corp.d175.s3	MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.   	miRNA-corp.d175.s3.e2	Non-Specific_miRNAs	MicroRNA 	3
miRNA-corp.d175.s3	MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.   	miRNA-corp.d175.s3.e3	Relation_Trigger	regulation of Alzheimer's Amyloid precursor protein expression 	4
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e1	Diseases	AD 	2
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e2	Genes/Proteins	Amyloid precursor protein 	3
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e3	Genes/Proteins	APP 	4
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e4	Diseases	AD 	5
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e5	Non-Specific_miRNAs	microRNA 	6
miRNA-corp.d175.s4	Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD).  	miRNA-corp.d175.s4.e6	Diseases	sporadic Alzheimer's disease 	7
miRNA-corp.d175.s5	We therefore investigated whether miRNAs could participate in the regulation of APP gene expression.  	miRNA-corp.d175.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d175.s5	We therefore investigated whether miRNAs could participate in the regulation of APP gene expression.  	miRNA-corp.d175.s5.e1	Genes/Proteins	APP 	2
miRNA-corp.d175.s5	We therefore investigated whether miRNAs could participate in the regulation of APP gene expression.  	miRNA-corp.d175.s5.e2	Relation_Trigger	regulation of APP gene expression 	3
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e0	Specific_miRNAs	miR-20a 	1
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e1	Specific_miRNAs	miR-17-5p 	2
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e2	Specific_miRNAs	miR-106b 	3
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e3	Genes/Proteins	APP 	4
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e5	Relation_Trigger	regulate APP expression 	6
miRNA-corp.d175.s6	We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines.  	miRNA-corp.d175.s6.e6	Specific_miRNAs	miR-20a 	7
miRNA-corp.d176.s0	These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.    	miRNA-corp.d176.s0.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d176.s0	These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.    	miRNA-corp.d176.s0.e1	Relation_Trigger	activation 	2
miRNA-corp.d176.s0	These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.    	miRNA-corp.d176.s0.e2	Species	HSV-1 	3
miRNA-corp.d176.s0	These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.    	miRNA-corp.d176.s0.e3	Species	HSV-1 	4
miRNA-corp.d176.s0	These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.    	miRNA-corp.d176.s0.e4	Diseases	Alzheimer 	5
miRNA-corp.d176.s1	A known miRNA-146a target in the brain, complement factor H, was downregulated.  	miRNA-corp.d176.s1.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d176.s1	A known miRNA-146a target in the brain, complement factor H, was downregulated.  	miRNA-corp.d176.s1.e1	Genes/Proteins	complement factor H 	2
miRNA-corp.d176.s1	A known miRNA-146a target in the brain, complement factor H, was downregulated.  	miRNA-corp.d176.s1.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d176.s1	A known miRNA-146a target in the brain, complement factor H, was downregulated.  	miRNA-corp.d176.s1.e3	Relation_Trigger	target 	4
miRNA-corp.d176.s2	Expression of cytoplasmic phospholipase A2, the inducible prostaglandin synthase cyclooxygenase-2, and the neuroinflammatory cytokine interleukin-1beta were each upregulated.  	miRNA-corp.d176.s2.e0	Genes/Proteins	interleukin-1beta 	1
miRNA-corp.d176.s2	Expression of cytoplasmic phospholipase A2, the inducible prostaglandin synthase cyclooxygenase-2, and the neuroinflammatory cytokine interleukin-1beta were each upregulated.  	miRNA-corp.d176.s2.e1	Genes/Proteins	prostaglandin synthase cyclooxygenase-2 	2
miRNA-corp.d176.s2	Expression of cytoplasmic phospholipase A2, the inducible prostaglandin synthase cyclooxygenase-2, and the neuroinflammatory cytokine interleukin-1beta were each upregulated.  	miRNA-corp.d176.s2.e2	Relation_Trigger	upregulated 	3
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e0	Specific_miRNAs	microRNA (miRNA)-146a 	1
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e2	Relation_Trigger	upregulation 	3
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e3	Relation_Trigger	associated 	4
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e4	Species	HSV-1 	5
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e5	Diseases	infection 	6
miRNA-corp.d176.s3	We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease.  	miRNA-corp.d176.s3.e6	Species	human 	7
miRNA-corp.d176.s4	Herpes simplex virus type-1 (HSV-1) infection of human brain cells induces changes in gene expression favorable to the propagation of the infecting agent and detrimental to the function of the host cells.  	miRNA-corp.d176.s4.e0	Relation_Trigger	changes in gene expression 	1
miRNA-corp.d176.s4	Herpes simplex virus type-1 (HSV-1) infection of human brain cells induces changes in gene expression favorable to the propagation of the infecting agent and detrimental to the function of the host cells.  	miRNA-corp.d176.s4.e1	Species	Herpes simplex virus type-1 (HSV-1 	2
miRNA-corp.d176.s4	Herpes simplex virus type-1 (HSV-1) infection of human brain cells induces changes in gene expression favorable to the propagation of the infecting agent and detrimental to the function of the host cells.  	miRNA-corp.d176.s4.e2	Diseases	Herpes simplex virus type-1 (HSV-1) infection 	3
miRNA-corp.d176.s4	Herpes simplex virus type-1 (HSV-1) infection of human brain cells induces changes in gene expression favorable to the propagation of the infecting agent and detrimental to the function of the host cells.  	miRNA-corp.d176.s4.e3	Species	human 	4
miRNA-corp.d176.s5	HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.   	miRNA-corp.d176.s5.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d176.s5	HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.   	miRNA-corp.d176.s5.e1	Species	HSV-1 	2
miRNA-corp.d176.s5	HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.   	miRNA-corp.d176.s5.e2	Diseases	HSV-1 infection 	3
miRNA-corp.d176.s5	HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.   	miRNA-corp.d176.s5.e3	Diseases	Alzheimer 	4
miRNA-corp.d176.s5	HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.   	miRNA-corp.d176.s5.e4	Species	human 	5
miRNA-corp.d177.s0	We concluded that patients with partial recurrent seizures of temporal origin have poor subjective sleep quality that improves significantly after epilepsy surgery.    	miRNA-corp.d177.s0.e0	Diseases	partial recurrent seizures 	1
miRNA-corp.d177.s0	We concluded that patients with partial recurrent seizures of temporal origin have poor subjective sleep quality that improves significantly after epilepsy surgery.    	miRNA-corp.d177.s0.e1	Diseases	epilepsy 	2
miRNA-corp.d177.s0	We concluded that patients with partial recurrent seizures of temporal origin have poor subjective sleep quality that improves significantly after epilepsy surgery.    	miRNA-corp.d177.s0.e2	Species	patients 	3
miRNA-corp.d177.s1	ESS and PSQI scores were also analyzed by gender, antiepileptic drug class, age, and seizure frequency, with no significant differences.  	miRNA-corp.d177.s1.e0	Diseases	seizure 	1
miRNA-corp.d177.s3	Two questionnaires were used to assess daytime sleepiness (Epworth Sleepiness Scale [ESS]) and sleep quality (Pittsburgh Sleep Quality Index [PSQI]).  	miRNA-corp.d177.s3.e0	Diseases	daytime sleepiness 	1
miRNA-corp.d177.s4	PSQI evaluation revealed higher and statistically significant scores in three components as well as in the global score, when analyzed by predominance of daytime or nocturnal seizures.  	miRNA-corp.d177.s4.e0	Diseases	nocturnal seizures 	1
miRNA-corp.d177.s5	Evaluation of sleep quality in patients with refractory seizures who undergo epilepsy surgery.   	miRNA-corp.d177.s5.e0	Diseases	epilepsy 	1
miRNA-corp.d177.s5	Evaluation of sleep quality in patients with refractory seizures who undergo epilepsy surgery.   	miRNA-corp.d177.s5.e1	Diseases	seizures 	2
miRNA-corp.d177.s5	Evaluation of sleep quality in patients with refractory seizures who undergo epilepsy surgery.   	miRNA-corp.d177.s5.e2	Species	patients 	3
miRNA-corp.d177.s6	The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures.  	miRNA-corp.d177.s6.e0	Diseases	excessive daytime sleepiness 	1
miRNA-corp.d177.s6	The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures.  	miRNA-corp.d177.s6.e1	Diseases	seizures 	2
miRNA-corp.d177.s6	The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures.  	miRNA-corp.d177.s6.e2	Diseases	epilepsy 	3
miRNA-corp.d177.s6	The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures.  	miRNA-corp.d177.s6.e3	Species	patients 	4
miRNA-corp.d177.s7	Forty-eight patients were enrolled in this research study.  	miRNA-corp.d177.s7.e0	Species	patients 	1
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e1	Non-Specific_miRNAs	microRNAs 	2
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e3	Relation_Trigger	downregulate 	4
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e4	Diseases	neoplasms 	5
miRNA-corp.d178.s0	Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects.  	miRNA-corp.d178.s0.e5	Species	human 	6
miRNA-corp.d178.s1	Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta.  	miRNA-corp.d178.s1.e0	Genes/Proteins	IFN-beta 	1
miRNA-corp.d178.s1	Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta.  	miRNA-corp.d178.s1.e1	Diseases	glioma 	2
miRNA-corp.d178.s1	Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta.  	miRNA-corp.d178.s1.e2	Specific_miRNAs	miR-21 	3
miRNA-corp.d178.s1	Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta.  	miRNA-corp.d178.s1.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d178.s1	Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta.  	miRNA-corp.d178.s1.e4	Non-Specific_miRNAs	miRNAs 	5
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e0	Diseases	glioma 	1
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e1	Genes/Proteins	signal transducers and activators of transcription 3 	2
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e2	Non-Specific_miRNAs	microRNAs 	3
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e3	Relation_Trigger	modulation 	4
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e4	Relation_Trigger	activation 	5
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e5	Genes/Proteins	type I IFN 	6
miRNA-corp.d178.s2	The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.   	miRNA-corp.d178.s2.e6	Species	human 	7
miRNA-corp.d178.s3	Type I IFNs are involved in double-stranded RNA responses.  	miRNA-corp.d178.s3.e0	Genes/Proteins	Type I IFNs 	1
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e2	Specific_miRNAs	miR-21 	3
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e3	Specific_miRNAs	miR-21 	4
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e4	Genes/Proteins	IFN-beta 	5
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e5	Relation_Trigger	levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 	6
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e6	Relation_Trigger	reduction in miR-21 levels 	7
miRNA-corp.d178.s4	The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression.  	miRNA-corp.d178.s4.e7	Relation_Trigger	suppression 	8
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e2	Specific_miRNAs	miR-21 	3
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e3	Genes/Proteins	IFN-beta 	4
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e4	Relation_Trigger	suppression 	5
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e5	Relation_Trigger	suppression 	6
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e6	Relation_Trigger	inhibited 	7
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e7	Genes/Proteins	IFN-beta 	8
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e8	Relation_Trigger	activators 	9
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e9	Genes/Proteins	STAT3 	10
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e10	Genes/Proteins	signal transducers and activators of transcription 3 	11
miRNA-corp.d178.s5	We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression.  	miRNA-corp.d178.s5.e11	Relation_Trigger	suppression 	12
miRNA-corp.d178.s6	We analyzed the effect of IFN-beta treatment on miR-21 expression in glioma cells and intracranial glioma xenografts.  	miRNA-corp.d178.s6.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d178.s6	We analyzed the effect of IFN-beta treatment on miR-21 expression in glioma cells and intracranial glioma xenografts.  	miRNA-corp.d178.s6.e1	Diseases	glioma 	2
miRNA-corp.d178.s6	We analyzed the effect of IFN-beta treatment on miR-21 expression in glioma cells and intracranial glioma xenografts.  	miRNA-corp.d178.s6.e2	Genes/Proteins	IFN-beta 	3
miRNA-corp.d178.s6	We analyzed the effect of IFN-beta treatment on miR-21 expression in glioma cells and intracranial glioma xenografts.  	miRNA-corp.d178.s6.e3	Diseases	intracranial glioma 	4
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e1	Genes/Proteins	IFN-beta 	2
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e2	Genes/Proteins	IFN-beta 	3
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e3	Diseases	glioma 	4
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e4	Diseases	glioma 	5
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e5	Relation_Trigger	suppressed 	6
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e6	Relation_Trigger	reduced miR-21 expression 	7
miRNA-corp.d178.s7	IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors.  	miRNA-corp.d178.s7.e7	Diseases	intracranial tumors 	8
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e0	Specific_miRNAs	miR-21 	1
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e2	Genes/Proteins	IFN-beta 	3
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e3	Genes/Proteins	STAT3 	4
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e4	Relation_Trigger	downregulation 	5
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e5	Relation_Trigger	negatively regulated 	6
miRNA-corp.d178.s8	Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation.  	miRNA-corp.d178.s8.e6	Relation_Trigger	activation 	7
miRNA-corp.d178.s9	These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis.    	miRNA-corp.d178.s9.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d178.s9	These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis.    	miRNA-corp.d178.s9.e1	Relation_Trigger	transcriptional regulation 	2
miRNA-corp.d179.s0	This study reveals the occurrence of novel mechanisms of HIF regulation, which might contribute to developing novel strategies for therapeutic intervention of HIF-related pathologies, including heart attack, cancer, and stroke.    	miRNA-corp.d179.s0.e0	Diseases	heart attack 	1
miRNA-corp.d179.s0	This study reveals the occurrence of novel mechanisms of HIF regulation, which might contribute to developing novel strategies for therapeutic intervention of HIF-related pathologies, including heart attack, cancer, and stroke.    	miRNA-corp.d179.s0.e1	Diseases	cancer 	2
miRNA-corp.d179.s0	This study reveals the occurrence of novel mechanisms of HIF regulation, which might contribute to developing novel strategies for therapeutic intervention of HIF-related pathologies, including heart attack, cancer, and stroke.    	miRNA-corp.d179.s0.e2	Diseases	stroke 	3
miRNA-corp.d179.s0	This study reveals the occurrence of novel mechanisms of HIF regulation, which might contribute to developing novel strategies for therapeutic intervention of HIF-related pathologies, including heart attack, cancer, and stroke.    	miRNA-corp.d179.s0.e3	Relation_Trigger	regulation 	4
miRNA-corp.d179.s1	One remarkable hit was the argonaute 1 (ago1) gene, a central element of the microRNA (miRNA) translational silencing machinery.  	miRNA-corp.d179.s1.e0	Genes/Proteins	ago1 	1
miRNA-corp.d179.s1	One remarkable hit was the argonaute 1 (ago1) gene, a central element of the microRNA (miRNA) translational silencing machinery.  	miRNA-corp.d179.s1.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d179.s1	One remarkable hit was the argonaute 1 (ago1) gene, a central element of the microRNA (miRNA) translational silencing machinery.  	miRNA-corp.d179.s1.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d179.s1	One remarkable hit was the argonaute 1 (ago1) gene, a central element of the microRNA (miRNA) translational silencing machinery.  	miRNA-corp.d179.s1.e3	Genes/Proteins	argonaute 1 	4
miRNA-corp.d179.s2	Further studies confirmed the physiological role of the miRNA machinery in HIF-dependent transcription.  	miRNA-corp.d179.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d179.s3	After 3 rounds of selection, 30 genes emerged as critical HIF regulators in hypoxia, most of which had not been previously associated with HIF biology.  	miRNA-corp.d179.s3.e0	Relation_Trigger	regulators 	1
miRNA-corp.d179.s3	After 3 rounds of selection, 30 genes emerged as critical HIF regulators in hypoxia, most of which had not been previously associated with HIF biology.  	miRNA-corp.d179.s3.e1	Relation_Trigger	associated 	2
miRNA-corp.d179.s3	After 3 rounds of selection, 30 genes emerged as critical HIF regulators in hypoxia, most of which had not been previously associated with HIF biology.  	miRNA-corp.d179.s3.e2	Diseases	hypoxia 	3
miRNA-corp.d179.s4	The list of genes includes components of chromatin remodeling complexes, transcription elongation factors, and translational regulators.  	miRNA-corp.d179.s4.e0	Relation_Trigger	translational regulators 	1
miRNA-corp.d179.s5	Molecular mechanisms that mediate oxygen-dependent HIF regulation operate at the level of the alpha subunit, controlling protein stability, subcellular localization, and transcriptional coactivator recruitment.  	miRNA-corp.d179.s5.e0	Relation_Trigger	regulation 	1
miRNA-corp.d179.s7	Drosophila genome-wide RNAi screen identifies multiple regulators of HIF-dependent transcription in hypoxia.   	miRNA-corp.d179.s7.e0	Relation_Trigger	regulators of HIF-dependent transcription 	1
miRNA-corp.d179.s7	Drosophila genome-wide RNAi screen identifies multiple regulators of HIF-dependent transcription in hypoxia.   	miRNA-corp.d179.s7.e1	Diseases	hypoxia 	2
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e2	Genes/Proteins	BACE1 	3
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e3	Diseases	AD 	4
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e4	Genes/Proteins	APP 	5
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e5	Diseases	AD 	6
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e6	Genes/Proteins	APP 	7
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e7	Genes/Proteins	APP 	8
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e8	Non-Specific_miRNAs	microRNA 	9
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e9	Non-Specific_miRNAs	miRNA 	10
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e10	Non-Specific_miRNAs	miRNAs 	11
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e11	Relation_Trigger	binding sites 	12
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e12	Relation_Trigger	associated 	13
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e13	Species	patients 	14
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e14	Species	patients 	15
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e15	Species	patients 	16
miRNA-corp.d180.s0	In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%).  	miRNA-corp.d180.s0.e16	Species	patients 	17
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e1	Diseases	AD 	2
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e2	Genes/Proteins	amyloid precursor protein 	3
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e3	Genes/Proteins	APP 	4
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e4	Genes/Proteins	Abeta 	5
miRNA-corp.d180.s1	Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.  	miRNA-corp.d180.s1.e5	Genes/Proteins	BACE1 	6
miRNA-corp.d180.s2	APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.   	miRNA-corp.d180.s2.e0	Genes/Proteins	APP 	1
miRNA-corp.d180.s2	APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.   	miRNA-corp.d180.s2.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d180.s2	APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.   	miRNA-corp.d180.s2.e2	Diseases	Alzheimer disease 	3
miRNA-corp.d180.s2	APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.   	miRNA-corp.d180.s2.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d180.s3	Further genetic screening of the miR-29 cluster encoding the miR-29a/b-1 genes showed 10 variants in close proximity of this cluster.  	miRNA-corp.d180.s3.e0	Specific_miRNAs	miR-29 	1
miRNA-corp.d180.s3	Further genetic screening of the miR-29 cluster encoding the miR-29a/b-1 genes showed 10 variants in close proximity of this cluster.  	miRNA-corp.d180.s3.e1	Specific_miRNAs	miR-29a/b-1 	2
miRNA-corp.d180.s4	Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk.  	miRNA-corp.d180.s4.e0	Specific_miRNAs	miR-29 	1
miRNA-corp.d180.s4	Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk.  	miRNA-corp.d180.s4.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d180.s4	Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk.  	miRNA-corp.d180.s4.e2	Diseases	AD 	3
miRNA-corp.d180.s4	Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk.  	miRNA-corp.d180.s4.e3	Relation_Trigger	association 	4
miRNA-corp.d180.s4	Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk.  	miRNA-corp.d180.s4.e4	Relation_Trigger	Association 	5
miRNA-corp.d180.s5	However, we did observe statistical interaction between rs535860 (BACE1 3' UTR) and rs34772568 (near miR29a; odds ratio [OR](interaction), 0.4; 95% confidence interval [CI], 0.17-0.96; P=0.033).  	miRNA-corp.d180.s5.e0	Specific_miRNAs	miR29a 	1
miRNA-corp.d180.s5	However, we did observe statistical interaction between rs535860 (BACE1 3' UTR) and rs34772568 (near miR29a; odds ratio [OR](interaction), 0.4; 95% confidence interval [CI], 0.17-0.96; P=0.033).  	miRNA-corp.d180.s5.e1	Genes/Proteins	BACE1 	2
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e0	Genes/Proteins	BACE1 	1
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e1	Genes/Proteins	APP 	2
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e2	Diseases	AD 	3
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d180.s6	While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.    	miRNA-corp.d180.s6.e5	Species	patient 	6
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e0	Relation_Trigger	Differential regulation 	1
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e1	Genes/Proteins	interleukin-1 receptor-associated kinase-1 	2
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e2	Genes/Proteins	IRAK-1 	3
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e3	Genes/Proteins	IRAK-2 	4
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e4	Specific_miRNAs	microRNA-146a 	5
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e5	Diseases	Alzheimer disease 	6
miRNA-corp.d181.s0	Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.   	miRNA-corp.d181.s0.e6	Species	human 	7
miRNA-corp.d181.s1	Specific microRNAs (miRNAs), small non-coding RNAs that support homeostatic gene expression, are significantly altered in abundance in human neurological disorders.  	miRNA-corp.d181.s1.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d181.s1	Specific microRNAs (miRNAs), small non-coding RNAs that support homeostatic gene expression, are significantly altered in abundance in human neurological disorders.  	miRNA-corp.d181.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d181.s1	Specific microRNAs (miRNAs), small non-coding RNAs that support homeostatic gene expression, are significantly altered in abundance in human neurological disorders.  	miRNA-corp.d181.s1.e2	Diseases	neurological disorders 	3
miRNA-corp.d181.s1	Specific microRNAs (miRNAs), small non-coding RNAs that support homeostatic gene expression, are significantly altered in abundance in human neurological disorders.  	miRNA-corp.d181.s1.e3	Species	human 	4
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e0	Relation_Trigger	increased expression 	1
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e1	Relation_Trigger	down-regulates expression 	2
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e2	Specific_miRNAs	miRNA-146a 	3
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e3	Genes/Proteins	interleukin-1 receptor-associated kinase-1 	4
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e4	Genes/Proteins	IRAK-1 	5
miRNA-corp.d181.s2	In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling.  	miRNA-corp.d181.s2.e5	Genes/Proteins	IL-1 	6
miRNA-corp.d181.s3	Here we extend those observations to the hippocampus and neocortex of Alzheimer disease (AD) brain and to stressed human astroglial (HAG) cells in primary culture.  	miRNA-corp.d181.s3.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d181.s3	Here we extend those observations to the hippocampus and neocortex of Alzheimer disease (AD) brain and to stressed human astroglial (HAG) cells in primary culture.  	miRNA-corp.d181.s3.e1	Diseases	AD 	2
miRNA-corp.d181.s3	Here we extend those observations to the hippocampus and neocortex of Alzheimer disease (AD) brain and to stressed human astroglial (HAG) cells in primary culture.  	miRNA-corp.d181.s3.e2	Species	human 	3
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e0	Relation_Trigger	up-regulation 	1
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e1	Relation_Trigger	down-regulation 	2
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e2	Relation_Trigger	up-regulation 	3
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e3	Diseases	AD 	4
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e4	Genes/Proteins	IRAK-2 	5
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e5	Genes/Proteins	IRAK-1 	6
miRNA-corp.d181.s4	In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2.  	miRNA-corp.d181.s4.e6	Specific_miRNAs	miRNA-146a 	7
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e0	Genes/Proteins	interleukin-1β 	1
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e1	Genes/Proteins	IL-1β 	2
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e2	Genes/Proteins	amyloid-β-42 	3
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e3	Genes/Proteins	Aβ42 	4
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e4	Genes/Proteins	IRAK-1 	5
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e5	Genes/Proteins	IRAK-2 	6
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e6	Genes/Proteins	IRAK-2 	7
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e7	Genes/Proteins	IRAK-1 	8
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e8	Specific_miRNAs	miRNA-146a 	9
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e9	Specific_miRNAs	miRNA-146a 	10
miRNA-corp.d181.s5	Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells.  	miRNA-corp.d181.s5.e10	Relation_Trigger	increases in miRNA-146a and IRAK-2 expression 	11
miRNA-corp.d181.s6	NF-κB-mediated transcriptional control of human IRAK-2 was localized to between -119 and +12 bp of the immediate IRAK-2 promoter.  	miRNA-corp.d181.s6.e0	Genes/Proteins	IRAK-2 	1
miRNA-corp.d181.s6	NF-κB-mediated transcriptional control of human IRAK-2 was localized to between -119 and +12 bp of the immediate IRAK-2 promoter.  	miRNA-corp.d181.s6.e1	Genes/Proteins	IRAK-2 	2
miRNA-corp.d181.s6	NF-κB-mediated transcriptional control of human IRAK-2 was localized to between -119 and +12 bp of the immediate IRAK-2 promoter.  	miRNA-corp.d181.s6.e2	Species	human 	3
miRNA-corp.d181.s7	The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated.  	miRNA-corp.d181.s7.e0	Relation_Trigger	up-regulated 	1
miRNA-corp.d181.s7	The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated.  	miRNA-corp.d181.s7.e1	Genes/Proteins	IRAK-2 	2
miRNA-corp.d181.s7	The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated.  	miRNA-corp.d181.s7.e2	Genes/Proteins	IRAK-1 	3
miRNA-corp.d181.s7	The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated.  	miRNA-corp.d181.s7.e3	Specific_miRNAs	miRNA-146a 	4
miRNA-corp.d181.s7	The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated.  	miRNA-corp.d181.s7.e4	Relation_Trigger	inhibitors 	5
miRNA-corp.d181.s8	Incubation of a protected antisense miRNA-146a was found to inhibit miRNA-146a and restore IRAK-1, whereas IRAK-2 remained unaffected.  	miRNA-corp.d181.s8.e0	Relation_Trigger	inhibit 	1
miRNA-corp.d181.s8	Incubation of a protected antisense miRNA-146a was found to inhibit miRNA-146a and restore IRAK-1, whereas IRAK-2 remained unaffected.  	miRNA-corp.d181.s8.e1	Genes/Proteins	IRAK-1 	2
miRNA-corp.d181.s8	Incubation of a protected antisense miRNA-146a was found to inhibit miRNA-146a and restore IRAK-1, whereas IRAK-2 remained unaffected.  	miRNA-corp.d181.s8.e2	Genes/Proteins	IRAK-2 	3
miRNA-corp.d181.s8	Incubation of a protected antisense miRNA-146a was found to inhibit miRNA-146a and restore IRAK-1, whereas IRAK-2 remained unaffected.  	miRNA-corp.d181.s8.e3	Specific_miRNAs	miRNA-146a 	4
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e1	Genes/Proteins	NF-κB 	2
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e2	Relation_Trigger	regulation 	3
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e3	Relation_Trigger	down-regulation 	4
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e4	Relation_Trigger	up-regulation 	5
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e5	Genes/Proteins	IRAK-2 	6
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e6	Genes/Proteins	IRAK-1 	7
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e7	Diseases	AD 	8
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e8	Genes/Proteins	IRAK-1 	9
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e9	Genes/Proteins	IRAK-2 	10
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e10	Genes/Proteins	Aβ42 	11
miRNA-corp.d181.s9	These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response.  	miRNA-corp.d181.s9.e11	Genes/Proteins	IL-1 	12
miRNA-corp.d181.s10	The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling.    	miRNA-corp.d181.s10.e0	Specific_miRNAs	miRNA-146a 	1
miRNA-corp.d181.s10	The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling.    	miRNA-corp.d181.s10.e1	Relation_Trigger	inhibitors 	2
miRNA-corp.d181.s10	The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling.    	miRNA-corp.d181.s10.e2	Genes/Proteins	IRAK-2 	3
miRNA-corp.d181.s11	The interactive signaling of NF-κB and miRNA-146a further illustrate interplay between inducible transcription factors and pro-inflammatory miRNAs that regulate brain IRAK expression.  	miRNA-corp.d181.s11.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d181.s11	The interactive signaling of NF-κB and miRNA-146a further illustrate interplay between inducible transcription factors and pro-inflammatory miRNAs that regulate brain IRAK expression.  	miRNA-corp.d181.s11.e1	Specific_miRNAs	miRNA-146a 	2
miRNA-corp.d181.s11	The interactive signaling of NF-κB and miRNA-146a further illustrate interplay between inducible transcription factors and pro-inflammatory miRNAs that regulate brain IRAK expression.  	miRNA-corp.d181.s11.e2	Genes/Proteins	IRAK 	3
miRNA-corp.d181.s11	The interactive signaling of NF-κB and miRNA-146a further illustrate interplay between inducible transcription factors and pro-inflammatory miRNAs that regulate brain IRAK expression.  	miRNA-corp.d181.s11.e3	Relation_Trigger	regulate brain IRAK expression 	4
miRNA-corp.d182.s0	MicroRNAs (miRNAs) are short noncoding regulatory RNA molecules that modulate protein expression by inhibiting mRNA translation or promoting mRNA degradation.  	miRNA-corp.d182.s0.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d182.s0	MicroRNAs (miRNAs) are short noncoding regulatory RNA molecules that modulate protein expression by inhibiting mRNA translation or promoting mRNA degradation.  	miRNA-corp.d182.s0.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d182.s0	MicroRNAs (miRNAs) are short noncoding regulatory RNA molecules that modulate protein expression by inhibiting mRNA translation or promoting mRNA degradation.  	miRNA-corp.d182.s0.e2	Relation_Trigger	inhibiting mRNA translation 	3
miRNA-corp.d182.s0	MicroRNAs (miRNAs) are short noncoding regulatory RNA molecules that modulate protein expression by inhibiting mRNA translation or promoting mRNA degradation.  	miRNA-corp.d182.s0.e3	Relation_Trigger	regulatory RNA molecules that modulate protein expression 	4
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e0	Specific_miRNAs	miR-34a 	1
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e2	Genes/Proteins	bcl2 	3
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e4	Relation_Trigger	up-regulated 	5
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e5	Relation_Trigger	inhibits bcl2 translation 	6
miRNA-corp.d182.s1	miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.   	miRNA-corp.d182.s1.e6	Species	mouse 	7
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e1	Specific_miRNAs	miR-34a 	2
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e2	Genes/Proteins	bcl2 	3
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e4	Non-Specific_miRNAs	miRNA 	5
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e5	Relation_Trigger	highly expressed 	6
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e6	Relation_Trigger	differentially expressed 	7
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e7	Relation_Trigger	interaction with the 3'-untranslated region 	8
miRNA-corp.d182.s2	During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA.  	miRNA-corp.d182.s2.e8	Species	mice 	9
miRNA-corp.d182.s3	However, little is understood about the roles of miRNAs in Alzheimer's disease.  	miRNA-corp.d182.s3.e0	Diseases	Alzheimer's disease 	1
miRNA-corp.d182.s3	However, little is understood about the roles of miRNAs in Alzheimer's disease.  	miRNA-corp.d182.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d182.s4	No effect on bcl2 mRNA level was observed.  	miRNA-corp.d182.s4.e0	Genes/Proteins	bcl2 	1
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e0	Specific_miRNAs	miR-34a 	1
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e1	Specific_miRNAs	miR-34a 	2
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e2	Genes/Proteins	bcl2 	3
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e3	Genes/Proteins	bcl2 	4
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e4	Relation_Trigger	inversely correlated 	5
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e5	Relation_Trigger	expression directly inhibits 	6
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e6	Relation_Trigger	inhibits bcl2 translation 	7
miRNA-corp.d182.s5	We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells.  	miRNA-corp.d182.s5.e7	Species	mice 	8
miRNA-corp.d182.s6	Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3.  	miRNA-corp.d182.s6.e0	Genes/Proteins	bcl2 	1
miRNA-corp.d182.s6	Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3.  	miRNA-corp.d182.s6.e1	Specific_miRNAs	miR-34a 	2
miRNA-corp.d182.s6	Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3.  	miRNA-corp.d182.s6.e2	Genes/Proteins	caspase-3 	3
miRNA-corp.d182.s6	Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3.  	miRNA-corp.d182.s6.e3	Relation_Trigger	decrease of active 	4
miRNA-corp.d182.s6	Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3.  	miRNA-corp.d182.s6.e4	Relation_Trigger	increased the level of bcl2 protein 	5
miRNA-corp.d182.s7	Western blot analysis of active caspase-3 showed higher levels in APPswe/PSDeltaE9 mice and stable transfecant cell line of miR-34a than in controls.  	miRNA-corp.d182.s7.e0	Specific_miRNAs	miR-34a 	1
miRNA-corp.d182.s7	Western blot analysis of active caspase-3 showed higher levels in APPswe/PSDeltaE9 mice and stable transfecant cell line of miR-34a than in controls.  	miRNA-corp.d182.s7.e1	Genes/Proteins	caspase-3 	2
miRNA-corp.d182.s7	Western blot analysis of active caspase-3 showed higher levels in APPswe/PSDeltaE9 mice and stable transfecant cell line of miR-34a than in controls.  	miRNA-corp.d182.s7.e2	Relation_Trigger	higher levels 	3
miRNA-corp.d182.s7	Western blot analysis of active caspase-3 showed higher levels in APPswe/PSDeltaE9 mice and stable transfecant cell line of miR-34a than in controls.  	miRNA-corp.d182.s7.e3	Species	mice 	4
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e0	Specific_miRNAs	miR-34a 	1
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e1	Specific_miRNAs	miR-34a 	2
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e2	Genes/Proteins	bcl2 	3
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e3	Diseases	Alzheimer's disease 	4
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e4	Genes/Proteins	bcl2 	5
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e5	Relation_Trigger	functional target 	6
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e6	Relation_Trigger	abnormal expression 	7
miRNA-corp.d182.s8	These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.    	miRNA-corp.d182.s8.e7	Relation_Trigger	affecting the expression 	8
miRNA-corp.d183.s0	Therein lies the therapeutic potential of miRNA, as it may now be possible to induce or inhibit RNAi in a given diseased cell population by controlling the cells' miRNA expression profile.  	miRNA-corp.d183.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d183.s0	Therein lies the therapeutic potential of miRNA, as it may now be possible to induce or inhibit RNAi in a given diseased cell population by controlling the cells' miRNA expression profile.  	miRNA-corp.d183.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d183.s0	Therein lies the therapeutic potential of miRNA, as it may now be possible to induce or inhibit RNAi in a given diseased cell population by controlling the cells' miRNA expression profile.  	miRNA-corp.d183.s0.e2	Relation_Trigger	inhibit 	3
miRNA-corp.d183.s1	This review outlines the potential of miRNA as a therapeutic strategy against high-grade gliomas, and also the technological hurdles that need to be addressed before this promising technique can be administered in a clinical setting.    	miRNA-corp.d183.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d183.s1	This review outlines the potential of miRNA as a therapeutic strategy against high-grade gliomas, and also the technological hurdles that need to be addressed before this promising technique can be administered in a clinical setting.    	miRNA-corp.d183.s1.e1	Diseases	high-grade gliomas 	2
miRNA-corp.d183.s2	Thus, miRNA can be considered the cells' answer to siRNA.  	miRNA-corp.d183.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d183.s3	Discovered over a decade ago, miRNA is fast becoming recognized as crucial in regulating gene expression in cancers.  	miRNA-corp.d183.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d183.s3	Discovered over a decade ago, miRNA is fast becoming recognized as crucial in regulating gene expression in cancers.  	miRNA-corp.d183.s3.e1	Relation_Trigger	regulating gene expression 	2
miRNA-corp.d183.s3	Discovered over a decade ago, miRNA is fast becoming recognized as crucial in regulating gene expression in cancers.  	miRNA-corp.d183.s3.e2	Diseases	cancers 	3
miRNA-corp.d183.s4	Malignant brain tumors, including high-grade gliomas, are among the most lethal of all cancers.  	miRNA-corp.d183.s4.e0	Diseases	brain tumors 	1
miRNA-corp.d183.s4	Malignant brain tumors, including high-grade gliomas, are among the most lethal of all cancers.  	miRNA-corp.d183.s4.e1	Diseases	high-grade gliomas 	2
miRNA-corp.d183.s4	Malignant brain tumors, including high-grade gliomas, are among the most lethal of all cancers.  	miRNA-corp.d183.s4.e2	Diseases	cancers 	3
miRNA-corp.d183.s5	MicroRNA and brain tumors: a cause and a cure?   	miRNA-corp.d183.s5.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d183.s5	MicroRNA and brain tumors: a cause and a cure?   	miRNA-corp.d183.s5.e1	Diseases	brain tumors 	2
miRNA-corp.d183.s6	MicroRNA (miRNA), an endogenously expressed form of siRNA, not only presents an alternate method to induce RNAi in a given diseased tissue or organ, but also exposes a unique set of diagnostic markers that can be used to identify, and then differentiate between tumor grades.  	miRNA-corp.d183.s6.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d183.s6	MicroRNA (miRNA), an endogenously expressed form of siRNA, not only presents an alternate method to induce RNAi in a given diseased tissue or organ, but also exposes a unique set of diagnostic markers that can be used to identify, and then differentiate between tumor grades.  	miRNA-corp.d183.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d183.s6	MicroRNA (miRNA), an endogenously expressed form of siRNA, not only presents an alternate method to induce RNAi in a given diseased tissue or organ, but also exposes a unique set of diagnostic markers that can be used to identify, and then differentiate between tumor grades.  	miRNA-corp.d183.s6.e2	Diseases	tumor 	3
miRNA-corp.d183.s7	However, practical difficulties in tissue- or organ-specific targeting of therapeutic quantities of siRNA still preclude its applicability in a clinical setting.  	miRNA-corp.d183.s7.e0	Relation_Trigger	targeting 	1
miRNA-corp.d183.s8	With the discovery of RNA interference (RNAi) for target-specific gene silencing via small interfering RNA (siRNA), a novel method to target malignant gliomas has been exposed, an endeavor that is aggressively being carried out in numerous laboratories.  	miRNA-corp.d183.s8.e0	Diseases	malignant gliomas 	1
miRNA-corp.d183.s8	With the discovery of RNA interference (RNAi) for target-specific gene silencing via small interfering RNA (siRNA), a novel method to target malignant gliomas has been exposed, an endeavor that is aggressively being carried out in numerous laboratories.  	miRNA-corp.d183.s8.e1	Relation_Trigger	target 	2
miRNA-corp.d183.s9	Despite considerable advances, including multi-modal treatments with surgery, radiotherapy, and chemotherapy, the overall prognosis remains dismal for patients diagnosed with these tumors.  	miRNA-corp.d183.s9.e0	Diseases	tumors 	1
miRNA-corp.d183.s9	Despite considerable advances, including multi-modal treatments with surgery, radiotherapy, and chemotherapy, the overall prognosis remains dismal for patients diagnosed with these tumors.  	miRNA-corp.d183.s9.e1	Species	patients 	2
miRNA-corp.d184.s0	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.  	miRNA-corp.d184.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d184.s0	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.  	miRNA-corp.d184.s0.e1	Genes/Proteins	RNU44 	2
miRNA-corp.d184.s0	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.  	miRNA-corp.d184.s0.e2	Genes/Proteins	RNU49 	3
miRNA-corp.d184.s1	Relative quantification of miRNA expression was calculated using the 2(-DeltaDeltaCt) method.  	miRNA-corp.d184.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e0	Specific_miRNAs	let-7a 	1
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e1	Specific_miRNAs	miR-15a 	2
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e2	Specific_miRNAs	miR-16 	3
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e3	Specific_miRNAs	miR-21 	4
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e4	Specific_miRNAs	miR-141 	5
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e5	Specific_miRNAs	miR-143 	6
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e6	Specific_miRNAs	miR-145 	7
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e7	Specific_miRNAs	miR-150 	8
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e8	Diseases	corticotropinomas 	9
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e9	Relation_Trigger	differential expression 	10
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e10	Relation_Trigger	expression correlates 	11
miRNA-corp.d184.s2	Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.  	miRNA-corp.d184.s2.e11	Diseases	tumor 	12
miRNA-corp.d184.s3	MATERIAL AND METHODS: ACTH-secreting pituitary tumor samples were obtained during transphenoidal surgery from patients with Cushing disease and normal pituitary tissues from autopsies.  	miRNA-corp.d184.s3.e0	Diseases	Cushing disease 	1
miRNA-corp.d184.s3	MATERIAL AND METHODS: ACTH-secreting pituitary tumor samples were obtained during transphenoidal surgery from patients with Cushing disease and normal pituitary tissues from autopsies.  	miRNA-corp.d184.s3.e1	Diseases	ACTH-secreting pituitary tumor 	2
miRNA-corp.d184.s3	MATERIAL AND METHODS: ACTH-secreting pituitary tumor samples were obtained during transphenoidal surgery from patients with Cushing disease and normal pituitary tissues from autopsies.  	miRNA-corp.d184.s3.e2	Species	patients 	3
miRNA-corp.d184.s4	CONCLUSION: Our results support the possibility that altered miRNA expression profile might be involved in corticotrophic tumorigenesis.  	miRNA-corp.d184.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d184.s4	CONCLUSION: Our results support the possibility that altered miRNA expression profile might be involved in corticotrophic tumorigenesis.  	miRNA-corp.d184.s4.e1	Relation_Trigger	altered miRNA expression profile 	2
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e0	Specific_miRNAs	miR-145 	1
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e1	Specific_miRNAs	miR-21 	2
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e2	Specific_miRNAs	miR-150 	3
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e3	Specific_miRNAs	let-7a 	4
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e4	Specific_miRNAs	miR-16 	5
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e5	Specific_miRNAs	miR-15a 	6
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e6	Specific_miRNAs	miR-141 	7
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e7	Specific_miRNAs	miR-143 	8
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e8	Relation_Trigger	underexpression 	9
miRNA-corp.d184.s5	RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.  	miRNA-corp.d184.s5.e9	Diseases	ACTH-secreting pituitary tumors 	10
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e0	Specific_miRNAs	miR-141 	1
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e3	Relation_Trigger	lower miR-141 expression 	4
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e4	Diseases	tumor 	5
miRNA-corp.d184.s6	There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.  	miRNA-corp.d184.s6.e5	Species	patients 	6
miRNA-corp.d184.s7	MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.   	miRNA-corp.d184.s7.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d184.s7	MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.   	miRNA-corp.d184.s7.e1	Relation_Trigger	differentially expressed 	2
miRNA-corp.d184.s7	MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.   	miRNA-corp.d184.s7.e2	Diseases	ACTH-secreting pituitary tumors 	3
miRNA-corp.d184.s8	More than 50% of miRNA genes are located in cancer-associated genomic regions or in fragile sites of the genome.  	miRNA-corp.d184.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d184.s8	More than 50% of miRNA genes are located in cancer-associated genomic regions or in fragile sites of the genome.  	miRNA-corp.d184.s8.e1	Diseases	cancer 	2
miRNA-corp.d184.s9	CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression.  	miRNA-corp.d184.s9.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d184.s9	CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression.  	miRNA-corp.d184.s9.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d184.s9	CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression.  	miRNA-corp.d184.s9.e2	Relation_Trigger	regulators of gene expression 	3
miRNA-corp.d184.s9	CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression.  	miRNA-corp.d184.s9.e3	Relation_Trigger	targeting 	4
miRNA-corp.d184.s9	CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression.  	miRNA-corp.d184.s9.e4	Diseases	cancer 	5
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e2	Diseases	corticotropinomas 	3
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e3	Relation_Trigger	down-regulated 	4
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e4	Relation_Trigger	up-regulated 	5
miRNA-corp.d184.s10	However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.    	miRNA-corp.d184.s10.e5	Relation_Trigger	target 	6
miRNA-corp.d185.s0	Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures.   	miRNA-corp.d185.s0.e0	Diseases	intracerebral hemorrhage 	1
miRNA-corp.d185.s0	Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures.   	miRNA-corp.d185.s0.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d185.s0	Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures.   	miRNA-corp.d185.s0.e2	Diseases	ischemic stroke 	3
miRNA-corp.d185.s0	Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures.   	miRNA-corp.d185.s0.e3	Diseases	kainate seizures 	4
miRNA-corp.d185.s1	MicroRNAs (miRNAs) regulate gene expression and have a critical role in many biologic and pathologic processes.  	miRNA-corp.d185.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d185.s1	MicroRNAs (miRNAs) regulate gene expression and have a critical role in many biologic and pathologic processes.  	miRNA-corp.d185.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d185.s1	MicroRNAs (miRNAs) regulate gene expression and have a critical role in many biologic and pathologic processes.  	miRNA-corp.d185.s1.e2	Relation_Trigger	regulate gene expression 	3
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e4	Diseases	brain injury 	5
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e5	Diseases	brain injury 	6
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e6	Relation_Trigger	changes in miRNA expression 	7
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e7	Relation_Trigger	correlate 	8
miRNA-corp.d185.s2	The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.    	miRNA-corp.d185.s2.e8	Relation_Trigger	regulated 	9
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e0	Specific_miRNAs	miR-298 	1
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e1	Specific_miRNAs	miR-155 	2
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e2	Specific_miRNAs	miR-362-3p 	3
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e3	Non-Specific_miRNAs	miRNAs 	4
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e4	Diseases	injuries 	5
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e5	Relation_Trigger	upregulated 	6
miRNA-corp.d185.s3	A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries.  	miRNA-corp.d185.s3.e6	Relation_Trigger	downregulated 	7
miRNA-corp.d185.s4	Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury.  	miRNA-corp.d185.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d185.s4	Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury.  	miRNA-corp.d185.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d185.s4	Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury.  	miRNA-corp.d185.s4.e2	Relation_Trigger	downregulated 	3
miRNA-corp.d185.s4	Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury.  	miRNA-corp.d185.s4.e3	Diseases	injury 	4
miRNA-corp.d185.s4	Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury.  	miRNA-corp.d185.s4.e4	Relation_Trigger	upregulated 	5
miRNA-corp.d185.s5	MicroRNA response profiles were different for each condition.  	miRNA-corp.d185.s5.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d185.s6	Brain and whole-blood miRNA expression profiles were assessed 24 h later using TaqMan rodent miRNA arrays.  	miRNA-corp.d185.s6.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d185.s6	Brain and whole-blood miRNA expression profiles were assessed 24 h later using TaqMan rodent miRNA arrays.  	miRNA-corp.d185.s6.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e0	Diseases	brain hemorrhage 	1
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e1	Diseases	ischemic strokes 	2
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e2	Diseases	kainate-induced seizures 	3
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e3	Genes/Proteins	thrombin 	4
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e4	Species	rats 	5
miRNA-corp.d185.s7	Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures.  	miRNA-corp.d185.s7.e5	Species	rats 	6
miRNA-corp.d185.s8	We hypothesized that miRNA expression profiles in injured brain (hippocampus) would show common as well as unique profiles when compared with those of blood.  	miRNA-corp.d185.s8.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d185.s8	We hypothesized that miRNA expression profiles in injured brain (hippocampus) would show common as well as unique profiles when compared with those of blood.  	miRNA-corp.d185.s8.e1	Diseases	injured brain 	2
miRNA-corp.d186.s0	A MicroRNA feedback circuit in midbrain dopamine neurons.   	miRNA-corp.d186.s0.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d186.s1	MicroRNAs (miRNAs) are evolutionarily conserved, 18- to 25-nucleotide, non-protein coding transcripts that posttranscriptionally regulate gene expression during development.  	miRNA-corp.d186.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d186.s1	MicroRNAs (miRNAs) are evolutionarily conserved, 18- to 25-nucleotide, non-protein coding transcripts that posttranscriptionally regulate gene expression during development.  	miRNA-corp.d186.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d186.s1	MicroRNAs (miRNAs) are evolutionarily conserved, 18- to 25-nucleotide, non-protein coding transcripts that posttranscriptionally regulate gene expression during development.  	miRNA-corp.d186.s1.e2	Relation_Trigger	regulate gene expression 	3
miRNA-corp.d186.s2	miRNAs also occur in postmitotic cells, such as neurons in the mammalian central nervous system, but their function is less well characterized.  	miRNA-corp.d186.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d186.s3	We investigated the role of miRNAs in mammalian midbrain dopaminergic neurons (DNs).  	miRNA-corp.d186.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d186.s4	We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease.  	miRNA-corp.d186.s4.e0	Specific_miRNAs	miR-133b 	1
miRNA-corp.d186.s4	We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease.  	miRNA-corp.d186.s4.e1	Diseases	Parkinson's disease 	2
miRNA-corp.d186.s4	We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease.  	miRNA-corp.d186.s4.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d186.s4	We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease.  	miRNA-corp.d186.s4.e3	Relation_Trigger	specifically expressed 	4
miRNA-corp.d186.s4	We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease.  	miRNA-corp.d186.s4.e4	Species	patients 	5
miRNA-corp.d186.s5	miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3.  	miRNA-corp.d186.s5.e0	Specific_miRNAs	miR-133b 	1
miRNA-corp.d186.s5	miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3.  	miRNA-corp.d186.s5.e1	Genes/Proteins	Pitx3 	2
miRNA-corp.d186.s5	miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3.  	miRNA-corp.d186.s5.e2	Relation_Trigger	regulates 	3
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e2	Relation_Trigger	deregulated 	3
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e3	Relation_Trigger	impairment 	4
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e4	Genes/Proteins	E2F1 	5
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e5	Genes/Proteins	DP 	6
miRNA-corp.d187.s0	Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.    	miRNA-corp.d187.s0.e6	Non-Specific_miRNAs	miRNA 	7
miRNA-corp.d187.s1	Further, pathogenic LRRK2 promoted the association of phospho-4E-BP1 with hAgo2.  	miRNA-corp.d187.s1.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s1	Further, pathogenic LRRK2 promoted the association of phospho-4E-BP1 with hAgo2.  	miRNA-corp.d187.s1.e1	Genes/Proteins	hAgo2 	2
miRNA-corp.d187.s1	Further, pathogenic LRRK2 promoted the association of phospho-4E-BP1 with hAgo2.  	miRNA-corp.d187.s1.e2	Relation_Trigger	association 	3
miRNA-corp.d187.s2	The molecular mechanism of LRRK2 action is not known.  	miRNA-corp.d187.s2.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s3	Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.  	miRNA-corp.d187.s3.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s3	Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.  	miRNA-corp.d187.s3.e1	Relation_Trigger	regulate 	2
miRNA-corp.d187.s3	Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.  	miRNA-corp.d187.s3.e2	Non-Specific_miRNAs	microRNA 	3
miRNA-corp.d187.s3	Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.  	miRNA-corp.d187.s3.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d187.s4	Drosophila e2f1 and dp messenger RNAs are translationally repressed by let-7 and miR-184*, respectively.  	miRNA-corp.d187.s4.e0	Genes/Proteins	e2f1 	1
miRNA-corp.d187.s4	Drosophila e2f1 and dp messenger RNAs are translationally repressed by let-7 and miR-184*, respectively.  	miRNA-corp.d187.s4.e1	Specific_miRNAs	let-7 	2
miRNA-corp.d187.s4	Drosophila e2f1 and dp messenger RNAs are translationally repressed by let-7 and miR-184*, respectively.  	miRNA-corp.d187.s4.e2	Specific_miRNAs	miR-184 	3
miRNA-corp.d187.s4	Drosophila e2f1 and dp messenger RNAs are translationally repressed by let-7 and miR-184*, respectively.  	miRNA-corp.d187.s4.e3	Relation_Trigger	translationally repressed 	4
miRNA-corp.d187.s5	Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis.  	miRNA-corp.d187.s5.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s5	Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis.  	miRNA-corp.d187.s5.e1	Genes/Proteins	LRRK2 	2
miRNA-corp.d187.s5	Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis.  	miRNA-corp.d187.s5.e2	Non-Specific_miRNAs	miRNAs 	3
miRNA-corp.d187.s5	Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis.  	miRNA-corp.d187.s5.e3	Genes/Proteins	E2F1 	4
miRNA-corp.d187.s5	Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis.  	miRNA-corp.d187.s5.e4	Genes/Proteins	DP 	5
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e1	Specific_miRNAs	let-7 	2
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e2	Specific_miRNAs	let-7 	3
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e3	Specific_miRNAs	miR-184 	4
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e4	Specific_miRNAs	let-7 	5
miRNA-corp.d187.s6	Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2.  	miRNA-corp.d187.s6.e5	Relation_Trigger	target 	6
miRNA-corp.d187.s7	Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects.  	miRNA-corp.d187.s7.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s7	Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects.  	miRNA-corp.d187.s7.e1	Specific_miRNAs	miR-184 	2
miRNA-corp.d187.s7	Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects.  	miRNA-corp.d187.s7.e2	Specific_miRNAs	let-7 	3
miRNA-corp.d187.s7	Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects.  	miRNA-corp.d187.s7.e3	Relation_Trigger	attenuated 	4
miRNA-corp.d187.s7	Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects.  	miRNA-corp.d187.s7.e4	Relation_Trigger	increasing the level 	5
miRNA-corp.d187.s8	LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).  	miRNA-corp.d187.s8.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s8	LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).  	miRNA-corp.d187.s8.e1	Relation_Trigger	associated 	2
miRNA-corp.d187.s8	LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).  	miRNA-corp.d187.s8.e2	Genes/Proteins	human Argonaute-2 	3
miRNA-corp.d187.s8	LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).  	miRNA-corp.d187.s8.e3	Genes/Proteins	hAgo2 	4
miRNA-corp.d187.s8	LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).  	miRNA-corp.d187.s8.e4	Species	human 	5
miRNA-corp.d187.s9	In aged fly brain, dAgo1 protein level was negatively regulated by LRRK2.  	miRNA-corp.d187.s9.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s9	In aged fly brain, dAgo1 protein level was negatively regulated by LRRK2.  	miRNA-corp.d187.s9.e1	Relation_Trigger	level was negatively regulated 	2
miRNA-corp.d187.s10	Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.   	miRNA-corp.d187.s10.e0	Genes/Proteins	LRRK2 	1
miRNA-corp.d187.s10	Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.   	miRNA-corp.d187.s10.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d187.s10	Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.   	miRNA-corp.d187.s10.e2	Relation_Trigger	negatively regulates 	3
miRNA-corp.d187.s10	Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.   	miRNA-corp.d187.s10.e3	Relation_Trigger	regulates microRNA-mediated translational 	4
miRNA-corp.d187.s10	Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.   	miRNA-corp.d187.s10.e4	Relation_Trigger	translational repression 	5
miRNA-corp.d187.s11	Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease characterized by age-dependent degeneration of dopaminergic neurons.  	miRNA-corp.d187.s11.e0	Genes/Proteins	leucine-rich repeat kinase 2 	1
miRNA-corp.d187.s11	Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease characterized by age-dependent degeneration of dopaminergic neurons.  	miRNA-corp.d187.s11.e1	Genes/Proteins	LRRK2 	2
miRNA-corp.d187.s11	Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease characterized by age-dependent degeneration of dopaminergic neurons.  	miRNA-corp.d187.s11.e2	Diseases	Parkinson's disease 	3
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e1	Genes/Proteins	C11Orf9 	2
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e2	Genes/Proteins	CLDN11 	3
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e3	Genes/Proteins	MPZL2 	4
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e4	Genes/Proteins	DDR1 	5
miRNA-corp.d188.s0	The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1.  	miRNA-corp.d188.s0.e5	Relation_Trigger	predicted targets 	6
miRNA-corp.d188.s1	CONCLUSIONS/SIGNIFICANCE: We demonstrate miRNA profiles during distinct stages in oligodendroglial differentiation that may provide key markers of OL maturation.  	miRNA-corp.d188.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s2	Principal component analysis revealed four main clusters of miRNA expression corresponding to early, mid, and late progenitors, and mature OLs. These results were supported by correlation analyses between adjacent stages.  	miRNA-corp.d188.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s2	Principal component analysis revealed four main clusters of miRNA expression corresponding to early, mid, and late progenitors, and mature OLs. These results were supported by correlation analyses between adjacent stages.  	miRNA-corp.d188.s2.e1	Relation_Trigger	correlation 	2
miRNA-corp.d188.s3	Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process.  	miRNA-corp.d188.s3.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d188.s3	Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process.  	miRNA-corp.d188.s3.e1	Relation_Trigger	differentially-expressed 	2
miRNA-corp.d188.s3	Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process.  	miRNA-corp.d188.s3.e2	Relation_Trigger	regulate 	3
miRNA-corp.d188.s3	Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process.  	miRNA-corp.d188.s3.e3	Relation_Trigger	target 	4
miRNA-corp.d188.s3	Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process.  	miRNA-corp.d188.s3.e4	Relation_Trigger	targets 	5
miRNA-corp.d188.s4	Our results reveal pronounced trends in miRNA expression and their potential mRNA target interactions that could provide valuable insight into the molecular mechanisms of differentiation.    	miRNA-corp.d188.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s4	Our results reveal pronounced trends in miRNA expression and their potential mRNA target interactions that could provide valuable insight into the molecular mechanisms of differentiation.    	miRNA-corp.d188.s4.e1	Relation_Trigger	potential mRNA target 	2
miRNA-corp.d188.s5	A comparison of miRNAs from our cultured OLs and OL progenitors showed significant similarities with published results from equivalent cells found in the rat and mouse central nervous system.  	miRNA-corp.d188.s5.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d188.s5	A comparison of miRNAs from our cultured OLs and OL progenitors showed significant similarities with published results from equivalent cells found in the rat and mouse central nervous system.  	miRNA-corp.d188.s5.e1	Species	mouse 	2
miRNA-corp.d188.s5	A comparison of miRNAs from our cultured OLs and OL progenitors showed significant similarities with published results from equivalent cells found in the rat and mouse central nervous system.  	miRNA-corp.d188.s5.e2	Species	rat 	3
miRNA-corp.d188.s6	MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells.   	miRNA-corp.d188.s6.e0	Non-Specific_miRNAs	MicroRNA 	1
miRNA-corp.d188.s6	MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells.   	miRNA-corp.d188.s6.e1	Species	human 	2
miRNA-corp.d188.s8	MicroRNAs (miRNAs) are considered the "micromanagers" of gene expression with suggestive roles in cellular differentiation and maintenance.  	miRNA-corp.d188.s8.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d188.s8	MicroRNAs (miRNAs) are considered the "micromanagers" of gene expression with suggestive roles in cellular differentiation and maintenance.  	miRNA-corp.d188.s8.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d188.s10	These cells may provide immense therapeutic potential for lost sensory and motor function in demyelinating conditions, such as spinal cord injury, multiple sclerosis, and transverse myelitis.  	miRNA-corp.d188.s10.e0	Diseases	spinal cord injury 	1
miRNA-corp.d188.s10	These cells may provide immense therapeutic potential for lost sensory and motor function in demyelinating conditions, such as spinal cord injury, multiple sclerosis, and transverse myelitis.  	miRNA-corp.d188.s10.e1	Diseases	multiple sclerosis 	2
miRNA-corp.d188.s10	These cells may provide immense therapeutic potential for lost sensory and motor function in demyelinating conditions, such as spinal cord injury, multiple sclerosis, and transverse myelitis.  	miRNA-corp.d188.s10.e2	Diseases	transverse myelitis 	3
miRNA-corp.d188.s12	Total RNA was subjected to miRNA profiling and validations preformed using real-time qRT-PCR.  	miRNA-corp.d188.s12.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s13	Although unique patterns of miRNA expression in various cell lineages have been characterized, this is the first report documenting their expression during oligodendrocyte maturation from human embryonic stem (hES) cells.  	miRNA-corp.d188.s13.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s13	Although unique patterns of miRNA expression in various cell lineages have been characterized, this is the first report documenting their expression during oligodendrocyte maturation from human embryonic stem (hES) cells.  	miRNA-corp.d188.s13.e1	Species	human 	2
miRNA-corp.d188.s14	Here, we performed a global miRNA analysis to reveal and identify characteristic patterns in the multiple stages leading to OL maturation from hES cells including those targeting factors involved in myelin production.  	miRNA-corp.d188.s14.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d188.s14	Here, we performed a global miRNA analysis to reveal and identify characteristic patterns in the multiple stages leading to OL maturation from hES cells including those targeting factors involved in myelin production.  	miRNA-corp.d188.s14.e1	Relation_Trigger	targeting 	2
miRNA-corp.d189.s0	Recent evidence indicates that miRNAs can function both as tumor suppressors and as oncogenes.  	miRNA-corp.d189.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d189.s0	Recent evidence indicates that miRNAs can function both as tumor suppressors and as oncogenes.  	miRNA-corp.d189.s0.e1	Relation_Trigger	tumor suppressors 	2
miRNA-corp.d189.s1	MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs.  	miRNA-corp.d189.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d189.s1	MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs.  	miRNA-corp.d189.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d189.s1	MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs.  	miRNA-corp.d189.s1.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d189.s1	MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs.  	miRNA-corp.d189.s1.e3	Relation_Trigger	target 	4
miRNA-corp.d189.s2	Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy.  	miRNA-corp.d189.s2.e0	Diseases	astrocytic tumors 	1
miRNA-corp.d189.s2	Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy.  	miRNA-corp.d189.s2.e1	Specific_miRNAs	miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c 	2
miRNA-corp.d189.s2	Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy.  	miRNA-corp.d189.s2.e2	Species	human 	3
miRNA-corp.d189.s3	It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.  	miRNA-corp.d189.s3.e0	Diseases	glioblastoma 	1
miRNA-corp.d189.s3	It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.  	miRNA-corp.d189.s3.e1	Specific_miRNAs	miR-21 and 221 	2
miRNA-corp.d189.s3	It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.  	miRNA-corp.d189.s3.e2	Specific_miRNAs	miR-128 and 181 	3
miRNA-corp.d189.s3	It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.  	miRNA-corp.d189.s3.e3	Relation_Trigger	upregulated 	4
miRNA-corp.d189.s3	It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.  	miRNA-corp.d189.s3.e4	Relation_Trigger	downregulated 	5
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e0	Specific_miRNAs	miRNA-21 	1
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e1	Specific_miRNAs	miRNA-221 	2
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e2	Relation_Trigger	hyperexpressed 	3
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e3	Relation_Trigger	higher levels 	4
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e4	Diseases	high-grade gliomas 	5
miRNA-corp.d189.s4	miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.  	miRNA-corp.d189.s4.e5	Diseases	tumor 	6
miRNA-corp.d189.s5	miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue.  	miRNA-corp.d189.s5.e0	Specific_miRNAs	miR-21 and 221 	1
miRNA-corp.d189.s5	miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue.  	miRNA-corp.d189.s5.e1	Specific_miRNAs	miRNA 181b 	2
miRNA-corp.d189.s5	miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue.  	miRNA-corp.d189.s5.e2	Diseases	glioma 	3
miRNA-corp.d189.s5	miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue.  	miRNA-corp.d189.s5.e3	Relation_Trigger	overexpressed 	4
miRNA-corp.d189.s5	miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue.  	miRNA-corp.d189.s5.e4	Relation_Trigger	downregulated 	5
miRNA-corp.d189.s6	The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.    	miRNA-corp.d189.s6.e0	Diseases	brain tumors 	1
miRNA-corp.d189.s6	The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.    	miRNA-corp.d189.s6.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d189.s6	The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.    	miRNA-corp.d189.s6.e2	Relation_Trigger	target 	3
miRNA-corp.d189.s6	The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.    	miRNA-corp.d189.s6.e3	Diseases	tumors 	4
miRNA-corp.d189.s6	The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.    	miRNA-corp.d189.s6.e4	Diseases	tumors 	5
miRNA-corp.d189.s7	This study is the first analysis of miRNAs in astrocytic tumor at different stages of malignancy.  	miRNA-corp.d189.s7.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d189.s7	This study is the first analysis of miRNAs in astrocytic tumor at different stages of malignancy.  	miRNA-corp.d189.s7.e1	Diseases	astrocytic tumor 	2
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e0	Specific_miRNAs	miR-21 and 221 	1
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e1	Specific_miRNAs	miR-181b 	2
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e2	Relation_Trigger	upregulation 	3
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e3	Relation_Trigger	downregulation 	4
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e4	Diseases	grade II-IV astrocytic tumors 	5
miRNA-corp.d189.s8	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.   	miRNA-corp.d189.s8.e5	Species	human 	6
miRNA-corp.d190.s0	Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases.  	miRNA-corp.d190.s0.e0	Genes/Proteins	REST 	1
miRNA-corp.d190.s0	Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases.  	miRNA-corp.d190.s0.e1	Relation_Trigger	deregulation 	2
miRNA-corp.d190.s0	Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases.  	miRNA-corp.d190.s0.e2	Diseases	brain cancer 	3
miRNA-corp.d190.s0	Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases.  	miRNA-corp.d190.s0.e3	Diseases	stroke 	4
miRNA-corp.d190.s0	Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases.  	miRNA-corp.d190.s0.e4	Diseases	neurodegenerative diseases 	5
miRNA-corp.d190.s2	REST and its primary cofactor, CoREST, dynamically recruit highly malleable macromolecular complexes to widely distributed genomic regulatory sequences, including the repressor element-1/neuron restrictive silencer element (RE1/NRSE).  	miRNA-corp.d190.s2.e0	Genes/Proteins	REST 	1
miRNA-corp.d190.s2	REST and its primary cofactor, CoREST, dynamically recruit highly malleable macromolecular complexes to widely distributed genomic regulatory sequences, including the repressor element-1/neuron restrictive silencer element (RE1/NRSE).  	miRNA-corp.d190.s2.e1	Genes/Proteins	CoREST 	2
miRNA-corp.d190.s2	REST and its primary cofactor, CoREST, dynamically recruit highly malleable macromolecular complexes to widely distributed genomic regulatory sequences, including the repressor element-1/neuron restrictive silencer element (RE1/NRSE).  	miRNA-corp.d190.s2.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d190.s2	REST and its primary cofactor, CoREST, dynamically recruit highly malleable macromolecular complexes to widely distributed genomic regulatory sequences, including the repressor element-1/neuron restrictive silencer element (RE1/NRSE).  	miRNA-corp.d190.s2.e3	Relation_Trigger	repressor 	4
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e2	Genes/Proteins	REST 	3
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e3	Genes/Proteins	CoREST 	4
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e4	Relation_Trigger	targeting 	5
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e5	Relation_Trigger	repression 	6
miRNA-corp.d190.s3	Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs).  	miRNA-corp.d190.s3.e6	Relation_Trigger	activation 	7
miRNA-corp.d190.s4	In turn, these ncRNAs have similarly been implicated in the regulation of chromatin architecture and dynamics, transcription, post-transcriptional processing, and RNA editing and trafficking.  	miRNA-corp.d190.s4.e0	Relation_Trigger	regulation 	1
miRNA-corp.d190.s5	In addition, REST and CoREST expression and function are tightly regulated by context-specific transcriptional and post-transcriptional mechanisms including bidirectional feedback loops with various ncRNAs.  	miRNA-corp.d190.s5.e0	Genes/Proteins	REST 	1
miRNA-corp.d190.s5	In addition, REST and CoREST expression and function are tightly regulated by context-specific transcriptional and post-transcriptional mechanisms including bidirectional feedback loops with various ncRNAs.  	miRNA-corp.d190.s5.e1	Genes/Proteins	CoREST 	2
miRNA-corp.d190.s5	In addition, REST and CoREST expression and function are tightly regulated by context-specific transcriptional and post-transcriptional mechanisms including bidirectional feedback loops with various ncRNAs.  	miRNA-corp.d190.s5.e2	Relation_Trigger	regulated 	3
miRNA-corp.d190.s6	Regulation of non-coding RNA networks in the nervous system--what's the REST of the story?   	miRNA-corp.d190.s6.e0	Relation_Trigger	Regulation 	1
miRNA-corp.d190.s7	The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity.  	miRNA-corp.d190.s7.e0	Genes/Proteins	repressor element-1 silencing transcription factor 	1
miRNA-corp.d190.s7	The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity.  	miRNA-corp.d190.s7.e1	Genes/Proteins	neuron-restrictive silencing factor 	2
miRNA-corp.d190.s7	The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity.  	miRNA-corp.d190.s7.e2	Genes/Proteins	REST 	3
miRNA-corp.d190.s7	The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity.  	miRNA-corp.d190.s7.e3	Genes/Proteins	NRSF 	4
miRNA-corp.d190.s7	The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity.  	miRNA-corp.d190.s7.e4	Relation_Trigger	regulators 	5
miRNA-corp.d191.s0	The miRNAs in a whole cell regulate greater than 30% of all protein-coding genes.  	miRNA-corp.d191.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d191.s0	The miRNAs in a whole cell regulate greater than 30% of all protein-coding genes.  	miRNA-corp.d191.s0.e1	Relation_Trigger	regulate 	2
miRNA-corp.d191.s1	MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs.  	miRNA-corp.d191.s1.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d191.s1	MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs.  	miRNA-corp.d191.s1.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d191.s1	MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs.  	miRNA-corp.d191.s1.e2	Relation_Trigger	translational repression 	3
miRNA-corp.d191.s1	MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs.  	miRNA-corp.d191.s1.e3	Relation_Trigger	regulate 	4
miRNA-corp.d191.s1	MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs.  	miRNA-corp.d191.s1.e4	Relation_Trigger	target 	5
miRNA-corp.d191.s2	MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.   	miRNA-corp.d191.s2.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d191.s2	MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.   	miRNA-corp.d191.s2.e1	Non-Specific_miRNAs	microRNA 	2
miRNA-corp.d191.s2	MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.   	miRNA-corp.d191.s2.e2	Diseases	Alzheimer's disease 	3
miRNA-corp.d191.s2	MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.   	miRNA-corp.d191.s2.e3	Relation_Trigger	aberrant microRNA expression 	4
miRNA-corp.d191.s2	MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.   	miRNA-corp.d191.s2.e4	Species	human 	5
miRNA-corp.d191.s3	This review will briefly summarize recent studies that focus attention on aberrant miRNA expression in Alzheimer's disease brains.    	miRNA-corp.d191.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d191.s3	This review will briefly summarize recent studies that focus attention on aberrant miRNA expression in Alzheimer's disease brains.    	miRNA-corp.d191.s3.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d191.s3	This review will briefly summarize recent studies that focus attention on aberrant miRNA expression in Alzheimer's disease brains.    	miRNA-corp.d191.s3.e2	Relation_Trigger	aberrant miRNA expression 	3
miRNA-corp.d191.s4	However, at present, the pathological implications of deregulated miRNA expression in neurodegenerative diseases remain largely unknown.  	miRNA-corp.d191.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d191.s4	However, at present, the pathological implications of deregulated miRNA expression in neurodegenerative diseases remain largely unknown.  	miRNA-corp.d191.s4.e1	Relation_Trigger	deregulated miRNA expression 	2
miRNA-corp.d191.s4	However, at present, the pathological implications of deregulated miRNA expression in neurodegenerative diseases remain largely unknown.  	miRNA-corp.d191.s4.e2	Diseases	neurodegenerative diseases 	3
miRNA-corp.d191.s6	The vast majority of presently identified miRNAs are expressed in the brain in a spatially and temporally controlled manner.  	miRNA-corp.d191.s6.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d192.s0	Our studies suggest that ban functions downstream of toxicity of the SCA3 protein, to prevent degeneration.  	miRNA-corp.d192.s0.e0	Genes/Proteins	SCA3 	1
miRNA-corp.d192.s1	These findings indicate that miRNA pathways dramatically modulate polyQ- and tau-induced neurodegeneration, providing the foundation for new insight into therapeutics.    	miRNA-corp.d192.s1.e0	Relation_Trigger	modulate 	1
miRNA-corp.d192.s1	These findings indicate that miRNA pathways dramatically modulate polyQ- and tau-induced neurodegeneration, providing the foundation for new insight into therapeutics.    	miRNA-corp.d192.s1.e1	Genes/Proteins	tau 	2
miRNA-corp.d192.s1	These findings indicate that miRNA pathways dramatically modulate polyQ- and tau-induced neurodegeneration, providing the foundation for new insight into therapeutics.    	miRNA-corp.d192.s1.e2	Non-Specific_miRNAs	miRNA 	3
miRNA-corp.d192.s2	To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein.  	miRNA-corp.d192.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d192.s2	To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein.  	miRNA-corp.d192.s2.e1	Relation_Trigger	modulated 	2
miRNA-corp.d192.s2	To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein.  	miRNA-corp.d192.s2.e2	Genes/Proteins	SCA3 	3
miRNA-corp.d192.s2	To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein.  	miRNA-corp.d192.s2.e3	Non-Specific_miRNAs	miRNA 	4
miRNA-corp.d192.s2	To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein.  	miRNA-corp.d192.s2.e4	Genes/Proteins	spinocerebellar ataxia type 3 (SCA3) protein 	5
miRNA-corp.d192.s3	MicroRNAs (miRNAs) have been shown to modulate programmed cell death during development.  	miRNA-corp.d192.s3.e0	Non-Specific_miRNAs	MicroRNAs 	1
miRNA-corp.d192.s3	MicroRNAs (miRNAs) have been shown to modulate programmed cell death during development.  	miRNA-corp.d192.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d192.s3	MicroRNAs (miRNAs) have been shown to modulate programmed cell death during development.  	miRNA-corp.d192.s3.e2	Relation_Trigger	modulate 	3
miRNA-corp.d192.s4	In parallel genetic screens, we identified the miRNA bantam (ban) as a potent modulator of both polyQ and tau toxicity in flies.  	miRNA-corp.d192.s4.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d192.s4	In parallel genetic screens, we identified the miRNA bantam (ban) as a potent modulator of both polyQ and tau toxicity in flies.  	miRNA-corp.d192.s4.e1	Relation_Trigger	modulator 	2
miRNA-corp.d192.s4	In parallel genetic screens, we identified the miRNA bantam (ban) as a potent modulator of both polyQ and tau toxicity in flies.  	miRNA-corp.d192.s4.e2	Genes/Proteins	tau 	3
miRNA-corp.d192.s5	These studies revealed a striking enhancement of polyQ toxicity upon reduction of miRNA processing in Drosophila and human cells.  	miRNA-corp.d192.s5.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d192.s5	These studies revealed a striking enhancement of polyQ toxicity upon reduction of miRNA processing in Drosophila and human cells.  	miRNA-corp.d192.s5.e1	Species	human 	2
miRNA-corp.d192.s6	MicroRNA pathways modulate polyglutamine-induced neurodegeneration.   	miRNA-corp.d192.s6.e0	Relation_Trigger	modulate 	1
miRNA-corp.d192.s6	MicroRNA pathways modulate polyglutamine-induced neurodegeneration.   	miRNA-corp.d192.s6.e1	Non-Specific_miRNAs	MicroRNA 	2
miRNA-corp.d192.s8	Nine human neurodegenerative diseases are due to expansion of a CAG repeat- encoding glutamine within the open reading frame of the respective genes.  	miRNA-corp.d192.s8.e0	Diseases	neurodegenerative diseases 	1
miRNA-corp.d192.s8	Nine human neurodegenerative diseases are due to expansion of a CAG repeat- encoding glutamine within the open reading frame of the respective genes.  	miRNA-corp.d192.s8.e1	Species	human 	2
miRNA-corp.d193.s0	Western blot was applied to analyze the expression of eiF4E3 in both experimental group and control group.  	miRNA-corp.d193.s0.e0	Genes/Proteins	eiF4E3 	1
miRNA-corp.d193.s1	RESULT: EiF4E3 was the most likely potential targeting protein of microRNA-338.  	miRNA-corp.d193.s1.e0	Relation_Trigger	potential targeting protein 	1
miRNA-corp.d193.s1	RESULT: EiF4E3 was the most likely potential targeting protein of microRNA-338.  	miRNA-corp.d193.s1.e1	Specific_miRNAs	microRNA-338 	2
miRNA-corp.d193.s1	RESULT: EiF4E3 was the most likely potential targeting protein of microRNA-338.  	miRNA-corp.d193.s1.e2	Genes/Proteins	EiF4E3 	3
miRNA-corp.d193.s2	The potential targeting proteins were then selected according to their secondary structures using RNA structure 4.6 software and their involvement in cerebral ischemia and reperfusion injury was studied.  	miRNA-corp.d193.s2.e0	Diseases	cerebral ischemia 	1
miRNA-corp.d193.s2	The potential targeting proteins were then selected according to their secondary structures using RNA structure 4.6 software and their involvement in cerebral ischemia and reperfusion injury was studied.  	miRNA-corp.d193.s2.e1	Diseases	reperfusion injury 	2
miRNA-corp.d193.s2	The potential targeting proteins were then selected according to their secondary structures using RNA structure 4.6 software and their involvement in cerebral ischemia and reperfusion injury was studied.  	miRNA-corp.d193.s2.e2	Relation_Trigger	targeting 	3
miRNA-corp.d193.s3	Dual-luciferase reporter assay was used to testify whether microRNA-338 can recognize the 3'UTR of target protein.  	miRNA-corp.d193.s3.e0	Specific_miRNAs	microRNA-338 	1
miRNA-corp.d193.s3	Dual-luciferase reporter assay was used to testify whether microRNA-338 can recognize the 3'UTR of target protein.  	miRNA-corp.d193.s3.e1	Relation_Trigger	recognize the 3'UTR 	2
miRNA-corp.d193.s3	Dual-luciferase reporter assay was used to testify whether microRNA-338 can recognize the 3'UTR of target protein.  	miRNA-corp.d193.s3.e2	Relation_Trigger	target 	3
miRNA-corp.d193.s4	OBJECTIVE: To analyze the interaction between the microRNA-338 and its targeting proteins during the cerebral ischemia and reperfusion injury.  	miRNA-corp.d193.s4.e0	Specific_miRNAs	microRNA-338 	1
miRNA-corp.d193.s4	OBJECTIVE: To analyze the interaction between the microRNA-338 and its targeting proteins during the cerebral ischemia and reperfusion injury.  	miRNA-corp.d193.s4.e1	Diseases	cerebral ischemia 	2
miRNA-corp.d193.s4	OBJECTIVE: To analyze the interaction between the microRNA-338 and its targeting proteins during the cerebral ischemia and reperfusion injury.  	miRNA-corp.d193.s4.e2	Diseases	reperfusion injury 	3
miRNA-corp.d193.s4	OBJECTIVE: To analyze the interaction between the microRNA-338 and its targeting proteins during the cerebral ischemia and reperfusion injury.  	miRNA-corp.d193.s4.e3	Relation_Trigger	targeting 	4
miRNA-corp.d193.s5	METHODS: TargetScan was used to predict the targets of microRNA-338.  	miRNA-corp.d193.s5.e0	Specific_miRNAs	microRNA-338 	1
miRNA-corp.d193.s5	METHODS: TargetScan was used to predict the targets of microRNA-338.  	miRNA-corp.d193.s5.e1	Relation_Trigger	targets 	2
miRNA-corp.d193.s6	[Interaction of microRNA-338 and its potential targeting protein eiF4E3].   	miRNA-corp.d193.s6.e0	Relation_Trigger	potential targeting protein 	1
miRNA-corp.d193.s6	[Interaction of microRNA-338 and its potential targeting protein eiF4E3].   	miRNA-corp.d193.s6.e1	Specific_miRNAs	microRNA-338 	2
miRNA-corp.d193.s6	[Interaction of microRNA-338 and its potential targeting protein eiF4E3].   	miRNA-corp.d193.s6.e2	Genes/Proteins	eiF4E3 	3
miRNA-corp.d193.s7	However, there was no significant difference in the expression of eiF4E3 between these two groups.  	miRNA-corp.d193.s7.e0	Genes/Proteins	eiF4E3 	1
miRNA-corp.d193.s8	The secondary structure of local region of eiF4E3 recognizing microRNA-338 was conservative.  	miRNA-corp.d193.s8.e0	Specific_miRNAs	microRNA-338 	1
miRNA-corp.d193.s8	The secondary structure of local region of eiF4E3 recognizing microRNA-338 was conservative.  	miRNA-corp.d193.s8.e1	Genes/Proteins	eiF4E3 	2
miRNA-corp.d193.s10	CONCLUSION: MicroRNA-338 can recognize the 3'UTR of eiF4E3 while it has no significant effect on the expression of eiF4E3.  	miRNA-corp.d193.s10.e0	Relation_Trigger	recognize the 3'UTR 	1
miRNA-corp.d193.s10	CONCLUSION: MicroRNA-338 can recognize the 3'UTR of eiF4E3 while it has no significant effect on the expression of eiF4E3.  	miRNA-corp.d193.s10.e1	Specific_miRNAs	MicroRNA-338 	2
miRNA-corp.d193.s10	CONCLUSION: MicroRNA-338 can recognize the 3'UTR of eiF4E3 while it has no significant effect on the expression of eiF4E3.  	miRNA-corp.d193.s10.e2	Genes/Proteins	eiF4E3 	3
miRNA-corp.d193.s10	CONCLUSION: MicroRNA-338 can recognize the 3'UTR of eiF4E3 while it has no significant effect on the expression of eiF4E3.  	miRNA-corp.d193.s10.e3	Genes/Proteins	eiF4E3 	4
miRNA-corp.d193.s11	The post-target-recognizing regulation for miRNA do exist and this mechanism is possibly related to the tertiary structure of target mRNA.    	miRNA-corp.d193.s11.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d193.s11	The post-target-recognizing regulation for miRNA do exist and this mechanism is possibly related to the tertiary structure of target mRNA.    	miRNA-corp.d193.s11.e1	Relation_Trigger	regulation 	2
miRNA-corp.d193.s11	The post-target-recognizing regulation for miRNA do exist and this mechanism is possibly related to the tertiary structure of target mRNA.    	miRNA-corp.d193.s11.e2	Relation_Trigger	target 	3
miRNA-corp.d194.s0	We conclude that lentiviral expression of anti-ADK miRNA constitutes a versatile tool to generate therapeutically effective adenosine releasing hMSCs, thus representing a model system to generate patient identical autologous adult stem cell grafts.    	miRNA-corp.d194.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d194.s0	We conclude that lentiviral expression of anti-ADK miRNA constitutes a versatile tool to generate therapeutically effective adenosine releasing hMSCs, thus representing a model system to generate patient identical autologous adult stem cell grafts.    	miRNA-corp.d194.s0.e1	Species	patient 	2
miRNA-corp.d194.s1	While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection.  	miRNA-corp.d194.s1.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d194.s1	While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection.  	miRNA-corp.d194.s1.e1	Diseases	status epilepticus 	2
miRNA-corp.d194.s1	While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection.  	miRNA-corp.d194.s1.e2	Genes/Proteins	ADK 	3
miRNA-corp.d194.s1	While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection.  	miRNA-corp.d194.s1.e3	Diseases	seizure 	4
miRNA-corp.d194.s1	While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection.  	miRNA-corp.d194.s1.e4	Species	mice 	5
miRNA-corp.d194.s2	hMSCs with a knockdown of ADK or cells expressing a scrambled control sequence were transplanted into hippocampi of mice 1 week prior to the intraamygdaloid injection of kainic acid (KA).  	miRNA-corp.d194.s2.e0	Genes/Proteins	ADK 	1
miRNA-corp.d194.s2	hMSCs with a knockdown of ADK or cells expressing a scrambled control sequence were transplanted into hippocampi of mice 1 week prior to the intraamygdaloid injection of kainic acid (KA).  	miRNA-corp.d194.s2.e1	Species	mice 	2
miRNA-corp.d194.s3	Following lentiviral transduction of hMSCs with anti-ADK miRNA expression cassettes we demonstrate up to 80% downregulation of ADK and a concentration of 8.5 ng adenosine per ml of medium after incubating 10(5) cells for 8 h.  	miRNA-corp.d194.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d194.s3	Following lentiviral transduction of hMSCs with anti-ADK miRNA expression cassettes we demonstrate up to 80% downregulation of ADK and a concentration of 8.5 ng adenosine per ml of medium after incubating 10(5) cells for 8 h.  	miRNA-corp.d194.s3.e1	Genes/Proteins	ADK 	2
miRNA-corp.d194.s3	Following lentiviral transduction of hMSCs with anti-ADK miRNA expression cassettes we demonstrate up to 80% downregulation of ADK and a concentration of 8.5 ng adenosine per ml of medium after incubating 10(5) cells for 8 h.  	miRNA-corp.d194.s3.e2	Relation_Trigger	downregulation 	3
miRNA-corp.d194.s4	Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients.  	miRNA-corp.d194.s4.e0	Relation_Trigger	downregulation 	1
miRNA-corp.d194.s4	Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients.  	miRNA-corp.d194.s4.e1	Genes/Proteins	adenosine kinase 	2
miRNA-corp.d194.s4	Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients.  	miRNA-corp.d194.s4.e2	Genes/Proteins	ADK 	3
miRNA-corp.d194.s4	Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients.  	miRNA-corp.d194.s4.e3	Species	human 	4
miRNA-corp.d194.s4	Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients.  	miRNA-corp.d194.s4.e4	Species	patients 	5
miRNA-corp.d194.s5	Autologous patient-derived adenosine-releasing cell implants would constitute a major therapeutic advance to avoid both xenotransplantation and immunosuppression.  	miRNA-corp.d194.s5.e0	Species	patient 	1
miRNA-corp.d194.s7	Cell therapies based on focal delivery of the inhibitory neuromodulator adenosine were previously shown to provide potent seizure suppression in animal models of epilepsy.  	miRNA-corp.d194.s7.e0	Diseases	seizure 	1
miRNA-corp.d194.s7	Cell therapies based on focal delivery of the inhibitory neuromodulator adenosine were previously shown to provide potent seizure suppression in animal models of epilepsy.  	miRNA-corp.d194.s7.e1	Diseases	epilepsy 	2
miRNA-corp.d194.s7	Cell therapies based on focal delivery of the inhibitory neuromodulator adenosine were previously shown to provide potent seizure suppression in animal models of epilepsy.  	miRNA-corp.d194.s7.e2	Relation_Trigger	inhibitory 	3
miRNA-corp.d194.s7	Cell therapies based on focal delivery of the inhibitory neuromodulator adenosine were previously shown to provide potent seizure suppression in animal models of epilepsy.  	miRNA-corp.d194.s7.e3	Relation_Trigger	suppression 	4
miRNA-corp.d194.s8	Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.   	miRNA-corp.d194.s8.e0	Diseases	seizure 	1
miRNA-corp.d194.s8	Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.   	miRNA-corp.d194.s8.e1	Relation_Trigger	downregulation 	2
miRNA-corp.d194.s8	Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.   	miRNA-corp.d194.s8.e2	Genes/Proteins	adenosine kinase 	3
miRNA-corp.d194.s8	Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.   	miRNA-corp.d194.s8.e3	Species	human 	4
miRNA-corp.d195.s0	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.   	miRNA-corp.d195.s0.e0	Diseases	glioma 	1
miRNA-corp.d195.s0	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.   	miRNA-corp.d195.s0.e1	Specific_miRNAs	miR-26a 	2
miRNA-corp.d195.s0	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.   	miRNA-corp.d195.s0.e2	Genes/Proteins	PTEN 	3
miRNA-corp.d195.s0	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.   	miRNA-corp.d195.s0.e3	Non-Specific_miRNAs	microRNA 	4
miRNA-corp.d195.s0	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.   	miRNA-corp.d195.s0.e4	Relation_Trigger	amplified 	5
miRNA-corp.d195.s1	Activated oncogenic signaling is central to the development of nearly all forms of cancer, including the most common class of primary brain tumor, glioma.  	miRNA-corp.d195.s1.e0	Diseases	glioma 	1
miRNA-corp.d195.s1	Activated oncogenic signaling is central to the development of nearly all forms of cancer, including the most common class of primary brain tumor, glioma.  	miRNA-corp.d195.s1.e1	Diseases	brain tumor 	2
miRNA-corp.d195.s1	Activated oncogenic signaling is central to the development of nearly all forms of cancer, including the most common class of primary brain tumor, glioma.  	miRNA-corp.d195.s1.e2	Relation_Trigger	Activated 	3
miRNA-corp.d195.s1	Activated oncogenic signaling is central to the development of nearly all forms of cancer, including the most common class of primary brain tumor, glioma.  	miRNA-corp.d195.s1.e3	Diseases	cancer 	4
miRNA-corp.d195.s3	Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors.  	miRNA-corp.d195.s3.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d195.s3	Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors.  	miRNA-corp.d195.s3.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d195.s3	Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors.  	miRNA-corp.d195.s3.e2	Relation_Trigger	modulation 	3
miRNA-corp.d195.s3	Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors.  	miRNA-corp.d195.s3.e3	Diseases	tumors 	4
miRNA-corp.d195.s3	Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors.  	miRNA-corp.d195.s3.e4	Diseases	cancer 	5
miRNA-corp.d195.s4	Here we report the identification miR-26a as a direct regulator of PTEN expression.  	miRNA-corp.d195.s4.e0	Genes/Proteins	PTEN 	1
miRNA-corp.d195.s4	Here we report the identification miR-26a as a direct regulator of PTEN expression.  	miRNA-corp.d195.s4.e1	Specific_miRNAs	miR-26a 	2
miRNA-corp.d195.s4	Here we report the identification miR-26a as a direct regulator of PTEN expression.  	miRNA-corp.d195.s4.e2	Relation_Trigger	regulator of PTEN expression 	3
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e0	Genes/Proteins	PTEN 	1
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e1	Specific_miRNAs	miR-26a 	2
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e2	Diseases	glioma 	3
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e3	Relation_Trigger	amplified 	4
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e4	Relation_Trigger	association with monoallelic PTEN loss 	5
miRNA-corp.d195.s5	We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss.  	miRNA-corp.d195.s5.e5	Species	human 	6
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e0	Genes/Proteins	PTEN 	1
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e1	Genes/Proteins	PTEN 	2
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e2	Diseases	glioma 	3
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e3	Specific_miRNAs	miR-26a 	4
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e4	Relation_Trigger	repression 	5
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e5	Diseases	tumor 	6
miRNA-corp.d195.s6	Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.  	miRNA-corp.d195.s6.e6	Species	murine 	7
miRNA-corp.d195.s7	Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.    	miRNA-corp.d195.s7.e0	Genes/Proteins	PTEN 	1
miRNA-corp.d195.s7	Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.    	miRNA-corp.d195.s7.e1	Diseases	glioma 	2
miRNA-corp.d195.s7	Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.    	miRNA-corp.d195.s7.e2	Relation_Trigger	regulation 	3
miRNA-corp.d195.s7	Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.    	miRNA-corp.d195.s7.e3	Relation_Trigger	dysregulation 	4
miRNA-corp.d195.s7	Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.    	miRNA-corp.d195.s7.e4	Diseases	tumors 	5
miRNA-corp.d196.s0	The research was divided into two studies: the first one the test was adapted, and in order to check its capacity to investigate the deficits of SOM, it has applied in groups of 10 (ten) subjects, one group with patients that have Alzheimer disease and the other one with healthy elderly (p<0.001).  	miRNA-corp.d196.s0.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d196.s0	The research was divided into two studies: the first one the test was adapted, and in order to check its capacity to investigate the deficits of SOM, it has applied in groups of 10 (ten) subjects, one group with patients that have Alzheimer disease and the other one with healthy elderly (p<0.001).  	miRNA-corp.d196.s0.e1	Species	patients 	2
miRNA-corp.d196.s1	This study had the purpose to adapt a test based in these experiments in order to check the performance of SOM and the participation of hippocampus into SOM in patients with mesial temporal sclerosis (MTS).  	miRNA-corp.d196.s1.e0	Diseases	mesial temporal sclerosis 	1
miRNA-corp.d196.s1	This study had the purpose to adapt a test based in these experiments in order to check the performance of SOM and the participation of hippocampus into SOM in patients with mesial temporal sclerosis (MTS).  	miRNA-corp.d196.s1.e1	Diseases	MTS 	2
miRNA-corp.d196.s1	This study had the purpose to adapt a test based in these experiments in order to check the performance of SOM and the participation of hippocampus into SOM in patients with mesial temporal sclerosis (MTS).  	miRNA-corp.d196.s1.e2	Species	patients 	3
miRNA-corp.d196.s2	Experimental studies have identified pyramidal cells in hippocampus in rats with participation in the spatial orientation memory (SOM), which are named location cells.  	miRNA-corp.d196.s2.e0	Species	rats 	1
miRNA-corp.d196.s3	[Spatial orientation memory: evaluation in patents with Alzheimer disease and temporal lobe epilepsy].   	miRNA-corp.d196.s3.e0	Diseases	Alzheimer disease 	1
miRNA-corp.d196.s3	[Spatial orientation memory: evaluation in patents with Alzheimer disease and temporal lobe epilepsy].   	miRNA-corp.d196.s3.e1	Diseases	temporal lobe epilepsy 	2
miRNA-corp.d196.s4	The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p<0,05 between MTS and SAH and between controlled and SAH.  	miRNA-corp.d196.s4.e0	Diseases	mesial temporal sclerosis 	1
miRNA-corp.d196.s4	The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p<0,05 between MTS and SAH and between controlled and SAH.  	miRNA-corp.d196.s4.e1	Diseases	MTS 	2
miRNA-corp.d196.s4	The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p<0,05 between MTS and SAH and between controlled and SAH.  	miRNA-corp.d196.s4.e2	Diseases	MTS 	3
miRNA-corp.d196.s4	The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p<0,05 between MTS and SAH and between controlled and SAH.  	miRNA-corp.d196.s4.e3	Species	patients 	4
miRNA-corp.d196.s5	It was shown that the test of SOM is suitable to evaluate deficits, but it seems the SOM is not a specific function of human hippocampus.    	miRNA-corp.d196.s5.e0	Species	human 	1
miRNA-corp.d197.s0	Potential role of miRNAs and their inhibitors in glioma treatment.   	miRNA-corp.d197.s0.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d197.s0	Potential role of miRNAs and their inhibitors in glioma treatment.   	miRNA-corp.d197.s0.e1	Diseases	glioma 	2
miRNA-corp.d197.s0	Potential role of miRNAs and their inhibitors in glioma treatment.   	miRNA-corp.d197.s0.e2	Relation_Trigger	inhibitors 	3
miRNA-corp.d197.s1	Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs.  	miRNA-corp.d197.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d197.s1	Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs.  	miRNA-corp.d197.s1.e1	Relation_Trigger	regulators 	2
miRNA-corp.d197.s1	Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs.  	miRNA-corp.d197.s1.e2	Relation_Trigger	suppression of translation 	3
miRNA-corp.d197.s1	Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs.  	miRNA-corp.d197.s1.e3	Relation_Trigger	target 	4
miRNA-corp.d197.s1	Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs.  	miRNA-corp.d197.s1.e4	Relation_Trigger	expression that act through suppression 	5
miRNA-corp.d197.s2	Several hundred miRNAs have been identified in humans, and these show characteristic expression patterns, depending on tissue type, cell type or environmental stimuli.  	miRNA-corp.d197.s2.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d197.s2	Several hundred miRNAs have been identified in humans, and these show characteristic expression patterns, depending on tissue type, cell type or environmental stimuli.  	miRNA-corp.d197.s2.e1	Species	humans 	2
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e2	Diseases	brain tumor 	3
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e3	Diseases	glioblastoma 	4
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e4	Diseases	glioblastoma 	5
miRNA-corp.d197.s3	Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior.  	miRNA-corp.d197.s3.e5	Diseases	cancer 	6
miRNA-corp.d197.s4	These studies have opened the door to the possibility of utilizing miRNAs or miRNA antagonists as therapeutic agents for the treatment of brain tumors.    	miRNA-corp.d197.s4.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d197.s4	These studies have opened the door to the possibility of utilizing miRNAs or miRNA antagonists as therapeutic agents for the treatment of brain tumors.    	miRNA-corp.d197.s4.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d197.s4	These studies have opened the door to the possibility of utilizing miRNAs or miRNA antagonists as therapeutic agents for the treatment of brain tumors.    	miRNA-corp.d197.s4.e2	Diseases	brain tumors 	3
miRNA-corp.d198.s1	RESULTS: Both Pol II and Pol III promoters have been successfully combined with a second expression cassette containing a codon-optimized tetracycline repressor and selectable marker.  	miRNA-corp.d198.s1.e0	Relation_Trigger	repressor 	1
miRNA-corp.d198.s2	We have therefore developed pHUSH, an inducible expression system that allows regulated expression of shRNA, miRNA or cDNA cassettes on a single viral vector.  	miRNA-corp.d198.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d198.s2	We have therefore developed pHUSH, an inducible expression system that allows regulated expression of shRNA, miRNA or cDNA cassettes on a single viral vector.  	miRNA-corp.d198.s2.e1	Relation_Trigger	regulated expression 	2
miRNA-corp.d198.s3	However, most systems require multiple plasmids that must be independently engineered into the target system, resulting in experimental delay and an increased potential for selection of a cell subpopulation that differs significantly from the parental line.  	miRNA-corp.d198.s3.e0	Relation_Trigger	target 	1
miRNA-corp.d198.s6	CONCLUSION: We have successfully developed and employed a single vector system that enables Doxycycline regulated RNAi or transgene expression in a variety of in vitro and in vivo model systems.  	miRNA-corp.d198.s6.e0	Relation_Trigger	regulated 	1
miRNA-corp.d198.s7	We provide examples of how pHUSH has been successfully employed to study the function of target genes in a number of cell types within in vitro and in vivo assays, including conditional gene knockdown in a murine model of brain cancer.  	miRNA-corp.d198.s7.e0	Relation_Trigger	target 	1
miRNA-corp.d198.s7	We provide examples of how pHUSH has been successfully employed to study the function of target genes in a number of cell types within in vitro and in vivo assays, including conditional gene knockdown in a murine model of brain cancer.  	miRNA-corp.d198.s7.e1	Diseases	brain cancer 	2
miRNA-corp.d198.s7	We provide examples of how pHUSH has been successfully employed to study the function of target genes in a number of cell types within in vitro and in vivo assays, including conditional gene knockdown in a murine model of brain cancer.  	miRNA-corp.d198.s7.e2	Species	murine 	3
miRNA-corp.d199.s0	SIGNIFICANCE: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in children, suggesting a higher incidence of CPC in southern Brazil.    	miRNA-corp.d199.s0.e0	Genes/Proteins	TP53 	1
miRNA-corp.d199.s0	SIGNIFICANCE: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in children, suggesting a higher incidence of CPC in southern Brazil.    	miRNA-corp.d199.s0.e1	Diseases	CPC 	2
miRNA-corp.d199.s0	SIGNIFICANCE: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in children, suggesting a higher incidence of CPC in southern Brazil.    	miRNA-corp.d199.s0.e2	Diseases	CPC 	3
miRNA-corp.d199.s0	SIGNIFICANCE: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in children, suggesting a higher incidence of CPC in southern Brazil.    	miRNA-corp.d199.s0.e3	Species	children 	4
miRNA-corp.d199.s1	Family history of cancer (with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/14) of them were compatible with Li-Fraumeni-like syndrome.  	miRNA-corp.d199.s1.e0	Diseases	cancer 	1
miRNA-corp.d199.s1	Family history of cancer (with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/14) of them were compatible with Li-Fraumeni-like syndrome.  	miRNA-corp.d199.s1.e1	Diseases	Li-Fraumeni-like syndrome 	2
miRNA-corp.d199.s1	Family history of cancer (with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/14) of them were compatible with Li-Fraumeni-like syndrome.  	miRNA-corp.d199.s1.e2	Diseases	cancer 	3
miRNA-corp.d199.s2	Cure (>5 years survival free of disease) was observed in 18.1% of the CPC cases with the R337H mutation (2/11), 71.4% of the Pp (5/7), and 25% of CPC cases negative for the R337H mutation (2/8).  	miRNA-corp.d199.s2.e0	Diseases	CPC 	1
miRNA-corp.d199.s2	Cure (>5 years survival free of disease) was observed in 18.1% of the CPC cases with the R337H mutation (2/11), 71.4% of the Pp (5/7), and 25% of CPC cases negative for the R337H mutation (2/8).  	miRNA-corp.d199.s2.e1	Diseases	CPC 	2
miRNA-corp.d199.s4	We found 63.3% (14/22) of the CPC patients positive for the germline R337H mutation; CPC samples were either heterozygous (n = 7), lost only the wild-type (n = 4), or only the R337H copy (n = 2).  	miRNA-corp.d199.s4.e0	Diseases	CPC 	1
miRNA-corp.d199.s4	We found 63.3% (14/22) of the CPC patients positive for the germline R337H mutation; CPC samples were either heterozygous (n = 7), lost only the wild-type (n = 4), or only the R337H copy (n = 2).  	miRNA-corp.d199.s4.e1	Species	patients 	2
miRNA-corp.d199.s6	The patients, all parents, and some relatives submitted samples for blood DNA analysis.  	miRNA-corp.d199.s6.e0	Species	patients 	1
miRNA-corp.d199.s7	In addition, we have also examined the presence of the mutation in DNA from paraffin-embedded tumor samples to evaluate loss of heterozygosity.  	miRNA-corp.d199.s7.e0	Diseases	tumor 	1
miRNA-corp.d199.s8	BACKGROUND: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children.  	miRNA-corp.d199.s8.e0	Diseases	Choroid plexus carcinomas 	1
miRNA-corp.d199.s8	BACKGROUND: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children.  	miRNA-corp.d199.s8.e1	Diseases	CPC 	2
miRNA-corp.d199.s8	BACKGROUND: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children.  	miRNA-corp.d199.s8.e2	Diseases	tumors 	3
miRNA-corp.d199.s8	BACKGROUND: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children.  	miRNA-corp.d199.s8.e3	Species	children 	4
miRNA-corp.d199.s9	Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil.   	miRNA-corp.d199.s9.e0	Diseases	carcinoma 	1
miRNA-corp.d199.s9	Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil.   	miRNA-corp.d199.s9.e1	Genes/Proteins	TP53 	2
miRNA-corp.d199.s10	Blood and/or tumor DNA was extracted and analyzed using PCR-RFLP and results were confirmed by sequencing 240 bp of the TP53 exon 10.  	miRNA-corp.d199.s10.e0	Diseases	tumor 	1
miRNA-corp.d199.s10	Blood and/or tumor DNA was extracted and analyzed using PCR-RFLP and results were confirmed by sequencing 240 bp of the TP53 exon 10.  	miRNA-corp.d199.s10.e1	Genes/Proteins	TP53 	2
miRNA-corp.d199.s11	Surgical resection was possible in 28 children.  	miRNA-corp.d199.s11.e0	Species	children 	1
miRNA-corp.d199.s12	METHODOLOGY/PRINCIPAL FINDINGS: The present series included 29 patients that were admitted to the same institution from 1992 to 2010, including 22 children with CPC (0.08-13.6 years of age at diagnosis) and 7 children with papilloma of the choroid plexus (Pp; 0.5-9.8 years of age).  	miRNA-corp.d199.s12.e0	Diseases	papilloma 	1
miRNA-corp.d199.s12	METHODOLOGY/PRINCIPAL FINDINGS: The present series included 29 patients that were admitted to the same institution from 1992 to 2010, including 22 children with CPC (0.08-13.6 years of age at diagnosis) and 7 children with papilloma of the choroid plexus (Pp; 0.5-9.8 years of age).  	miRNA-corp.d199.s12.e1	Species	patients 	2
miRNA-corp.d199.s12	METHODOLOGY/PRINCIPAL FINDINGS: The present series included 29 patients that were admitted to the same institution from 1992 to 2010, including 22 children with CPC (0.08-13.6 years of age at diagnosis) and 7 children with papilloma of the choroid plexus (Pp; 0.5-9.8 years of age).  	miRNA-corp.d199.s12.e2	Species	children 	3
miRNA-corp.d199.s12	METHODOLOGY/PRINCIPAL FINDINGS: The present series included 29 patients that were admitted to the same institution from 1992 to 2010, including 22 children with CPC (0.08-13.6 years of age at diagnosis) and 7 children with papilloma of the choroid plexus (Pp; 0.5-9.8 years of age).  	miRNA-corp.d199.s12.e3	Species	children 	4
miRNA-corp.d199.s13	Given the high frequency of the germline R337H mutation in the TP53 gene in southern Brazil, we have evaluated the frequency of the R337H mutation in families with CPC in children.  	miRNA-corp.d199.s13.e0	Genes/Proteins	TP53 	1
miRNA-corp.d199.s13	Given the high frequency of the germline R337H mutation in the TP53 gene in southern Brazil, we have evaluated the frequency of the R337H mutation in families with CPC in children.  	miRNA-corp.d199.s13.e1	Diseases	CPC 	2
miRNA-corp.d199.s13	Given the high frequency of the germline R337H mutation in the TP53 gene in southern Brazil, we have evaluated the frequency of the R337H mutation in families with CPC in children.  	miRNA-corp.d199.s13.e2	Species	children 	3
miRNA-corp.d200.s0	Here, we present an overview of the current progress in miRNA research related to CNS disorders and also highlight the utility of LNA (locked nucleic acid)-modified oligonucleotides in the detection and modulation of miRNA activity.    	miRNA-corp.d200.s0.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d200.s0	Here, we present an overview of the current progress in miRNA research related to CNS disorders and also highlight the utility of LNA (locked nucleic acid)-modified oligonucleotides in the detection and modulation of miRNA activity.    	miRNA-corp.d200.s0.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d200.s0	Here, we present an overview of the current progress in miRNA research related to CNS disorders and also highlight the utility of LNA (locked nucleic acid)-modified oligonucleotides in the detection and modulation of miRNA activity.    	miRNA-corp.d200.s0.e2	Relation_Trigger	modulation 	3
miRNA-corp.d200.s0	Here, we present an overview of the current progress in miRNA research related to CNS disorders and also highlight the utility of LNA (locked nucleic acid)-modified oligonucleotides in the detection and modulation of miRNA activity.    	miRNA-corp.d200.s0.e3	Diseases	CNS disorders 	4
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e0	Non-Specific_miRNAs	miRNAs 	1
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e1	Diseases	Alzheimer's disease 	2
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e2	Diseases	schizophrenia 	3
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e3	Genes/Proteins	BACE1 	4
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e4	Relation_Trigger	targets 	5
miRNA-corp.d200.s1	Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII).  	miRNA-corp.d200.s1.e5	Genes/Proteins	beta-secretase 	6
miRNA-corp.d200.s2	The intricate molecular networks mediated by an miRNA form a robust mechanism for rapid and potent responses to cellular events throughout the development of the human brain.  	miRNA-corp.d200.s2.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d200.s2	The intricate molecular networks mediated by an miRNA form a robust mechanism for rapid and potent responses to cellular events throughout the development of the human brain.  	miRNA-corp.d200.s2.e1	Species	human 	2
miRNA-corp.d200.s3	Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets.  	miRNA-corp.d200.s3.e0	Non-Specific_miRNAs	miRNA 	1
miRNA-corp.d200.s3	Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets.  	miRNA-corp.d200.s3.e1	Non-Specific_miRNAs	miRNA 	2
miRNA-corp.d200.s3	Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets.  	miRNA-corp.d200.s3.e2	Relation_Trigger	regulation 	3
miRNA-corp.d200.s3	Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets.  	miRNA-corp.d200.s3.e3	Diseases	CNS disorders 	4
miRNA-corp.d200.s3	Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets.  	miRNA-corp.d200.s3.e4	Relation_Trigger	targets 	5
miRNA-corp.d200.s4	Hundreds of non-coding regulatory RNA molecules called microRNAs (miRNAs) have been identified in the mammalian central nervous system (CNS) and are reported to mediate pivotal roles in many aspects of neuronal functions.  	miRNA-corp.d200.s4.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d200.s4	Hundreds of non-coding regulatory RNA molecules called microRNAs (miRNAs) have been identified in the mammalian central nervous system (CNS) and are reported to mediate pivotal roles in many aspects of neuronal functions.  	miRNA-corp.d200.s4.e1	Non-Specific_miRNAs	miRNAs 	2
miRNA-corp.d200.s4	Hundreds of non-coding regulatory RNA molecules called microRNAs (miRNAs) have been identified in the mammalian central nervous system (CNS) and are reported to mediate pivotal roles in many aspects of neuronal functions.  	miRNA-corp.d200.s4.e2	Relation_Trigger	regulatory 	3
miRNA-corp.d200.s5	In recent years, there has been a shift in the conventional paradigms for transcriptional and translational regulation as extensive sequencing efforts have yielded new insights into the landscape of the human genome and transcriptome.  	miRNA-corp.d200.s5.e0	Relation_Trigger	translational regulation 	1
miRNA-corp.d200.s5	In recent years, there has been a shift in the conventional paradigms for transcriptional and translational regulation as extensive sequencing efforts have yielded new insights into the landscape of the human genome and transcriptome.  	miRNA-corp.d200.s5.e1	Species	human 	2
miRNA-corp.d200.s6	microRNAs in CNS disorders.   	miRNA-corp.d200.s6.e0	Non-Specific_miRNAs	microRNAs 	1
miRNA-corp.d200.s6	microRNAs in CNS disorders.   	miRNA-corp.d200.s6.e1	Diseases	CNS disorders 	2
